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and to my family, 
for getting me here and getting me through. 
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The squirming facts exceed the squamous mind, 
If one may say so.  And yet relation appears, 
A small relation expanding like the shade 
Of a cloud on sand, a shape on the side of a hill. 
... 
This proves nothing.  Just one more truth, one more 
Element in the immense disorder of truths. 
It is April as I write.  The wind is blowing after days of constant rain. 
All this, of course, will come to summer soon. 
But suppose the disorder of truths should ever come 
To an order, most Plantagenet, most fixed… 
A great disorder is an order. 
-  Wallace Stevens, “Connoisseur of Chaos” 
 
 
“It’s the wanting to know that makes us matter.  Otherwise, we’re going out the way we came in.” 
- Tom Stoppard, Arcadia  
 
“The doubter is a true man of science; he doubts only himself and his interpretations, but he believes in 
science.”  
- Claude Bernard 
 
“Some of the channels close.  The rest of the channels stay open until they close.” 
“Calling something an ‘apparent Kd’ is like calling a horse an apparent car because they both move.” 
“You are comparing apples to kumquats.” 
- Robert L. Macdonald 
 
Now these points of data make a beautiful line 
And we’re out of beta, we’re releasing on time 
So I’m glad I got burned, think of all the things we’ve learned 
For the people who are still alive  
- GLaDOS 
 
“I feel like a quote out of context.” 
- Ben Folds 
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CHAPTER I 
INTRODUCTION 
 
GABAergic neurotransmission: ubiquitous, diverse, and essential 
Approximately 30% of all cortical neurons release γ-aminobutyric acid (GABA), the 
predominant inhibitory neurotransmitter in the brain1.  Unlike monoaminergic neurons, which 
signal primarily through specific projection pathways, GABAergic neurons are distributed 
throughout the brain and most signal via local rather than long-range circuits.  These inhibitory 
“interneurons” are morphologically and functionally diverse; different populations express 
different neurochemical markers, exhibit different dendritic arborizations, fire at different rates, 
and form synapses with different regions of target cells.  Although interneurons mediate the 
majority of inhibitory neurotransmission, long-range GABAergic projection neurons also exist.  
Both the local-circuit and long-range populations are essential for proper CNS function, as 
GABAergic signaling is necessary for processes ranging from neuronal migration to sensory 
perception to maintenance of sleep and wakefulness. 
GABA metabolism and transport: GADs, GATs, and GABA-Ts 
Biosynthesis of GABA occurs within GABAergic neurons themselves via a branch of the 
tricarboxylic acid (TCA) cycle called the GABA shunt.  In this metabolic pathway, α-
ketoglutarate is transaminated to yield glutamate, which then is decarboxylated by glutamic acid 
decarboxylase (GAD) to yield GABA.  The latter constitutes the rate-limiting step of GABA 
biosynthesis and, notably, converts the most abundant excitatory neurotransmitter into the most 
abundant inhibitory neurotransmitter.  Degradation of GABA is accomplished in astrocytes by 
GABA transaminase (GABA-T), which produces succinic semialdehyde.  Finally, succinic 
1
semialdehyde is metabolized by succinic semialdehyde dehydrogenase to succinate, which can re-
enter the TCA cycle and close this metabolic loop. 
Despite the simplicity of the GABA shunt, metabolism and transport of GABA is, 
unsurprisingly, a heavily regulated process that involves multiple enzymatic isoforms, cofactors, 
transporters, and cell types2.  The rate-limiting enzyme, GAD, exists in two forms: GAD65 and 
GAD67, each encoded by a separate gene and named according to its molecular weight in kDa3, 4.  
Although these two enzymes catalyze identical reactions, their localization and regulatory 
properties (Table 1) suggest that they play very different roles in GABAergic neurotransmission.  
For instance, GAD67 is distributed throughout the cytoplasm of GABAergic neurons, exists 
predominantly as an active holoenzyme bound to its requisite cofactor pyridoxal phosphate, and 
synthesizes approximately 70% of all GABA present in the brain.  In contrast, GAD65 is 
membrane-bound, localized to nerve terminals and synaptic vesicles, exists primarily as a 
dormant apoenzyme that can be activated rapidly after binding pyridoxal phosphate, and 
synthesizes approximately 30% of all GABA.  Mice deficient in GAD67 suffer from severe cleft 
palate and die shortly after birth5, whereas mice deficient in GAD65 exhibit only a few overt 
abnormalities, including increased anxiety and decreased seizure threshold6-8.  Finally, GAD67 
expression developmentally precedes that of GAD659.  Because of these divergent properties, it 
has been proposed that GAD67 maintains homeostatic levels of GABA and aids synaptogenesis, 
while GAD65 rapidly synthesizes GABA for neurotransmission and adaptation to changing 
metabolic states10.   
After neurotransmitter release, the concentration of GABA in the synaptic cleft is thought 
to reach 1.5-3 mM11-13.  Clearance occurs via rapid reuptake by GABA transporters (GATs) 
located on plasma membranes of both presynaptic neurons and astrocytes.  Four homologous 
GATs have been identified in humans: GAT-1, GAT-2, GAT-3, and BGT-1 (betaine/GABA 
transporter-1).  Of these, GAT-1 and GAT-3 are highly expressed in cerebral cortex – GAT-1 is 
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Table 1: Characteristics of glutamic acid decarboxylase (GAD) isoforms  
 GAD65 GAD67 
Location Terminals/vesicles Whole cell 
% GABA synthesized 30% 70% 
Predominant form Apoenzyme Holoenzyme 
KO phenotype 
Anxiety 
Epilepsy 
Cleft palate 
Perinatal lethal 
Effect of expression in 
excitatory cells 
Excitatory  inhibitory No effect 
Autoantibodies Stiff-person syndrome None 
Effects of phosphorylation 
Activates 
(PKCε/PP2A) 
Inhibits 
(PKA/calcineurin) 
Effects of palmitoylation Targets to presynaptic Not palmitoylated 
 
primarily in presynaptic neuron terminals and GAT-3 primarily in perisynaptic regions of 
astrocytes14.  These two isoforms have similar affinities for GABA, though it has been suggested 
that GAT-3 has a slightly lower Km(GABA)15.  GAT-2 and BGT-1 are expressed at lower levels, 
located in meninges and extrasynaptic locations, and display significantly lower affinities for 
GABA16, 17.  Similar to many other neurotransmitter transporters, the GATs are twelve-
transmembrane domain proteins that co-transport two sodium ions, one chloride ion, and one 
GABA molecule18.  
After neuronal reuptake, GABA is repackaged into synaptic vesicles by the vesicular 
GABA transporter (VGAT), which can transport glycine as well and thus is also known as the 
vesicular inhibitory amino acid transporter (VIAAT).  This is a H+/neurotransmitter antiporter; 
GABA is exchanged for protons flowing down the concentration gradient established by the 
vacuolar H+/ATPase that acidifies vesicles19.  In contrast, after astrocytic reuptake, GABA is 
catabolized and its metabolites re-enter the TCA cycle as described above.  Ultimately, these 
metabolites return to neurons and replenish the supply of glutamate/GABA precursors, but the 
metabolites themselves do not represent the major transported molecules.  Rather, α-ketoglutarate 
is converted to glutamate, which is amidated by glutamine synthetase to form glutamine.  Two 
glutamine transporter complexes have been identified: confusingly, System N mediates efflux 
from astrocytes while System A mediates influx into neurons.  Both complexes consist of 
3
multiple sodium-coupled neutral amino acid transporters (SNATs).  System N is a reversible 
Na+/Gln symporter and H+ antiporter comprising SNAT3 and SNAT5 (also known as SN1 and 
SN2, respectively), while System A is a unidirectional Na+/Gln symporter only and comprises 
SNAT1, SNAT2, and SNAT420.   
GABA, excitation, and inhibition: developmental changes in chloride reversal potential 
As previously discussed, GABA serves as the predominant inhibitory neurotransmitter in 
adult brain; that is, binding of GABA to its receptors causes neuronal hyperpolarization.  
However, hyperpolarization occurs only due to prevailing chloride ion gradients.  Specifically, 
ionotropic GABAA receptors (ligand-gated chloride channels) mediate hyperpolarization because 
the mature resting membrane potential is more negative than the chloride reversal potential.  This, 
in turn, occurs because in mature neurons, [Cl-]out is approximately twenty times greater than    
[Cl-]in.   
Two different transporters are primarily responsible for maintaining the chloride gradient 
in neurons (Figure 1).  NKCC1 is a Na+-K+-2Cl- co-transporter that is driven by sodium and 
potassium gradients and usually increases [Cl-]in, and KCC2 is the neuron-specific splice variant 
of the K+-Cl- co-transporter family that usually decreases [Cl-]in.  Neuronal expression of NKCC1 
peaks during late embryonic and early postnatal stages and subsequently declines through 
development; in adult mice, CNS expression of NKCC1 is largely restricted to glial cells21.  
Conversely, expression of KCC2 remains low or undetectable in most rat brain regions until 
reaching robust adult expression levels during the second postnatal week22.  These changes in 
transporter expression levels correlate with the developmental switch in GABAergic 
neurotransmission from excitatory to inhibitory21.  The mechanisms that alter expression of 
chloride transporters remain incompletely defined, though several trophic factors seem to 
contribute23, 24 and, interestingly, GABA-mediated excitation itself may induce KCC2 
upregulation25.  After the “developmental switch” has occurred, chloride transporter expression 
4
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Figure 1. Developmental changes in chloride reversal potential.
A. The NKCC1 cotransporter is highly expressed in embryonic and postnatal neurons, 
where it co-imports one sodium, one potassium, and two chloride ions, thereby producing 
a high intracellular chloride concentration.  When GABA binds to the GABAA receptor, 
chloride efflux occurs through the ion channel and the neuron becomes depolarized.   B. 
Later in development (by the second postnatal week in rats), NKCC1 expression levels 
decrease and KCC2 cotransporter expression levels increase.  Chloride and potassium are 
extruded from the neuron, leading to lower intracellular chloride concentrations.  When 
GABA binds to the GABAA receptor, chloride influx occurs through the ion channel and 
the neuron becomes hyperpolarized. Other ion channels, such as the voltage-dependent 
calcium channel (VDCC) and chloride channels (CLC2) help to maintain these gradients.
A B
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(and, consequently, GABA-mediated inhibition) usually remains stable.  However, abnormal 
NKCC1/KCC2 expression patterns and depolarizing GABAergic transmission have been 
observed in pathological conditions including epilepsy26, neuropathic pain27, ischemia28, and 
schizophrenia29.  
Types of GABA receptors  
Two classes of receptors mediate GABAergic signaling: ionotropic GABAA receptors 
and metabotropic GABAB receptors (Figure 2).  GABAB receptors are class C guanine 
nucleotide-binding (G-protein) coupled receptors (GPCRs).  Notably, this receptor class also 
includes metabotropic glutamate receptors30.  GABAB receptors are obligate heterodimers 
comprising GABAB1 subunits, which bind agonist, and GABAB2 subunits, which bind and 
activate G-proteins.  In addition to the seven transmembrane domains common to all GPCRs, 
each GABAB receptor subunit contains a large, two-lobed extracellular domain.  GABA binds in 
a cleft between the two lobes and induces a conformational change in which the two lobes of the 
GABAB1 subunit move closer together, which in turn allows a stronger intersubunit association 
between lobes two of the GABAB1 and GABAB2 subunits.  It remains unclear what further 
conformational changes occur in GABAB receptor subunits during signal transduction, but it has 
been established that the three intracellular loops of GABAB2 subunits are necessary for coupling 
to G-proteins.  GABAB receptors specifically activate Gi/o-type heterotrimeric G-proteins; that is, 
they trigger GTP/GDP exchange at the Gαi/o subunit, which dissociates from the other two G-
protein subunits and subsequently inhibits formation of cyclic AMP (cAMP), thereby evoking 
downstream signaling events31.  However, it is the Gβγ complex that ultimately affects neuronal 
inhibition by modulating the function of two different ion channels.  First, the complex activates 
postsynaptic G protein-coupled inwardly-rectifying potassium channels (GIRKs), allowing 
potassium efflux and consequent hyperpolarization.  Additionally, the Gβγ complex inhibits both 
presynaptic and postsynaptic voltage-gated calcium (Cav ) channels.  Presynaptic Cav channel 
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Figure 2. Schematic of GABAA and GABAB receptors.
A. Schematic of an individual GABAA receptor subunit, including an extracellular ligand-
binding N-terminal domain, four transmembrane domains (numbered), and a large intra-
cellular loop between the third and fourth transmembrane domains.  B. Schematic of a 
heteropentameric GABAA receptor.  (N-terminal domains and cytoplasmic loops have been 
omitted for clarity.  When GABA (G, green triangle) binds to a pocket at the interface of 
two N-terminal domains, chloride (Cl, yellow circle) can pass through the ion pore.  C. 
Schematic of two GABAB receptor subunits.  Each is a traditional G-protein coupled recep-
tor with seven transmembrane domains and three intracellular loops.  When GABA (G, 
green triangle) binds to the N-terminal domain, the subunits dimerize and activate Gi/o-
type G-proteins.  The G(βγ) complex activates inwardly-rectifying potassium channels 
(GIRKs), causing potassium efflux and neuronal hyperpolarization.
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inhibition prevents vesicle fusion and neurotransmitter release, while postsynaptic Cav channel 
inhibition impairs action potential generation32.  Thus, GABAB receptors mediate three different 
forms of slow neuronal inhibition. 
In contrast to GABAB receptors, GABAA receptors are chloride ion channels belonging to 
the Cys-loop receptor superfamily of pentameric ligand-gated ion channels (LGIC), which also 
includes nicotinic acetylcholine receptors (nAChRs), 5-hydroxytryptamine type 3 receptors (5-
HT3Rs), and glycine receptors (GlyRs)33.  GABAA receptor pentamers are assembled from an 
array of nineteen different subunit subtypes that confer diverse functional properties but contain 
common structural motifs.  All GABAA receptor subunits comprise a large, N-terminal, 
extracellular ligand-binding domain; four α-helical transmembrane domains, one of which lines 
the ion pore; and, between the third and fourth transmembrane domains, a large intracellular loop 
that contains many motifs for post-translational modification and binding of accessory proteins.  
GABAA receptors will be the focus of this dissertation and, as such, will be discussed in greater 
depth in subsequent sections. 
It is worth noting that, for many years, a subset of GABAA receptors was considered to 
be a separate class of “GABAC receptors”.  This classification was justified by the unusual 
pharmacology, physiology, and distribution of the subunits composing these receptors34.  
However, current consensus disfavors the use of GABAC and, accordingly, this dissertation will 
refer to all GABA-gated LGICs as GABAA receptors from this point forward. 
Molecular biology of GABAA receptors 
Among neurotransmitter receptors, GABAA receptors are remarkable for their diversity.  
In mammals, seven subunit families with nineteen subunit subtypes have been identified: α1-6, 
β1-3, γ1-3, δ, ε, θ, π, and ρ1-3 (Figure 3A).  Amino acid sequence identity among subunits ranges 
from about 30-50% between families to about 60-80% within families (Tyndale, Olsen, and 
Tobin, 1995).  Gene localization and phylogenetic tree analysis have indicated that this 
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�
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Figure 3. GABAA receptor subunit genes.
A. Dendrogram of GABAA receptor subunit genes.  Lines are proportional to the diver-
gence between each gene.  Note that families are clustered, with the ε subunit being most 
similar to the γ subunit family and the θ subunit being most similar to the β subunit family. 
The δ and π subunit genes, which are not found in clusters, are most similar to one another 
(though still very divergent). B. Schematic of the chromosomal locations of the GABAA 
receptor gene clusters. Chromosomes are indicated to the left of each panel and arrowheads 
indicate the direction of transcription. Line length is proportional to the distance between 
genes, which is indicated (in kilobases) below the panels.  
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complexity largely derives from repeated duplication of an ancestral gene cluster35.  Most 
GABAA receptor subunits exist in β-α-(α)-γ gene clusters of varying size, where the β subunit 
genes are transcribed in the opposite direction as the α and γ subunit genes (i.e., the β and α 
subunit transcriptional units are oriented head-to-head) (Figure 4B).  In humans, the β1, α4, α2, 
and γ1 subunit genes are located on chromosome 4p1236; the β2, α6, α1, and γ2 subunit genes are 
located on chromosome 5q3437; and the β3, α5, and γ3 subunit genes are located on chromosome 
15q11-1338, 39.  Furthermore, the human Xq28 chromosome contains a θ-α3-ε cluster; both the 
gene orientation and phylogeny suggest that this represents another duplication of the ancestral 
cluster, with the rapidly-evolving θ and ε subunits replacing β and γ subunits, respectively40, 41.  
The remaining five subunit genes (δ, π, and ρ1-3) do not occur in comparable clusters.  Like the 
β2, α6, α1, and γ2 subunit genes, the π subunit gene is located on the long arm of chromosome 5, 
but approximately 9 Mb telomeric to the γ2 subunit42.  The δ subunit is located on chromosome 
1p3643; the ρ3 subunit is located on chromosome 3q11-13, and the ρ1 and ρ2 subunits are located 
on chromosome 6q14-2144.  The corresponding mouse and rat chromosomal locations are listed in 
Table 2.   
Expression patterns of GABAA receptor subunits 
Although GABAA receptors occur throughout the brain, receptor isoforms are likely to 
vary greatly because each subunit subtype has a unique temporal and spatial expression pattern.  
It must be noted, however, that it is the exception rather than the rule for brain regions to be 
entirely devoid of a given subunit subtype.  Furthermore, by far the most comprehensive 
expression pattern studies have been conducted in rat brain, and expression patterns are similar 
but not identical among species.  Consequently, the summary below serves as an overview of the 
most distinctive expression patterns rather than a complete list. 
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Temporal regulation of subunit expression 
The α subunit subtypes appear to undergo similar changes in expression levels in 
developing rats45-47, monkeys48, and humans49.  Generally, α1 subunit expression is undetectable 
in early embryonic stages and steadily increases until α1 subunits become the predominant α 
subunit subtype in adult brain.  In contrast, α2-6 subunit expression levels peak at various points 
during prenatal and early postnatal life and decline thereafter, though expression of each subtype 
remains high in select regions of adult brain.  Expression of α2 and α3 subunits is particularly 
strong in embryonic brain.  Among β and γ subunits, β1, γ1, and γ3 subtype levels mostly 
decrease throughout development and are quite low in adult organisms.  The β2 and γ2 subtypes 
display the opposite pattern; they continually increase and ultimately become the predominant 
subtypes of their respective families in most adult brain regions.  The β3 subtype has more 
dynamic expression patterns; its expression increases during embryonic and early postnatal stages, 
then decreases overall but remains even higher than β2 subunit expression in certain areas.  No δ 
subunit mRNA is present in early embryonic brain, and expression levels increase until adulthood.  
Although few systematic studies of ε and θ subunit temporal expression patterns have been 
conducted, it appears that the distribution of both subunits becomes more restricted over time 
(therefore, levels decrease overall), but in regions that retain ε and θ expression into adulthood, 
levels remain constant or increase from late embryonic stages onward40.  Developmental changes 
in expression of π subunits have not been studied to date.  Finally, ρ(1-3) subunit levels appear to 
increase during embryonic stages, peak within in the first two postnatal weeks, and then decline 
until adulthood50, 51. 
Spatial regulation of subunit expression 
Once subunit levels stabilize in the adult organism, each displays a characteristic spatial 
distribution (though some changes do still occur throughout life52).  Multiple studies have used 
techniques including in situ hybridization45, 53, 54, quantitative PCR51, and immunohistochemistry47, 
12
55-57 to characterize these expression patterns at both regional and cellular levels in rat brain.  
Within the α subunit family, α1 subunits are the most abundant subtype.  They are expressed at 
extremely high levels throughout most nuclei, cell types, and subcellular regions in cortex, 
hippocampus, basal ganglia, thalamus, hypothalamus, midbrain, cerebellum, brain stem, and 
cranial nerve nuclei.  α2 subunits have a slightly more restricted but still widespread distribution; 
they have been detected throughout cortex, striatum, amygdala, hypothalamus, raphe nucleus, 
superior colliculus, and spinal cord, as well as in restricted regions/nuclei of thalamus, 
hippocampus, and cerebellum.  α3 subunit expression patterns are very similar to those of α2 
subunits, though they are somewhat more restricted.  Presence of α3 subunits is particularly 
notable within lower cortical layers, basal ganglia, thalamic reticular nucleus (but not motor 
thalamus), anterior and lateral hypothalamus, midbrain, medulla, and cranial nerve nuclei.  In 
most brain regions, α4 subunit levels are lower than those of all preceding α subunits; however, 
high levels are present in lower cortical layers, dentate gyrus, basal ganglia, and motor thalamus.  
Significant α5 subunit expression exists in olfactory bulb, lower cortical layers, hippocampus, and 
some midbrain and hypothalamic nuclei.  Notably, subcellular localization of α5 subunits is 
almost exclusively extrasynaptic.  Finally, α6 subunits are found exclusively within the cerebellar 
granule cell layer.  Despite its low overall levels, β1 subunits are widely expressed through cortex, 
lateral septum, amygdala, thalamus, midbrain, medulla, and cranial nerve nuclei.  Furthermore, 
particularly high β1 subunit expression levels are found in hippocampus, thalamic reticular 
nucleus, and hypothalamic supraoptic nucleus.  β2 subunits are nearly ubiquitously expressed; 
notable exceptions include hippocampal granule cell layer, thalamic reticular nucleus, superior 
olive, and some cranial nerve nuclei.  β3 subunits are also widely expressed, and regions with 
very high β3 subunit levels frequently have lower β2 subunit levels (though cerebellar granule 
cell and cortical layers contain high levels of both).  As such, β3 subunit levels are high in 
thalamic reticular nucleus and throughout hippocampus and hypothalamus.  γ1 subunits are 
sparsely expressed and found almost exclusively in globus pallidus, substantia nigra, central and 
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medial amygdaloid nuclei, and superior colliculus.  In contrast, γ2 subunits are perhaps the most 
universally expressed subtype, as they have been detected in every brain region studied to date.  
Notably, different distributions have been reported for the short (γ2S) and long (γ2L) γ2 subunit 
splice variants, with γ2S subunits predominant in cerebral cortex, hippocampus, and olfactory 
bulb, and γ2L subunits predominant in medulla, inferior colliculus, and cerebellum58.  In some 
ways, γ3 subunit expression patterns combine the characteristics of the other two γ subunits; γ3 
subunit expression is widespread but sparse, with the highest levels reported in substantia nigra, 
hypothalamus, and raphe nucleus.  The highest levels of δ subunits are found in cerebellar granule 
cells, dentate molecular layer, and throughout the thalamic nuclei.  On a subcellular level, they 
are exclusively extrasynaptic.  The ε and θ subunits have remarkably overlapping distributions 
with the exception of cortex, where ε but not θ subunits have been detected in early life only40.  In 
adult animals, they have both been detected in substantia nigra pars compacta, medial and central 
thalamus, amygdala, and raphe nucleus.  Additionally, levels of both ε and θ subunits are 
particularly high in locus coeruleus, hypothalamus, and monoaminergic neurons in general59-61.  
In brain, π subunits have been detected only at low levels in hippocampus, temporal cortex, and 
ventral pallidum62, 63.  However, they are abundant in peripheral tissues including taste buds64, 
lung65, pancreas66, 67, prostate62, breast68, and uterus62.  Interestingly, changes in π subunit 
expression levels have been associated with cancers of many of those organs.  For several years, ρ 
subunits were thought to be expressed almost exclusively in retina69, 70; indeed, ρ subunit-
containing receptors were classified as “GABAC receptors” until recently, in part because of their 
isolated and sparse expression in brain.  However, studies using quantitative RT-PCR as well as 
in situ hybridization have since detected all three ρ subunits in multiple brain regions.  ρ2 
subunits are the most abundant subtype and have been found in hippocampus (CA1), lateral 
geniculate nucleus, superior colliculus, basal ganglia, pituitary, substantia nigra pars compacta, 
visual cortex, and cerebellum50, 71-74.  The ρ1 and ρ3 subunits are also expressed (albeit at lower 
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levels) primarily in hippocampus and superior colliculus.  Clearly, a common theme among ρ 
subunits is their expression in areas related to visual signaling. 
Finally, it should be noted that many chromosomally clustered subunits also display 
overlapping expression patterns.  This fact has led researchers to propose that clustering 
facilitates coordinate expression, but little evidence exists to corroborate that theory.  Indeed, very 
little is known to date about the elements regulating transcription of GABAA receptor genes75.  
Because selective subunit expression constitutes the first opportunity for neurons to control which 
of the myriad possible GABAA receptor isoforms will assemble, this area remains ripe for future 
study.   
Biogenesis of GABAA receptors 
The processes of synthesis, folding, oligomerization, and intracellular trafficking provide 
additional control over the distribution of GABAA receptor isoforms.  As such, significant 
research effort has been expended to identify elements regulating receptor biogenesis.  In addition 
to typical post-translational modifications, these elements include specific sequences and 
structural motifs within subunits that contribute to selective oligomerization as well as numerous 
associated proteins that escort isoforms along their intracellular journeys.   
Transcription and translation 
Human GABAA receptor subunit mRNAs contain 9-10 coding exons (9-13 total exons), 
and several subunits undergo alternative splicing.  Notable examples in which both isoforms are 
functional and widely expressed include α1, α2, and α5 subunits, which have multiple 5’-UTRs; 
β3 subunits, which have alternative first exons and 5’ UTRs that produce different signal and 
mature peptides; and β2 and γ2 subunits, which have “short” and “long” variants due to 
alternative splicing in the M3-M4 intracellular loop76.  Additionally, α3 subunits undergo 
developmentally-regulated adenosine-to-inosine RNA editing77, 78.  
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Endoplasmic reticulum: folding and oligomerization  
All GABAA receptor subunits are predicted to contain signal peptides79 and to be co-
translationally inserted into the membrane of the endoplasmic reticulum (ER)80, where they fold 
and oligomerize in a process that depends heavily upon ER-resident chaperones such as 
immunoglobulin heavy-chain binding protein (BiP) and calnexin81.  As with other Cys-loop 
receptors, the process of subunit oligomerization occurs quickly but inefficiently; though 
oligomers may appear within five minutes, it is likely that 70% of subunits are degraded without 
ever being incorporated into a pentameric receptor.  Furthermore, the full process of assembly 
and trafficking is quite slow, and receptors may not appear on the cell surface until several hours 
after transfection80, 82.   
The vast majority of neurons simultaneously express many subunit subtypes.  
Consequently, they presumably should have some sort of hierarchical yet flexible assembly 
mechanism that favors association between certain subunits and, ultimately, directs the 
incorporation of assembly intermediates (e.g. dimers, trimers) into full receptors.  Some clues 
have been provided by knockout (KO) mouse studies; for instance, α6 subunit KO mice have 
reduced δ subunit expression, suggesting that these two subunits preferentially assemble.  
Multiple studies have identified amino acid sequences and individual residues that are important 
for specific subunit interactions83, 84.  Such sequences have been found in α185-89, α685, β388-91, γ288, 
92, and γ393 subunits, primarily in the large N-terminal domain, though there have been some 
reports of assembly sequences in the M3-M4 loop94, 95 (Table 3 and Appendix 1).  Interestingly, 
constructs lacking the transmembrane domains were also capable of oligomerization96.  Although 
homology modeling based on nAChR97 and acetylcholine binding protein (AChBP)98 has 
provided some insight into the structural basis of these interactions (Figure 4), many sequences 
seem not to contact adjacent subunits; rather, they may simply facilitate oligomerization by 
encouraging proper protein folding.  (Note that most sequences were identified using rodent 
subunits and numbered from the mature peptide.  In the following section and in Table 3, 
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Table 3. Sequences and residues important for subunit oligomerization. 
Subunit Residues* Interacts with Comments 
α1, α6 86-95 (esp. Q95) β3  does not affect assembly with γ2  
α1  108-128 γ2(130-143) does not affect assembly w/ β3  
α1 82-96 β3 sufficient for co-IP of β3 not sufficient for co-IP of α1 or γ2    
α1 A136 β3, γ2  
β3  G196,K198,E204,R205 self? γ2? 
necessary/sufficient for surf exp of β3 
and β3γ2  
not sufficient for spontaneous activity 
β3  77-91 α1 
removal: α1 IPs 30% of β3 and γ2 IPs 
similar  
% β3 (compared to co-IP of WT β3) 
β3 101-114 (esp. 110-114) α1 
does not affect assembly w/ γ2  
on (-) side of β3; interacts w/ (+) side of 
α1 
γ2  130-143 α1 does not affect assembly w/ β3  
γ2 122-131 α1, β3  
γ2 106-120 α1(mainly) 
when α1β3γ2(mut) transfected and α1 
IPed,  
20% of γ2, 54% α1, and 65% β3 
precipitated 
γ3  86-100 α1, β3  γ3(86-94) binds slightly to α1 
γ2 T164, P166 β3 predicted to be on (-) face (α1 interface),  but only affects oligomerization with β3 
ε N229, K231, E233, K237  
(homologous to β3 GKER) α2? β3? 
may affect whether 1 or 2 ε  
incorporated into α2β3ε 
*All residue numbers include the signal peptide. 
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numbering has been adjusted to correspond to the immature human protein sequences used in 
Appendix 1.) 
Within the α subunit family, assembly sequences have been identified in α1 and α6 
subtypes.  Mutating either of two invariant tryptophans, W97 and W116, prevented formation of 
the β2(-)/α1(+) interface, completion of the pentamer, and trafficking to the cell surface85.  An α6 
splice variant (α6S) lacking residues 76-86 (present in all other α subunits, including α6L, the  
most commonly expressed variant of α6) could not access the cell surface when co-transfected 
with β3 and γ2 subunits.  This led to the discovery that α subunit residues 86-95, particularly Q95, 
were important for oligomerization of α1 and β3 subunits86.  Two subsequent studies confirmed 
that overlapping sequences – 85-96 and 82-96 of the α1 subunit – were necessary for assembly of 
αβ receptors; moreover, one established that R66 apparently allows α1 subunits to discriminate 
among β subunits, because that residue was critical for formation of α1β2 but not α1β1 or α1β3 
receptors88, 89.  Regarding α1-γ2 oligomerization, residues 108-128 of the α1 subunit were found 
to interact directly with residues 130-143 of the γ2 subunit but not with β3 subunits87, 92.  Finally, 
the α1(A136C) subunit mutation impaired α1 subunit assembly with both β3 and γ2 subunits99. 
Within the β subunit family, specific assembly sequences have been found only in the β3 
subtype.  Unlike most other GABAA receptor subunits, β3 subunits can reach the cell surface as 
homopentamers, and the residues G196, K198, E204, and R205 were found to be necessary and 
sufficient for β subunit homo-oligomerization and surface expression90.  All other studies of β3 
subunit assembly signals have focused upon the more common heteromeric receptors.  Residues 
77-91 of the β3 subunit formed one of the signals found to be important for heteromeric assembly; 
replacing this sequence with the homologous sequence from the ρ1 subunit strongly impaired 
association of the β3 and α1 subunits.  In α1β3γ2 co-transfections, residues 76-89 of the β3 
subunit, particularly residues 85-89, were similarly important for assembly with α1 but not with 
γ2 subunits.  Radioligand binding studies and comparison with the AChBP structure indicated 
that these residues contribute to the β3(-)/α1(+) interface91.   
18
A B
C D E
Figure 4. Identified assembly sequences in α, β, and γ GABA
A
 receptor subunits.
A. Homology model of a ternary αβγ GABA
A
 receptor isoform viewed from the extracellu-
lar N-terminal domain.  Subunits were threaded in the order γ-β-α-β-α (anticlockwise in 
this view).  α subunits are pink, β subunits are pale blue, and γ subunits are pale green.  
Sequences shown to interact with α subunits are colored red, sequences shown to interact 
with β subunits are dark blue, and sequences shown to interact with both α and β subunits 
are purple. Panels B-E are side views (from the membrane side) of this homology model.  
B. View of the γ-β subunit interface.  C. View of the β-α subunit interface.  D. View of the 
α-β subunit interface.  E. View of the α-γ subunit interface. 
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Assembly sequences have also been studied in the γ subunit family.  As previously 
mentioned, residues 130-143 of the γ2 subunit interacted directly with residues 108-128 of the α1 
subunit, while residues 122-131 of the γ2 subunit interacted with the β3 subunit87, 92.  Residues 
106-120 of the γ2 subunit are also important for formation of the α1-γ2 interface; when added to 
an otherwise non-assembling α1 peptide, residues 106-120 of the γ2 subunit were sufficient to co-
immunoprecipitate the α1 subunit but not the β3 subunit88.  Several γ2 subunit point mutations 
have also been observed to affect assembly – mutating T164 and P166 interfered specifically with 
the formation of γ2-β3 intermediates99, and the epilepsy-associated γ2 mutation R82Q was 
reported to impair binding to β2 subunits100.  An assembly sequence has also been reported in the 
γ3 subunit; residues 86-100 of the γ3 subunit are sufficient to induce binding to both the α1 and 
β3 subunits93. 
It should be noted that many of these sequences lie in homologous regions. Indeed, the 
assembly sequences of α1 (82-96), β3 (77-91), and γ2 (106-120) subunits were originally 
investigated because they are homologous to the previously-identified γ3 subunit (86-100) 
sequence.  Additionally, it has been suggested that residues on the ε subunit (N229, K231, E233, 
K237) that are homologous to the β3 subunit residues mediating homomeric assembly may 
influence whether one or two ε subunits are incorporated into α2β3ε receptors101.   
Despite this wealth of information pointing to mechanisms that promote selective 
oligomerization, to date there has been no direct demonstration of the order of GABAA receptor 
subunit assembly.  The nAChR assembly intermediates were detected nearly two decades ago, 
and their order of oligomerization was subsequently determined using radiolabeled compounds 
known to bind only at specific subunit interfaces.  However, when similar studies were attempted 
with GABAA receptors, only pentamers could be isolated from rat brain lysate or transfected 
fibroblasts cultured at 37˚C.  When fibroblasts were instead cultured at 25˚C, dimers could be 
detected but no order of assembly could be determined96.  This line of research has been largely 
abandoned in recent years and remains a potentially rich area for future study. 
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Exit from the endoplasmic reticulum and transport through the Golgi apparatus 
Subunits that cannot form pentamers in the ER are shuttled to the proteasome and 
degraded, while successfully assembled receptors enter the secretory pathway.  From this point 
forward, biogenesis depends heavily upon GABAA receptor-associated proteins, as illustrated in 
Figure 5 and summarized in Table 4.  ER exit is facilitated by PLIC-1 and PLIC-2 (proteins that 
link integrin-associated protein with the cytoskeleton), which contain a ubiquitin-like N-terminal 
domain and a ubiquitin-associated C-terminal domain102.  The latter domain interacts with the 
intracellular loops of α and β subunits103, inhibits the degradation of polyubiquitinated subunits104, 
and thereby facilitates GABAA receptor surface expression.  It has been established that PLICs 
increase surface expression without affecting endocytosis104; however, they were detected in 
Golgi, cisternae, and other intracellular vesicles of neurons103, suggesting they may play 
additional roles in GABAA receptor trafficking. 
Once in the Golgi apparatus, GABAA receptor subunits undergo many post-translational 
modifications facilitated by associated proteins.  One of the most common Golgi modifications is 
palmitoylation, the formation of a reversible thioester linkage between a 16-carbon palmitic acid 
and a cysteine residue.  Palmitoylation primarily serves to promote stable membrane attachment 
(and, potentially, targeting to lipid rafts), but it may also regulate trafficking, stability, and 
protein-protein interactions105.  The majority of protein palmitoylation is accomplished by 
members of the DHHC (Asp-His-His-Cys) family of zinc-finger proteins106; to date, 25 members 
of this family have been identified in humans107.  DHHC3, which is also known as GODZ (Golgi-
specific DHHC Zinc-finger protein), interacts with and palmitoylates cysteines located in the M3-
M4 loop of γ1-3 subunits.  The GODZ binding site has been mapped to residues 337-350 of the 
γ2 subunit, which are highly conserved within the γ subunit family108.  Notably, this sequence 
contains four cysteine residues that could accept palmitate groups, though the specific 
palmitoylation site(s) have not been identified.  When neuronal GODZ was eliminated using 
shRNA, mIPSC amplitude and frequency were reduced, as were the numbers of γ2 subunit 
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immunoreactive puncta.  Moreover, neighboring GAT- and VIAAT-positive neurons tended not 
to form synapses with the transfected neurons109.  Taken together, these data indicate that GODZ 
palmitoylates γ2 subunits in the Golgi apparatus and facilitates plasma membrane insertion of γ2 
subunit-containing receptors. 
Trans-Golgi network and beyond 
The list of proteins that bind to GABAA receptors in secretory vesicles has grown 
immensely over the past decade.  Arguably, the best-characterized of these is the aptly-named 
GABAA receptor-associated protein (GABARAP).  It is a 14 kDa ubiquitin-like protein belonging 
to the microtubule-associated protein family, which also includes three close GABARAP 
homologues called GABARAP-like proteins (GABARAPL1-3).  All are widely expressed, but 
GABARAPL1 (also known as GEC1) levels are somewhat enriched in brain.  These proteins are 
cytosolic, but they associate with intracellular lipid membranes through a C-terminal 
phospholipid110.   
The GABARAP crystal structure revealed an N-terminal microtubule-binding domain 
and two hydrophobic pockets that bind numerous proteins, including the cytoplasmic loop of 
GABAA receptor γ subunits111-114.  In hippocampal neurons, native GABARAP 
immunofluorescence was seen throughout the soma and processes; however, it appeared to 
colocalize with γ2 subunits only in the Golgi apparatus and intracellular vesicles115.  When 
GABARAP was overexpressed in the same system, γ2 subunit surface levels increased.  
Interestingly, when γ2 subunit cDNA was transfected in excess (i.e., α1:β2:γ2 at 1:1:10), 
GABARAP appeared to have no effect, suggesting that GABARAP might help determine 
receptor stoichiometry by promoting the formation of ternary α1β2γ2 receptors over binary α1β2 
receptors116.  The combination of GABARAP-γ2 intracellular colocalization and GABARAP’s 
ability to bind microtubules suggests that GABARAP facilitates surface expression of γ2 subunit-
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Figure 5. Schematic of a GABAergic synapse.
Presynaptic neuron (top), glial cell (right), and postsynaptic (bottom) neurons at a 
GABAergic synapse.  GABA transport and GABAA receptor-associated proteins are illus-
trated.  Note that the synaptic GABAA receptor represents isoforms including 
α(1,2,3,4,6)βγ and the extrasynaptic GABAA receptor represents isoforms including α5βγ 
and α(1,4,6)βδ.  
ER = endoplasmic reticulum
PLIC = Proteins that Link Integrin-associated protein with the Cytoskeleton
GODZ = Golgi-specific DHHC Zinc-finger protein
GABARAP = GABAA Receptor-Associated Protein 
NSF = N-ethylmaleimide-Sensitive Factor 
PRIP = Phospholipase-C-Related catalytically Inactive Protein
PP1α = Protein Phosphatase 1α
BIG2 = Brefeldin-A-Inhibited GDP/GTP exchange factor 2
GRIF-1 = GABAA Receptor-Interacting Factor-1
AP2 = clathrin-Adaptor Protein 2
HAP1 = Huntingtin-Associated Protein 1
VIAAT = vesicular inhibitory amino acid transporter
GAD = Glutamic Acid Decarboxylase
GAT = GABA Transporter
Glu = glutamate
Gln = glutamine
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containing receptors by promoting exit from the Golgi apparatus and vesicular transport toward 
the plasma membrane.   
Many of GABARAP’s other binding partners suggest trafficking effects beyond simple 
microtubule association.  For instance, GABARAP binds to N-ethylmaleimide-sensitive factor 
(NSF), which disaggregates SNARE proteins via ATP hydrolysis and is necessary for 
intracellular membrane fusion.  NSF also binds to the cytoplasmic loop of β1-3 subunits and 
decreases GABAA receptor cell surface levels by approximately 20% in both transfected 
fibroblasts and cultured neurons, apparently by regulating receptor insertion rather than 
endocytosis117.  Because the β subunit binding site (β3 residues 419-439) contains a 
phosphorylation site that can affect surface expression, it has been proposed that NSF could have 
different effects on GABAA receptor trafficking depending on whether it binds to GABARAP or 
β subunits themselves.  
Similarly, Phospholipase-C-Related catalytically Inactive Proteins (PRIP1, PRIP2) bind 
both to GABARAP and to the intracellular domain of GABAA receptor β and (weakly) γ2 
subunits.  It is unclear if PRIPs act as a bridging protein between GABARAP and β subunits, but 
they do compete with γ2 subunits for binding to GABARAP118.  When the PRIP-β subunit 
association was disrupted by either a PRIP-binding peptide or PRIP gene deletion, surface 
expression of γ2 subunit-containing GABAA receptors declined119.  Interestingly, there was a 
concomitant increase of α1 and β3 subunit surface levels in the PRIP-KO mice, suggesting that 
PRIPs may help determine receptor composition and/or stoichiometry120.  PRIPs also inactivate 
Protein Phosphatase 1α (PP1α), which can dephosphorylate sites on β subunits that affect both 
function and internalization of GABAA receptors121.  In summary, PRIP-1 and -2 have extremely 
complex effects on receptor trafficking and function and can act both through and independent of 
their association with GABARAP. 
Brefeldin-A-Inhibited GDP/GTP exchange factor 2 (BIG2) is another GABAA receptor-
associated protein that is primarily localized to the Golgi apparatus.  As its name suggests, BIG2 
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is a guanine nucleotide exchange factor (GEF) that catalyzes GDP/GTP exchange on the small G-
protein ADP-Ribosylation Factor (ARF)122, 123.  Activation of ARF by GDP/GTP exchange is 
required for membrane budding in the Golgi apparatus, which allows proteins to progress through 
the trans-Golgi network and the exocytotic pathway.  In addition to its GEF functions, BIG2 
binds with high affinity to the intracellular loops of β subunits.  When this interaction was 
disrupted, GABAA receptors accumulated in the perinuclear ER, and when exogenous BIG2 was 
overexpressed, GABAA receptor surface expression increased124.  Although the highest BIG2 
levels were detected in the Golgi apparatus, GABAAR/BIG2 colocalization also occurred in 
somatic and dendritic vesicles but not at synapses.  Thus, it seems likely that BIG2 facilitates 
multiple steps in GABAA receptor forward trafficking. 
Yet another protein that facilitates intracellular forward trafficking is GABAA Receptor-
Interacting Factor-1 (GRIF-1, also known as TRAK2), a kinesin-associated protein that binds to 
the β2 subunit cytoplasmic loop.  GRIF-1 is soluble and thus widely distributed throughout the 
cytoplasm, and it colocalizes with β2 subunits in intracellular vesicles125-127.  The exact 
mechanism by which GRIF-1 promotes GABAA receptor forward trafficking has not been 
determined, but its kinesin-binding abilities obviously suggest that it could facilitate vesicle 
movement along the cytoskeleton.  Interestingly, mice lacking the closely-related gene TRAK1 
displayed hypertonia and reduced GABAA receptor expression. 
Plasma membrane targeting and maintenance 
Studies have suggested that Akt-mediated phosphorylation of β3 subunits may promote 
de novo receptor surface delivery128, 129 and that insertion is primarily extrasynaptic130, but little 
else is known about factors regulating plasma membrane fusion of vesicles containing newly-
synthesized GABAA receptors.  However, it is clear that once GABAA receptors reach the plasma 
membrane, they can be localized to synaptic or extrasynaptic sites.  In either case, the receptors 
often form clusters with the help of scaffolding proteins.  Postsynaptic clustering is mediated by 
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gephyrin, a multi-domain scaffolding protein capable of oligomerizing with itself and with 
GABAA and glycine receptors131.  Gephyrin likely assumes a hexagonal lattice structure, as its N-
terminal domain forms trimers and its C-terminal domain forms dimers, and the lattice links to 
the cytoskeleton through a central tubulin-binding domain132, 133.  However, the gephyrin-
cytoskeleton interaction is likely much more complex, as gephyrin has been shown to interact 
with regulators of microfilament dynamics including profilin I and II134.  Despite gephyrin’s 
ubiquitous presence at inhibitory synapses135, years of investigation failed to identify a direct 
interaction between gephyrin and native GABAA receptor subunits.  The interaction site was long 
assumed to be in the γ2 subunit, as cultured neurons from γ2 subunit KO mice lacked 
postsynaptic GABAA receptor and gephyrin clusters136, 137 and transfection of various γ2 subunit 
domains affected clustering138.  However, recent studies have identified direct interactions 
between gephyrin and α1-3 subunits139.  In any case, it is clear that gephyrin-mediated 
postsynaptic clustering of GABAA receptors is important but not absolutely required for normal 
inhibitory transmission and synapse development138, 140. 
Extrasynaptic GABAA receptors can also form clusters.  Interestingly, most of these 
contained the relatively rare α5 subunit together with the usually-synaptic γ2 subunit, and clusters 
persisted in the absence of gephyrin141-143.  A yeast two-hybrid (Y2H) screen using the 
intracellular loop of α5 subunits as bait identified the binding partner radixin, one member of the 
Ezrin-Radixin-Moesin (ERM) protein family known to crosslink actin and plasma membrane 
proteins144.  In rat brain, α5 subunit-containing receptors and radixin colocalized in puncta, 90% 
of which were extrasynaptic.  In contrast, radixin colocalized only slightly with gephyrin and/or 
VIAAT.  When radixin levels were reduced in by antisense oligonucleotide injection, α5 (but not 
α1) subunit clusters nearly disappeared from cultured hippocampal neurons.  Similarly, brain 
slices from radixin KO mice had greatly reduced α5 subunit clustering.  Taken together, these 
data suggest that the majority of clustered extrasynaptic GABAA receptors contain α5 subunits 
and that clusters are maintained by radixin crosslinking with actin cytoskeleton. 
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Endocytosis and post-endocytic sorting 
Most neuronal GABAA receptors are internalized via clathrin-mediated endocytosis, and 
the clathrin-Adaptor Protein 2 (AP2) plays a key role in targeting receptors to clathrin-coated 
pits145.  AP2 is a tetramer comprising α, β2, σ2, and μ2 subunits; the latter binds to the 
intracellular loops of β1-3 and γ2 GABAA receptor subunits.  Several AP2 binding motifs have 
been identified; various regions of μ2 subunits can bind basic, dileucine, or tyrosine-containing 
hydrophobic YXXφ sequences on target proteins146.  Each of these motifs is important for AP2-
mediated endocytosis of GABAA receptors.  AP2 has been demonstrated to bind to β1-3(367LL368), 
β3(405RRR407), and γ2(414YECL417) subunit sequences147-149.  In each case, phosphorylation of 
tyrosines within or serines near the binding motif impairs AP2-GABAA receptor association, 
thereby reducing receptor endocytosis and increasing inhibitory transmission.  It should be noted 
that the role of phosphorylation in GABAA receptor expression, trafficking, and physiology is 
considerably more complex, but a comprehensive exploration of these effects would require a 
dedicated review. 
After endocytosis, GABAA receptors can be recycled to the cell membrane or targeted for 
lysosomal degradation.  Huntingtin-Associated Protein 1 (HAP1) plays a key role in this decision.  
HAP1, which bears polyglutamine repeats in Huntington disease, is a cytosolic protein that binds 
to kinesin family motor protein 5 (KIF5), thereby linking other binding partners to the 
cytoskeleton and intracellular trafficking machinery150.  With regard to GABAA receptors, HAP1 
binds the intracellular loop of β subunits, inhibits lysosomal degradation, and promotes receptor 
recycling.  In cultured neurons, HAP1 overexpression increased GABAA receptor surface 
expression and mIPSC amplitude151.  Furthermore, the physiological importance of HAP1 was 
demonstrated by two recent studies.  First, HAP1 is abundantly expressed in hypothalamus, and 
expression levels were recently shown to be directly correlated with food intake (i.e., decreasing 
HAP1 expression led to decreased feeding)152.  Finally, the GABAA 
receptor/HAP1/KIF5/microtubule complex was disrupted in the HD mouse model.  
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Unsurprisingly, this led to reduced GABAA receptor surface expression and GABAergic 
neurotransmission, which might suggest a mechanism for neuronal excitotoxicity in Huntington 
disease150. 
Tertiary and quaternary structure of GABAA receptors 
Thus far, we have discussed the major structural elements of GABAA receptors and their 
component subunits.  The receptor comprises five subunits, each of which includes a large, 
extracellular N-terminal domain containing assembly signals; four transmembrane domains (M1-
M4); and a large intracellular loop between the third and fourth transmembrane domains (M3-M4 
loop) containing binding sites for many receptor-associated proteins.  However, to understand the 
mechanisms of ligand binding and channel gating, it is necessary to provide a more detailed 
description of receptor structure. 
To date, no GABAA receptors have been crystallized.  Accordingly, homology models 
have used the structures of nAChRs97, 153 and AChBP (homologous to the extracellular domain of 
the nAChR)98 solved within the past decade.  More recently, prokaryotic LGICs have also been 
crystallized154-156; however, all of these channels are cation-selective and accordingly were not 
ideal for modeling GABAA receptors, particularly in certain transmembrane domains157, 158.  The 
first structure of an anionic Cys-loop receptor, the glutamate-gated chloride channel of C. elegans 
(GluCl) was reported in 2011159.  All original homology models presented in this dissertation use 
the GluCl template, but prior studies obviously did not. 
Major structural elements are common to all crystallized Cys-loop receptors (Figure 6).  
Each subunit is approximately 160Å long (extracellular, transmembrane, intracellular) and about 
40Å wide.  The extracellular N-terminal domain, which contains the binding sites for most 
ligands, comprises a distal α helix and ten β strands linked by loops.  The β strands combine to 
form a β sandwich; strands 4, 7, 9, and 10 form an outer sheet while the rest form an inner sheet 
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facing the ion channel pore (see Appendix 1).  These two sheets are linked by the eponymous 
Cys-loop and can pivot relative to one another during gating. 
The aforementioned secondary and tertiary structure elements were found in all Cys-loop 
receptor crystal structures.  However, the GABAA receptor N-terminal domain structure is also 
widely discussed in terms of “loops” A-F.  These “loops” do not necessarily consist of the linkers 
between consecutive β-sheets; rather, they represent regions experimentally determined to be 
accessible to ligands.  Most studies defining these loops used the scanning cysteine accessibility 
mutagenesis method (SCAM), in which individual amino acids are systematically mutated to 
cysteine, exposed to sulfhydryl-reactive compounds, and then assessed for reagent binding and 
receptor function160.  Clearly, this approach is limited by the possibility that the point mutations 
themselves may perturb receptor conformation; however, it provides a useful approximation in 
the absence of a crystal structure.  Thus, loops A-F have been defined as illustrated in Table 5 and 
Appendix 1 of this dissertation.  Briefly, in the primary structure, loops occur in the order D-A-E-
B-F-C (see Table 5 for corresponding secondary structure elements).  Loops A-C are located on 
the “principal” or “(+)” side of subunits, while loops D-F are located on the “complementary” or 
“(-)” side (Figure 6B).  The interfaces between these motifs in different subunits constitute the 
binding sites for GABA, benzodiazepines, and their analogues, as discussed further in subsequent 
sections.   
The four transmembrane (TM) domains are oriented such that M1 lies on the 
complementary side, M2 lines the ion pore, M3 lies on the principal side, and M4 lies on the 
outer side of the receptor facing the lipid membrane. The transmembrane helices (particularly M3 
and M4) are rather loosely packed, leaving solvent-accessible cavities both within and between 
subunit transmembrane domains158; indeed, many modulators appear to bind within these cavities.  
Perhaps unsurprisingly, the pore-lining M2 domain is the most highly conserved region among 
GABAA receptor subunits.  It contains major components of the ion selectivity filter and the 
channel gate, which in turn determine channel conductance.  Once again, the solvent-accessible 
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Figure 6. Secondary and tertiary structure of GABAA receptor subunit N-terminal 
domains.
A. Schematic of the β-strand composition of the GABA
A
 receptor subunit N-terminal 
domain.  Black arrows represent strands comprising the inner sheet and grey arrows repre-
sent strands comprising the outer sheet.  “Loops” A-F are indicated, as is the Cys-loop 
(structurally, loop 7 between strands β-6 and β-7).  The N-terminus is indicated at the top.   
B. Homology model of a GABA
A
 receptor subunit.  β-strands on the inner and outer sheets 
are colored as in Panel A.
A B
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residues of this region (i.e., those on the pore-lining face of the M2 helix) have been identified 
using SCAM.  The N-terminal residues are mostly hydrophilic and are thought to interact with the 
hydration shell surrounding the chloride ions.  While this function would be expected to improve 
conductance, it would not necessarily discriminate among hydrated ions and thus should not 
constitute the selectivity filter.  Rather, it is likely that anion selectivity occurs approximately 
two-thirds of the way toward the cytoplasmic side of the channel; positively-charged sulfhydryl 
compounds can react with residues above this point161, 162.  However, several other gate and filter 
locations have been proposed.  First, the extracellular sides of both M1 and M2 contain highly 
conserved positively-charged residues that could compose a selective vestibule163.  Second, a 
conserved leucine located approximately in the middle of the M2 domain is profoundly important 
for channel kinetics; it has also been suggested to line the narrowest point of the channel and thus 
constitute the gate.  Finally, the intracellular M1-M2 linker has also been demonstrated to affect 
selectivity. 
 
Table 5. Structural elements of GABAA receptor subunit interfaces. 
Loop Face Approximate  
residues (β-α) 
Structural  
elements (GluCl) 
A + β2(21-25) 
β-strand 4, 
loop 4 
B + β2(79-85) 
β-strand 7, 
loop 8 
C + β2(24-31) 
β-strand 9 & 10, 
loop 10 
D - α1(86-96) β-strand 2 
E - α1(145-157) 
β-strands 5 & 6, 
loop 6 
F - α1(203-212) 
β-strand 8, 
loop 9 
 
Wherever the exact gating location may be, it clearly lies far from the ligand binding sites.  
Consequently, extensive efforts have been made to determine the transduction mechanism 
coupling ligand binding to channel gating.  Current models suggest that GABA binding provokes 
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a constriction of the binding pocket (i.e., movement of loops A-F, especially loops C and F)164, 165.  
This causes a wave of conformational changes to propagate through the β-sandwich domain, 
which in turn allows conserved acidic residues in loop 2 (β subunits) and loop 7 (α and β subunits) 
to approach conserved basic residues in their respective M2-M3 linkers.  Cross-linking studies 
suggest that the cascade concludes with a rotation of M2 that essentially twists the channel 
open166, 167.  
Physiology of GABAA receptor isoforms 
The major elements of structure, binding, and gating are thought to be common to all 
GABAA receptor subunits.  However, receptor isoforms exhibit widely divergent functional 
properties.  Because most individual neurons express many subunits simultaneously, the 
physiological characteristics of individual isoforms can be studied most accurately by recording 
currents from fibroblasts (or other cells that do not express endogenous GABAA receptors) that 
have been transfected with specific subunit combinations.  Under these conditions, it is possible 
to analyze both the “microscopic” (single-channel) and the “macroscopic” (population) behavior 
of individual receptor isoforms.  Microscopic kinetic properties include channel conductance, 
open time, and closed time.  Macroscopic kinetic properties include activation (channel opening 
in response to agonist), desensitization (decreased current in the continued presence of agonist), 
and deactivation (channel closure after removal of agonist).  Each of these varies among GABAA 
receptor isoforms. 
Unsurprisingly, perhaps the most widely studied isoform is α1βxγ2, which is thought to 
be the predominant isoform in whole brain.  On a single-channel level, these receptors have a 
main conductance of approximately 26-30 pS, as well as several subconductance levels.  
Openings tend to occur in bursts and, based on the distribution of channel open times, the channel 
appears to enter at least three open states and at least five closed states (Figure 7A)168.  Kinetic 
analysis has suggested that the receptor must pass through closed states rather than transitioning 
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Figure 7. Representative single-channel and macropatch recordings from GABAA 
receptor isoforms.
Representative single-channel (A-C) and whole-cell (D-F) currents recorded from 
HEK293T cells expressing αβγ (A,D), αβδ (B,E), or αβ (C,F).  Currents were evoked using 
1 mM (saturating) GABA. 
αβδ
αβγ
αβ
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directly between open states; however, some interpretations differ.  Macropatch or whole cell 
recordings reveal that α1βxγ2 receptors activate quickly, desensitize rapidly and extensively, and 
deactivate somewhat slowly (Figure 7B).  When the time courses of desensitization and 
deactivation are fitted with a sum of exponential functions, it appears that α1βxγ2 receptors 
desensitize multiphasically and deactivate biphasically.   
In contrast, α1βxδ receptors appear to have only two brief open states and several longer 
closed states (Figure 7C).  Macroscopically, they activate more slowly, desensitize less 
extensively, and deactivate more quickly (Figure 7E).  Notably, the peak current amplitude of 
α1βxδ receptors is approximately tenfold lower than that of α1βxγ2 receptors (Figure 7D).   
As previously mentioned, GABAA receptors that contain only α and β subunits can be 
expressed and activated by GABA.  These “binary” receptors constitute another major receptor 
category that has been systematically compared with “ternary” αβγ and αβδ receptors.  Compared 
to α1βxγ2 receptors, α1βx receptors have a lower main conductance (~18 pS) and burst less often 
(Figure 7C).  They activate more slowly, desensitize more extensively, and deactivate more 
quickly.  Furthermore, their peak current amplitude is less than half as large (Figure 7F).   
It is perhaps unsurprising that αβ, αβγ, and αβδ receptor isoforms have very different 
physiological characteristics.  However, different subunit subtypes alter receptor kinetics as well; 
indeed, the wide array of GABAA receptor subunits might have evolved because they confer 
diverse physiological properties that facilitate fine-tuning of neuronal inhibition.  Systematic 
comparisons of α(1-6)β3γ2 receptor currents have demonstrated that each isoform has a unique 
combination of GABA sensitivity, activation rate, desensitization rate and extent, deactivation 
rate, and recovery rate169.  For instance, α6β3γ2 receptors were far more sensitive to GABA than 
any other isoform, while α3β3γ2 receptors were the slowest to activate170.   
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Neuronal physiology: types of inhibitory transmission 
There are two major types of GABAergic neurotransmission.  “Phasic” inhibition 
describes the large, transient currents produced by synaptic receptors in response to the high 
concentrations of GABA periodically released by presynaptic vesicles.  In contrast, “tonic” 
inhibition consists of smaller, more constant currents produced by extrasynaptic receptors in 
response to low concentrations of ambient GABA that escaped synaptic reuptake.  Because 
receptor subunit composition is a major determinant of subcellular localization, phasic inhibition 
is mediated by synaptic γ subunit-containing receptors, while tonic inhibition is mediated mostly 
by extrasynaptic δ subunit-containing receptors.  Each isoform is physiologically well adapted to 
its role.  For instance, the synaptic γ subunit-containing receptors have a relatively low affinity 
for GABA, activate quickly, desensitize extensively, and deactivate slowly – all properties 
allowing them to respond to rapid changes in neurotransmitter release.  In contrast, the 
extrasynaptic δ subunit-containing receptors have a relatively high affinity for GABA, activate 
slowly, and desensitize minimally, allowing them to respond to constant low levels of GABA.  
Although any individual phasic current produces more charge transfer than any individual tonic 
current, the sum of all tonic currents may provide the majority of inhibitory tone in the brain. 
Pharmacology 
GABA and analogues (muscimol, THIP, β-alanine) 
The GABA binding site is located at the interface between the principal side of β subunits 
and the complementary side of α subunits.  Because the proposed subunit arrangement of GABAA 
receptors is γ-β-α-β-α (anticlockwise as viewed from the synaptic cleft), each receptor contains 
two binding sites, which have been mapped using SCAM.  Among the first identified residues 
were those defining loop D of the α1 subunit, including residues T88, D90, F92, R94, and S96.  
The alternating pattern of these residues suggested that at least part of “loop” D actually consisted 
of a β-sheet171.  Other necessary α subunit residues included R147 in loop E172 and residues from 
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P202-D219 in loop F173.  Meanwhile, β subunit residues including R131 in loop C174 and V117, 
D119, Y121, and Y123 in loop A175 were found to be essential for GABA binding, thus defining 
the binding pocket as the intersubunit region between β and α subunit N-terminal domains.   
Several other agonists act at the GABA binding site.  These include the endogenous 
compounds β-alanine and taurine and the dissociative mushroom alkaloid muscimol.  Partial 
agonists include the muscimol analogue tetrahydroisoxazolepyridinol (THIP; gaboxadol) and 
isoguvacine, while competitive antagonists include the plant alkaloid bicuculline and the GABA 
derivative gabazine.  None of these compounds is currently approved for clinical use, but all are 
valuable experimental tools. 
Benzodiazepines 
No drugs have been so closely identified with GABAA receptors as the benzodiazepines; 
indeed, many years of literature refer to benzodiazepine-sensitive GABAA receptor isoforms as 
benzodiazepine receptors.  Unsurprisingly, the benzodiazepine binding site and mechanism are 
particularly well defined.  The binding pocket is located at the interface between the N-terminal 
domains of most α and γ subunits, in a position homologous to the GABA binding site at the β-α 
subunit interface.  Receptors containing α4 or α6 subunits do not respond to benzodiazepines176-
178, and receptors containing γ1 or γ3 subunits are less sensitive than receptors containing γ2 
subunits179.  The basis for α subunit selectivity lies in the residue homologous to α1(H129), which 
is a histidine in benzodiazepine-sensitive α subunits (i.e., α1, α2, α3, and α5) and an arginine in 
benzodiazepine-insensitive α subunits (i.e., α4 and α6)180.   
H129 is located in loop A on the (+) side of sensitive α subunits, which is predicted to 
form the interface with γ subunits.  Supporting this, mutating individual residues in the γ2 subunit 
loops D and E181 or essentially any residue in loop F182 impaired benzodiazepine binding.  
However, other studies have suggested that γ2 loop F residues do not directly participate in the 
binding site, but rather undergo a conformational change after benzodiazepine binding that helps 
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to transduce the signal182.  Dissecting the signal transduction cascade has proved significantly 
more difficult than identifying the binding site, and residues throughout the γ2 subunit 
transmembrane domains and intracellular loop have been implicated as well183, 184. 
 
Table 6. Binding sites, specificity, and effects of major drug classes acting at GABAA receptors. 
Compound Residues Region Isoforms Type Effects Citation 
GABA 
α1(T88, D90, 
F92, R94, S96, 
R147, P202-
D219) 
N-
terminal 
β-α 
interface agonist   
benzodiazepines α1(H140) 
γ2(F116, M169) 
N-
terminal 
α(1-3,5)-γ 
interface 
(+) 
allosteric ↑# of openings 
185 
barbiturates  M1-4 all (+) allosteric 
↑GABAA burst 
duration 
185, 186 
etomidate β2(M286), 
β2(Y468) M2-4 β2, β3 
(+) 
allosteric 
↑ GABA 
efficacy 
↓IPSC charge 
transfer 
187, 188 
neurosteroids α1(Q269,N435, Y438) M1, M4 δ 
(+) 
allosteric 
↑ GABA 
efficacy 
prolong IPSCs 
↑ open 
duration 
187, 189-
193 
isoflurane α1(L269, S297, A327)    
↑ desensitized 
currents 
prolong IPSCs 
194-196 
picrotoxin open-channel block M2? all 
(-) 
allosteric 
↓GABAA burst 
duration 
186 
 
Clinically-used benzodiazepines include diazepam, lorazepam, midazolam, and a number 
of other derivatives that differ primarily in metabolic half-life and time to onset of action.  They 
produce a wide range of physiological effects, including sedation, anxiolysis, amnesia, and 
muscle relaxation; additionally, they increase seizure threshold.  As such, they have been used to 
treat conditions such as insomnia, anxiety disorders, and epilepsy.  Additionally, although 
benzodiazepines do not produce deep enough anesthesia for most surgical procedures, they are 
useful for preoperative sedation, induction of general anesthesia, and light anesthesia for minor 
but uncomfortable procedures such as endoscopies.   
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The discovery that α subunit residue H129 is essential for benzodiazepine binding has 
allowed investigators to determine which receptor isoforms mediate which of these effects by 
creating mice that contain the H129R mutation in α1, α2, α3, or α5 subunits and administering 
benzodiazepines.  The resulting behavioral studies indicated that α1βγ receptors mediate sedation, 
anterograde amnesia, and anticonvulsant actions197; both α2βγ and α3βγ receptors mediate 
anxiolysis198, 199, myorelaxation184 and some spinal analgesia200; and α5βγ receptors mediate 
tolerance to sedation and possibly some amnestic effects201, 202.  This specificity may be due to α 
subunit expression patterns; for instance, α1 subunits are expressed throughout the cortex, α2 
subunits are highly expressed in limbic areas, and α2 and α3 subunits predominate in spinal cord.  
Because some benzodiazepine effects are therapeutic (anxiolysis, increased seizure threshold) and 
some are undesirable (sedation in non-anesthetic applications), there has been significant demand 
for subunit-specific drugs. One such drug is zolpidem, which acts predominantly at α1 subunits 
and thus is widely used to treat insomnia.  Another, TPA-023, is a partial agonist for α2- and α3 
subunit-containing receptors but an antagonist at α1 and α5 subunit-containing receptors; 
consequently, it is an effective anxiolytic and anticonvulsant but induces little sedation or 
dependence203, 204. 
Several benzodiazepine site antagonists and inverse agonists have been developed as well.  
One of these is flumazenil (Ro 15-1788), an antagonist that is used clinically to reverse symptoms 
of benzodiazepine overdose205.  Inverse agonists include the β-carbolines (e.g., DMCM), which 
reduce chloride flux.  Unsurprisingly, inverse agonists are anxiogenic and proconvulsant and 
therefore have no clinical application.  However, they are useful research tools for investigators 
studying anxiety and epilepsy206.   
Barbiturates 
For years, barbiturates were widely used to treat anxiety, insomnia, and epilepsy.  Due to 
their low therapeutic index (LD50/ED50), they have largely been supplanted by other 
40
anxiolytics/sedatives/anticonvulsants, but they are still occasionally used as anesthetic inducing 
agents.  Interestingly, barbiturates have three distinct actions on GABAA receptors.  At low 
concentrations (< 100 μM), they potentiate maximum GABA responses by increasing the 
duration of channel opening bursts185; at intermediate concentrations (approx. 100-1000 μM), 
they directly activate the receptor; and at higher concentrations (≥ 1 mM), they block the 
channel207.  Although all GABAA receptor isoforms seem to respond to barbiturates, receptor 
subunit composition does affect barbiturate efficacy and potency.  Both α and β subunit subtypes 
influence receptor responses, but α subunits appear to be more important.  Potentiation occurred 
at similar barbiturate concentrations (EC50 20-35 μM) for all α(x)β2γ2 receptors, but the degree of 
potentiation varied widely (α6 > α5 > α1 ≈ α2 ≈ α3).  With regard to direct activation, subunit 
composition affected both efficacy and potency; barbiturate EC50 was approximately tenfold 
lower and maximum response was two- to fourfold greater for α6 subunit-containing receptors 
than for all other isoforms.  Similarly, inhibition required higher barbiturate concentrations for α6 
subunit-containing receptors than for other tested isoforms.  The β subunit subtype affected 
barbiturate efficacy and potency only for direct activation and only when certain α subunits were 
coexpressed.  All α6β(x)γ2 receptors had similar EC50 and maximum response values, but EC50 
was higher and maximum response lower for α1β1γ2 receptors than for α1β2γ2 or α1β3γ2 
receptors207. 
Theoretically, different binding sites are responsible for these different actions. To date, 
such sites have not been fully defined, but various studies have identified specific residues that 
are important for barbiturate activity.  The α subunit-dependent differences in barbiturate efficacy 
seem to depend upon an α6 subunit residue in the extracellular N-terminal domain, T88208, and 
barbiturates may directly activate α1 and α6 subunit-containing receptors with entirely different 
signal transduction pathways209.  Barbiturates are very lipophilic compounds; consequently, most 
of the identified residues are located in the transmembrane domains of various subunits.  
Residues essential for barbiturate action have been identified in the first174, second175, and third210 
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transmembrane domains, and some of these were important for potentiation but not for direct 
activation211.   
Anesthetics 
Given that short-acting barbiturates are used as inducing agents in anesthesia, it is 
perhaps unsurprising that many other anesthetics have similar actions at GABAA receptors.  
These include both volatile (isoflurane, sevoflurane) and intravenous (etomidate, propofol) agents.  
Like barbiturates, anesthetics potentiate GABAergic responses at low concentrations and directly 
activate receptors at higher concentrations.  Furthermore, important residues but not full binding 
sites have been identified for most compounds. 
Clinical anesthesia involves several components: sedation (decreased arousal), hypnosis 
(loss of consciousness), immobility, analgesia, and amnesia212.  Different GABAA receptor 
isoforms located in different regions of the central nervous system are assumed be responsible for 
specific components.  For instance, the considerable population of GABAA receptors present in 
spinal cord likely mediate immobility, while hippocampal receptors likely mediate amnesia.  
More specifically, particular subunits have been demonstrated to mediate particular actions of the 
intravenous agents etomidate and propofol.  In heterologous systems, β2 or β3 subunit-containing 
receptors were both potentiated and directly activated by etomidate, but β1 subunit-containing 
receptors were poorly potentiated and could not be directly activated213, 214.  The Drosophila 
GABAA receptor (Rdl) was similarly unresponsive to etomidate.  The responsive subunits differ 
from the unresponsive subunits in a specific TM2 residue: the amino acid homologous to human 
β3 subunit residue N290, which is an asparagine in both β2 and β3 subunits, a serine in β1 
subunits, and a methionine in the Rdl receptor.  Mutagenesis studies confirmed that β3 subunit 
residue N290 was necessary and sufficient for etomidate responses.  Subsequently, knockin (KI) 
mice with β2(N289S) or β3(N290S) subunit mutations were created, given etomidate, and 
subjected to behavioral tests.  The β3(N290S) KI mice could still move in response to noxious 
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stimuli after etomidate administration, while the β2(N289S) KI mice recovered more quickly 
from light anesthesia215.  Taken together, this suggested that β3 subunit-containing receptors are 
responsible for the immobilizing effects of etomidate, while β2 subunit-containing receptors are 
responsible for sedation, and both isoforms likely contribute to hypnosis. 
Recently, photoaffinity labeling with a tritiated etomidate analogue was used to map the 
etomidate binding site.  The ligand labeled residues in the first and third transmembrane domains 
of α and β subunits (M263 in α1 and M311in β3 subunits); both conserved within their respective 
subunit families)216.  Another recent study found that the β3(N290S) subunit mutation reduced 
etomidate efficacy more than affinity217.  Therefore, it seems likely that anesthetics bind to a 
pocket in the transmembrane domain (perhaps at the β(+)/α(-) interface), but they require the β 
subunit M2 asparagine for gating.   
For several years, propofol and etomidate were thought to have identical binding sites.  
Recently, however, some residues important for binding of only one of these have been identified.  
Mutation of a conserved tyrosine in the β2 subunit M4 domain reduced GABAA receptor 
response to propofol but not etomidate218.  The kinetics of IPSCs also seem to be differently 
affected by etomidate and propofol188. 
The volatile anesthetics (isoflurane and derivatives) also seem to bind to site(s) in the 
transmembrane domains, but likely in a distinct pocket.  The α subunit may be more critical for 
volatile anesthetic binding, as essential residues have been identified in the first, second, and third 
transmembrane domains of α1 and α2 subunits194.  At the channel level, volatile anesthetics 
appear to prolong IPSC decay, thereby increasing overall charge transfer196. 
In summary, most general anesthetics bind to pockets in the GABAA receptor 
transmembrane domains and either improve efficacy and potency of GABA-gated currents or, at 
higher concentrations, directly activate the receptor.  In both cases, they increase overall 
inhibitory charge transfer, which could produce the various components of anesthesia by acting 
on receptors located in different parts of the CNS.  Although many important residues have been 
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identified, neither precise binding sites nor gating mechanisms have been fully defined.  Finally, 
it remains unclear how those mechanisms differ when anesthetics potentiate or directly activate 
receptors.  
Neurosteroids 
Most steroid hormones originate from peripheral organs such as the ovaries and adrenal 
glands and are capable of crossing the blood-brain barrier.  Some neurons and glia express 
enzymes that synthesize steroids both de novo from cholesterol and from peripherally derived 
precursors; the products of both pathways are classified as neurosteroids.  It has been known for 
years that cholesterol can cause CNS depression and that the synthetic steroid alphaxalone 
functions as an anesthetic.  Eventually, it was demonstrated that alphaxalone could enhance 
GABA-evoked currents, and subsequent studies found that endogenous neurosteroids such as 
allopregnanolone and tetrahydro-deoxycorticosterone (THDOC) had similar effects.  This could 
have very interesting physiological implications, as neurosteroid levels vary in response to the 
ovulatory cycle, pregnancy, and both acute and chronic stress. 
Similar to barbiturates and other anesthetics, neurosteroids have dual actions on GABAA 
receptors.  At low nanomolar concentrations, they potentiate GABA currents219, and at higher 
nanomolar to micromolar concentrations they directly activate the receptor.  Two distinct binding 
sites, identified using point mutagenesis and homology modeling, were proposed to mediate these 
effects.  The potentiation binding site was localized to a hydrophobic pocket deep in the α subunit 
transmembrane domain, formed in part by α1 subunit residues Q269 (M1), N435 (M4), and Y438 
(M4).  In contrast, the direct activation binding site was localized to the interface between the β 
and α subunit transmembrane domains; α1 subunit residue T264 (M1 domain) and β2 subunit 
residue Y308 (M3 domain) contributed to the binding pocket220.   
Neurosteroids act on both synaptic and extrasynaptic GABAA receptors in many brain 
regions, but their efficacy and potency vary widely.  They prolong mIPSCs mediated by synaptic 
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receptors, primarily by increasing the channel open duration193.  Extrasynaptic (predominantly δ 
subunit-containing) receptors are particularly sensitive to neurosteroids191, but this likely reflects 
the fact that GABA is a relatively low-efficacy partial agonist for δ subunit-containing receptors 
and neurosteroids shift activation to higher-efficacy gating patterns192. 
Ethanol 
More mechanisms of action may have been proposed for ethanol than for any other drug.  
Potential targets include (but are not limited to) lipid rafts221, NMDA receptors by way of Fyn 
kinase222, purine receptors223, opioid receptors214, glycine receptors224, and GABAA receptors225.  
Even ethanol’s GABAA receptor-mediated effects are multifactorial; potentiation may occur due 
to altered subunit phosphorylation, increased neurosteroid production, enhanced presynaptic 
GABA release, or changes in subunit expression, trafficking and localization.  Given these 
diverse effects, it is unsurprising that neither distinct binding sites nor subunit specificity for 
ethanol has been identified for GABAA receptors.  However, ethanol efficacy and potency do 
seem to be greatest at extrasynaptic, δ subunit-containing receptors, where they enhance tonic 
inhibitory currents226, 227.   
Promiscuous pharmacology 
Table 6 presents a summary of the major drugs found to act at GABAA receptor isoforms, 
their targets, and their functional effects.  However, it is important to note that most drugs 
discussed above do not act solely at GABAA receptors.  Both thiopental and pentobarbital 
inhibited nAChRs at clinically relevant concentrations228.  Propofol potentiated glycine 
receptors229 and inhibited both voltage-gated potassium channels230 and L-type calcium 
channels231, while isoflurane potentiated 5HT-3 and kainate receptors and inhibited AMPA and 
neuronal nicotinic acetylcholine receptors212.  Most neurosteroid research has focused on GABAA 
receptors, but some action has been found at NMDA and nicotinic acetylcholine receptors232.  
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Finally, as previously discussed, ethanol’s targets are particularly broad.  Therefore, it should not 
be assumed that all effects produced by these drugs are mediated by GABAA receptors.  
Loss of GABAA receptor subunits: lessons from KO mice 
Over the last 10-15 years, several GABAA receptor subunit KO mice have been created 
and studied.  The α1-6, β2, β3, γ2, and δ subunits have all been individually eliminated, and the 
resulting phenotypes vary from mild behavioral abnormalities to pre- and perinatal lethality 
(summarized in Table 7).   
One of the first (and most surprising) of these animals was the α1 subunit KO mouse.  
Approximately 60% of all adult rodent GABAA receptors may contain α1 subunits and, in 
agreement with this estimation, muscimol binding sites (i.e., all GABAA receptors with a β-α 
subunit interface) were reduced by 50% in α1 subunit KO mice.  Nonetheless, these mice had few 
overt phenotypic abnormalities.  They experienced increased perinatal mortality, but even this 
declined after a few generations.  Interestingly, expression of α2 and α3 subunits increased and 
expression of β2/3 and γ2 subunits decreased over the same period233.  Future studies found that 
α1 subunit KO mouse displayed decreased seizure threshold (but no spontaneous seizures), mild 
essential tremor, reduced response to synaptic or applied GABA (but no change in spontaneous 
IPSCs) and impaired dendritic spine maturation234-236.  Considering the prevalence of α1 subunit-
containing receptors, it is quite remarkable that α1 gene deletion produces so few harmful effects. 
Mice lacking α2 subunits were created much more recently.  These animals exhibited 
some increases in anxiety behavior and fear learning and, as expected, did not respond to the 
anxiolytic effects of benzodiazepines or barbiturates237.  Other psychiatric disorders may be 
affected by α2 subunit-containing receptors as well; α2 subunit KO mice became immobile more 
quickly than wild-type mice when subjected to tail suspension or forced swim tests, both of which 
are tests used to assess depressive behaviors238.   
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 Table 7. Phenotypes of GABAA receptor subunit knockout mice. 
Subunit General Subunit expression Motor 
Mood/ 
anxiety 
Seizure/ 
EEG Pharmacology Refs 
α1 
↓ body 
weight 
↓ 
dendritic 
spine 
maturati
on 
↑ α2, α3 
↓ α6, 
β2, β3, 
γ2 
mostly 
normal, 
tremor 
(handling) 
↓ fear 
learning 
↓ threshold 
no 
spontaneous 
 233-235 
α2 grossly normal   
↑ anxiety 
(CER) 
depressive 
behavior 
no 
spontaneous 
no anxiolysis by 
BZD/PB 
237, 238 
α3 grossly normal none 
↑ 
locomotor 
↓ PPI for 
acoustic 
startle 
(sensorimotor 
gating defect) 
no 
spontaneous 
resistant to 
evoked 
absence 
 239-242 
α4 grossly normal 
↓ δ (DG, 
CA1)  -  
no gaboxadol 
response 
243, 244 
α5 
better 
spatial 
memory 
↑eδ (hipp)  - none ↓ EtOH reward 245-247 
α6 grossly normal 
↓rδ (cb) 
↑ K 
channel 
impaired 
by BZD -  
↓ muscimol 
affinity 
248-250 
β2 grossly normal ↓ α1-6 
↑ in 
unfamiliar 
areas 
- none  233 
β3 
~90% 
neonatal 
lethal 
cleft 
palate 
↓ α2, α3 
hyperactive 
motor 
impairment 
↓ fear 
conditioning 
clonic 
absence 
interictal 
spikes 
 251-254 
γ2 
lethal by 
P18 
(hom) 
↓ 
clustering 
hyper-
activity 
impaired 
reflexes 
abnormal 
gait 
chronic 
anxiety (het, 
KD) 
↓ single-
channel 
conductance 
no BZD response 
(hom) 
~normal BZD (het, 
KD) 
136, 255-
258 
δ 
↓ 
fertility 
some 
prenatal 
death 
(hom) 
↓ α4 
(fore) 
↑ γ2 
(fore, cb, 
thal, str) 
   
↓ γ2 (fore 
response 
↓ neurosteroid 
effect 
↓ EtOH 
consumption 
and withdrawal 
191, 259-
262 
 
Abbreviations: DG, dentate gyrus; CER, conditioned emotional response; BZD, benzodiazepine; PB, pentobarbital; 
KD, knockdown; PPI, prepulse inhibition; EtOH, ethanol; het, heterozygous; hom, homozygous; fore, forebrain; cb, 
cerebellum; thal, thalamus; str, striatum. 
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Similarly, α3 subunit KO mice were created recently and exhibit phenotypes suggesting 
that α3 subunit-containing receptors may contribute to mood disorders.  Schizophrenia generally 
involves sensorimotor gating defects and hyperdopaminergic neurotransmission, and α3 subunit  
KO mice recapitulate both phenotypes.  Sensorimotor gating is commonly assessed by prepulse 
inhibition of acoustic startle reflex, in which an initial quiet sound typically reduces startling in 
response to a subsequent louder sound.  The α3 subunit KO mice were startled to similar degrees 
with or without first hearing the quieter sound.  Additionally, midbrain dopamine neurons 
displayed reductions in GABA-induced whole-cell current, resulting in hyperdopaminergic 
transmission that was rectified by D2 receptor antagonists.239  Some evidence also indicates that 
α3 subunit KO mice may be less susceptible to depression, as they spent less time floating than 
wildtype mice in a forced swim test240.  Because α3 subunit expression is high in thalamic 
reticular nucleus (nRT), which inhibits oscillations in the thalamocortical circuitry controlling 
sleep and arousal, the α3 subunit KO mice might be expected to lose nRT inhibition and 
consequently experience increased thalamocortical oscillations resulting in absence seizures or 
sleep disturbances.  However, the mice displayed no significant abnormalities in sleep or waking 
EEGs, no apparent absence seizures, and normal thalamocortical oscillations in brain slices241.  
Further investigation revealed that α3 subunit KO mice experienced considerable compensatory 
responses that increased thalamic inhibitory neurotransmission and conferred resistance to 
oscillation and absence seizures242.   
Expression of α4 subunits is also high in thalamus, but in a pattern complementary to that 
of α3 subunits (i.e., in relay neurons of motor thalamus).  As was the case for so many other 
GABAA receptor subunit KO mice, α4 subunit KO mice displayed no overt abnormalities.  
However, slice recording revealed an absence of thalamic tonic current, and the mice did not 
respond to the anesthetic effects of gaboxadol (THIP)243.  Other areas of high α4 subunit 
expression include dentate gyrus and CA1, where they are frequently paired with δ subunits.  
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Unsurprisingly, α4 subunit KO mice display reduced δ subunit surface expression in hippocampal 
pyramidal cells, particularly in pubertal female mice244. 
Mice lacking α5 subunits display a particularly interesting phenotype.  Receptors 
containing α5 subunits usually mediate the majority of tonic current in hippocampus, but some 
tonic current is preserved (albeit reduced) in α5 subunit KO mice due to upregulation of δ 
subunits.  Phasic inhibition may or may not be affected; some studies found no change, while 
others observed a reduction in IPSC amplitude245, 246.  What does seem clear, however, is that α5 
subunit deletion enhances learning and memory, particularly spatial memory245.  Furthermore, α5 
KO mice were resistant to the rewarding effects of alcohol247.  As such, there has been 
considerable effort to develop inverse agonists for α5 subunit-containing GABAA receptors. 
The α6 subunits are expressed only in cerebellar granule cells, which contain only a few 
additional subunit subtypes (primarily α1, β2, β3, γ2, and δ).  Global deletion of the α6 subunit 
caused loss of δ subunit protein and tonic current in granule cells248.  However, in an excellent 
example of neuronal compensation, granule cell excitability was unaffected in α6 subunit KO 
mice due to a concomitant increase in “leak” current through K+ channel TASK-1248, 249.  In other 
respects, α6 subunit KO mice were mostly normal, but they did exhibit more motor impairment 
than wild-type mice after diazepam administration250.  This also suggests complex interactions 
among receptor isoforms, because α6 subunit-containing receptors are insensitive to diazepam. 
Within the β subunit family, the β2 and β3 subtype genes have been deleted.  Considering 
that both subunits are widely expressed, deletion produced remarkably different effects.  Mice 
lacking β2 subunits were created and studied at the same time as the α1 subunit KO mice and had 
a similar, unexpectedly normal phenotype233.  Despite lacking 50% of all α subunits and 
muscimol binding sites, β2 KO mice had only slightly reduced GABA-evoked currents in 
cerebellar Purkinje neurons, normal rotarod performance, and increased locomotor activity.   
In contrast, nearly 90% of β3 KO mice died pre- or perinatally.  Some but not all of the 
increased mortality could be attributed to cleft palate, because only 60% of all KO animals had 
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cleft palate, and 30% of animals with normal palates also died within a few days of birth251.  
Furthermore, those that survived the perinatal period still had reduced longevity in addition to 
numerous other abnormalities, such as hyperactivity, incoordination, overt seizures, and interictal 
EEG abnormalities.  The latter two symptoms worsened with age; at eight weeks, only 
intermittent slowing was apparent, but by 14 weeks the mice experienced both clonic and absence 
seizures as well as sharp interictal spikes252.  Interestingly, despite reports that the β3 subunit gene 
is not imprinted, the phenotype of β3 heterozygous knockout mice depended on both the parental 
origin of β3 subunit deficiency and the gender of the heterozygote.  EEG abnormalities were 
worse if the deficiency was of maternal origin, and β3 subunit levels were reduced less drastically 
in male mice with deficiency of paternal origin253.  Given their various deficits, β3 heterozygous 
KO mice have been suggested as models for both Angelman syndrome252 and autism spectrum 
disorders254. 
Deletion of γ2 subunits produces an equally severe phenotype.  Despite normal 
morphology (including brain, intestinal tract, and peripheral organs known to express GABAA 
receptor subunits), all homozygotes died before P18.  Most of these died within a few days of 
birth, and those that survived longer had progressive motor abnormalities including hyperactive 
limb movement, impaired righting reflexes, and gait abnormalities255.  On the cellular level, γ2 
subunit deletion reduced receptor clustering and shifted single-channel conductance to the lower 
level characteristic of αβ receptors136, 256.  Interestingly, heterozygous KO mice lost only about 
20% of their γ2 subunit protein, suggesting that γ2 subunits are normally expressed in excess257.  
However, global heterozygotes257, adult/forebrain specific heterozygotes258, and γ2 subunit 
knockdown mice259 (which lost on average 65% of γ2 subunit protein) all displayed heightened 
anxiety.  Because the lethality obviously makes γ2 subunit global homozygous KO mice 
impossible to study beyond the first 2-3 weeks of life, several other temporally and spatially 
selective KO lines have been generated.  Mice that lost γ2 subunit expression in the third 
postnatal week also lost synaptic GABAA receptor clusters, indicating that the γ2 subunit is 
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essential for both formation and maintenance of clusters137.  Deletion of γ2 subunits from 
gonadotropin-releasing hormone (GnRH) positive neurons had little effect260, but deletion from 
parvalbumin (Pv) positive neurons caused progressive deficits in body weight, motor skills, pain 
sensitivity, anxiety, prepulse inhibition, and spatial learning, but no increase in 
mortality261.  Taken together, these studies support the observation that γ2 subunit expression is 
widespread and essential, and that neither γ1 nor γ3 subunits can compensate for γ2 subunit loss. 
Finally, δ subunit KO mice have also been created.  Heterozygotes had slightly reduced 
litter sizes and homozygotes were born at slightly less than the expected Mendelian ratio, 
suggesting some prenatal death.  Muscimol binding assays indicated that homozygotes lost nearly 
50% of all GABAA receptors; however, the number of benzodiazepine binding sites actually 
increased in some brain regions (thalamus, striatum, and cerebellum) of δ KO mice, suggesting 
that γ2 subunit expression increased in compensation191.  In agreement, future studies found γ2 
subunit upregulation in most regions that typically express high levels of δ subunits.  In contrast, 
those same regions had significantly decreased α4 subunit expression levels262.  These changes in 
cellular expression were accompanied by increased rates of hippocampal mIPSC decay but no 
changes in mIPSC amplitude or frequency263.  The δ subunit KO mice were less sensitive to 
behavioral effects of neuroactive steroids191, gaboxadol264, and ethanol265, which contributed to 
the conclusion that δ subunit-containing isoforms mediate most responses to these drugs. 
Heterogeneity in vivo: native GABAA receptor isoforms 
Many of the studies mentioned thus far have been conducted in heterologous expression 
systems or in cultured neurons.  Because of the great potential for GABAA receptor heterogeneity, 
it is necessary to use such systems to investigate properties of specific subunits (e.g., assembly 
sequences) and isoforms (e.g., kinetic and pharmacological properties).  Unfortunately, these 
studies cannot answer a crucial question: what GABAA receptor isoforms actually exist in the 
brain?  In an attempt to construct a standardized response to that question, the International Union 
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of Pharmacology recently established a list of potential native GABAA receptor isoforms266 that 
were divided into three categories (“identified”, “existence with high probability”, and “tentative”) 
based on multiple types of evidence.  The authors also specified a logical strategy, summarized 
below, for determining whether or not a receptor isoform exists in vivo.  First, the long list of 
potential isoforms can be narrowed based on subunit co-expression patterns, which can be 
ascertained by in situ hybridization and immunoreactivity.  If subunits are indeed co-expressed in 
a specific cell type, evidence for direct association of those subunits should be sought, primarily 
through co-immunoprecipitation.  Subunits that associate should be co-expressed in heterologous 
systems, where electrophysiology can be performed and characteristic kinetics and pharmacology 
can be assessed.  These characteristic properties can then be sought in neurons.  Finally, KO 
animals can be created and studied for the absence of characteristic physiology and pharmacology 
associated with isoforms containing the deleted subunit.  The list of “identified” and “high 
probability” isoforms, along with their localization (regional and subcellular) and basic forms of 
inhibition (phasic or tonic), is presented in Table 8. 
Isoforms that have been unequivocally identified 
 Each of the six α subunits has been co-immunoprecipitated from brain with β2/3 and γ2 
subunits.  Each subunit combination can be expressed in heterologous systems and responds 
differently to the array of benzodiazepine site ligands (e.g., flumazenil binds to receptors 
containing any α subunit, classic benzodiazepines bind only to receptors containing α1, α2, α3, or 
α5 subunits, and zolpidem binds with differing affinities to the benzodiazepine-sensitive 
receptors).  These properties allow only tentative identification of α(2,3)βγ2 and α(4,6)βγ2 
receptors; however, wild-type expression patterns and co-depletion in KO mice supports the 
existence of all four isoforms.  Finally, the benzodiazepine-insensitive KI mice provide strong 
evidence that each benzodiazepine-sensitive isoform exists.  Consequently, all αβγ2 isoforms are 
considered to have been identified in vivo.  Four of the remaining identified isoforms contain δ 
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 Table 8. GABAA receptor isoforms likely to exist in vivo. 
 
 Areas of high expression Subcellular localization 
Type of 
inhibition Refs 
Identified 
α1β2γ2 
cerebral cortex (all layers) 
hippocampus (interneurons, 
principal cells) 
thalamus (relay nuclei) 
cerebellum (Purkinje and granule 
cells) 
synaptic, extrasynaptic phasic, tonic 233 
α2βγ2 
cerebral cortex (layers I-IV) 
hippocampus (pyramidal cells) 
striatum 
hypothalamus 
motor neurons 
synaptic (most), 
extrasynaptic phasic, tonic 
198 
α3βγ2 
cerebral cortex (layers V-VI) 
hippocampus 
thalamus (nRT) 
cerebellum 
synaptic (most), 
extrasynaptic phasic, tonic 
198 
α4βγ2 hippocampus (granule cells) thalamus (relay nuclei) synaptic, extrasynaptic phasic, tonic 
268 
α4β2δ thalamus (relay nuclei) extrasynaptic tonic 
268, 
269 
α4β3δ dentate gyrus (granule cells); thalamus extrasynaptic tonic 
268 
α5βγ2 hippocampus (pyramidal cells) 
extrasynaptic – clustered 
(minor synaptic 
population) 
tonic 270 
α6βγ2 cerebellum (granule cells) extrasynaptic phasic 
271, 
272 
α6β2δ cerebellum (granule cells) extrasynaptic tonic 
271-
273 
α6β3δ cerebellum (granule cells) extrasynaptic tonic 
271-
273 
ρ retina (bipolar cells) synaptic, extrasynaptic? tonic? 
274-
276 
Existence with high probability 
α1β3γ2 cortex? hippocampus? synaptic? phasic? 
267, 
277 
α1βδ hippocampus (interneurons) extrasynaptic tonic 278 
α5β3γ2 hippocampus (pyramidal cells, granule cells) extrasynaptic tonic 
279 
αβ1γ/αβ1δ cerebral cortex ? ? 
280-
282 
αβ hippocampus (pyramidal cells) extrasynaptic tonic 
283, 
284 
α1α6βγ/ 
α1α6βδ cerebellum (granule cells) synaptic/extrasynaptic phasic 
271, 
273 
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subunits, which confer distinctive physiological and pharmacological properties (e.g., non-
desensitizing currents and neurosteroid sensitivity).  Demonstration of these properties in vivo267, 
combined with co-localization, co-immunoprecipitation, and gene deletion studies268, have 
allowed identification of the δ subunit-containing receptors listed in Table 8269.   
The last isoform that has been identified unequivocally in vivo comprises ρ subunits 
alone.  These receptors were previously classified as GABAC receptors largely because they are 
sensitive to GABA but insensitive to both the GABAA receptor antagonist bicuculline and the 
GABAB receptor agonist baclofen.  Currents with these pharmacological properties occur in cells 
that express ρ subunits (e.g., retinal bipolar cells), strongly suggesting that those cells express ρ 
subunit-containing pentamers. Evidence for both homomeric and heteromeric ρ isoforms has been 
reported270, 271; consequently, the subunit subtypes present in these receptors remain undefined. 
Isoforms that exist with high probability 
Finally, we will briefly discuss the evidence supporting the “existence with high 
probability” of certain key GABAA receptor isoforms listed in Table 8.  Each of these isoforms 
assembles efficiently and has been studied extensively in heterologous systems80, 168, 193, 272-276; 
moreover, the subunits are co-expressed in vivo45, 55, 57.  Most were not classified as “identified” 
simply because few animal studies have been conducted.  First, although α1 and γ2 subunits seem 
to partner most frequently with the β2 subunit, expression patterns indicate that this cannot 
always be the case, because certain areas expressing α1 and γ2 subunits do not express β2 
subunits55.  In these areas, it is quite likely that α1β3γ2 receptors are formed, as indicated by 
various pharmacological properties277.  Substantial evidence supports the existence of the α5β3γ2 
isoform: the three subunits have been colocalized55, α5 and β3 subunits were co-depleted in KO 
mice266, α5 subunit-selective etomidate effects have been identified278, and electrophysiology 
suggests that this isoform mediates tonic inhibition in the hippocampus279.  In fact, α5β3γ2 
receptors remain in the “high probability” category only because to date, α5 and β3 subunits have 
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not been co-immunoprecipitated266.  Likewise, the widely-accepted α1βδ isoform clearly 
assembled in heterologous systems and responded to known modulators of δ subunit-containing 
receptors.  One recent report claimed to identify this isoform in molecular layer interneurons of 
the hippocampus280.  Finally, as previously mentioned, two different αβ isoforms have been 
identified in rat brain via sequential co-immunoprecipitation281 and electrophysiology282. 
Pathology related to GABAA receptor dysfunction 
Psychiatric disorders 
GABAA receptor subunit gene loci have been associated with schizophrenia, bipolar 
disorder, and major depressive disorder283-288, and as previously mentioned, several of the 
GABAA receptor subunit KO animals display behavioral phenotypes that are considered to model 
these conditions.  In humans, reduced GABA levels have been found in CSF, plasma, and brain 
tissue of depressed patients.  Furthermore, brains of suicide victims showed changes in GABAA 
receptor subunit mRNA levels; compared to controls, α1, α3, α4, and δ subunits were reduced, 
while α5, β3, and γ2 subunits were increased289.  Studies of schizophrenic patients have sought 
evidence for GABAergic dysfunction throughout the GABA synthetic and signaling pathways290.  
Although results varied widely, reported findings in postmortem schizophrenic brain include 
increases in muscimol binding sites and decreases in GAD activity and expression, GABA 
concentration, and benzodiazepine sites291.  Interestingly, a study of postmortem bipolar cortex 
found no changes in muscimol binding sites together with increases in benzodiazepine binding 
sites, suggesting that bipolar disorder and schizophrenia might alter GABAA receptor 
stoichiometry in opposite ways292.  However, that is highly speculative, because nearly equal 
numbers of studies have and have not found linkage between GABAA receptor subunit loci and 
bipolar disorder.  Perhaps the strongest connection was found recently, when two separate groups 
reported an association between several subunit genes and bipolar disorder with psychotic 
features286, 293.   
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Autism 
The search for a connection between GABAA receptors and autism spectrum disorders 
(ASDs)294-299 began at the Angelman/Prader-Willi syndrome locus on the long arm of 
chromosome 15, where deletions, duplications, translocations, and inversions were found in 
autistic patients300.  This region contains the β3-α5-γ3 subunit gene cluster, and ASD-associated 
polymorphisms have been identified in all three genes296, 297, 301, 302.  Further studies found 
reductions in α5 subunit protein and benzodiazepine binding sites in autistic brain298, 299 and 
linkage to other GABAA receptor subunit genes, including GABRA4, GABRA5, GABRB1, 
GABRR1, and GABRR2303, 304.   
Epilepsy 
By definition, epileptic seizures result from abnormal excessive or synchronous neuronal 
activity.  Two or more unprovoked seizures meet the diagnostic criteria for epilepsy, which is 
further classified as symptomatic (secondary to trauma, stroke or tumor) or idiopathic (primary).  
Most idiopathic epilepsies are likely genetic disorders; within the past two decades, numerous 
mutations have been identified in epileptic individuals and families.  Considering that epilepsy is 
a disorder of hyperexcitability, it is perhaps unsurprising that most of these mutations were found 
in genes encoding ion channels, including several GABAA receptor subunits.   
Epilepsy mutations and polymorphisms in GABAA receptor subunit genes 
Epilepsy syndromes have been linked to mutations and variants in the GABRA1, 
GABRB3, GABRG2, and GABRD genes (Table 9).  The syndromes vary widely in severity, 
ranging from the relatively benign childhood absence epilepsy to the catastrophic Dravet 
syndrome.  Similarly, the mutations range from point mutations that alter channel kinetics to 
nonsense mutations that induce complete subunit degradation.  
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Four α1 subunit mutations have been reported.  The first was found in a four-generation 
family with juvenile myoclonic epilepsy.  The mutation, an alanine to aspartate mutation in the 
third transmembrane domain (A322D) was autosomal dominant and resulted in reduced whole-
cell current amplitude305.  Future studies found that mutant subunits were misfolded and mostly 
retained in the ER and degraded by proteasomes.  Mutant subunits could oligomerize with wild-
type subunits and thereby reduce surface expression of normal receptors as well.  The few 
α1(A322D) subunits that were successfully incorporated into pentamers and trafficked to the cell 
surface produced receptors with abnormal current kinetics306-308.   
Two other α1 subunit mutations were found in French-Canadian families with varying 
epilepsy phenotypes.  The D219N mutation, located in the ninth β-strand (outer sheet) region, 
caused partial ER retention of mutant subunits and consequently reduced receptor surface 
expression by approximately 50%.  The remaining mutant surface receptors desensitized more 
slowly and deactivated more quickly than wild-type receptors.  The other mutation, 
K353delins18X, caused aberrant translation of 18 amino acids from an intronic sequence, 
followed by a premature stop codon in the M3-M4 loop.  The resulting protein lacked 103 amino 
acids present in wild-type subunits and could not traffic beyond the ER309.  Finally, an α1 subunit 
mutation was found in a single patient with childhood absence epilepsy.  A single base pair 
deletion produced a frameshift, translation of two abnormal amino acids, and a subsequent stop 
codon in the third transmembrane domain (S326fs328X).  Similar to the A322D and 
K353delins18X mutant subunits, α1(S326fs328X) subunits did not reach the cell surface.  Taken 
together, these three mutations suggest that the fourth transmembrane domain is essential for 
proper folding, oligomerization, and surface trafficking of α1 subunits.  
Three separate point mutations in β3 subunits were recently found in families with childhood 
absence epilepsy.  Two of these (P11S and S15F) were located in the signal peptide of one of the 
β3 subunit splice variants, while the other (G32R) was predicted to lie at the beginning of the N-
terminal α helix.  Interestingly, all three mutant subunits had abnormal increases in N-
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glycosylation and decreased the current density of α1β3γ2 receptors310.  Surface expression of 
β3(P11S) subunits was slightly reduced due to accelerated degradation of mutant subunits296, but 
no explanation has been found for the increased N-glycosylation of either signal peptide mutant.  
On the other hand, the G32R mutation increased occupancy of an adjacent N-glycosylation site
296. This increase appeared to result from introduction of a positive charge at residue 32, but 
glycosylation was not responsible for decreased current density.  Rather, the G32R mutation 
disfavored incorporation of γ2 subunits and made α1β3γ2 receptors more likely to enter shorter 
open states311. 
The majority of epilepsy-associated GABAA receptor mutations have been found in γ2 
subunits.  Although dysfunctional GABAergic transmission was long suspected to contribute to 
epilepsy, no genetic evidence for GABAA receptor involvement existed until 2001, when a point 
mutation in the GABRG2 gene was found to segregate with GEFS+ in a multigenerational 
family312.  The mutation, K328M, affected a charged residue in the M2-M3 linker, which 
participates in the binding-gating transduction pathway.  Receptors containing γ2(K328M) 
subunits produced currents with smaller amplitudes and more rapid desensitization than wild-type 
receptors313.  Shortly thereafter, another γ2 subunit mutation was found in a large family with 
various epilepsy phenotypes including childhood absence epilepsy and febrile seizures314.  The 
mutation, R82Q, altered a residue in loop 1, which does not have a defined role in GABA binding 
or channel gating.  There have been contradictory reports313, 315 regarding the functional 
consequences of the R82Q mutation; however, there is a general consensus that most mutant 
subunits are retained in the ER, both pre- and post-oligomerization316.  As a result, cells 
expressing γ2(R82Q) subunits have fewer surface receptors and many (but not all) of the 
remaining receptors contain only α and β subunits.  Loop 1 is a highly conserved region on the 
principal side of subunits, and homology modeling predicts that γ2(R82) forms a salt bridge 
network with γ2(E217) and β2(R117) that is disrupted by the R82Q mutation316.  Consequently, 
the mutation likely impairs oligomerization and causes conformational changes that propagate 
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 Table 9. Epilepsy-associated mutations and polymorphisms in GABAA receptor subunits 
Mutation IGE Type Location Protein Current Refs 
α1(D219N) IGE point β9 ↓ surface expression  320 
α1(A322D) JME point M3 misfolding degradation ↓ amplitude 
316-319 
α1(S236fs328X) CAE frameshift/ nonsense M3 NMD/ERAD  
322 
α1(K353delins18X) IGE insertion/ splice site M3-M4 loop no surface expression no current 
320 
β3(P11S) CAE point signal peptide hyperglycosylation; degradation ↓ amplitude 
321 
β3(S15F) CAE point signal peptide hyperglycosylation ↓ amplitude 321 
β3(G32R) CAE point α1 helix 
γ-β interface 
hyperglycosylation; 
altered assembly 
↓ amplitude; 
shift to shorter 
open states 
321, 323 
γ2(Q40X) DS nonsense N-terminus degradation ↓ amplitude  
(αβ-like)  
324 
γ2(R82Q) CAE/FS point loop 1 
γ-β interface 
ER retention; 
degradation ↓ amplitude  
325-329 
γ2(P83S) IGE point loop 1 
γ-β interface no effect? no effect? 
320, 326 
γ2(R177G) FS point β6  impaired assembly ↓ amplitude  330 
γ2(IVS6+2TG) CAE/FS splice site/PTC intron 6 ER retention/stress 
↓ amplitude  
(αβ-like) 
331, 332 
γ2(K328M) GEFS+ point M2-M3 linker none 
↑ deactivation 
↓ single-channel 
mean open time 
326, 333 
γ2(Q390X) DS/GEFS+ nonsense M3-M4 loop ER retention 
↓ receptor expression ↓ amplitude 
334, 335 
γ2(Q429X) GEFS+ nonsense M3-M4 loop ? ? 336 
δ(E177A) GEFS+ point β7 ? 
↓ amplitude; 
↓ single-channel 
mean open time 
337, 338 
δ(R220H) GEFS+ point β9 ? 
↓ amplitude; 
↓ single-channel 
mean open time 
337, 338 
Abbreviations: IGE, idiopathic generalized epilepsy; JME, juvenile myoclonic epilepsy; CAE, childhood absence epilepsy; DS, 
Dravet syndrome (severe myoclonic epilepsy of infancy); FS, febrile seizures; GEFS+, generalized epilepsy with febrile seizures plus; 
NMD, nonsense-mediated decay; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum-associated degradation 
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across both γ2 and β2 subunits and affect the distant GABA and benzodiazepine binding sites317.  
Of note, R82Q is the only GABAA receptor epilepsy-associated mutation for which a KI mouse 
has been created and studied.  Heterozygous γ2(R82Q) KI mouse had a CAE-like phenotype; at 
approximately three weeks of age, they developed abnormal spike-and-wave discharges that 
coincided with behavioral arrest and could be treated with the anti-absence drug ethosuximide.  
Furthermore, the γ2(R82Q) subunit had reduced surface expression and oligomerized poorly with 
other GABAA receptor subunits in neurons cultured from the KI mice318. 
Truncation/nonsense mutations throughout the γ2 subunit sequence have also been found 
in epileptic families319.  One such mutation, Q40X, actually truncated the transcript at the first 
residue of the mature peptide.  Such a mutation would be expected to trigger nonsense-mediated 
decay, essentially producing a haploinsufficiency condition, but it is also possible that some of 
the signal peptide could escape decay and produce dominant negative effects.  Another nonsense 
mutation associated with CAE and FS, IVS6+2TS6ne such mutation, Q40X, actually truncated 
the intron 6, producing a truncated protein that contained most of the γ2 subunit N-terminal 
domain with a novel 29-aa C-terminus.  This tail was strongly hydrophobic and allowed the 
abnormal protein to be inserted into ER membranes, oligomerize with α and β subunits, and 
thereby escape degradation.  However, most of the truncated proteins were retained in the ER.  
Consequently, most surface receptors were binary αβ receptors, which produce much less charge 
transfer than ternary αβγ receptors.  Additionally, the truncated protein induced ER stress, which 
could prove to be a novel mechanism of epileptogenesis320, 321.  Two other γ2 subunit truncation 
mutations, Q390X and Q429X, have been reported322, 323.  Both were associated with GEFS+, 
were located in the last exon (and therefore should not trigger nonsense-mediated decay) and 
might produce proteins truncated in the M3-M4 intracellular loop.  The γ2(Q351X) subunits 
oligomerized with α and β subunits but trapped them in the ER324. The other M3-M4 nonsense 
mutation, Q429X, would be expected to produce similar results, but this remains to be studied. 
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Finally, two epilepsy-associated variants, E177A and R220H, have been identified in δ 
subunits.  Both were point mutations in outer-sheet β strands of the δ subunit N-terminal domain 
that were found in families with febrile seizures325.  Furthermore, both mutations reduced the 
current amplitude of αβδ receptors by two separate mechanisms; receptor surface expression was 
reduced and the remaining mutant surface receptors had shorter open durations326.  
Rationale for experimental chapters: the immense disorder of truths 
Assembly and trafficking of wild-type GABAA receptor isoforms 
Despite the wealth of knowledge that has been accumulated regarding GABAA receptor 
assembly and trafficking, some very fundamental questions remain unanswered.  First, although 
each subunit has a characteristic temporal and spatial expression pattern, most neurons express 
many GABAA receptor subunits at once.  It is clear that pentamers do not assemble at random, 
because many subunit combinations produce unproductive oligomers in vitro and only a small 
subset of the mathematically possible receptor isoforms have been identified in vivo.  
Consequently, certain “rules” of assembly must exist to limit receptor heterogeneity.  At present, 
these rules and their mechanisms remain poorly defined.  For instance, it is not known if certain 
subunit pairs have stronger affinities for one another than others, or if the preferential 
oligomerization induced by such affinities could be overcome simply by subunit expression levels 
and mass action.  Likewise, there have been no successful attempts to ascertain the order of 
subunit assembly.  For the closely-related nicotinic acetylcholine receptors, this information has 
been known for nearly two decades.  Finally, for years GABAA receptor stoichiometry and 
subunit arrangement have been assumed to be (γ/δ/ε)-β-α-β-α.  However, remarkably little 
empirical evidence supports this assumption, and nearly all such evidence relies on concatenated 
subunit constructs that constrain subunit assembly.  As such, the first part of this dissertation will 
address free assembly and trafficking of selected GABAA receptor subunits. 
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Characterization of epilepsy-associated mutations in GABAA receptor subunits 
As previously discussed, numerous epilepsy-associated mutations have been identified in 
four different GABAA receptor subunits.  Two have been introduced into KI or transgenic mice, 
some have been studied extensively in heterologous systems, and many have been characterized 
only perfunctorily.  Furthermore, these mutations produce monogenic epilepsies, which affect 
approximately 2% of all idiopathic generalized epilepsy patients.  A recent paper reported exome 
sequencing of all ion channel genes in a cohort of epileptic patients and non-epileptic controls327 .  
The authors hoped to find patterns of ion channel variants (or “channotypes”) that predict 
epilepsy risk, but no such patterns emerged.  Cases and controls did not differ significantly in 
numbers of total variants, variants in established epilepsy genes, or rare variants predicted to be 
severe.  Consequently, the authors concluded that the risk of hyperexcitability due to ion channel 
polymorphisms must depend heavily upon locations and levels of channel expression as well as 
compensatory mechanisms that occur during brain development.  This conclusion is at once 
unsurprising and disappointing, as it confirms that neural networks are incredibly complex and 
that polygenic epilepsies are incredibly difficult to study.  In fact, the results suggest a potentially 
insurmountable problem: networks can be studied only in animals, but it is impossible to make 
animals with all possible mutations.  Furthermore, it is difficult even to predict which variants 
will be harmful and worth studying.   
The second part of this dissertation takes a few small steps toward addressing this 
seemingly intractable problem.  It is impossible to study all variants or even all channels; 
however, it may be possible to construct a framework that allows us to predict which variants in 
certain channels are likely to be deleterious.  As such, the later chapters present thorough 
characterizations of some reported monogenic mutations, high-throughput screening of several 
previously unstudied variants, and homology mapping of both harmful and benign variants in an 
attempt to address “the immense disorder of truths”. 
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 CHAPTER II 
ASSEMBLY, STOICHIOMETRY, AND SUBUNIT ARRANGEMENT 
OF α1β2 GABAA RECEPTORS: ANALYSIS BY FLOW CYTOMETRY  
 
 
Abstract 
GABAA receptors are heteropentameric ligand-gated chloride channels assembled from a 
large family of subunit subtypes (α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3).  However, subunits 
clearly do not assemble at random; rather, strict “rules” govern receptor formation, as only some 
of the myriad possible subunit combinations form pentamers that reach the cell surface.  Both α 
and β subunit subtypes are required to form the GABA binding site, and it is commonly thought 
that all isoforms existing in vivo contain both subunits.  Despite years of study, the stoichiometry 
of αβ receptors remains disputed.  It has been reported that αβ isoform stoichiometry is 
exclusively 3α:2β, exclusively 2α:3β, or various mixtures thereof.  The overwhelming majority of 
research has been conducted by evaluating the functionality of receptors formed by artificially 
tethered subunits, and these “concatemers” have well-established shortcomings. 
Although it might seem that determining the precise stoichiometry of αβ GABAA 
receptor isoforms is an experimentally intriguing but physiologically irrelevant endeavor, 
stoichiometry was shown to alter agonist sensitivity of closely-related α4β2 nicotinic 
acetylcholine receptor isoforms.  Here, we used techniques including flow cytometry and 
fluorescence resonance energy transfer (FRET) to assess the subunit composition and 
stoichiometry of GABAA receptors assembled from untethered α1 and β2 subunits.  Both α1 and 
β2 subunits were required for efficient surface expression of either subunit, but surface 
expression was significantly higher for α1 than for β2 subunits.  Indeed, the α1HA/β2HA subunit 
surface protein ratio was too high to be explained by even a homogeneous 3α:2β receptor 
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population.  Additionally, all patterns of subunit adjacency (α1-α1, β2-β2, and α1-β2) were 
detected using FRET, and β2-β2 subunit FRET would not be expected in 3α:2β receptors.  We 
conclude that α1β2 receptors expressed in cultured fibroblasts formed a heterogeneous population 
including receptors with both 3α:2β and 2α:3β stoichiometries, but “excess” α1 subunit surface 
protein suggested that α1 subunits might display unexpected patterns of oligomerization and 
assembly.   
 
Introduction 
GABAA receptors, the ligand-gated ion channels that mediate the vast majority of fast 
inhibitory signaling in the central nervous system, are heteropentamers assembled from a large 
array of subunit subtypes (α1-6, β1-3, γ1-3, δ, ε, π, θ, and ρ1-3).  As a result of this subunit 
diversity, nearly half a million unique receptor isoforms could potentially exist.  However, it has 
become abundantly clear that subunits do not associate indiscriminately and that many “rules” 
govern receptor assembly and trafficking266.  Indeed, GABA binds only to β-α and ρ-ρ subunit 
interfaces, so it is debatable if any isoform lacking one of these interfaces should even be 
considered a GABAA receptor.  Thus, the simplest GABA-gated isoforms that have been 
identified in vivo are “binary” αβ receptors and homopentameric ρ receptors281, 282.  Of note, the 
latter display remarkably different subunit expression patterns and receptor pharmacology than 
other GABAA receptor isoforms; until recently, they were considered to be a separate class of 
“GABAC receptors” and have been studied far less extensively than traditional GABAA receptor 
isoforms. 
Decades of research have focused upon determining the stoichiometry and subunit 
arrangement of isoforms that are apparently expressed in transfected cells and in vivo84, 116, 328, 329  
The majority of studies have addressed this question using “concatenated” or “tandem” subunit 
constructs, in which multiple subunit sequences are joined by artificial peptide linkers.  
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Traditionally, various combinations of concatemers and individual subunits are expressed in 
Xenopus oocytes or fibroblasts, electrophysiology is performed to determine what combinations 
yield functional receptors, and receptor composition and subunit arrangement are deduced from 
the resulting data.   
Although concatenated subunits have been a valuable tool, the technique has well-
documented drawbacks330.  Chief among these is the possibility that the concatemers might not 
actually constrain stoichiometry at all.  The linking elements could be cleaved, releasing free 
subunits to assemble at will; this may be a particular concern when non-N-terminal subunit 
sequences include the signal peptide.  Alternatively, the concatemers may remain intact, but some 
subunits may be excluded or “loop out” from the receptor pentamer.  In addition to the “false 
positive” conclusions that could be drawn from degraded or overly flexible concatemers, “false 
negative” conclusions are possible as well.  For instance, a subunit combination might assemble 
successfully but fail to produce a current because concatenation interferes with conformational 
changes that occur during gating.   
Both GABAA receptors and nicotinic acetylcholine receptors (nAChRs) are members of 
the Cys-loop ligand gated ion channel family.  The α4β2 neuronal nicotinic acetylcholine receptor 
(nAChR) isoform has highlighted the potential importance of determining receptor stoichiometry.  
Initially, it was unclear whether the receptor contained three α and two β subunits or two α and 
three β subunits (3α:2β or 2α:3β receptor stoichiometries, respectively).  It was subsequently 
discovered that oocytes transfected with α4 and β2 subunits had a biphasic concentration response 
curve, suggesting the presence of a heterogeneous receptor population331.  Acetylcholine affinity 
was much higher when a 1:10 ratio rather than a 10:1 ratio of α4:β2 subunit cDNA was 
transfected; consequently, it was concluded that 2α:3β nAChR isoforms were more sensitive to 
nicotine than 3α:2β receptors.  Interestingly, chronic nicotine administration increased expression 
of high-affinity 2α:3β isoforms, while transfection of subunits bearing an epilepsy-associated 
mutation increased expression of low-affinity 3α:2β isoforms332, 333.  To date, no similar 
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phenomena have been reported for binary αβ GABAA receptor isoforms, but to our knowledge 
similar experiments have not been conducted.  The apparent physiological importance of nAChR 
stoichiometry provides yet another reason to investigate GABAA receptor stoichiometry in greater 
detail. 
Here, we used techniques including flow cytometry and fluorescence resonance energy 
transfer (FRET) to assess the subunit composition and stoichiometry GABAA receptors 
assembled from untethered α1 and β2 subunits.  We confirmed that both α1 and β2 subunits were 
required for efficient surface expression of either subunit and using differential epitope-tagging 
we established that more α1 than β2 subunit protein was located on the cell surface.  Particularly 
when protein was denatured, the ratio of α1HA/β2HA subunit surface protein was too large to be 
explained by a homogeneous 3α:2β receptor population.  Moreover, all patterns of subunit 
adjacency (α1-α1, β2-β2, and α1-β2) were detected using FRET, and β2-β2 subunit FRET would 
not be expected in 3α:2β receptors.  Therefore, it seems likely that α1β2 receptors expressed in 
cultured fibroblasts form a heterogeneous population including receptors with both 3α:2β and 
2α:3β stoichiometries.  Additionally, the “excess” α1 subunit surface protein suggested that α1 
subunits might display unexpected patterns of oligomerization and assembly.  
 
Materials and Methods 
Cell culture and expression of recombinant GABAA receptors 
Human GABAA receptor α1, β2, γ2L, and δ subunits were individually sub-cloned into 
the pcDNA3.1+ mammalian expression vector (Invitrogen, Grand Island, NY).  Due to the lack 
of a highly specific, commercially available antibody targeting an extracellular domain on the 
γ2L and δ subunits, the HA (YPYDVPDYA) epitope was inserted between amino acids 4 and 5 
of the mature peptide.  This insertion site was selected for its minimal effect on receptor 
expression and function (REFS; Supplemental Figure X).  The coding region of each vector was 
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sequenced by the Vanderbilt University Medical Center DNA Sequencing Facility and verified 
against published sequences. 
HEK293T cells (American Type Culture Collection, Manassas, VA) were maintained at 
37°C in humidified 5% CO2 / 95% air using Dulbecco’s Modified Eagle Medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Invitrogen), 100 i.u./ml penicillin (Invitrogen), and 
100 μg/ml streptomycin (Invitrogen).  Cells were plated at a density of ~106 cells per 10 cm 
culture dish (Corning Glassworks, Corning, NY) and passaged every 2-4 days.  For flow 
cytometry experiments, cells were plated at a density of 4x105 cells per 6 cm culture dish 
(Corning Glassworks) and transfected ~24 hours later with the indicated amounts of subunit 
cDNA (see Results) using FuGene6 (Roche Diagnostics, Indianapolis, IN) per manufacturer 
protocol.  In conditions where less than 3 μg of subunit cDNA was transfected, empty pcDNA3.1 
vector was added such that a total of 3 μg of cDNA was used for each experimental condition 
(e.g., the “mock” transfection condition consisted of 3 µg of empty pcDNA 3.1 vector cDNA).  
For surface biotinylation and immunoblotting, cells were plated at a density of 1.2x106 cells per 
10 cm culture dish (Corning) and transfected with a total of 9 μg of cDNA  
Flow Cytometry 
Cells were harvested ~48 hours after transfection using 37°C trypsin/EDTA (Invitrogen) 
and placed immediately in 4°C FACS buffer composed of phosphate-buffered saline (PBS), 2% 
fetal bovine serum (FBS) (Invitrogen), and 0.05% sodium azide (VWR).  Cells were then 
transferred to 96-well plates and washed twice in FACS buffer (i.e., pelleted by centrifugation at 
450 x g, vortexed, and resuspended).  For surface protein staining, cells were incubated in 
antibody-containing FACS buffer for 1 h at 4°C, washed in FACS buffer three times, and 
resuspended in 2% w/v paraformaldehyde (PFA) (Electron Microscopy Sciences).  For total 
protein staining, samples were first fixed and permeabilized using Cytofix/Cytoperm (BD 
Biosciences) for 15 min.  After washing twice with Permwash (BD Biosciences) to remove 
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residual fixative, cells were resuspended in antibody-containing Permwash for 1 h at 4°C.  
Following incubation with antibody, samples were washed four times with Permwash and twice 
with FACS buffer before resuspension in 2% paraformaldehyde.  The anti-α1 antibody was 
obtained from Millipore (clone bd24), conjugated to the Alexa647 fluorophore using an 
Invitrogen kit, and used at 4 μg/ml for surface staining and 2 μg/ml for total protein staining.  The 
anti-β2 antibody was obtained from Millipore (clone 62-3G1) and used at 8 μg/ml for surface 
staining and 4 μg/ml for total protein staining.  Because anti-β2 antibody conjugation proved 
inefficient, an anti-IgG1-Alexa647 secondary antibody was used at a 1:500 dilution for most 
experiments.  Because accurate FRET analysis requires directly conjugated antibodies, a different 
anti-β2 subunit antibody clone (bd17; same epitope as 62-3G1 but suspended in PBS alone) was 
obtained from Millipore, conjugated to Alexa555 or Alexa647 fluorophores as described above, 
and used at a 1:50 dilution for all FRET experiments.  The anti-HA antibody (clone 16B12) was 
obtained from Covance as an Alexa647 conjugate and used at a 1:250 dilution for surface staining 
and a 1:500 dilution for total protein staining. 
Samples were run on a LSR II flow cytometer (BD Biosciences).  For each staining 
condition, 50,000 cells were analyzed.  Nonviable cells were excluded from analysis based on 
forward- and side-scatter profiles, as determined from staining with 7-amino-actinomycin D (7-
AAD) (Invitrogen).  The Alexa555 fluorophore was excited using a 535 nm laser and detected 
with a 575/26 bandpass filter.  The Alexa647 fluorophore was excited using a 635 nm laser and 
detected with a 675/20 bandpass filter.  Data were acquired using FACSDiva (BD Biosciences) 
and analyzed off-line using FlowJo 7.1 (Treestar).  To compare surface and total expression 
levels of GABAA receptor subunits, the mean fluorescence intensity of mock transfected cells 
was subtracted from the mean fluorescence intensity of each positively transfected condition.  
The remaining fluorescence was then normalized to that of a control condition, yielding a relative 
fluorescence intensity ("Relative FI").  Statistical significance was determined using Student’s t-
test or ANOVA, as appropriate.  Data were expressed as mean ± SEM. 
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Surface biotinylation 
Forty-eight hours after transfection, cells were washed twice with Dulbecco’s phosphate-
buffered saline (DPBS; PBS with 0.1 mM CaCl2 and 1 mM CaCl2) and then incubated for 40 
minutes with 1 mg/ml NHS-SS-biotin (Pierce) diluted in DPBS.  The biotinylation reaction was 
quenched by washing with 0.1 M glycine in DPBS, and plates were washed twice with DPBS 
before lysis with radioimmune precipitation assay buffer (RIPA buffer; 50 mM Tris-HCl pH 7.4, 
1 % Triton-100, 250 mM NaCl, 5 mM EDTA) containing protease inhibitor cocktail (Sigma).  
Lysates were cleared by centrifugation at 16,000 x g for 15 minutes and equal protein amounts 
were incubated overnight with High-Capacity NeutrAvidin agarose resin (Pierce).  The following 
day, the NeutrAvidin resin was washed four times with RIPA buffer before protein elution with 
Invitrogen sample buffer + 5 % β-mercaptoethanol (1 hr, room temperature).  All steps prior to 
elution were performed on ice and/or at 4˚C.  
Glycosidase digestion 
Surface biotinylation was performed as described above, but biotinylated protein was 
simultaneously eluted from NeutrAvidin resin and denatured by incubation in 1x glycoprotein 
denaturing buffer (New England Biolabs) containing 50 mM dithiothreitol for 30 minutes at 50˚C.  
Eluates were divided into 15 μl aliquots and digested with 1 unit of peptide-N-glycosidase F 
(PNGase F) in manufacturer-supplied buffers (New England Biolabs) at 37˚C for 2 h.   
Immunoblotting 
SDS-PAGE electrophoresis was performed at 175 V for 2-3 hours, followed by transfer 
to a PVDF membrane (Li-Cor Biosciences, Lincoln, NE) at 100V for 1 hour.  Membranes were 
blocked for one hour in Li-Cor blocking buffer and incubated overnight with antibodies dissolved 
in PBS with 0.1% Tween (PBST).  Antibodies included mouse-anti HA (clone 16B12, Millipore, 
diluted 1:5000), rabbit polyclonal anti-β2 (Millipore, diluted 1:200), and anti –Na+/K+ ATPase α 
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chain as a loading control (Abcam, diluted 1: 10,000).  Membranes were secondarily probed with 
a IRDye secondary antibodies (Li-Cor).  Membranes were washed with PBST and imaged and 
quantified using a Li-Cor Odyssey infrared imaging system and software. 
 
Results 
Due to the possible defects previously discussed, all concatemers must be evaluated for 
potentially confounding malfunctions before they can be used to draw conclusions regarding 
receptor stoichiometry.  Figure 1 presents the results of some of these control experiments.  A 
very limited repertoire of concatemers is necessary to investigate the stoichiometry of binary αβ 
receptors, but even within that subset, considerable problems emerged.  For instance, the β2-α1 
subunit concatemer produced currents when transfected alone (Figure 1A).  Obviously, no 
combination of dimers should form a pentameric receptor, so this is highly concerning.  It is 
possible that similar transfection conditions (i.e., conditions that should not permit pentamer 
assembly) could result in aberrant forward trafficking of non-functional isoforms, so surface 
expression of concatenated subunits was also assessed using flow cytometry (discussed further 
below).  Interestingly, the α1-β2 concatemer could be detected on the cell surface when 
transfected alone (Figure 1B, left panel).  If it functions as intended, this concatemer should reach 
the cell surface when transfected with α1 subunits (if the receptor stoichiometry is 3α:2β) or with 
β2 subunits (if the stoichiometry is 2α:3β), but not when transfected alone.  These conditions 
were tested using α1 and β2 subunits with hemagglutinin (HA) epitope tags engineered into the 
N-terminal domain; insertion of this tag disrupts the native epitope of the anti-α1 subunit 
antibody, so any α1 subunits detected by that antibody must derive from the concatemer.  
Surprisingly, surface expression of the α1-β2 subunit concatemer was not dramatically higher 
when it was transfected together with α1 (Figure 1B, middle panel) or β2 (Figure 1B, right panel) 
subunits than when it was transfected alone, suggesting that abnormal assembly of α1-β2 
70
AB α-β α-β + α1HAα-β + β2HA
α β
N
C
C
N
αβ
N
C
C
N
%
 o
f m
ax
.
log fluorescence intensity 
1 mM GABA  4 s
1 nA
Figure 1. Concatenated subunit constructs may not effectively constrain receptor 
stoichiometry.
A. HEK293T cells were transfected with a GABAA receptor subunit concatemer in which 
a polyglutamine linker was used to connect the C-terminus of the β2 subunit to the 
N-terminus of the α1 subunit (left panel).  Macroscopic currents were recorded from lifted 
cells (right panel).  B. HEK293T cells were transfected with a GABAA receptor subunit 
concatemer in which a polyglutamine linker was used to connect the C-terminus of the α1 
subunit to the N-terminus of the β2 subunit (left panel).  Concatemers were transfected 
either alone (second panel) or in the presence of α1HA (third panel) or β2HA (right panel), 
and surface expression of α1-β2 subunit concatemers was assessed using a fluorescently-
tagged anti-α1 subunit antibody and flow cytometry.  Representative flow cytometry histo-
grams are presented; the abscissa indicates fluorescence intensity (FI; proportional to 
expression levels) in arbitrary units plotted on a logarithmic scale, and the ordinate 
indicates percentage of maximum cell count (% of max).  Histograms for cells transfected 
with subunit combinations (dark gray) and cells transfected with blank vector (light gray) 
are overlaid. 
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concatenated subunits was a significant problem.  Of note, identical concatemers (including 
linkers) have been used in previous studies, so these problems should not simply reflect improper 
construct design.  
Flow cytometry indicated that both a1 and β2 subunits were required for surface expression 
and full total cellular expression levels in intact cells. 
Given the apparent flaws of the α1/β2 subunit concatemers, studying assembly of α1β2 
receptors with individual, untethered subunits became necessary.  Using flow cytometry, the 
surface and total cellular protein expression of multiple subunits transfected in multiple 
combinations can be assessed efficiently and quantitatively.  Flow cytometry also permits 
evaluation of protein expression in a relatively “natural” context; whereas immunoblotting 
requires cell lysis and often protein denaturation, flow cytometry allows selection of folded 
proteins expressed in intact cells.  Thus, HEK293T cells were transfected with untethered α1, β2, 
or α1 and β2 subunit cDNA and surface and total cellular expression of both subunits were 
identified for each condition using fluorescently-conjugated, subunit-specific antibodies.  Viable 
cells were selected based on a combination of forward scatter, side scatter, and viability stain 
profiles (data not shown); a consistent subset of cells excluded the viability stain 7-
aminoactinomycin-D (7-AAD), indicating that their membranes were intact at the time of cell 
harvest.  Subunit expression levels were quantified by determining the mean fluorescence 
intensity (FI) of this viable cell subset for each transfection condition; nonspecific staining was 
assessed by measuring the mean FI of cells transfected only with blank vector, and this 
background was subtracted from each experimental condition.  
In agreement with previous reports80, 81, 90, neither α1 subunits nor β2 subunits were 
expressed efficiently on the cell surface in the absence of the other subunit (Figure 2A, 2B).  
When α1 subunit cDNA was transfected alone, α1 subunit surface levels were only 2.9 ± 0.3 % of 
those seen when α1 and β2 subunit cDNAs were co-transfected, and when β2 subunit cDNA was 
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Figure 2. Flow cytometry indicated that surface expression and full total cellular 
expression of α1 and β2 subunits required co-transfection of α1 and β2 subunit cDNA.
HEK293T cells were transfected with combinations of GABAA receptor subunit cDNAs 
(α1 alone, β2 alone, or both α1 and β2; 1 μg each) and surface and total cellular subunit 
expression was evaluated using flow cytometry.  A. Representative flow cytometry histo-
grams acquired from surface anti-α1 and anti-β2 antibodies are presented; the abscissa 
indicates fluorescence intensity (FI; proportional to expression levels) in arbitrary units 
plotted on a logarithmic scale, and the ordinate indicates percentage of maximum cell 
count (% of max).  Histograms for cells transfected with subunit combinations (dark gray) 
and cells transfected with blank vector (light gray) are overlaid.  B. The relative fluores-
cence intensity was quantified by subtracting the mean FI obtained from cells transfected 
with blank vector from the mean FI obtained from cells transfected with GABAA receptor 
subunits and normalizing the resulting net FI to that of the α1β2 transfection conditions.  
C-D. Total cellular detection of α1 and β2 subunits are presented as in panels A and B.
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transfected alone, no β2 surface expression could be detected.  Total cellular expression of α1 and 
β2 subunits (Figure 2C, 2D) was also significantly lower when subunits were transfected 
separately rather than together (α1 = 55.3 ± 2.2 % and β2 = 24.7 ± 1.2 % compared to respective 
α1β2 co-transfection levels).  Importantly, these data also demonstrated that the antibodies were 
wholly subunit-specific; no α1 subunit signal was detected when only β2 subunit cDNA was 
transfected and vice versa.   
Differential epitope tagging indicated that there were slightly more α1 than β2 subunits on the 
cell surface, but the exact ratio remained uncertain 
These results demonstrated that flow cytometry is an efficient means of assessing subunit 
expression patterns, but did not provide insight into the stoichiometry or subunit arrangement of 
α1β2 receptors.  To address receptor stoichiometry in the context of freely-assembled subunits, 
differential epitope tagging was employed.  That is, HA epitope tags were inserted between the 
fourth and fifth amino acids of the mature α1 and β2 subunit peptides, an epitope-tagged subunit 
was co-expressed with a non-tagged subunit (i.e., α1HAβ2 or α1β2HA), a fluorescently-conjugated 
anti-HA antibody was used to detect subunit expression levels with flow cytometry, and the 
fluorescence intensities of α1HA and β2HA subunits were compared.  It is, of course, possible that 
inserting the epitope tag could alter normal receptor assembly.  However, it is commonly 
accepted that epitope tags can be inserted at this position in GABAA receptor subunit peptides 
without affecting receptor expression or function81, 130, 334.  Nonetheless, potential byproducts of 
epitope tagging were assessed by comparing the levels of partnering subunits transfected with 
tagged or untagged subunits (i.e., β2 subunit expression levels were compared in α1HAβ2 and 
α1β2 transfection conditions).  The effects of FLAG and c-myc tags were tested as well, and the 
HA epitope tag was ultimately selected because it had the smallest effect on partnering subunit 
expression levels.   
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Therefore, relative HA fluorescence intensity was used to determine the relative amounts 
of α1 and β2 subunit protein produced from equimolar subunit cDNA co-transfection (Figure 3).  
This should indirectly indicate receptor stoichiometry; if all α1β2 receptors contained three α1 
and two β2 subunits, the α1HA/β2HA ratio should be 1.5, and if all contained two α1 and three β2 
subunits, the ratio should be 0.67.  However, several circumstances could account for other ratios.  
First, it is important to remember that the antibody would detect any subunits expressed on the 
cell surface.  Thus, the presence of any free α1HA or β2HA subunits would skew the α1HA/β2HA 
ratio and make it unrepresentative of the components of pentameric receptors.  As demonstrated 
in Figure 2, α1 and β2 subunits were negligibly expressed on the cell surface when only one 
subunit was transfected, so it seems unlikely that a substantial fraction of free or homomeric α1 or 
β2 subunits appears in the presence of partnering subunits.  It is also possible that some (or all) 
α1β2 receptors have unexpected stoichiometries such as 4α:1β or 1α:4β.  However, no study has 
concluded that such a stoichiometry occurs, and importantly neither of these isoforms could 
contain two GABA binding sites (β-α subunit interfaces).  Nonetheless, these possibilities must 
be considered when drawing conclusions about stoichiometry from the results of differential 
epitope tagging. 
First, one microgram each of α1 and β2 subunit cDNA was transfected per 6 cm plate of 
HEK293T cells (Figure 3A).  In these experiments, α1 subunit (α1HAβ2) expression levels were 
124 ± 8.0 % of β2 subunit (α1β2HA) expression levels.  In other words, the α1HA/β2HA ratio was 
1.24 ± 0.08, suggesting that there was neither a homogeneous population of 3α:2β receptors or 
2α:3β receptors.  By looking at partnering subunit levels, however, it appeared that the HA tag 
might reduce subunit expression to a greater extent when inserted into β2 subunits rather than α1 
subunits.  As mentioned previously, subunit levels tended to be slightly lower when a tagged 
rather than non-tagged partnering subunit was co-expressed (e.g., α1 subunit levels were lower in 
the α1β2HA condition than in the α1β2 condition).  However, HA-tagging β2 subunits appeared to 
affect partnering α1 subunit levels more than HA-tagging α1 subunits affected partnering β2 
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Figure 3. Differential epitope tagging indicated that α1β2 GABAA receptors could not 
have uniform stoichiometry.
A. HEK293T cells were transfected with 1 μg each of α1HA and β2 (black bars) or α1 and      
β2HA (grey bars) subunit cDNA and the α1, β2, and HA FIs were determined using flow 
cytometry.  Black bars represent relative levels of α1 subunits (α1HA) and grey bars repre-
sent relative levels of β2 subunits (β2HA); β2HA levels were taken as a relative FI of 1.0 and 
α1HA levels were normalized accordingly.  The “corrected” values (right side) were 
adjusted to account for potential confounding effects of the HA tag.  To correct α1HA levels, 
β2 subunit levels were compared in α1HAβ2 and α1β2 transfections.  Any change in β2 
subunit levels between the two conditions was taken as an effect of the HA tag, and α1HA 
levels were adjusted proportionally. (Anti-α1 subunit antibodies could not be used to com-
pare α1HA and α1 subunit levels because the HA tag disrupted the native epitope.)  Simi-
larly, to correct β2HA levels, α1 subunit levels were compared in α1β2HA and α1β2 transfec-
tions.  B. Identical to Panel A except that 0.5 μg of each subunit cDNA was transfected. 
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subunit levels.  If this partnering subunit decrease occurred because the HA tag reduced overall 
receptor expression, levels of the tagged subunit itself would be expected to decrease 
concomitantly.  (Unfortunately, this theory could not be tested directly because the HA tag 
disrupts binding of the native α1 and β2 subunit antibodies suitable for flow cytometry; thus, 
levels of β2 and β2HA subunits could not be compared using an anti-β2 subunit antibody.)  If the 
HA tag did decrease expression of both subunits similarly, then partnering subunit ratios could be 
used to correct for the adverse tag effects.  When α1HA and β2HA levels were adjusted accordingly, 
the α1HA/β2HA ratio decreased to 1.06 ± 0.07.  Of course, it is debatable whether the “corrected” 
or “uncorrected” ratio is the best estimate of relative α1 and β2 subunit levels, but as such both 
methods are presented here.   
There is another potential confounder in addition to the effects of the tag itself.  Results 
could be inaccurate if transfected fibroblasts simply expressed so much protein that surplus 
subunits were forced into abnormal receptor isoforms.  To address this possibility, the equimolar 
differential tagging experiments were repeated using only 0.5 μg each of α1 and β2 subunit 
cDNA (Figure 3B).  Interestingly, in this context the α1HA/β2HA subunit protein ratio was greater 
(1.78 ± 0.05). After adjusting for tag effects as described previously, the ratio decreased to 1.34 ± 
0.03, but still it was greater than the corrected ratio obtained using 1 μg of each subunit cDNA.   
a1 subunits appeared to “drive” receptor surface expression, but receptor stoichiometry could 
not be forced by cDNA transfection ratios 
Although the exact α1HA/β2HA subunit protein ratio varied depending on subunit cDNA 
levels and whether or not the raw levels were adjusted for HA tag effects, all conditions indicated 
that there was more α1 than β2 subunit protein on the cell surface.  This, in turn, suggested that 
the majority of α1β2 receptors contained three α1 and two β2 subunits.  To examine this 
possibility in more detail, titrations were conducted to see if the receptor stoichiometry is flexible; 
that is, whether or not the α1HA/β2HA subunit surface protein ratio could be altered by transfecting 
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different relative amounts of α1HA and β2HA subunit cDNA (the technique used to deduce 
stoichiometry of α4β2 nAChRs).  Comprehensive titrations were performed by transfecting each 
subunit cDNA at fivefold and twofold deficiencies and excess while the partnering subunit cDNA 
levels were held constant, then repeating the titrations with the opposite subunit tagged so that 
ratios could be determined for each transfection condition (Figure 4).  For instance, Panel A 
presents the results of transfecting 0.5 μg of β2 subunit cDNA together with 0.1, 0.25, 0.5, 1, or 
2.5 μg of α1 subunit cDNA when either the α1 subunit (black line) or β2 subunit (grey line) was 
HA-tagged.  In Panel B, titrations were performed similarly, but α1 subunit cDNA was held 
constant at 0.5 μg while β2 subunit cDNA levels were varied.  Interestingly, surface expression 
patterns differed depending on which subunit cDNA levels remained constant.  When β2 subunit 
cDNA levels were held constant, surface levels of both α1 and β2 subunits were proportional to 
α1 subunit cDNA levels across the entire tested range; that is, both α1 and β2 subunit surface 
levels continued to increase even when α1 subunit cDNA was transfected at fivefold excess (2.5 
μg α1 : 0.5 μg β2).  In contrast, when α1 subunit cDNA was held constant, α1 and β2 subunit 
surface levels increased only up to the point of equimolar transfection (0.5 μg α1 : 0.5 μg β2).  
Subunit surface levels did not increase further when 1 μg of β2 subunit cDNA was transfected, 
and they decreased when 2.5 μg of β2 subunit cDNA were transfected.   
The titrations also produced surprising α1HA/β2HA subunit protein ratios.  If receptor 
stoichiometry were determined simply by relative subunit cDNA amounts, the α1HA/β2HA subunit 
protein ratio should be highest when there is a fivefold excess of α1 subunit cDNA (0.5 μg α1 : 
0.1 μg β2 and 2.5 μg α1 : 0.5 μg β2 transfection conditions) and lowest when there is a fivefold 
excess of β2 subunit cDNA (0.5 μg α1 : 2.5 μg β2 and 0.1 μg α1 : 0.5 μg β2 transfection 
conditions).  However, the α1HA/β2HA subunit protein ratio did not vary greatly; if anything, it 
trended toward higher values when β2 subunit cDNA was transfected in excess.  This suggested 
that whatever the relative amount of α1 and β2 subunits might be, it was mostly independent of 
cDNA availability. 
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Figure 4. α1 and β2 subunits played different roles in receptor assembly and surface 
trafficking
A. HEK293T cells were transfected with 0.5 μg of α1 subunit cDNA and 0.1, 0.25, 0.5, 1.0, 
or 2.5 μg of β2 subunit cDNA.  The black line represents transfections where the α1 subunit 
was epitope-tagged (α1HAβ2) and the grey line represents transfections where the β2 
subunit was epitope-tagged (α1β2HA).  In each transfection condition, HA levels were 
measured using flow cytometry, quantified as described previously, and normalized to the 
levels obtained in the equimolar transfection condition (e.g., α1HAβ2 levels are normalized 
to the HA fluorescence intensity obtained when 0.5 μg of α1HA subunit and 0.5 μg of β2 
subunit cDNAs were transfected).  B. Identical to Panel A, but β2 subunit cDNA was held 
constant; i.e., HEK293T cells were transfected with 0.5 μg of β2 subunit cDNA and 0.1, 
0.25, 0.5, 1.0, or 2.5 μg of α1 subunit cDNA.  C. Transfections were identical to Panel A 
(β2 subunit cDNA held constant; α1 subunit cDNA levels indicated on the abscissa), but 
the α1HA/β2HA ratios are presented.  D. Transfections were identical to Panel B (α1 subunit 
cDNA held constant; β2 subunit cDNA levels indicated on the abscissa), but the α1HA/β2HA 
ratios are presented.
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Using surface biotinylation, α1HA/β2HA subunit protein ratios appeared to be even higher 
While it seems preferable to study expression of proteins in their native conformations, 
there are scenarios in which denatured proteins might yield more accurate results.  For instance, 
antibodies are approximately three times larger than GABAA receptor subunits (150 kDa vs. 50 
kDa), so steric hindrance might prevent antibodies from binding to all subunits in a receptor and 
relative ratios could be skewed.  Due to this possibility, some of the differential tagging 
experiments were repeated using HA antibody Fab fragments (50 kDa), but similar ratios were 
observed (data not shown).  However, considering that GABAA receptor subunits and Fab 
fragments are approximately equal in size, steric hindrance might still occur.  Moreover, even if 
antibody binding were not sterically hindered, protein folding could render some HA epitope tags 
inaccessible to antibodies and thereby alter the apparent ratios of α1 and β2 subunits. 
To address these possibilities, differentially tagged subunit cDNA titrations were 
performed again, but the α1HA/β2HA subunit surface protein ratio was assessed using surface 
biotinylation, denaturing SDS-PAGE, and immunoblotting (Figure 5).  Because denaturing 
conditions were used, neither steric hindrance nor epitope inaccessibility should pose an issue.  
Remarkably, the α1HA/β2HA subunit protein ratios obtained using surface biotinylation were even 
higher than those obtained using flow cytometry, ranging from approximately 2.5 to 5.5 (Figure 
5A, 5B).   
One more potentially confounding variable remained.  As discussed, the HA epitope tag 
was inserted between the fourth and fifth amino acids of each mature subunit protein, and this 
insertion position has been shown not to affect receptor expression or function significantly.  
However, the seventh amino acid in the mature β2 subunit peptide (residue 32 including the 
signal peptide) is an N-linked glycosylation site that has been shown to be occupied by a 
glycan335.  The homologous glycosylation site on α1 subunits occurs at residue 11 of the mature 
peptide.  N-glycans can be relatively large, so it is possible that the β2 subunit glycan inhibited 
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Figure 5. The α1HA/β2HA ratio obtained using denaturing SDS-PAGE and immunoblot-
ting was substantially higher than the ratio obtained using flow cytometry. 
A. HEK293T cells were transfected with the indicated amounts of GABAA receptor 
subunit cDNA (above gel).  Surface protein was isolated using biotinylation, denaturing 
SDS-PAGE was performed, and Western blots were probed with anti-HA antibodies.  In 
the top panel, α1 subunits were HA-tagged (α1HAβ2); in the bottom panel, β2 subunits were 
HA-tagged (α1β2HA).  B. Integrated intensity of protein bands in Panel A were quantified 
using Li-Cor Odyssey software, and the ratio of  α1HA/β2HA was calculated and graphed.  C. 
Identical to Panel A, but surface protein was deglycosylated with PNGaseF before SDS-
PAGE.  D. Bands in Panel C were quantified as described for Panel B.  
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HA antibody binding to the neighboring epitope tag (thereby underestimating β2 subunit levels) 
but that the α1 subunit glycan was distant enough from the epitope tag that HA antibody binding 
was not affected.  As such, immunoblotting was repeated after removing all N-glycans with 
peptide-N-glycosidase F (PNGase F) (Figure 5C).  Astonishingly, α1HA/β2HA ratios increased yet 
again, ranging from approximately 4.0 to approximately 7.5 depending on subunit cDNA levels 
(Figure 5D).  Taken together, the results presented in Figures 3-5 suggest that differential epitope 
tagging might not be an ideal method for determining precise subunit ratios and receptor 
stoichiometry, but it seems very likely that equimolar amounts of α1 and β2 subunit cDNA yield 
more α1 than β2 subunit protein on the cell surface.  
FRET indicated that the α1β2 receptor population could not have a uniform 3α:2β or 2α:3β 
subunit stoichiometry. 
Even if differential epitope tagging could accurately determine receptor stoichiometry, it 
could not identify subunit arrangement.  That is, even if the α1HA/β2HA ratio had been precisely 
1.5, it would remain unclear if the subunits alternated (α1-β2-α1-β2-α1) or not (α1-α1-α1-β2-
β2) – though, as discussed, the latter arrangement is unlikely because it contains only one GABA 
binding site.  Conversely, assessing subunit arrangement could help determine receptor 
stoichiometry.  If α1 and β2 subunits alternate, a uniform 3α:2β or 2β:3α population could be 
identified by the presence of specific subunit interfaces.  Both populations would contain α1-β2 
subunit interfaces, but 3α:2β receptors would not have β2-β2 subunit interfaces, while 2α:3β 
receptors would not have α1-α1 subunit interfaces.   
Homology modeling predicts that the distal N-terminal (antibody-accessible) domains of 
adjacent GABAA receptor subunits are predicted to be separated by ~50 Å, while those of non-
adjacent subunits are separated by ~80 Å.  Therefore, adjacency of freely-assembled subunits 
must be assessed by a method that can differentiate those two distances.  Fluorescence resonance 
energy transfer (FRET) is such a method, because energy transfer efficiency is inversely 
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proportional to the sixth power of the distance between donor and acceptor fluorophores 336.  
Because fluorophores have a defined Forster radius (the distance at which FRET efficiency is 
50% of maximum), careful selection of fluorophores should allow for exclusive monitoring of 
subunit adjacency.  The Alexa555 and Alexa647 fluorophore pair employed here has a Forster 
radius of 51 Å (www.invitrogen.com), meaning that essentially no energy transfer should occur 
between the non-adjacent subunits that are 80 Å apart.  In agreement with this, FRET did not 
occur between non-adjacent concatemer subunits (data not shown).  More importantly, 
considering the potential defects of the concatemers, FRET did not occur between individual γ2L 
subunits when α1, β2, and γ2L subunit cDNAs were co-transfected (Chapter III). 
To determine subunit adjacency using FRET and flow cytometry, cells transfected with 
HA-tagged α1 and β2 subunits were incubated with anti-HA and anti-α1 subunit antibodies 
conjugated to Alexa555 (donor) and/or Alexa647 (acceptor) fluorophores.  To determine α1-α1 
subunit adjacency, α1HA and β2 subunit cDNAs were transfected; to determine β2-β2 subunit 
adjacency, α1 and β2HA subunit cDNAs were transfected, and to determine α1-β2 subunit 
adjacency, α1 and β2HA subunit cDNAs were transfected but stained with anti-HA-A555 and anti-
α1-A647.  Figure 6 presents results of these experiments together with necessary controls.  FRET 
was identified by using a laser of the appropriate wavelength to excite the donor fluorophore (e.g., 
a 535 nm laser to excite Alexa555) and a filter that isolates emission from the acceptor 
fluorophore (e.g., a 675/20 nm bandpass filter to detect Alexa647 fluorescence).  Ideally, the only 
fluorescence detected in the acceptor channel would be emitted from acceptor fluorophores that 
were excited by energy transfer.  However, fluorophores have excitation and emission spectra 
that span a range of wavelengths.  As such, some Alexa555 emission might “leak” into the 675/20 
bandpass filter range, or alternatively some Alexa647 fluorophores might be excited by the 535 
nm laser.  Accurate assessment of protein adjacency with FRET requires that fluorescence 
detection channels be adjusted or “compensated” for this type of spectral leak. 
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Spectral compensation was performed by staining each sample with only HA-A555 
(donor, top row) or only HA-A647 (acceptor, middle row) antibodies and plotting the resulting 
fluorescence intensity against the fluorescence detected in the FRET channel (the 535 nm laser 
coupled with the 675/20 bandpass filter).  If only the donor or acceptor fluorophore was used and 
therefore FRET could not occur, there should be no correlation between these two fluorescence 
intensities.  As shown in Figure 6, no correlation existed after spectral compensation was applied.  
The FRET threshold (horizontal line) was defined such that less than 1% of cells were positive 
when stained with HA-A555 or HA-A647 antibodies alone.  When cells were stained with both 
HA-A555 and HA-A647 antibodies, strong FRET signals were detected between individual α1 
subunits (left column), between individual β2 subunits (middle column), and between α1 and β2 
subunits (right column).  It should be noted that these results could be replicated using several 
different epitope tags, antibodies, and fluorophores; furthermore, several conditions were FRET-
negative in experiments conducted using different subunit subtypes (Chapter III). As such, it 
seems unlikely that all possible FRET patterns were found simply because energy transfer 
occurred aberrantly between non-adjacent subunits.  Thus, another piece of evidence indicated 
that α1β2 receptor stoichiometry was heterogeneous, comprising a mixture of 3α:2β and 2α:3β 
isoforms. 
 
Discussion  
The combination of flow cytometry and FRET provides an efficient, quantitative method for 
evaluating subunit requirements, assembly patterns, and subunit arrangement of GABAA 
receptor isoforms 
Due to the large number of GABAA receptor subunit genes, neurons have the potential to 
produce a truly staggering variety of unique GABAA receptor isoforms.  The receptor diversity is 
probably invaluable for fine-tuning neuronal physiology, but it also poses challenges for 
researchers.  Because most neurons express a considerable subset of the available subunits, 
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Figure 6. Flow cytometric analysis of GABAA receptor α1 and β2 subunit FRET also 
suggested that α1β2 receptors did not assemble with uniform stoichiometry.
HEK293T cells were transfected with 1 μg of α1 subunit cDNA and, 1 μg of β2 subunit 
cDNA.  To determine subunit adjacency, each subunit was individually HA-tagged and 
cells were incubated with both anti-HA-Alexa555 and anti-HA-Alexa647 or anti-
α1-Alexa647 before being subjected to flow cytometry.  The left column presents α1-α1 
subunit adjacency (α1 HA-tagged); the middle column presents β2-β2 subunit adjacency (β
2 HA-tagged); and the right column presents α1-β2 subunit adjacency. The x-axis indicates 
fluorescence intensity of the donor (Alexa555; top row) or acceptor (Alexa647; middle and 
bottom rows) fluorophore, while the y-axis indicates fluorescence intensity of the FRET 
channel (excitation of Alexa 555 and emission of Alexa647).  The horizontal line repre-
sents the FRET threshold (see Methods) and the percentage of cells emitting above this 
threshold is indicated at the top of each dot plot. 
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recordings represent the aggregate currents produced by many different isoforms.  Similarly, 
immunohistochemistry generally cannot identify receptor subunit composition or stoichiometry; 
colocalized subunits may be within the same receptor or simply in adjacent receptors.  Resolution 
thresholds are continually improving, but atomic force or electron microscopy is still necessary to 
reliably assess subunit composition in situ.  For this reason, a substantial portion of the GABAA 
receptor literature comprises evaluation of individual receptor isoforms expressed in fibroblasts.  
However, knowledge about the structure of receptors formed even in such a constrained system 
remains somewhat limited.  The high-throughput techniques of flow cytometry and FRET have 
great potential to comprehensively evaluate the subunit composition and stoichiometry of 
GABAA receptor isoforms.  Here, these techniques were used to study one of the simplest 
possible isoforms, α1β2.  Although data quality, acquisition, and analysis were satisfactory and 
efficient, receptor assembly itself proved to be far more complicated than expected. 
 α1β2 receptor populations are unlikely to be homogeneous 
We anticipated that relative subunit expression levels and subunit adjacency patterns 
would identify a 3α:2β or 2α:3β receptor stoichiometry.  However, the α1HA/β2HA subunit level 
ratio was not consistent with either stoichiometry, and all possible subunit interfaces (α1-α1, β2-
β2, and α1-β2) appeared to form. As such, it seems almost certain that the α1β2 receptor 
population was heterogeneous, even though it remained difficult to define its components.   
When one microgram of each subunit cDNA was transfected and subunit expression 
levels were “corrected” for the potential effects of the epitope tags, there appeared to be 
approximately equal levels of α1 and β2 subunits on the cell surface (Figure 3).  However, the 
correction was based on an indirect measure of epitope tag effects, and separate experiments 
using lower subunit cDNA levels (0.5 μg/subunit) yielded a higher α1HA/β2HA subunit level ratio.  
Using surface biotinylation, the ratio appeared to be higher still.  Taken together, these data 
strongly suggested that α1 subunit surface levels were higher than β2 subunit surface levels.  
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However, the discrepancy clearly could not be explained wholly by a 3α:2β receptor population, 
because depending upon specific techniques and transfection conditions, α1HA/β2HA ratios ranged 
from around 1 to slightly less than 8.  It therefore seemed that the cell surface contained a 
puzzling excess of α1 subunit protein. 
To understand this phenomenon, it is necessary to consider how these “extra” α1 subunits 
were arranged – e.g., as monomers, homomultimers, or components of fully assembled 
pentameric receptors.  Although it is possible that some α subunits were present as monomers, the 
strong α-α FRET patterns suggested that the majority of surface α subunits must be adjacent to at 
least one other α1 subunit.  Furthermore, individual GABAA receptor subunits are thought to be 
retained in the endoplasmic reticulum (ER) and eventually degraded by ER-associated 
degradation (ERAD).  The excess α1 subunits could be self-associated as homodimers, trimers, or 
tetramers, but nearly all α1 subunits were found in pentamers when α1 and β3 subunits were 
coexpressed 329.  Efficient α1 subunit homopentamerization and forward trafficking would be 
consistent with all of these observations.  However, very few α1 subunits appeared to reach the 
cell surface in any arrangement when α1 subunit cDNA was transfected in isolation (Figure 2).  
Thus, if a large population of α1 homopentamers appeared when α1 subunit cDNA was co-
transfected with β2 subunit cDNA, β2 subunits would have to somehow promote their formation. 
This possibility seems counterintuitive – it is clear that GABA-gated α1β2 receptor 
isoforms assemble very efficiently when the subunits are co-expressed, so why should β2 subunit 
expression facilitate expression of presumably non-functional isoforms?  A potential explanation 
includes basic subunit association properties together with experimental artifacts.  First, the 
effects of β2 subunit overexpression on α1HA/β2HA levels must be considered.  If α1β2 GABAA 
receptor assembly occurred in the same way as α4β2 nAChR assembly, surplus β2 subunit cDNA 
would promote formation of 2α:3β receptor isoforms.  However, changing the relative amounts of 
α1 and β2 subunit cDNAs did not produce significant changes in the α1HA/β2HA ratio.  
Interestingly, though, there was a trend toward an increased α1HA/β2HA ratio when β2 subunit 
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cDNA was transfected in excess (Figure 4 C-D).  This might occur if surplus β2 subunits form 
unproductive oligomers that are targeted for degradation, effectively causing a deficit of β2 
subunits available for α1-β2 subunit heterooligomerization and promoting formation of 3α:2β 
heteropentamers.   
This still cannot account for the fact that the α1HA/β2HA ratio was sometimes greater than 
1.5, particularly when assessed via Western blotting.  Given that two methods produced two 
mathematically inconsistent results, it seems likely that technical issues were responsible.  The 
major difference between flow cytometry and immunoblotting is, of course, that the former 
evaluates folded proteins and the latter evaluates denatured proteins.  Thus, it seems that the anti-
α1 subunit antibody could access more epitopes in denatured than in folded proteins.  As 
discussed, antibodies are much larger than GABAA receptor subunits, and it would probably be 
difficult for five antibodies to bind to a single pentamer.  If so (and assuming that surface α1 
subunit homomers were pentameric), the number of α1 subunits expressed on the cell surface 
when α1 subunit cDNA was transfected alone (Figure 2B) could be greatly underestimated.  
Robust formation of α1 subunit homopentamers could also explain why there seemed to be higher 
total cellular expression of α1 subunits compared to β2 subunits when both were co-expressed at 
equimolar amounts (Figure 2D); effectively, there would be more “room” available for α1 
subunits because they could access all subcellular compartments regardless of whether they 
homo- or heterooligomerized.  Finally, α1 subunit homopentamerization coupled with β2 
homooligomer degradation would be consistent with the results presented in Figure 4A-B.  That 
is, when α1 subunit cDNA was transfected in excess (Figure 4A, right side of graph), surplus α1 
subunits formed homopentamers and were trafficked to the cell surface, but when β2 subunit 
cDNA was transfected in excess (Figure 4B, right side of graph), surplus β2 subunits produced 
unproductive lower-order homooligomers that were degraded. 
There remains one interesting result that might not be explained by faulty detection of α1 
subunit homopentamers: α1 subunit overexpression increased surface expression of β2 as well as 
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α1 subunits; i.e., α1 subunits seemed to “drive” overall expression levels.  It is possible that any 
given amount of subunit cDNA produces far more β2 subunit protein than can be assembled and 
trafficked to the cell surface.  However, it is also possible that in addition to forming pentameric 
receptors, α1 subunits can serve as chaperones.  A recent study concluded that the short splice 
variant of γ2 subunits (γ2S) could externally modulate receptor function by binding to the outside 
of a pentameric receptor, essentially functioning as an accessory protein337.  If α1 subunits 
assumed a similar role, the “accessory” α1 subunits could promote receptor assembly and forward 
trafficking, which would account for the fact that α1 (but not β2) subunit overexpression 
increases both α1 and β2 subunit surface trafficking.  Presumably, receptors bearing “accessory” 
α1 subunits should sediment separately from simple pentameric receptors in gradient 
centrifugations, but this was not observed in previous experiments329. However, this could be 
reconciled with the accessory subunit theory if the interaction between the pentamer and the 
accessory subunits is relatively weak and was disrupted during the process of protein purification.  
That said, although it is an intriguing possibility, neither we nor the group reporting accessory 
γ2S subunits have presented direct evidence that individual GABAA receptor subunits bind to the 
outside of GABAA receptor pentamers even in heterologous expression systems.  In future studies, 
it would be interesting to perform atomic force or electron microscopy to determine whether or 
not GABAA receptor subunits can assume the dual roles of receptor component and molecular 
chaperone. 
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CHAPTER III 
GABAA RECEPTOR γ2L AND δ SUBUNITS ARE ASSEMBLED AND TRAFFICKED 
SIMILARLY BUT DEGRADED AT DIFFERENT RATES  
 
 
Abstract  
GABAA receptors are heteropentameric ligand-gated chloride channels assembled from a 
large family of homologous subunits (α1-6, β1-3, γ1-3, δ, ε, θ, and π).  While the subunit 
stoichiometry and arrangement of αβγ receptor isoforms have been extensively investigated, 
relatively little is known about the assembly of receptor isoforms containing the δ subunit.  
Furthermore, there is still no consensus regarding how these receptors should be studied, as there 
is contradictory information about the technical requirements for forming homogeneous 
populations of αβγ or αβδ receptor isoforms in heterologous systems.  We therefore used flow 
cytometry to compare the surface expression profiles of HEK293T cells transiently transfected 
with human α1β2γ2L and α1β2δ receptors.  Similar to γ2L subunits, δ subunits were poorly 
expressed on the cell surface when transfected alone or in combination with either α1 or β2 
subunits but were efficiently expressed when co-transfected with both α1 and β2 subunits.  In 
addition, both γ2L and δ subunits appeared to be incorporated into ternary receptors at the 
expense of β2 subunits.  However, far less δ subunit than γ2L subunit cDNA was required to 
eliminate functional signatures of α1β2 receptors and to produce comparable expression levels of 
all subunits; when 1 µg each of α1 and β2 subunit cDNAs were transfected, maximal receptor 
expression occurred with 1 µg of γ2L subunit cDNA but only 0.03 µg of δ subunit cDNA.  The 
fact that both subunits were incorporated at the expense of β subunits suggested that α1β2γ2L and 
α1β2δ receptors might have identical arrangements, while the stark difference in efficiency 
suggests that they might not.  To compare the arrangements of γ2L and δ subunits in ternary 
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receptors, we employed a flow cytometry-based FRET assay for subunit adjacency.  Both 
α1β2γ2L and α1β2δ receptors yielded significant FRET signals between all possible 
combinations of non-identical subunits (i.e., α1-β2, α1-γ2L, α1-δ, β2-γ2L, and β2-δ), but only 
minimal FRET signals between identical subunits (i.e., α1-α1, β2-β2, γ2L-γ2L, or δ-δ), 
suggesting similar subunit arrangements of alternating α1, β2, and γ2L or δ subunits but failing to 
provide a reason for the different “potency” of γ2L and δ subunit cDNAs.  Further investigation 
demonstrated that δ subunits degraded much more slowly than γ2L subunits and that this was not 
due to different subcellular distributions.  We conclude that α1β2γ2L and α1β2δ receptors 
assemble similarly, but surprisingly low levels of γ2L and particularly δ subunit cDNAs are 
required to eliminate α1β2 receptor populations.  Moreover, δ subunits are remarkably more 
stable than γ2L subunits, which might have important implications for adaptive neuronal 
physiology. 
Introduction 
GABAA receptors are ligand-gated ion channels that mediate the vast majority of fast 
inhibitory signaling in the central nervous system.  They are assembled as heteropentamers from 
a large family of subunit subtypes (α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3), and their subunit 
composition determines receptor kinetics, pharmacology, and subcellular localization.  For 
example, αβγ receptors give rise to large amplitude, extensively desensitizing currents and tend to 
be concentrated in synapses, where they mediate “phasic” inhibition.  In contrast, αβδ receptors 
give rise to small amplitude, minimally desensitizing currents and are predominantly found in 
peri- and extrasynaptic compartments, where they mediate “tonic” inhibition168, 272, 338, 339.   
There is a general consensus that αβγ GABAA receptor isoforms contain two α subunits, 
two β subunits, and one γ subunit, which are arranged γ-β-α-β-α (anticlockwise as viewed from 
the synaptic cleft)328, 340.  It is also commonly assumed that the γ subunit is replaced by other 
subunits in other isoforms.  For αβδ receptor isoforms, this conclusion was reached because in 
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most studies, γ and δ subunits were not colocalized in brain and functional receptors did not 
contain both γ and δ subunits in heterologous expression systems.  The most direct evidence for 
the assumed stoichiometry and arrangement was provided by atomic force microscopy, which 
indicated that α4β3δ receptor isoforms do in fact assemble in the δ-β-α-β-α arrangement341.  
However, most studies of stoichiometry consist of functional characterization of receptors 
assembled from concatenated subunit constructs, and even these have reached contradictory 
conclusions116, 328.  Furthermore, concatemeric constructs themselves can pose several technical 
problems.  Expression levels are typically low, necessitating use of Xenopus oocytes that may 
express endogenous subunits; some dimeric or trimeric constructs have produced current when 
transfected alone; and the resulting receptors variably recapitulated the functional properties of 
freely-assembled receptors116, 342.  Finally, it is possible that the constructs cannot even strictly 
constrain stoichiometry because individual subunits may “loop out” or linkers may be cleaved330. 
In short, there is a surprising dearth of conclusive data regarding the stoichiometry and 
arrangement of subunits in GABAA receptor isoforms, including those formed through 
heterologous expression.  As such, we sought to examine certain simple questions.  First, do 
HEK293T cells express endogenous subunits and if not, are the previously reported subunit 
combinations necessary for surface expression accurate?  Is it possible to achieve a functionally 
homogeneous population of αβγ or αβδ receptor isoforms via heterologous expression?  If so, 
how much γ2L or δ cDNA relative to α and β cDNA should be used?  Finally, is there an efficient 
and direct method to determine the stoichiometry and/or subunit arrangement of freely-assembled 
receptors retaining their native conformation? 
To address these questions, we expressed various combinations of GABAA receptor 
subunits in HEK293T cells and assessed surface and total cellular expression of all subunits using 
flow cytometry.  We determined that our cell line contained no detectable endogenous GABAA 
receptor subunits, but there were clear rules for subunit surface trafficking.  Surprisingly, δ 
subunit-containing receptors did prove difficult to express, but this appeared to result from 
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excessive rather than inadequate amounts of δ subunit cDNA; peak subunit expression levels 
were achieved with tenfold less δ than γ2L subunit cDNA.   However, this phenomenon did not 
occur because γ2L and δ subunits were incorporated differently into receptor pentamers; rather, δ 
subunits were degraded at a markedly slower rate.  
 
Materials and Methods 
Cell culture and expression of recombinant GABAA receptors 
Human GABAA receptor α1, β2, γ2L, and δ subunits were individually sub-cloned into 
the pcDNA3.1+ mammalian expression vector (Invitrogen, Grand Island, NY).  Due to the lack 
of a highly specific, commercially available antibody targeting an extracellular domain on the 
γ2L and δ subunits, the HA (YPYDVPDYA) epitope was inserted between amino acids 4 and 5 
of the mature peptide.  This insertion site was selected for its minimal effect on receptor 
expression and function (see Chapter II).  The coding region of each vector was sequenced by the 
Vanderbilt University Medical Center DNA Sequencing Facility and verified against published 
sequences. 
HEK293T cells (American Type Culture Collection, Manassas, VA) were maintained at 
37°C in humidified 5% CO2 / 95% air using Dulbecco’s Modified Eagle Medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Invitrogen), 100 i.u./ml penicillin (Invitrogen), and 
100 μg/ml streptomycin (Invitrogen).  Cells were plated at a density of ~106 cells per 10 cm 
culture dish (Corning Glassworks, Corning, NY) and passaged every 2-4 days using trypsin-
EDTA (Invitrogen).  For flow cytometry and electrophysiology experiments, cells were plated at 
a density of 4x105 cells per 6 cm culture dish (Corning Glassworks) and transfected ~24 hours 
later with equal amounts (1 μg/subunit) of subunit cDNA using FuGene6 (Roche Diagnostics, 
Indianapolis, IN) per manufacturer protocol.  In conditions where less than 3 μg of subunit cDNA 
was transfected, empty pcDNA3.1 vector was added such that a total of 3 μg of cDNA was used 
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for each experimental condition (thus, the “mock” transfection condition consisted of 3 µg of 
empty pcDNA 3.1 vector cDNA).  An additional 1 μg of pHook-1 cDNA (encoding the cell 
surface antibody sFv) was included for electrophysiology experiments so positively transfected 
cells could be selected ~24 hours later by immunomagnetic bead separation, as previously 
described343.  Following selection, cells were re-plated at low density on collagen-coated 35 mm 
dishes for electrophysiological recording the following day. 
Electrophysiology 
Patch clamp recordings were performed at room temperature from excised outside-out 
membrane patches.  Cells were maintained during recordings in a bath solution consisting of (in 
mM): 142 NaCl, 8 KCl, 6 MgCl2, 1 CaCl2, 10 glucose, and 10 HEPES (pH adjusted to 7.4; 325-
330 mOsm).  All chemicals used for solution preparation were purchased from Sigma-Aldrich (St. 
Louis, MO).  Recording pipettes were pulled from thin-walled borosilicate capillary glass (Fisher, 
Pittsburgh, PA) on a Sutter P-2000 micropipette electrode puller (Sutter Instruments, San Rafael, 
CA) and fire polished with a microforge (Narishige, East Meadow, NY).  When filled with a 
pipette solution consisting of (in mM) 153 KCl, 1 MgCl2, 5 EGTA, 10 HEPES, and 2 MgATP 
(pH adjusted to 7.3; 300-310 mOsm) and submerged in the bath solution, this yielded open tip 
resistances of ~2 M Ω and a chloride equilibrium potential (ECl) of ~0 mV.  Currents were 
recorded at a holding potential of -20 mV using an Axopatch 200B amplifier (Molecular Devices, 
Foster City, CA), low-pass filtered at 2 kHz using a 4-Pole Bessel filter, digitized at 10 kHz using 
the Digidata 1322A (Molecular Devices), and stored offline for analysis.  GABA was prepared as 
a stock solution.  Working solutions were made on the day of the experiment by diluting stock 
solutions with the bath solution. 
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Kinetic Analysis 
Current kinetic properties were analyzed using Clampfit 9 (Molecular Devices).  Currents 
greater than 6 nA were excluded from analysis to minimize the confounding impact of series 
resistance error.  Rise time was defined as the time required for currents to increase from 10% to 
90% of their peak.  The time course of desensitization was fit with up to four exponential 
components.  The time course of deactivation was fit using the Levenberg-Marquardt least 
squares method to the form ∑ ane
(-t/τn)+ C, where t is time, n is the number of components, a is 
the relative amplitude, τ is the time constant, and C is the fraction of current remaining, with ∑ an 
= 1.  Additional components were accepted only if they significantly improved the fit, as 
determined by an F-test automatically performed by the analysis software on the sum of squared 
residuals.  Deactivation was typically biphasic, though as many as four components could be 
resolved with larger amplitude currents.  To facilitate comparison, the time course of deactivation 
was summarized as a weighted time constant in the form ∑ anτn with ∑ an = 1.  Solution exchange 
time was defined as the time for an open-tip liquid-junction current to increase from 10% to 90% 
of its maximum value.  Data were reported as mean ± SEM.  One-way ANOVA followed by a 
Dunnet’s multiple comparison test was used to compare results to the 1:1:0  and 1:1:1 µg 
transfection conditions, as indicated. 
Flow Cytometry 
Cells were harvested ~48 hours after transfection using 37°C trypsin/EDTA (Invitrogen) 
and placed immediately in 4°C FACS buffer composed of PBS (Mediatech), 2% fetal bovine 
serum (FBS) (Invitrogen), and 0.05% sodium azide (VWR).  Cells were then transferred to 96-
well plates, where they were washed twice in FACS buffer (i.e., pelleted by centrifugation at 450 
x g, vortexed, and resuspended).  For surface protein staining, cells were incubated in antibody-
containing FACS buffer for 1 h at 4°C, washed in FACS buffer three times, and resuspended in 
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2% w/v paraformaldehyde (PFA) (Electron Microscopy Sciences).  For total protein staining, 
samples were first fixed and permeabilized using Cytofix/Cytoperm (BD Biosciences) for 15 min.  
After washing twice with Permwash (BD Biosciences) to remove residual fixative, cells were 
resuspended in antibody-containing Permwash for 1 h at 4°C.  Following incubation with 
antibody, samples were washed four times with Permwash and twice with FACS buffer before 
resuspension in 2% paraformaldehyde.  The anti-α1 antibody was obtained from Millipore (clone 
bd24), conjugated to the Alexa647 fluorophore using an Invitrogen kit, and used at 4 μg/ml for 
surface staining and 2 μg/ml for total protein staining.  The anti-β2 antibody was obtained from 
Millipore (clone 62-3G1) and used at 8 μg/ml for surface staining and 4 μg/ml for total protein 
staining.  Because anti-β2 antibody conjugation proved inefficient, an anti-IgG1-Alexa647 
secondary antibody was used at a 1:500 dilution for most experiments.  Because accurate FRET 
analysis requires directly conjugated antibodies, a different anti-β2 subunit antibody clone (bd17; 
same epitope as 62-3G1 but suspended in PBS alone) was obtained from Millipore, conjugated to 
Alexa555 or Alexa647 fluorophores as described above, and used at a 1:50 dilution for all FRET 
experiments.  The anti-HA antibody (clone 16B12) was obtained from Covance as an Alexa-647 
conjugate and used at a 1:250 dilution for surface staining and a 1:500 dilution for total protein 
staining. 
Samples were run on a LSR II flow cytometer (BD Biosciences).  For each staining 
condition, 50,000 cells were analyzed.  Nonviable cells were excluded from analysis based on 
forward- and side-scatter profiles, as determined from staining with 7-amino-actinomycin D (7-
AAD) (Invitrogen).  The Alexa-555 fluorophore was excited using a 535 nm laser and detected 
with a 575/26 bandpass filter.  The Alexa-647 fluorophore was excited using a 635 nm laser and 
detected with a 675/20 bandpass filter.  Data were acquired using FACSDiva (BD Biosciences) 
and analyzed off-line using FlowJo 7.1 (Treestar).  To compare surface and total expression 
levels of GABAA receptor subunits, the mean fluorescence intensity of mock transfected cells 
was subtracted from the mean fluorescence intensity of each positively transfected condition.  
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The remaining fluorescence was then normalized to that of a control condition, yielding a relative 
fluorescence intensity ("Relative FI").  Statistical significance was determined using a one-sample 
t-test using a hypothetical mean of 1 (since data in each condition were normalized to wild-type 
expression).  Data were expressed as mean ± SEM. 
For protein degradation experiments, cells were plated at a density of 2x105 cells per 3 
cm culture dish and transfected as described above, but with a total of 1 μg of cDNA for each 
experimental condition.  Approximately 48 hours after transfection, 100 μL of 0.1% 
cycloheximide (Sigma-Aldrich) was added to culture dishes, which were subsequently returned to 
the 37°C incubator for the times indicated in the figure legends.  After incubation, cells were 
harvested, permeabilized, stained, and subjected to flow cytometry as previously described.   
Radiolabeling, immunoprecipitation, and SDS-PAGE 
HEK293T cells were plated and transfected with γ2LHA or δHA subunit cDNA as 
described above.  Two days after transfection, the culture medium was replaced with methionine-
free medium for 30 minutes and then replaced with medium containing 150 μCi/mL 35S-
methionine, and cells were returned to the incubator.  For synthesis studies, plates were removed 
after 5, 10, 15, or 20 minutes, immediately placed on ice, and washed with both non-radioactive 
media and PBS.  Membranes were lysed using radioimmune precipitation assay buffer (RIPA 
buffer; 50 mM Tris-HCl pH 7.4, 1% Triton-100, 250 mM NaCl, 5 mM EDTA) containing 
protease inhibitor cocktail (Sigma) and insoluble components were removed by centrifugation at 
15,000 x g for 20 minutes.  γ2LHA and δHA subunit proteins were incubated overnight with red 
anti-HA affinity gel (Sigma) and eluted using 125 μg/mL anti-HA peptide (Sigma).  Proteins 
were separated using SDS-PAGE (10% Bis-Tris gel).  The dried gel was exposed to a phosphor 
screen for two days and imaged using a Typhoon phosphorimager (Molecular Dynamics/GE 
Healthcare). The bands then were quantified using ImageJ.  Degradation studies were performed 
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identically except that after addition of radioactive medium, cells were returned to 37Co for 1, 2, 
3, 4, or 6 hrs.  
 
Results 
GABAA receptor δHA subunits had markedly different patterns of surface and total cellular 
expression compared to γ2LHA subunits when co-transfected with α1 and/or β2 subunits at 
equimolar ratios. 
To determine the subunit requirements for receptor surface trafficking, we transfected 
HEK293T cells with all possible combinations of α1, β2, γ2L, and δ subunit cDNAs, detected 
subunit protein with fluorescently-conjugated antibodies and evaluated fluorescence levels using 
flow cytometry.  Because no commercially-available antibodies raised against γ2 or δ subunits 
were suitable for flow cytometry, the HA epitope (YPYDVPDYA) was inserted between the 
fourth and fifth amino acids of γ2L and δ subunits and levels of these subunits were detected 
using an anti-HA antibody.  In agreement with previous results80, α1 (Figure 1A, 1D) and β2 
(Figure 1B, 1E) subunits were trafficked efficiently to the cell surface only when both α1 and β2 
subunit cDNA were coexpressed.  Low levels of α1 subunit surface expression were present in all 
α1 subunit-containing transfection conditions when the β2 subunit was not transfected (α1 = 2.9 ± 
0.3%, α1γ2LHA = 5.2 ± 0.2%, and α1δHA = 3.1 ± 0.5 of α1β2; n = 6), suggesting that small 
amounts of α1 subunits could be trafficked to the cell surface as monomers or homomultimers 
and that coexpressed γ2LHA or δHA subunits did not affect this process.  The most unexpected 
results involved the α1β2γ2LHA and α1β2δHA transfection conditions.  It is commonly thought that 
although αβγ and αβδ GABAA receptor isoforms differ greatly in their physiology and 
pharmacology168, the receptors are nearly identical in structure266.  Therefore, it was surprising 
that α1 subunit surface levels in the α1β2γ2LHA expression condition were approximately 90% of 
those in the α1β2 expression condition (93.0 ± 4.0% of α1β2, n = 6), but α1 subunit surface levels 
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Figure 1. GABAA receptor α1, β2, γ2LHA, and δHA subunit surface expression was highly 
sensitive to the presence and identity of partnering subunits.
HEK293T cells were transfected with various combinations of GABAA receptor subunit cDNAs 
and surface expression was evaluated using subunit-specific antibodies and flow cytometry.  
A-C. Representative flow cytometry histograms from cells transfected with the indicated 
combination of subunit cDNAs (left) and incubated with antibodies raised against α1 (A) or β
2/3 (B) GABAA receptor subunits or the HA epitope tag (C).  The abscissa indicates fluores-
cence intensity (FI) in arbitrary units plotted on a logarithmic scale, and the ordinate indicates 
percentage of maximum cell count (% of max).  Histograms for cells transfected with subunit 
combinations (dark gray) and cells transfected with blank vector (light gray) are overlaid. D-F. 
Quantifications of fluorescence intensities from cells transfected with the indicated combination 
of subunit cDNAs and incubated with antibodies raised against α1 (D) or β2/3 (E) GABAA 
receptor subunits or the HA epitope tag (F).  Mean fluorescence intensities from cells trans-
fected with blank vector alone were subtracted from mean fluorescence intensities of all other 
expression conditions.  All mock-subtracted fluorescence intensities were normalized to the 
mock-subtracted fluorescence intensity of the α1β2γ2LHA expression condition. 
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in the α1β2δHA expression condition were only approximately 10% of those in the α1β2 
expression condition (10.6 ± 0.4% of α1β2, n = 6).   
The β2 subunit surface expression patterns also suggested that α1β2γ2LHA and α1β2δHA 
isoforms might assemble differently (Figure 1B, 1E).  Once again, addition of δHA subunits 
decreased surface levels of partnering subunits more than addition of γ2LHA subunits.  
Specifically, β2 subunit surface levels in the α1β2γ2LHA expression condition were approximately 
30% of those in the in the α1β2 expression condition (31.6 ± 1.3% of α1β2, n = 5), but β2 subunit 
surface levels in the α1β2δHA expression condition were only approximately 5% of those in the in 
the α1β2 expression condition (6.2 ± 1.3% of α1β2, n = 5).  It was also noteworthy that 
incorporation of either γ2LHA or δHA subunits reduced β2 subunit surface expression far more than 
they reduced α1 subunit surface expression.  
Finally, we examined γ2LHA and δHA subunit surface levels using fluorescently-tagged 
anti-HA antibodies (Figure 1C, 1F).  Consistent with previous studies81, 344, we found that unless 
they were coexpressed with both α1 and β2 subunits, γ2LHA subunits reached the cell surface only 
at low levels (γ2LHA = 6.5 ± 0.9%, α1γ2LHA = 9.6 ± 1.6%, and β2γ2LHA = 8.9 ± 0.7 of α1β2γ2LHA; 
n = 6).  In contrast, δHA subunits reached the cell surface quite efficiently without regard to 
cotransfected subunits.  Surprisingly, surface HA levels did not differ significantly among δHA 
(26.1 ± 6.3%), α1δHA (37.0 ± 9.8%), β2δHA (26.7 ± 5.6%) and α1β2δHA (39.8 ± 8.1%) transfection 
conditions (all compared to α1β2γ2LHA; n = 6).   
The results presented in Figure 1 demonstrated that, when equimolar amounts of α1, β2, 
and γ2LHA or δHA subunits were expressed in fibroblasts, surface expression levels of all subunits 
were greatly suppressed by δHA subunits.  To determine if this reflected impairment of surface 
trafficking or of subunit expression, total cellular expression levels were assessed by repeating the 
previous experiments after cell permeabilization (Figure 2).  In general, the patterns of total 
cellular subunit expression resembled those of surface subunit expression but were less 
pronounced.  For instance, α1 subunit expression levels were approximately 80% when γ2LHA 
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subunits were included (α1β2γ2LHA = 81.3 ± 4.1% of α1β2; p < 0.01) but were approximately 
25% when δHA subunits were included (α1β2δHA = 24.5 ± 1.0% of α1β2; p < 0.001 compared to 
both α1β2 and α1β2γ2LHA).  Furthermore, when α1 subunits were transfected in the absence of β2 
subunits, the α1 subunits were expressed but at markedly lower levels (α1 = 55.3 ± 2.2%, 
α1γ2LHA = 50.0 ± 2.1%, and α1δHA = 20.6 ± 1.1% of α1β2; n = 6).  Total cellular expression of β2 
subunits also recapitulated less drastically the patterns seen in surface expression.  When γ2LHA 
subunits were included, β2 subunit expression decreased by almost half (α1β2γ2LHA = 60.5 ± 
3.9% of α1β2; p < 0.001), but when δHA subunits were included, β2 subunit expression was only 
approximately 10% (α1β2δHA = 11.6 ± 3.1% of α1β2; p < 0.001 compared to both α1β2 and 
α1β2γ2LHA).  In contrast to surface expression patterns, β2 subunits were expressed at low levels 
in the absence of α1 subunits (β2 = 24.7 ± 1.2%, β2γ2LHA = 24.0 ± 5.9%, and β2δHA = 9.0 ± 5.1% 
of α1β2; n = 5).   
Unlike α1 and β2 subunits, the total cellular expression patterns of γ2LHA and δHA 
subunits were quite different from their surface expression patterns.  First, when γ2LHA subunits 
were expressed alone or with either α1 or β2 subunits, γ2LHA levels were only about 50% 
compared to levels seen in the α1β2γ2LHA condition (γ2LHA = 46.2 ± 1.4%, α1γ2LHA = 59.6 ± 
1.0%, β2 γ2LHA = 59.6 ± 1.8% of α1β2γ2LHA , n = 5).  Second, total cellular δHA levels were 
equal to or higher than γ2LHA levels in all expression conditions.  On the cell surface, δHA 
subunits were expressed at similar levels regardless of coexpressed subunits, and all were less 
than 50% of γ2LHA levels present in the α1β2γ2LHA condition.  Total cellular δHA levels were also 
similar in all δ subunit-containing expression conditions, but they were not significantly different 
from γ2LHA levels in the α1β2γ2LHA condition (δHA = 96.9 ± 5.6%, α1δHA 89.5 ± 5.0%, β2δHA = 
91.2 ± 12.6%, and α1β2δHA = 83.7 ± 10.6% of α1β2γ2LHA; n = 6). 
In summary, α1, β2, and γ2LHA subunits all required both α1 and β2 subunits for efficient 
surface expression and for maximal total cellular expression, but δHA subunits could reach the cell 
surface alone or with any combination of coexpressed subunits.  Compared to γ2LHA subunits, 
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Figure 2. GABAA receptor α1, β2, 
γ2LHA, and δHA subunit total cellular 
expression was highly sensitive to the 
presence and identity of partnering 
subunits.
HEK293T cells were transfected with 
various combinations of GABAA 
receptor subunit cDNAs and total 
cellular subunit expression was evalu-
ated after permeabilization using flow 
cytometry.  A-C.  Fluorescence intensi-
ties were quantified from cells trans-
fected with the indicated combination 
of subunit cDNAs and incubated with 
antibodies raised against α1 (A) or β
2/3 (B) GABAA receptor subunits or 
the HA epitope tag (C).  Mean fluores-
cence intensities from cells transfected 
with blank vector alone were 
subtracted from mean fluorescence 
intensities of all other expression 
conditions.  All mock-subtracted 
fluorescence intensities were normal-
ized to the mock-subtracted fluores-
cence intensity of the α1β2γ2LHA 
expression condition.
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δHA subunits strongly reduced surface expression of all subunits and more moderately reduced 
total cellular expression of α1 and β2 subunits.  Despite these effects, total cellular expression of 
δHA subunits was robust; in other words, ample amounts of δHA subunits were produced, but they 
seemed to impede surface trafficking of all subunits.  Taken together, the expression levels of all 
four subunits could indicate that more δ subunits than γ subunits were incorporated into a receptor 
pentamer (i.e., α and β subunit levels were lower in the α1β2δHA condition than in the α1β2γ2LHA 
condition because δ subunits were more likely than γ subunits to displace α1 and β2 subunits), 
which would in turn mean that δ subunit-containing and γ subunit-containing receptors assemble 
quite differently.  On the other hand, coexpression of either γ2LHA or δHA subunits reduced 
expression of β2 subunits more than α1 subunits, which could indicate that both γ and δ subunits 
are usually incorporated into pentamers at the expense of β subunits.  Thus, some properties 
suggested that γ subunit-containing and δ subunit-containing receptors assembled similarly, while 
others suggested that the receptors assembled differently.  
GABAA receptor δHA subunits had nearly identical patterns of surface expression compared to 
γ2LHA subunits when co-transfected with α1 and β2 subunits at ten-fold lower levels. 
When subunits were transfected at equimolar ratios, the differences between γ2LHA and 
δHA levels were particularly striking.  For years, there has been a continuing debate in the GABAA 
receptor literature regarding what subunit cDNA ratios should be used in recombinant receptor 
studies276, 345, 346. We began with equimolar ratios because this should reflect the relative gene 
dosage in organisms; α1, β2, γ2, and δ GABAA receptor subunit genes are autosomal and none 
has been shown to be imprinted.  However, it is possible that γ and δ subunits incorporate into 
pentamers with different affinities and therefore require different transfection ratios.  To 
investigate this possibility, one microgram each of α1 and β2 subunit cDNA was transfected 
together with 0.001 – 10 μg of γ2LHA or δHA cDNA.   
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Increasing amounts of either γ2LHA or δHA subunit cDNAs appeared to produce similar 
patterns of subunit expression, but far less δHA subunit cDNA was required to produce 
comparable levels of subunit protein.  For instance, α1 subunit surface levels remained stable 
when low levels of either γ2LHA or δHA subunit cDNA was transfected (Figure 3A).  When ≥ 1 μg 
of γ2LHA subunit cDNA was transfected, α1 subunit levels progressively decreased (Figure 3A, 
black line).  However, only  ≥ 0.1 μg of δHA subunit cDNA was required to produce a similar 
decrease (Figure 3A, grey line).  Interestingly, it proved impossible to test subunit expression 
with higher δHA subunit levels due to widespread cell death when more than one microgram of 
δHA cDNA was transfected.   
Surface expression levels of β2 subunits responded somewhat differently to increasing 
amounts of γ2LHA or δHA cDNA.  There was no significant change in α1 subunit surface levels 
across a range of low levels of γ2LHA or δHA subunit cDNA, but β2 subunit levels did not exhibit a 
similar “plateau” phase.  Rather, all tested amounts of γ2LHA or δHA subunit cDNA caused 
concentration-dependent decreases in β2 subunit surface levels.  Similar to α1 subunit patterns, 
however, β2 subunit levels were equal when approximately tenfold less δHA than γ2LHA subunit 
cDNA was transfected.  Finally, γ2LHA and δHA subunit surface levels also had similar patterns 
but were different in subunit cDNA “potency.”  For both subunits, surface levels increased over a 
range of cDNA levels, peaked, and then decreased.  However, peak subunit surface expression 
occurred with 0.03 μg of δHA cDNA and 1 μg of γ2LHA cDNA.  Notably, these were also similar 
to the γ2LHA/δHA cDNA amounts at which α1 subunit protein levels began to decline. 
As seen with equimolar subunit expression (Figure 2), total cellular subunit expression 
patterns over a range of γ2LHA and δHA subunit cDNA levels were similar to surface expression 
patterns, though total cellular levels did not decrease quite as drastically as surface levels at the 
highest amounts of γ2LHA or δHA cDNA.  Levels of α1 subunits declined when more than 1 μg of 
γ2LHA subunit cDNA or 0.03 μg of δHA subunit cDNA was transfected, and levels of β2 subunits 
declined continuously, particularly when more than 0.01 μg of either γ2LHA or δHA subunit cDNA 
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Figure 3. GABAA receptor α1, β2, γ2LHA, and δHA subunits had similar surface expression 
levels and patterns but required markedly different amounts of γ2LHA or δHA cDNA.
Flow cytometry was used to evaluate surface expression of GABAA receptor subunits in 
HEK293T cells transfected with α1, β2, and varying amounts of γ2LHA or δHA subunit cDNAs.  
A-C.  Surface expression levels of α1 (A), β2 (B), and γ2LHA (C) subunits were evaluated in 
cells transfected with 1 μg α1 subunit cDNA, 1 μg β2 subunit cDNA, and 0.01–10 μg γ2LHA 
subunit cDNA. Mean fluorescence intensities from cells transfected with blank vector alone 
were subtracted from mean fluorescence intensities of all other expression conditions.  All 
mock-subtracted fluorescence intensities were normalized to the mock-subtracted fluorescence 
intensity of the 1 μg α1 : 1 μg β2 : 1 μg γ2LHA expression condition.  D-F.  Surface expression 
levels of α1 (D), β2 (E), and γ2LHA (F) subunits were evaluated in cells transfected with 1 μg α
1 subunit cDNA, 1 μg β2 subunit cDNA, and 0.001–1 μg δHA subunit cDNA. Mean fluorescence 
intensities from cells transfected with blank vector alone were subtracted from mean fluores-
cence intensities of all other expression conditions.  All mock-subtracted fluorescence intensi-
ties were normalized to the mock-subtracted fluorescence intensity of the 1 μg α1 : 1 μg β2 : 0.1 
μg δHA expression condition.
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was transfected.  Interestingly, the total cellular expression patterns of γ2LHA and δHA subunits 
themselves were somewhat different from their surface expression patterns.  Here, γ2LHA subunit 
levels peaked when 3 μg rather than 1 μg of cDNA was transfected, and levels declined from that 
peak by about 25% rather than 80% when 10 μg of cDNA was transfected.  Whereas δHA subunit 
surface levels peaked when 0.03 μg of cDNA was transfected and declined by about 75% when 1 
μg of cDNA was transfected, δHA total cellular levels increased over the entire range of cDNA 
amounts.  
These results suggest the following conclusions.  First, the fact that there was a range of 
γ2LHA/δHA subunit cDNA amounts that produced no change in α1 subunit levels, a decrease in β2 
subunit levels, and an increase in γ2LHA/δHA subunit levels implies that both γ2L and δ subunits 
preferentially replaced β2 subunits in surface receptors.  Because (1) neither α1 nor β2 subunits 
reached the cell surface at substantial levels when transfected alone (Figure 1), (2) GABAA 
receptors are pentameric347, and (3) each receptor has two GABA binding sites, both located at β-
α interfaces348, these patterns of subunit surface expression suggest that binary α1β2 receptors 
contain two α and three β subunits, and that γ and δ subunits replace one of the β subunits in 
ternary αβγ or αβδ receptors.  Second, surface levels of all subunits declined after γ2LHA/δHA 
subunit levels peak, and α1 and β2 subunit levels in particular were low at the highest tested 
amounts of γ2LHA/δHA subunit cDNA.  At these high levels of γ2LHA and δHA subunit cDNA (> 1 
μg γ2LHA and > 0.3 μg δHA), there was also considerable cell death.  Comparable levels of cell 
death were not seen in plates of cells treated with equal levels of transfection reagent alone or 
with transfection reagent plus blank pcDNA vector.  Taken together, these observations indicate 
that high levels of GABAA receptor subunit cDNA could impair both receptor trafficking and 
necessary cellular functions.  Further investigation will be required to identify the mechanism(s) 
responsible for these observations.  It will be interesting to determine if, for instance, large 
amounts of GABAA receptor subunits might exceed assembly capacity, thus causing ER retention, 
ER stress, and eventually apoptosis.  Finally, far less δHA than γ2LHA cDNA was required to 
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produce similar patterns and expression levels of all subunits.  Once again, this complicates the 
relatively simple question of whether or not γ subunit-containing and δ subunit-containing 
receptors assemble similarly or not.  The fact that both are incorporated at the expense of β 
subunits suggests that they do, while the stark difference in efficiency suggests that they may not.   
Low levels of both γ2L and δ subunits could eliminate the functional signature of α1β2 
receptors, but isoform populations may not become homogeneous. 
Frequently, the goal of heterologous expression studies involves identifying and 
characterizing properties of a particular receptor isoform (e.g., α1β2γ2).  Kinetic analysis, in 
particular, will be most accurate if the receptor population is homogeneous.  Thus, most 
disagreement regarding proper transfection ratios of subunit-encoding nucleic acids focuses on 
achieving homogeneity.  Because αβ receptors are expressed quite efficiently (Figure 1), some 
groups consider it necessary to transfect γ (or δ/ε/θ) subunit-encoding amino acids in excess (e.g. 
1:1:10 μg of α:β:γ cRNA)345, 346 to achieve a homogeneous ternary receptor population.  In 
contrast, other groups have found that the functional signature of α1β2 receptors (e.g., small 
single channel conductance, small current amplitude, slow current rise time, extensive fast 
desensitization, and slow deactivation) can be eliminated with equimolar cotransfection of the γ2 
subunit168, 276.  Finally, the subunit expression titrations presented here (Figure 3) suggest that 
significantly lower levels of δ subunits, in particular, would eliminate the α1β2 receptor 
population.  
To test the hypothesis that low levels of γ2/δ subunit cDNA could eliminate the 
functional signatures of α1β2 receptors, HEK293T cells were transfected with 1 μg each of α1 
and β2 subunit cDNA together with 0.01 – 10 μg of γ2 or δ subunit cDNA (for all conditions, 
both γ2 splice variants were compared; no significant differences were found, and data from the 
γ2S variant are presented here).  GABA was applied for 4 seconds and whole-cell currents were 
recorded and analyzed for peak amplitude and macroscopic kinetic properties including rise time, 
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extent of desensitization, and time of deactivation (Figure 4).  It should be noted that all 
experiments were conducted with the electrophysiologist blinded to transfection conditions, but 
this proved impossible for cells transfected with the highest tested levels of γ2 (10 μg) or δ (1 μg) 
cDNA due to widespread cell death and abnormal morphology.  Furthermore, the effects of > 1 
μg of δ subunit cDNA could not be tested due to nearly universal death and poor membrane 
integrity of surviving cells.   
For the most part, very low levels of γ2 subunit cDNA did produce significant changes in 
macroscopic current properties.  In these experiments, cells transfected with only α1 and β2 
subunit cDNAs had peak current amplitudes of 814 ± 266 pA (n = 14) (Figure 4B).  Surprisingly, 
adding only 0.01 μg of γ2 subunit cDNA significantly increased peak current amplitude to 3510 ± 
682 pA (n = 17, p < 0.05).  Higher γ2 subunit cDNA levels yielded similar increases in current 
amplitudes; all γ2 subunit cDNA amounts from 0.01 – 3 μg produced currents that were 
significantly larger than α1β2 currents.  The largest current occurred in the 1:1:0.3 μg transfection 
condition, which produced a peak current amplitude of 5866 ± 761 pA (n = 14, p < 0.001 
compared to α1β2).  However, none of these amplitudes was significantly different from that seen 
in the 1:1:1 μg transfection condition, despite the fact that γ2LHA subunit surface levels in the 
1:1:0.1 μg transfection condition were only about 15% of those in the 1:1:1 μg transfection 
condition.  Interestingly, there was a trend toward decreasing amplitude with high γ2 subunit 
cDNA amounts.  For the 1:1:10 μg transfection condition, peak current amplitude was only 2870 
± 480 pA (n = 21), which was 40% lower than the peak current amplitude seen in the 1:1:1 μg 
transfection condition (4530 ± 483 pA, n=25).  Despite this striking trend, peak current 
amplitudes of the 1:1:10 condition did not differ significantly from the peak current amplitude of 
any other experimental condition.  Nonetheless, these data suggest that high levels of γ2 subunit 
cDNA might promote formation of an unusual receptor population. 
It is somewhat understandable that a small αβγ receptor population could greatly increase 
current amplitude compared to a homogeneous αβ receptor population; due to various 
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Figure 4. GABA-evoked currents recorded from cells coexpressing α1, β2, and low levels of γ
2 and δ subunit cDNA had kinetic properties different from those of cells expressing only α1 
and β2 subunits.
GABA (1 mM; 4s) was applied to HEK293T cells transfected with 1 μg α1, 1 μg β2, and varying 
amounts of γ2L (A-E) or δ (F-J) subunit cDNA.  Whole-cell currents were recorded and 
analyzed to determine peak current amplitude (B, G); 10-90% rise time (C, H); percent fast 
desensitization (D) or overall desensitization (I) over 4 s from peak amplitude; and weighted 
time constant of deactivation (E, J).  Representative currents from a subset of transfection 
conditions are presented in panels A and F.
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microscopic kinetic properties, αβγ receptors yield about seven times the charge transfer of αβ 
receptors.  Consequently, if adding 0.01 μg of γ2LHA subunit cDNA converted 15% of surface 
α1β2 receptors into α1β2γ2L receptors, current amplitude would be expected to increase by 
approximately 90%.   It is possible, however, that macroscopic kinetic properties of αβ receptors 
would not be obscured.  Thus, currents obtained from each of these transfection conditions were 
analyzed for rise time, percent desensitization, and weighted deactivation times constants. 
These macroscopic current kinetic properties further supported the hypothesis that low 
levels of γ2 cDNA were sufficient to eliminate or greatly reduce the αβ receptor population.  The 
average 10-90% rise time (Figure 4C) of α1β2 receptor currents was 2.47 ± 0.19 ms (n = 14).  
This remained similar for the 1:1:0.01 μg transfection condition (2.23 ± 0.15 ms, n = 13), but 
decreased significantly for the 1:1:0.03 μg transfection condition (1.00 ± 0.10 ms, n = 9, p < 0.01).  
Rise times were similar (approximately 1 ms) when 0.03 – 1 μg of γ2 subunit cDNA was 
transfected, but trended upward when γ2 cDNA was used in excess.  At 1:1:3 μg, the 10-90% rise 
time was 1.79 ± 0.31 ms (n = 5), nearly slightly slower than that of the 1:1:1 μg transfection 
condition (1.48 ± 0.13 ms, n = 15), though this difference did not reach significance.  However, 
the 1:1:10 μg transfection condition yielded rise times dramatically longer than any other 
condition (3.48 ± 0.47 ms, n = 18; p < 0.05 compared to 1:1:0 and p < 0.001 compared to 1:1:1), 
again suggesting that abnormal isoforms might assemble when high levels of γ2 subunit cDNA 
are used. 
According to most reports, αβ and αβγ receptor isoforms both desensitize extensively, but 
αβ isoforms desensitize more rapidly.  To determine if a shift from α1β2 to α1β2γ2 receptor 
populations could be detected by changes in desensitization kinetics, 1 mM GABA was applied 
for 4 s to transfected cells and the desensitization time course of resulting currents was fitted with 
up to four exponential components (i.e., time constants; τ).  The percent of all desensitization 
contributed by the two shorter components (τ1 and τ2) was summed and defined as fast 
desensitization (Figure 4D).  For α1β2 receptors, 65% of all desensitization was contributed by τ1 
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and τ2, and this fraction dropped significantly when 0.01 μg of γ2 subunit cDNA was 
coexpressed (50 ± 5%, p < 0.05).  Only 0.03 μg of γ2 subunit cDNA was necessary to reduce fast 
desensitization to levels statistically indistinguishable from those produced by 1 μg of γ2 subunit 
cDNA (32 ± 5% and 23 ± 5%, respectively).  Interestingly, 10 μg of γ2 subunit cDNA reduced 
fast desensitization further, to a level that was significantly lower than 1 μg (5 ± 1%, p < 0.01).  
Thus, similar to the results for current rise time, the percentage of fast desensitization indicated 
that low levels of γ2 subunit cDNA were sufficient to produce kinetic properties different from 
those of α1β2 receptors, but high levels of γ2 subunit cDNA changed kinetic properties again, 
suggesting that a different receptor population may exist when γ2 subunit cDNA is transfected 
above equimolar amounts. 
The weighted time constant of deactivation (Figure 4E) also changed dramatically in 
response to the amount of γ2L subunit cDNA that was transfected (see Methods for calculation 
details).  Specifically, when more γ2L subunit cDNA was transfected, currents deactivated more 
rapidly (i.e., the deactivation time constant decreased).  For instance, the 1:1:0 μg transfection 
condition produced currents with a deactivation time constant of 498 ± 64 ms, while the 1:1:1 μg 
transfection condition produced currents with a deactivation time constant of 163 ± 27 ms and the 
1:1:10 μg transfection condition produced currents with a deactivation time constant of 68 ± 8 ms.  
In contrast to the patterns seen with current amplitude or rise time, deactivation accelerated rather 
steadily throughout the tested range of γ2L subunit cDNA levels, suggesting that the receptor 
population might not become homogeneous even when γ2L subunit cDNA is used in 
considerable excess.  In general, however, the macroscopic current properties of α1β2γ2L 
receptors seemed to indicate that low γ2L subunit levels could obscure the functional properties 
of α1β2 receptors, but receptor subunit composition might change again at very high γ2L subunit 
levels.  
Results from δ subunit titrations (Figure 4F-J) were similar but slightly more complex.  
GABA was applied for 4 s to HEK293T cells transfected with 1 μg each of α1 and β2 subunit 
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cDNA and 0 – 1 μg of δ subunit cDNA, and the resulting currents were analyzed for peak current 
amplitude (Figure 4G), 10-90% rise time (Figure 4H), percent desensitization (Figure 4I), and 
time constant of deactivation (Figure 4J).  In these experiments, cells expressing only α1 and β2 
subunits produced currents with peak amplitudes of 2811 ± 921 pA (n = 7).  When 0.01 μg of δ 
subunit cDNA was included, peak current amplitudes increased significantly to 6099 ± 880 pA (n 
= 6, p < 0.01 compared to 1:1:0 μg condition), but when 0.03 μg of δ subunit cDNA was included, 
peak current amplitude was only 2477 ± 453 pA (n = 8) – nearly indistinguishable from the 1:1:0 
μg condition.  When still more δ subunit cDNA was included, peak current amplitudes continued 
to decline, and equimolar transfection yielded peak current amplitudes of only 68.8 ± 24.1 pA (n 
= 6, p < 0.01 compared to 1:1:0 μg condition).  Theoretically, these small currents could have 
been produced by abnormal receptor isoforms that assembled due to high δ subunit levels, but it 
seems more likely that the small current amplitudes reflected the remarkably low subunit surface 
levels that were observed when 1 μg each of α1, β2, and δ subunit cDNA were transfected 
(Figures 1 and 3).  Given that the 1:1:0.3 and 1:1:1 μg α1β2δ currents were so small, all 
subsequent kinetic analysis should be interpreted with caution.  Additionally, it should be noted 
that similarly low subunit surface levels were present in cells transfected with 1:1:10 α1β2γ2, but 
current amplitudes remained relatively high (2800 ± 528 pA).  This discrepancy likely occurred 
because αβγ receptors produce larger currents than αβδ receptors, allowing current amplitude to 
compensate partially for the sharp decrease in surface levels.  
As δ subunit cDNA levels increased, 10-90% rise times became significantly slower.  
When only α1 and β2 subunits were transfected, currents had an average rise time of 3.7 ± 0.4 ms 
(n = 7), but when 0.03 μg of δ subunit cDNA was included, average rise time slowed to 9.9 ± 2.2 
ms (n = 8, p < 0.05 compared to 1:1:0 transfection condition).  The slowest rise times were 
observed in the 1:1:0.3 transfection condition, in which average rise time was 21.5 ± 2.7 ms (n = 
5, p < 0.001 compared to 1:1:0 transfection condition).  Interestingly, this was also significantly 
slower (p < 0.05) than average rise time in the 1:1:1 transfection condition (13.1 ± 1.2 ms, n = 6), 
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again suggesting that high transfection levels might not produce a homogeneous receptor 
population. 
It is commonly accepted that αβ receptor currents desensitize far more extensively than 
αβδ receptor currents 168.  In agreement, higher levels of δ subunit cDNA generally were 
correlated with lower desensitization percentage; in the 1:1:0 μg transfection condition, currents 
desensitized by 80.5 ± 3.2% (n = 7), while in the 1:1:1 μg transfection condition, currents 
desensitized by only 9.2 ± 3.0% (n = 6).  In all conditions other than 1:1:0.01 μg, desensitization 
percentage was significantly different than that of the 1:1:0 μg condition (p < 0.001).  However, 
all conditions other than 1:1:0.3 μg also desensitized differently than the 1:1:1 μg condition.  
Taken together, these data suggested that 0.03 μg of δ subunit cDNA was sufficient to greatly 
reduce current desensitization (i.e., to reduce the α1β2 receptor population), but that ≥ 0.3 μg of δ 
subunit cDNA might be necessary to achieve homogeneity.  However, as previously stated, the 
exceptionally small amplitude of the currents recorded from the 1:1:0.3 μg and 1:1:1 μg 
transfection conditions could render these observations suspect. 
Finally, the time course of channel deactivation was fitted for all transfection conditions 
and weighted deactivation time constants were calculated.  In previous studies, α1β3 and α1β3δ 
receptors deactivated at similar rates168, so it was perhaps unsurprising that there were no 
significant differences in deactivation time constants among all transfection conditions.  There 
was a trend toward slower deactivation when ≥ 0.03 μg of δ subunit cDNA was transfected (217.5 
± 64.2 ms, n = 8) compared to α1 and β2 subunits alone (104 ± 6.8 ms, n = 6), but substantial 
variability obscured any significance. 
Taken together, the electrophysiological data obtained from cells transfected with 1 μg α1 
and β2 subunit cDNA and 0 – 1 μg of δ subunit cDNA did not indicate a point at which a 
homogeneous α1β2δ receptor population appeared.  However, all kinetic parameters were 
significantly different from those of α1β2 receptors when only 0.03 μg of δ subunit cDNA was 
cotransfected with α1 and β2 subunits.  Furthermore, higher levels of δ subunit cDNA produced 
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such small currents (likely due to extremely low subunit surface levels) that kinetics were 
difficult to interpret; thus, the continual changes in kinetic parameters might not indicate that 
increasing δ subunit levels continually changed receptor stoichiometry.  Consequently, these data 
support but do not confirm the hypothesis that low levels of δ subunit cDNA are sufficient to 
eliminate α1β2 receptor populations.  
Low γ2 subunit cDNA levels were sufficient to produce pharmacological signatures of αβγ 
receptor isoforms.  
αβ and αβγ receptor isoforms can be distinguished pharmacologically in two different 
ways.  First, αβ, but not αβγ, receptor currents are strongly inhibited by Zn++ 349.  In contrast, αβ 
receptors are insensitive to diazepam (DZP), which binds to the interface between α and γ 
subunits and thereby enhances αβγ receptor GABA-evoked currents182, 255.  (Of note, αβδ 
receptors are partially Zn++-sensitive and entirely DZP-insensitive, so these techniques are not 
useful for differentiating αβ and αβδ receptors.)  To determine how much γ2 subunit cDNA was 
necessary to produce a Zn++-insensitive receptor population, peak current amplitude in response 
to GABA (1 mM, 4 s) was recorded (Imax(GABA)),  Zn++ (10 μM) was pre-applied for 10 seconds, 
and peak current amplitude was recorded again while GABA and Zn++ were co-applied 
(Imax(GABA+Zn++)).  Zn++ inhibition was quantified by dividing Imax(GABA+Zn++) by 
Imax(GABA) (Figure 5A).  As expected, cells transfected with only α1 and β2 subunits produced 
currents that were inhibited strongly by Zn++ co-application (peak current amplitude was 19 ± 1% 
of those evoked by GABA alone.)  When 0.01 or 0.03 μg of γ2 subunit cDNA was included, peak 
current amplitude was partially Zn++ sensitive (32 ± 13 and 84 ± 9% of Imax(GABA), respectively; 
p < 0.001 compared to αβ).  Surprisingly, when ≥ 0.1 μg of γ2 subunit cDNA was included, peak 
current amplitude was maximally Zn++ insensitive, again suggesting that low γ2 subunit levels are 
sufficient to produce currents that functionally resemble α1β2γ2 receptor currents.   
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Figure 5: Low levels of γ2 subunit cDNA were sufficient to produce Zn++-insensitive and 
DZP-sensitive currents.
A. HEK293T cells transfected with 1 μg α1, 1 μg β2, and varying amounts of γ2L subunit cDNA 
were pre-treated (10 s) with Zn++ (10 μM) and currents were recorded during a 4 s 
co-application of GABA (1 mM) and Zn++ (10 μM).  Zn++ resistance was calculated by divid-
ing the peak current amplitude in response to GABA + Zn++ by the peak current amplitude in 
response to GABA alone. B. Currents were recorded from HEK293T cells transfected with 1 μ
g α1, 1 μg β2, and varying amounts of γ2L subunit cDNA during a 4 s co-application of GABA 
(~EC20) and DZP (1 μM).  DZP enhancement was calculated by dividing the peak current 
amplitude in response to GABA + DZP by the peak current amplitude in response to GABA 
alone.
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As mentioned previously, αβγ receptors are inhibited by Zn++ but enhanced by DZP.  To 
determine how much γ2 subunit cDNA was necessary to produce a DZP sensitive receptor 
population, the percent enhancement of ~EC20 GABA-evoked peak current amplitude by 1 μM 
DZP was evaluated.   Even 0.01 μg of γ2 subunit cDNA permitted substantial DZP potentiation 
of peak current amplitude (134 ± 13% of control current), and 0.03 μg was sufficient to produce 
potentiation (204 ± 18%) indistinguishable from 1 μg (260 ± 26%) or 10 μg (257 ± 56%). In 
summary, both of the pharmacological methods that most reliably differentiate αβ and αβγ 
receptors indicated that remarkably low levels of γ2 subunit cDNA are necessary to produce 
α1β2γ2 receptors.  
GABAA receptor δHA subunits had nearly identical patterns of subunit adjacency compared to 
γ2LHA subunits when transfected at ten-fold lower levels. 
The data presented thus far revealed several interesting differences between γ2L and δ 
subunits.  First, the presence of both α1 and β2 subunits was required for surface expression of α1, 
β2, or γ2LHA subunits, but δHA subunits reached the surface without regard to coexpressed 
subunits.  Second, equimolar transfection of α1, β2, and γ2LHA subunits produced far higher 
surface levels of all subunits than equimolar transfection of α1, β2, and δHA subunits, but both 
γ2LHA and δHA subunits seemed to be expressed and trafficked at the expense of β2 subunits.  
When increasing amounts of either γ2LHA or δHA subunit cDNAs were cotransfected with 1 μg 
each of α1 and β2 subunit cDNAs, maximal surface expression of all subunits occurred with 1 μg 
of γ2LHA but only 0.03 μg of δHA subunit cDNA.  Beyond this point, α1 subunit levels began 
decreasing sharply, while β2 subunit levels began decreasing with even the smallest amount of 
γ2LHA or δHA subunit cDNA that was transfected.  Finally, patch clamp recording suggested that 
low levels of γ2LHA or δHA subunit cDNA could eliminate the physiological signatures of α1β2 
receptor isoforms (i.e., produce αβγ/αβδ receptor populations), but very high levels of γ2LHA or 
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δHA cDNA might produce receptors with yet another, different stoichiometry, particularly for 
α1β2γ2LHA receptors. 
As previously mentioned, it is commonly thought that γ and δ subunits are essentially 
interchangeable in receptor assembly; i.e., that receptor stoichiometry and arrangement are γ/δ-β-
α-β-α, anticlockwise as viewed from the synaptic cleft350.  However, more recent studies using 
have suggested that δ subunit-containing receptors may assemble in multiple different ways351.  
Both conclusions have been drawn mostly from functional characterization of receptors 
assembled from concatenated subunits, which artificially constrain subunit arrangement.  One 
goal of the present study was to determine if these two isoforms assemble similarly or differently 
when native subunits are used.  As discussed in Chapter II, patterns of subunit adjacency could 
help answer this question. 
Fluorescence resonance energy transfer (FRET) is an established methodology for 
monitoring protein-protein interactions336.  In contrast to conventional biochemical techniques 
(e.g., co-immunoprecipitation), FRET can be used to monitor proteins in their native 
conformations and to identify direct protein interactions.  Although FRET can be measured by 
spectrofluorimetry and microscopy, flow cytometry offers several advantages over these 
techniques.  Unlike spectrofluorimetry, measurements can be performed in individual cells, and 
importantly, donor emission can easily be distinguished from sensitized emission of the acceptor.  
While microscopy allows the subcellular localization of protein interactions to be evaluated, the 
technique is less sensitive, analysis is labor intensive and poorly quantitative, and selecting 
regions of interest is highly subjective.  Flow cytometry, in contrast, allows for rapid, quantitative, 
and unbiased analysis of FRET in large cell populations, and permits the simultaneous analysis of 
other cellular properties (e.g., viability).   
Based on homology modeling to nAChRs, GABAA receptors are thought to assemble into 
pseudo-symmetrical pentamers158.  As a result, each subunit is predicted to have two “adjacent” 
subunits and two “non-adjacent” subunits.  The amino termini (where our subunit- and epitope-
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specific antibodies bind) of adjacent subunits are separated by ~50 Å, while those of non-adjacent 
subunits are separated by ~80 Å.  Since FRET efficiency is inversely proportional to the sixth-
power of distance336, careful selection of fluorophores should allow for exclusive monitoring of 
subunit adjacency.  For example, the Alexa-555 and Alexa-647 fluorophore pair has a Forster 
radius (the distance at which FRET efficiency is 50% of maximum) of 51 Å 
(www.invitrogen.com), meaning that non-adjacent subunits should contribute minimally to the 
FRET signal.   
To determine if identical subunits were adjacent in α1β2, α1β2γ2L, or α1β2δ receptors, 
one subunit was HA-tagged at a time (e.g., α1HAβ2), and the resulting receptors were stained with 
the HA-A555 / HA-647 antibody mixture.  For α1β2 receptors (top row), FRET was observed 
between individual α1 subunits (Figure 6, left column) and individual β2 subunits (Figure 6, 
middle column).  Addition of 1 μg of the γ2L subunit (Figure 6, middle row) or 0.1 μg of the δ 
subunit (Figure 6, bottom row) produced essentially identical FRET patterns.  In both cases, 
subunit addition greatly reduced FRET between individual α1 subunits and essentially eliminated 
FRET between individual β2 subunits.  Consistent with incorporation of γ2L/δ subunits into the 
pentamer, FRET was also detected between α1 and γ2L/δ subunits and between β2 and γ2L/δ 
subunits).  FRET was not detected, however, between individual γ2L or δ subunits, suggesting 
either that a single γ2L or δ subunit was incorporated into each pentamer or, alternatively, that 
two γ2L or δ subunits were incorporated but separated by either an α1 or β2 subunit.  Considering 
the presumed stoichiometry of ternary GABAA receptors (2α:2β:1γ/δ), these results supported 
previous conclusions that the majority of α1β2γ2L/δ receptors were composed of alternating α1, 
β2, and γ2L/δ subunits.  If true, then the only possible arrangements around the pentamer would 
be γ/δ-α-β-α-β or γ/δ-β-α-β-α (clockwise when viewed from the synaptic cleft).  The FRET 
patterns also suggest that α1β2 receptors have a similar arrangement, with the γ2L/δ subunit 
position being occupied by either α1 or β2 subunits.   
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Figure 6. Flow cytometric analysis of GABAA receptor γ2LHA or δHA subunit FRET with 
partnering α1 and β2 subunits when transfected at “expression-equivalent” levels suggested 
that γ2LHA and δHA subunits assembled in similar patterns.
HEK293T cells were transfected with 1 μg of α1 subunit cDNA, 1 μg of β2 subunit cDNA, and 
either blank pcDNA vector or the amount of γ2LHA or δHA subunit cDNA that achieved maximal 
expression (Figure 3). The α1 and β2 subunit cDNAs were cotransfected with 1 μg pcDNA 
vector (top row), 1 μg γ2LHA subunit cDNA (middle row), or 0.1 δHA cDNA + 0.9 μg pcDNA 
vector (bottom row).  To determine subunit adjacency, each subunit was individually HA-tagged 
and cells were incubated with both anti-HA-Alexa555 and anti-HA-Alexa647 before being 
subjected to flow cytometry.  The left column presents α1-α1 subunit adjacency (α1 
HA-tagged); the middle column presents β2-β2 subunit adjacency (β2 HA-tagged); and the right 
column presents γ2L-γ2L or δ-δ subunit adjacency. For all dot plots, the x-axis indicates fluores-
cence intensity of the acceptor fluorophore (Alexa 647), while the y-axis indicates fluorescence 
intensity of the FRET channel (excitation of Alexa 555 and emission of Alexa 647).  The 
horizontal line indicates the FRET threshold (see Methods) and the percentage of cells emitting 
above this threshold is listed at the top of each dot plot.
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The ten-fold difference in GABAA receptor γ2LHA and δHA subunit total cellular expression 
persisted in the absence of partnering subunits. 
The phenomenon observed in Fig. 3 (peak subunit protein expression at tenfold lower 
levels of δ compared to γ2L subunit cDNA) could result from different levels of subunit 
synthesis/degradation or from more efficient incorporation of δ subunits into GABAA receptors.  
However, the FRET studies suggested that γ2LHA and δHA subunits incorporated similarly into 
pentamers.  Therefore, subunit mRNA and protein levels were evaluated in HEK293T cells 
transfected with varying concentrations of γ2LHA or δHA subunit cDNA alone (i.e., without α1 and 
β2 subunits).  Because α1 and β2 subunits were necessary for full surface expression of γ2LHA 
and δHA subunits, these experiments should determine if the greater efficiency of δHA subunit 
expression was an artifact of receptor assembly or due to some intrinsic difference between the 
subunits themselves.  To test the hypothesis that the difference between γ2LHA and δHA expression 
levels was a result of more efficient transcription, real-time PCR was performed on cells 
transfected with the same range of subunit cDNA used in the single-subunit protein studies.  
Transcript levels were determined by normalized difference in cycle number fold increase.  As 
cDNA levels increased, mRNA levels for γ2LHA and δHA subunits increased similarly and 
proportionally (Figure 6A), indicating that equivalent amounts of γ2LHA and δHA cDNA did not 
produce different amounts of protein because of differences in transcription efficiency.   
Next, HEK293T cells were transfected with 0.001 µg to 1 µg of γ2LHA or δHA subunit 
cDNA and total cellular levels of γ2LHA and δHA subunit protein were assessed using flow 
cytometry.  Total cellular expression of δHA subunits (solid grey line) was significantly higher 
than that of γ2LHA subunits (solid black line) when less than 1 μg of subunit cDNA was 
transfected (Figure 6B); for instance, levels of δHA subunit protein levels present when 0.03 µg of 
δHA cDNA was transfected were nearly identical to levels of γ2LHA subunit protein when 0.3 µg 
of γ2LHA cDNA was transfected.  Thus, the ten-fold difference in γ2LHA and δHA subunit 
expression levels (Figure 3) persisted in the absence of partnering subunits, suggesting that δHA 
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subunit cDNA was not more “potent” due to more efficient receptor assembly; rather, δHA and 
γ2LHA subunits might differ in efficiency of subunit production and/or degradation. 
Heterologous expression is useful for basic biochemical studies because many possible 
confounding variables can be controlled or eliminated.  However, this depends upon the design of 
the nucleic acid construct.  For instance, if the γ2LHA coding sequence and untranslated regions 
were significantly longer than those of the δHA subunit, then equimolar amounts of plasmid DNA 
might not represent equimolar amounts of subunit cDNA.  Full sequencing confirmed that the 
γ2LHA and δHA subunit inserts (translated and untranslated sequences) were approximately the 
same length; however, the sequences of their immediate 5’ untranslated regions differed slightly.  
This could be problematic, because the three base pairs preceding and two base pairs following a 
start codon constitute the Kozak sequence, which contributes to the efficiency of translation 
initiation.  Specifically, ribosome binding is strongly enhanced by the presence of purines at the -
3 and +4 positions with respect to the start codon352.  In our cDNA constructs, the Kozak 
sequence of γ2LHA subunit cDNA was TCC(AUG)A, while the corresponding sequence in δHA 
subunit cDNA was GCC(AUG)G; consequently, the δHA subunit would be predicted to be 
translated more efficiently than the γ2LHA subunit.  To rule out the possibility that the previous 
observations were due to this difference in cDNA sequence, the Kozak sequences were swapped.  
That is, plasmids were engineered such that the γ2LHA construct contained the Kozak sequence 
GCC(AUG)G and the δHA construct contained the Kozak sequence TCC(AUG)G (γ2L(T-3G)HA 
and δ(G-3T)HA, respectively).  
The single-subunit titration experiments were repeated using the γ2L(T-3G)HA and δ(G-
3T)HA constructs.  Surprisingly, the Kozak sequence mutations had little effect on subunit 
expression levels; there was no significant difference between γ2LHA (Figure 7, solid black line) 
and γ2L(T-3G)HA (Figure 7, dotted black line) or between δHA (Figure 7, solid grey line) and δ(G-
3T)HA (Figure 7, dotted grey line) subunit levels at any tested amount of subunit cDNA.  
Therefore, it seemed that the ten-fold difference in GABAA receptor γ2LHA and δHA subunit 
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Figure 7. The ten-fold difference in total cellular expression of γ2LHA and δHA subunit protein 
persisted in the absence of partnering subunits and was not due to different rates of transcrip-
tion or translation.
A. RNA was extracted from HEK293T cells transfected with 0.001-3 μg of γ2LHA (black line) 
or δHA (grey line) cDNA and relative mRNA levels of each subunit were determined by real-time 
PCR.  The x-axis indicates the amount of subunit cDNA transfected, and the y-axis indicates the 
ΔΔCt for subunit RNA normalized to the value for 1 μg cDNA.  All mRNA levels were normal-
ized to housekeeping genes.  B.  Flow cytometry was used to detect total cellular levels of γ2LHA 
(solid black line) and δHA (solid grey line) subunits when 0.001 – 3 μg of subunit cDNA was 
transfected in the absence of partnering α1 and β2 subunits.  To determine if translation initiation 
due to Kozak sequences could affect subunit expression levels, the experiments were repeated 
after the Kozak sequences were swapped (γ2L(T-3G)HA, dashed black line; δ(G-3T)HA, dashed 
grey line).  All mock-subtracted fluorescence intensities were normalized to that of cells trans-
fected with 1 μg of γ2LHA subunit cDNA.
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expression did not result from differences in subunit synthesis at either the stage of transcription 
or translation initiation.  
The ten-fold difference in GABAA receptor γ2LHA and δHA subunit expression could not be 
explained fully by different rates of synthesis or by degradation of newly-synthesized subunits. 
Because receptor assembly, transcription efficiency, and translation initiation were not 
responsible for the disparity in γ2LHA and δHA subunit protein levels, it stood to reason that 
something further along the biogenic pathway could explain that difference.  Although initiation 
of protein synthesis did not seem to differ between the two subunits, it is possible that the 
subsequent rate of protein synthesis differed significantly and thus was responsible for the higher 
levels of δ subunit protein.  To assess the rate of protein synthesis, HEK293T cells transfected 
with 1 μg of either γ2LHA or δHA subunit cDNA were incubated for 0-20 min in media containing 
150 μCi/mL 35S-methionine (Figure 8A).  At 5 min intervals, radiolabeled GABAA receptor 
subunit protein was precipitated by incubation with anti-HA beads.  After elution, protein was 
subjected to SDS-PAGE and exposed to a phosphor screen.  Integrated band density for each time 
point was calculated and normalized to the integrated band density of γ2LHA subunits that were 
radiolabeled for 20 min (Figure 8B).  Surprisingly, it appeared that despite being engineered into 
identical plasmids and thus being regulated by identical promoters, δHA subunits were synthesized 
at a slightly faster rate than γ2LHA subunits.  When levels at each time point were directly 
compared, δHA subunit levels were significantly greater than γ2LHA subunit levels at the 5, 10, and 
15 min time points (p < 0.01 for all).  In contrast, when the synthesis curves were fitted using a 
mixed procedure model produced in consultation with the Vanderbilt University Department of 
Biostatistics, the estimated difference in the synthesis curve slopes was not significantly different 
(p = 0.099).  Although somewhat difficult to interpret, these data suggested that different rates of 
synthesis could contribute to the disparity in subunit levels, but other factors such as subunit 
degradation likely contribute as well. 
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Figure 8. GABAA receptor γ2LHA and δHA subunits were synthesized at similar rates, and 
newly-synthesized γ2LHA and δHA subunits were degraded at similar rates.
Metabolic labeling was used to assess the synthesis and degradation rates of γ2LHA and δHA 
subunits.  A. HEK293T cells expressing equivalent amounts of γ2LHA or δHA subunits were 
cultured for 0 – 20 min in media containing 35S-methionine.  Subunit protein was isolated from 
cell lysates by immunoprecipitation and separated by SDS-PAGE.  The upper panel presents a 
representative gel exposure, and the lower panel presents a quantification of band intensity 
(IDV) averaged from four separate experiments.  Band intensities are normalized to that of the 
20 min incubation condition.  B.  HEK293T cells expressing equivalent amounts of γ2LHA or 
δHA subunits were cultured for 20 min in media containing 35S-methionine.  To assess degrada-
tion rates of this newly-synthesized protein population, radioactive media was subsequently 
replaced by regular media and cells were returned to incubators for 0 – 6 hours. Subunit protein 
was isolated from cell lysates by immunoprecipitation and separated by SDS-PAGE.  The upper 
panel presents a representative gel exposure, and the lower panel presents a quantification of 
band intensity (IDV) averaged from four separate experiments.  Band intensities are normalized 
to that of the 0 min chase condition.
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Radiolabeling was also used to determine the degradation rates of γ2LHA and δHA subunits.  
HEK293T cells transfected with 1 μg of either γ2LHA or δHA subunit cDNA were incubated for 20 
min in radioactive media.  Subsequently, the radioactive medium was replaced with normal 
culture medium, and cells were returned to the incubator.  After 0, 1, 2, 3, 4, or 6 hours, γ2LHA 
and δHA subunit proteins were extracted, immunoprecipitated, and processed as described above 
(Figure 8C).  Integrated band density for each subunit was calculated and normalized to the 0 hr 
time point.  Both subunits had a half-life of approximately 1.5 hrs and decayed with essentially 
identical time courses (Figure 8D).  It should be noted that a similar decay course has been 
reported for γ2S subunits353.  Thus, it seemed that different rates of degradation were not 
responsible for the differing levels of γ2LHA and δHA subunits. 
γ2LHA and δHA subunits at steady state had markedly different rates of degradation. 
To this point, it was evident that approximately tenfold less δHA than γ2LHA subunit 
cDNA was required to produce equivalent amounts of protein two days after transfection and that 
no biogenic step was obviously responsible for the disparity.  However, it is important to note that 
pulse-chase studies measure degradation only of protein that was synthesized during the 20-
minute labeling period.  This should represent only a fraction of all subunits, whereas flow 
cytometry measures total cellular protein.  It is possible that the γ2LHA and δHA subunit 
populations that were not radiolabeled could degrade differently.  To determine if the entire 
cellular populations of γ2LHA and δHA subunits were degraded at different rates, HEK293T cells 
were transfected with γ2LHA and δHA subunit cDNA and cultured as in previous experiments, but 
protein synthesis was inhibited by adding 100 μg/mL cycloheximide (CHX) to the culture 
medium two days after transfection.  Cells were cultured in the presence of CHX for 0-6 hrs 
before being harvested, permeabilized, incubated with antibodies, and subjected to flow 
cytometry.  Thus, the degradation rates of the total cellular subunit populations were assessed 
over a 6 hour time period. 
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In contrast to the results obtained using radiolabeling, γ2LHA subunits degraded 
significantly more quickly than δHA subunits (Figure 9A).  During the first hour of treatment, both 
subunits decayed similarly; after one hour, γ2LHA subunit levels (solid black line) had decreased 
to 77.2 ± 4.4% of 0 hr levels, while δHA subunit levels (solid grey line) had decreased to 81.9 ± 
4.8% of 0 hr levels.  After this point, however, degradation time courses diverged.  Surprisingly, 
δHA subunit levels remained stable at approximately 80% of 0 hr levels (6 hrs CHX: 86.0 ± 7.1%).  
In contrast, after three hours of CHX treatment, γ2LHA subunit levels were approximately half 
(53.8 ± 2.3%) of 0 hr levels, and they remained similar through the rest of the 6 hr treatment 
period (6 hrs: 49.1 ± 3.5% of 0 hr levels).  However, it is important to note that γ2LHA and δHA 
subunits had somewhat different cellular distributions when transfected alone.  In the absence of 
α1 and β2 subunits, γ2LHA subunits were mostly retained intracellularly, but many δHA subunits 
were trafficked to the cell surface.  A substantial fraction of intracellular protein is destined for 
proteasomal degradation, so the different degradation rates of γ2LHA and δHA subunits might 
simply reflect their different cellular distributions.  If so, γ2LHA and δHA subunits should degrade 
at similar rates when expressed together with α1 and β2 subunits, which enable surface trafficking 
of all subunits.  Interestingly, coexpression of α1 and β2 subunits did not affect degradation rates 
of either γ2LHA or δHA subunits.  The γ2LHA subunit population (dashed black line) had decreased 
by nearly half after 3 hrs of CHX application (γ2LHA = 53.8 ± 2.3% of 0 hr; α1β2γ2LHA = 60.8 ± 
9.9% of 0 hr) and then remained similar until the 6 hr time point (γ2LHA = 49.1 ± 3.5% of 0 hr; 
α1β2γ2LHA = 47.7 ± 5.3% of 0 hr).  Likewise, δHA levels decreased by around 20% within the 
first hour of treatment (1 hr: δHA = 81.9 ± 4.8% of 0 hr; α1β2δHA = 85.8 ± 12.0% of 0 hr) and then 
remained stable until the 6 hr time point (δHA = 86.0 ± 7.1% of 0 hr; α1β2δHA = 79.8 ± 10.7% of 0 
hr).  Thus, it seems that the different degradation rates of γ2LHA and δHA subunits are intrinsic to 
the proteins themselves rather than a consequence of different subcellular distributions.   
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Figure 9. GABAA receptor γ2LHA and δHA subunits had markedly different rates of degrada-
tion. 
To assess degradation rates of the entire pool of GABAA receptor subunits, HEK293T cells 
expressing γ2LHA or δHA subunits were incubated for 0 – 6 hours in the presence of 300 μM 
cycloheximide (CHX), harvested, incubated with anti-HA-Alexa647 antibody, and subjected to 
flow cytometry.  Mock-subtracted mean fluorescence intensities from each time point were 
normalized to that of the same subunit at the 0 hr time point.
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Discussion 
The combination of flow cytometry and FRET provides an efficient, quantitative method for 
evaluating subunit requirements, assembly patterns, and subunit arrangement of GABAA 
receptor isoforms 
Among ion channels, GABAA receptors are remarkable for their complexity.  The 
nineteen subunits, many of which are coexpressed in individual neurons, could produce hundreds 
or thousands of unique isoforms, and most isoforms that have been studied to date display 
characteristic physiological and pharmacological properties.  Thus, the potential functional 
diversity of neuronal GABAA receptors presents a fascinating and frustrating problem for 
researchers.  To narrow the scope of the problem and to characterize individual isoforms, GABAA 
receptor subunits are frequently expressed in heterologous systems, but even this approach 
requires enormous amounts of work and has reached contradictory conclusions.  Concatenated 
subunits provide the greatest control over assembly, but they are difficult to express, linkers must 
be optimized, and many concatemers may be cleaved or incorporate only partly into receptors.  
Traditional biochemical approaches are untenable for determining which of all possible isoforms 
are assembled and trafficked; furthermore, co-immunoprecipitation does not prove direct 
association between subunits.  Similarly, it is highly inefficient to transfect hundreds of possible 
subunit combinations (many of which might not even reach the cell surface) and perform full 
physiological characterizations.  Here, we showed that flow cytometry allows high-throughput, 
quantitative characterization of subunit expression resulting from many transfection combinations.  
When combined with FRET, this approach also provides insight into direct subunit adjacency and 
thereby helps to determine receptor stoichiometry and subunit arrangement.  Even when used to 
evaluate the most commonly expressed and widely studied subunit combinations, these 
techniques revealed novel properties of GABAA receptor subunits and isoforms.  
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Specific subunit combinations were necessary for full expression and surface trafficking of α1, 
β2, and γ2LHA subunits 
In agreement with numerous prior studies, our results indicated that both α1 and β2 
subunits were necessary for efficient surface trafficking of α1, β2, and γ2 subunits80, 81, 89.  All 
three subunits were expressed without regard to subunit combination, but their total cellular 
expression levels were greatest when both α1 and β2 subunits were transfected.  Interestingly, 
substantial amounts of δ subunits were expressed on the cell surface when transfected alone or 
with only α1 or only β2 subunits.  Previously, among GABAA receptor subunits, only β1, β3, γ2S, 
and ρ1-3 subunits have been reported to be trafficked independently to the cell surface, ostensibly 
as homopentamers90, 337, 344, 354, 355.  However, the most surprising result involved the relative 
subunit expression levels produced by equimolar amounts of α1, β2, and either γ2LHA and δHA 
subunit cDNA.  Although there have been previous reports that δ subunits were difficult to 
express, these focused on the δ subunit alone.  In our experiments, α1 and β2 subunit levels were 
also drastically lower when coexpressed with δHA rather than γ2LHA subunits, suggesting that δ 
subunit expression difficulties might derive from something other than insufficient δ subunit 
protein.   
Both γ2LHA and δHA subunits appeared to be incorporated into receptors at the expense of β2 
subunits, but receptor stoichiometry remained ambiguous 
Although γ2LHA and δHA subunit expression produced markedly different subunit 
expression levels, similar patterns emerged.  Specifically, addition of either γ2LHA or δHA subunit 
cDNA caused a greater reduction in β2 subunit expression than in α1 subunit expression.  A 
simple explanation for this phenomenon would be that α1β2 receptor stoichiometry is 2α:3β, and 
that γ2LHA or δHA subunits replace the third β2 subunit.  However, that interpretation contradicts 
the FRET patterns presented in Figure 5.  When no γ2LHA or δHA subunit cDNA was transfected, 
FRET occurred between individual α1 subunits and individual β2 subunits, as well as between α1 
and β2 subunits.  If FRET cannot occur either across one pentamer or between two pentamers 
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(possibilities that we excluded using concatenated subunits that allowed two or one epitope(s) per 
receptor, respectively), and receptors contain two GABA-binding β-α subunit interfaces 
(overwhelmingly supported by the literature), the only possible receptor population that could 
produce the α1β2 FRET patterns would be a mixed population of 3α:2β (α-α subunit FRET) and 
2α:3 β receptors (β-β subunit FRET).  This, in turn, would imply that most of the 3α:2β receptors 
were not affected by maximal γ2LHA and δHA subunit expression, which produced only a ~10% 
decrease in α1 subunit surface expression.  However, FRET patterns once again contradict this 
explanation, because FRET between individual α1 subunits decreased substantially with maximal 
γ2LHA and δHA subunit expression. 
It is also possible that FRET occurred between α1 subunits that were not incorporated 
into standard pentameric receptors.  Unlike β2 subunits, α1 subunits appeared on the cell surface 
when transfected alone, potentially in homooligomers that could produce FRET.  However, 
individual α1 subunit surface expression levels were very low (~5% of α1β2 levels).  Thus, unless 
coexpression of partnering subunits substantially increased the α1 homooligomer population, it is 
quantitatively unlikely that such a population could explain the relatively stable α1 subunit 
expression levels.  Alternatively, extra α1 subunits could be attached to α1β2/α1β2γ2L/α1β2δ 
receptor isoforms.  A recent study proposed that γ2S subunits can modulate GABAA receptor 
function as an “accessory subunit” that is attached to but not incorporated within the pentamer 337.  
To date, this interpretation has not been supported by microscopy, and further investigation 
would be necessary to determine if α1 subunits can play a similar role.   
Remarkably low amounts of δHA subunit cDNA yielded peak subunit expression levels 
As previously mentioned, several groups have reported difficulties expressing δ 
subunits356, 357 and some have attempted to overcome that technical problem by transfecting δ 
subunit RNA in tenfold excess compared to α and β subunit RNAs358.  Our γ2LHA/δHA subunit 
titrations indicate that this approach is both unnecessary and counterproductive, because peak δ 
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subunit expression occurred with only 0.03 μg of δHA subunit cDNA.  Equimolar expression of α1, 
β2, and δHA subunits produced extremely small currents that might not be suitable for kinetic 
analysis and, troublingly, induced cell death.  Taken together, these results suggest that 
heterologous studies of δ subunit-containing receptors should perhaps use δ subunit cDNA at a 
tenfold lower rather than higher level compared to α and β subunit cDNAs.  Of course, this raises 
the concern that αβ receptors might remain and contaminate the αβδ receptor population, but our 
titrations demonstrated that cells transfected with 1:1:0 or 1:1:0.1 μg (α1:β2:δ) produce currents 
with significantly different kinetic properties (particularly rise time and percent desensitization).  
Receptor homogeneity: eliminating αβ isoforms may not be the problem 
Numerous studies have been conducted under the assumption that it is impossible to 
obtain a homogeneous αβγ receptor population unless γ subunit cDNA is transfected in excess.  
Our results indicate that although γ2LHA subunit cDNA was not as “potent” as δHA subunit cDNA 
(and thus should not be used at similarly low levels), equimolar expression of α1, β2, and γ2L 
subunits should be sufficient to achieve a structurally and functionally homogeneous αβγ receptor 
population.  Equimolar α1β2γ2L transfection yielded peak γ2L subunit expression levels as well 
as currents that were kinetically and pharmacologically distinct from α1β2 receptor currents.  
Interestingly, even though 0.1 μg of γ2LHA subunit cDNA produced relatively low γ2LHA subunit 
surface expression levels (39.0 ± 10.3% of 1 μg γ2LHA; n = 7), the associated currents exhibited 
peak current amplitudes, percent fast desensitization, Zn++ resistance, and diazepam sensitivity 
that were statistically indistinguishable from those produced by equimolar expression.  This likely 
occurred because αβγ receptors effect far greater charge transfer than αβ receptors, essentially 
obscuring their functional signatures.  Although we do not think that a homogeneous population 
of α1β2γ2L receptors existed when 0.1 μg of γ2 subunit cDNA was transfected, the fact that α1β2 
receptor properties were obscured even at such low γ2 subunit levels again suggests that γ2 
subunits need not be expressed at tenfold molar excess. 
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As with δ subunits, overexpression of γ2L subunits might be deleterious as well as 
unnecessary.  In both cases, the highest cDNA levels actually produced lower protein levels and 
induced cell death, suggesting that excess γ2L/δ subunit protein might divert even assembled 
receptors to the proteasome, perhaps due to ER stress.  Indeed, it would be interesting to 
determine if ER-resident proteins (e.g., calnexin) or early apoptotic markers are upregulated in 
response to high γ2L/δ subunit cDNA levels.  However, our electrophysiological data indicated 
that there might be yet another problem associated with excess γ2L subunit transfection.  As 
discussed, the characteristic α1β2 receptor physiology and pharmacology disappeared with 
remarkably low γ2 subunit cDNA levels.  However, several properties changed again when γ2 
subunit cDNA was transfected in molar excess.  Notably, 1:1:10 transfection produced currents 
with remarkably slower rise times, less fast desensitization, and more rapid deactivation than 
1:1:1 transfection currents.  Interestingly, the lower fraction of fast desensitization seen in 1:1:10 
transfection might explain previous reports of α1β2γ2 receptor currents that desensitized 
minimally during 400 ms GABA application315.   
We propose that in both of these cases, currents might have been recorded from receptors 
containing two γ2 subunits.  Although a major goal of this study was to study freely-assembled 
receptors, this theory would be strengthened substantially if functional double-γ receptors could 
be obtained from tandem constructs.  Currents were recorded from cells expressing β2-α1-γ2 
tandems together with α1 and γ2 monomers and from cells expressing α1-γ2 tandems together 
with β2 monomers.  If the tandem constructs function properly, no “canonical” GABAA receptor 
isoform ([α/β/γ]-β-α-β-α) could be assembled in either condition.  Rather, any pentamer must 
contain at least two γ2 subunits.  Several other γ2 subunit-containing tandem/monomer 
combinations capable of producing receptors with two γ subunits were also tested (Table 1).  
Currents were produced by all combinations that could yield double-γ receptors with two non-
adjacent γ subunits, but no currents were produced by combinations that could yield only double-
γ receptors with adjacent γ subunits.  Finally, formation of double-γ2 subunit receptors with 
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minimal fast desensitization when γ2 subunits were expressed at molar excess could explain 
discrepancies between α1βγ2 currents reported by us313, 359 and by other groups315.  At equimolar 
transfection ratios, we have consistently obtained α1βγ2 receptor currents that desensitize 
approximately 70% over 400 ms313, while groups using γ2 subunit overexpression have reported 
currents that desensitized only about 35% over 500 ms315.  It has been argued that the discrepancy 
occurred because equimolar expression produces a mixture of αβ and αβγ receptors, but we 
demonstrated here that equimolar expression produced currents that were physiologically and 
pharmacologically distinct from α1β2 receptor currents.  In contrast, the putative double-γ2 
subunit receptors desensitized very slowly, similar to results reported by other groups.  For this 
reason as well, we suggest that “canonical” 2α : 2β : 1γ receptors be studied with equimolar 
subunit transfection. 
δHA subunits were markedly more stable than γ2LHA subunits 
The disparities between γ2LHA and δHA subunit protein levels and degradation rates 
constitute perhaps the most surprising results reported here.   Notably, these disparities occurred 
when γ2LHA/δHA subunits were expressed either singly or in a receptor context, indicating that 
they were intrinsic to the subunits themselves but also could be extended to the assembled 
receptors.  Substantial further investigation will be required to determine the basis for differences 
in γ2LHA and δHA subunit degradation rates.  Given that γ2L and δ subunits have only about 34% 
sequence identity, it is possible that a signal sequence or structural motif in γ2L or δ subunits 
could bind to accessory proteins that enhance degradation or stability, respectively.  Chimeric 
γ2/δ subunit cDNA constructs have been constructed360 and might be useful for addressing this 
possibility. 
It remains to be seen whether or not the differences in γ2L and δ subunit degradation 
occur in neurons as well as heterologous systems.  It is technically challenging but possible to 
conduct CHX degradation experiments in brain slices; this requires incubating very consistently 
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healthy brain slices in artificial cerebrospinal fluid with CHX for multiple hours and is beyond 
the scope of this paper.  Admittedly, such experiments might not recapitulate the data presented 
in the current study, but our data did indicate that the difference in degradation rates was an 
intrinsic property of the γ2L and δ subunit proteins.  Thus, it stands to reason that if the difference 
does not persist in neurons, some regulatory protein must block γ2L subunit degradation signals.  
As such, it would be interesting to assess subunit degradation rates in tissue from animals lacking 
various γ2L/δ subunit binding partners.  The implications of different degradation rates in vivo 
would still remain unclear, but it is tempting to speculate that they could serve as valuable 
regulatory mechanisms reflecting the different subcellular localization of γ2 and δ subunits.  As 
discussed, γ2 subunit-containing receptors are primarily postsynaptic and mediate fast phasic 
current, while δ subunit-containing receptors are exclusively extrasynaptic and mediate persistent 
tonic current.  Postsynaptic receptors must adapt more quickly to changes in neuronal physiology, 
so more rapid degradation of γ2 subunit-containing receptors could be advantageous. 
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CHAPTER IV 
THE GABRB3 MUTATION, G32R, ASSOCIATED WITH CHILDHOOD 
ABSENCE EPILEPSY, ALTERS α1β3γ2L GABAA RECEPTOR 
EXPRESSION AND CHANNEL GATING. 
 
 
Abstract 
A GABAA receptor β3 subunit mutation, G32R, has been associated with childhood 
absence epilepsy.  We evaluated the possibility that this mutation, which is located adjacent to the 
most N-terminal of three β3 subunit N-glycosylation sites, might reduce GABAergic inhibition by 
increasing glycosylation of β3 subunits.  The mutation had three major effects on GABAA 
receptors.  First, coexpression of β3(G32R) subunits with α1 or α3 and γ2L subunits in HEK293T 
cells reduced surface expression of γ2L subunits and increased surface expression of β3 subunits, 
suggesting a partial shift from ternary αβ3γ2L receptors to binary αβ3 and homomeric β3 
receptors.  Second, β3(G32R) subunits were more likely than β3 subunits to be N-glycosylated at 
N33, but increases in glycosylation were not responsible for changes in subunit surface 
expression.  Rather, both phenomena could be attributed to the presence of a basic residue at 
position 32.  Finally, α1β3(G32R)γ2L receptors had significantly reduced macroscopic current 
density.  This reduction could not be explained fully by changes in subunit expression levels 
(because γ2L levels decreased only slightly) or glycosylation (because reduction persisted in the 
absence of glycosylation at N33).  Single channel recording revealed that α1β3(G32R)γ2L 
receptors had impaired gating with shorter mean open time.  Homology modeling indicated that 
the mutation altered salt bridges at subunit interfaces, including regions important for subunit 
oligomerization.  Our results suggest both a mechanism for mutation-induced hyperexcitability 
and a novel role for the β3 subunit N-terminal α-helix in receptor assembly and gating. 
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Introduction 
Childhood absence epilepsy (CAE) is characterized by frequent absence seizures, during 
which patients manifest brief losses of consciousness and generalized, synchronous 3 Hz spike-
and-wave discharges on EEG.  The seizures typically begin at age 3-8 years, continue through 
adolescence, last 3-10 seconds, and occur up to 200 times per day.  CAE is highly genetic, and 
16-45% of patients have a positive family history361.  Mutations, polymorphisms, and variants 
associated with CAE have been identified in several genes encoding ion channels, including T-
type calcium362-365, chloride366, and GABAA receptor320, 324, 367 channels.   
GABAA receptors are pentameric, ligand-gated chloride channels that mediate the 
majority of fast inhibitory neurotransmission in the brain.  They assemble from an array of 19 
homologous subunits from eight subunit families: α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3266.  The 
predominant receptor isoforms in vivo likely contain two α, two β, and one γ or δ subunit (Figure 
1)328, 329, 340; however, some subunits (notably β3 subunits) may assemble less discriminately, 
forming homopentamers as well as heteropentamers90. 
Three separate CAE-associated mutations were recently identified in GABAA receptor β3 
subunits: GABRB3(P11S), GABRB3(S15F) and GABRB3(G32R)310.  Mutant subunit-containing 
receptors exhibited reduced current density.  Moreover, the mutant proteins all appeared to be 
“hyperglycosylated”, because they migrated at higher molecular masses than wildtype β3 
subunits unless digested with an enzyme that removed all N-glycans.  The investigators 
consequently hypothesized that hyperglycosylation might be responsible for the reduced current 
density, which might in turn lead to neuronal hyperexcitability and, ultimately, to the abnormal 
EEG patterns of absence seizures. 
Approximately half of all eukaryotic proteins carry N-linked glycans368.  The process of 
N-linked glycosylation begins in the ER lumen, where standard “core” glycans are attached to 
the side chain nitrogen of asparagines located in the glycosylation consensus sequon, Asn-Xaa-
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Ser/Thr (Xaa ≠ Pro)369, 370.  Sequons containing threonine residues have higher glycan occupancy 
than sequons containing serine residues371.  N-linked glycosylation serves several functions in 
biogenesis of multimeric proteins.  First, addition of glycans facilitates monomer folding and 
multimer assembly, thus preventing aggregation and degradation of newly synthesized subunits372, 
373.  Furthermore, glycan conjugation may favor assembly of certain subunits, thereby 
determining subunit stoichiometry374.  Finally, N-linked glycosylation can affect functional 
properties of ion channels once they reach the cell surface375.  Perhaps unsurprisingly, most 
congenital disorders of glycosylation cause severe pathology, often with significant neurological 
involvement376.  However, these disorders generally impair rather than enhance glycan 
attachment and processing.  In this study, we evaluated the possibility that the β3(G32R) subunit 
mutation, which is located adjacent to the first of three β3 subunit N-glycosylation sites (Figure 1), 
might reduce GABAergic inhibition by aberrantly increasing glycosylation. 
 
Experimental Procedures 
Molecular biology 
Complementary DNAs (cDNAs) encoding individual human GABAA receptor subunits 
(α1, NM_000806.5; α3, NM_000808.3; β3 variant 2, NM_021912.4; and γ2L, NM_000816.3) 
were cloned into the pcDNA3.1(+) vector.  The hemagglutinin (HA) epitope tag (YPYDVPDYA) 
was inserted between amino acids 4 and 5 of the mature γ2L subunit protein.  Point mutations 
were introduced using the QuikChange Site-Directed Mutagenesis Kit (Stratagene).  All 
constructs were sequenced by the Vanderbilt DNA core facility prior to use.  Note that all amino 
acids are numbered according to the immature peptide sequence. 
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α1
α1
β3
β3
γ2
G32
N33
G32
N33
B
A
GABAA β3   1  ---------------MCSGLLELLLPIWLSWTLGTRGSEPRS----VNDPGNMSFVKET-  40   
GABAA γ2   1  MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPK  60   
GABAA α1   1  ------------MRKSPGLSDCLWAWILLLSTLTGRSYGQPS---LQDELKDNTTVFTR-  44   
AChRα1     1  ---------------------MELSTVLLLLGLCSAGLVLGS----EHETR---------  26   
GABAA β3   41  ---------VDKLLKGYDIRLRPDFGG-PPVCVGMNIDIASIDMVSEVNMDYTLTMYFQQ 90   
GABAA γ2   61  VPEGDVTVILNNLLEGYDNKLRPDIGV-KPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQ 119  
GABAA α1   45  --------ILDRLLDGYDNRLRPGLGE-RVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQ 95   
AChRα1     27  --------LVAKLFEDYSSVVRPVEDHREIVQVTVGLQLIQLINVDEVNQIVTTNVRLKQ 78   
 
GABAA β3   91  YWRDKRLAYSG-IPLNLTLDNRVADQLWVPDTYFLNDKKSFVHGVTVKNRMIRLHPDGTV 149  
GABAA γ2   120 TWYDRRLKFNS-TIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRV 178  
GABAA α1   96  SWKDERLKFKG-PMTVLRLNNLMASKIWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTL 154  
AChRα1     79  QWVDYNLKWNPDDYGGVKKIHIPSEKIWRPDVVLYNNADGDFAIVKFTKVLLDYT--GHI 136  
 
GABAA β3   150 LYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWRGG---DKAVTGVERI 206  
GABAA γ2   179 LYTLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRS---SVEVGDTRSW 235  
GABAA α1   155 LYTMRLTVRAECPMHLEDFPMDAHACPLKFGSYAYTRAEVVYEWTREPARSVVVAEDGS- 213  
AChRα1     137 TWTPPAIFKSYCEIIVTHFPFDEQNCSMKLGTWTYDGSVVAINPESDQPDLSNFMESGEW 196  
 
GABAA β3   207 ELPQFSIVEHRLVSRNVVFATGAYPRLSLSFRLKRNIGYFILQTYMPSILITILSWVSFW 266  
GABAA γ2   236 RLYQFSFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFW 295  
GABAA α1   214 RLNQYDLLGQTVDSGIVQSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFW 273  
AChRα1     197 VIKEARGWKHWVFYSCCPTTP--YLDITYHFVMQRLPLYFIVNVIIPCLLFSFLTSLVFY 254  
Figure 1.  The G32R mutation was predicted to be adjacent to the first of three putative glycosyl-
ation sites in β3 subunits and to lie at subunit interfaces in assembled GABA
A
 receptors.
Α. The sequences of human α1, β3, and γ2L GABAA receptor subunits were aligned with the 
sequence of the human nicotinic acetylcholine receptor α1 subunit (AChRα1).  In the AChRα1 
sequence, α-helices are highlighted in orange, β-sheets are highlighted in blue, and the first trans-
membrane domain is underlined.  In the GABA
A
 receptor β3 subunit sequence, putative 
N-glycosylation sites are highlighted in green.  In all sequences, signal peptides are highlighted in 
gray and the cysteines forming the Cys-loop are highlighted in yellow.  Sites of epilepsy-associated 
mutations in GABA
A
 receptor subunits (β3(G32R) and γ2(R43Q)) are highlighted in red.  B. A 
model of the α1β3γ2L GABAA receptor, as viewed from the synaptic cleft, is presented.  The 
nicotinic acetylcholine receptor α1 subunit crystal structure (2qc1) was used to generate homology 
models of individual GABAA receptor subunits, which were threaded onto the Lymnaea stagnalis 
acetylcholine binding protein crystal structure in the order γ2L-β3-α1-β3-α1.  The α1, β3, and γ2L 
subunits are colored red, blue, and green, respectively.  Glycine 32 and asparagine 33 are presented 
as orange and cyan space-filling models, respectively.
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Cell culture and transfection 
HEK293T cell culture methods have been described previously 335.  For immunoblotting, 
1.2 x 106 cells were plated onto 100-mm diameter culture dishes; for flow cytometry, 4 x 105 cells 
were plated onto 60-mm diameter culture dishes; and for electrophysiology, 1 x 105 cells were 
plated onto 30-mm diameter culture dishes. 
Twenty-four hours after plating, cells were transfected with GABAA receptor subunit 
cDNAs using 3 μl FuGENE 6 (Roche) per 1 μg subunit cDNA.  For immunoblotting, 3 μg of 
each subunit cDNA was transfected (i.e., 9 μg cDNA altogether); for other experiments, cDNA 
amounts were scaled proportionally to the number of cells plated.  For “wildtype” or 
“homozygous” subunit expression flow cytometry experiments, 60-mm culture dishes were 
transfected with 1 μg each α1 (or α3) and γ2LHA subunit cDNAs and 1.0 μg of β3 or β3(G32R) 
subunit cDNAs, respectively.  For “heterozygous” expression flow cytometry experiments, 60-
mm culture dishes were transfected with 1 μg each α1 (or α3) and γ2LHA subunit cDNAs and 0.5 
μg each β3 and β3(G32R) subunit cDNAs.  The terms “wildtype”, “heterozygous” and 
“homozygous” are used as a shorthand designation for the subunit expression conditions and are 
not meant to imply any genetic condition.   
Surface biotinylation  
Biotinylation protocols have been described previously 335.  Briefly, culture plates were 
washed, incubated with 1 mg/ml NHS-SS-biotin (Pierce) diluted in Dulbecco’s PBS (DPBS) and 
lysed with radioimmune precipitation assay buffer (RIPA buffer; 50 mM Tris-HCl pH 7.4, 0.1 % 
Triton X-100, 250 mM NaCl, 5 mM EDTA) containing protease inhibitor cocktail (Sigma).  
Lysates were cleared by centrifugation at 16,000 x g for 15 minutes and subsequently incubated 
overnight with High-Capacity NeutrAvidin agarose resin (Pierce).  After overnight incubation, 
protein was eluted and subjected to immunoblotting.  
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Immunoblotting 
Proteins in sample buffer were separated on 4-12 % Bis-Tris NuPAGE gels (Invitrogen) 
and transferred to Odyssey PVDF membranes (Li-Cor).  A monoclonal antibody raised against 
intracellular residues 370-433 of the GABAA receptor β3 subunit (4 μg/ml, clone N87/25, UC 
Davis/NIH NeuroMab Facility) was used to detect β3 subunit protein, and anti-Na+/K+ ATPase 
antibody (0.2 μg/ml, clone 464.6, ab7671, Abcam) was used as a loading control.  Anti-mouse 
IRdye conjugated secondary antibodies (Li-Cor) were used in all cases.  Membranes were 
scanned using the Li-Cor Odyssey system and integrated intensities of bands were determined 
using Odyssey software. 
Glycosidase digestion 
Biotinylated protein was simultaneously eluted from NeutrAvidin resin and denatured by 
incubation in 1x glycoprotein denaturing buffer (New England Biolabs) containing 50 mM 
dithiothreitol for 30 minutes at 50˚C.  Eluates were divided into 15 μl aliquots and digested with 1 
unit of endo-β-N-acetylglucosaminidase H (endo H) or peptide-N-glycosidase F (PNGase F) in 
manufacturer-supplied buffers (New England Biolabs) at 37˚C for 2 h.   
Flow cytometry 
Staining protocols for flow cytometry have been described previously 335.  GABAA 
receptor subunits were detected with antibodies to human α1 subunits (N-terminus, clone BD24, 
Millipore; 2.5 μg/ml), human α3 subunits (N-terminal residues 29-43, polyclonal, Alomone; 1.5 
μg/ml), or the HA epitope tag (clone 16B12, Covance; 2.5 μg/ml).  The Molecular Probes 
Monoclonal Antibody Labeling Kit (Invitrogen), used per manufacturer instructions, was 
previously used to directly conjugate Alexa647 fluorophores to anti-α1 subunit and anti-HA tag 
antibodies.  Following antibody incubation, cells were washed three times with FACS buffer and 
either fixed with 2 % w/v paraformaldehyde, 1 mM EDTA diluted in PBS (anti-α1, anti-HA) or 
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incubated with anti-mouse-IgG1 secondary antibody conjugated to the Alexa 647 fluorophore 
(Invitrogen; anti-α3) before additional washing and fixation. 
For total cellular protein detection, cells were permeabilized for 15 minutes with 
Cytofix/Cytoperm (BD Biosciences) and washed twice with 1 x PermWash (BD Biosciences) 
before antibody incubation.  For these experiments, all antibodies were diluted to 2.5 μg/ml in 
PermWash.  After antibody incubation, cells were washed four times in PermWash and twice in 
FACS buffer before fixation with 2 % w/v paraformaldehyde, 1 mM EDTA diluted in PBS.   
Fluorescence intensity (FI) of all samples was determined using an LSR II 5-laser flow 
cytometer (BD Biosciences) and analyzed offline with FlowJo 7.5 (Tree Star).  For each sample, 
50,000 total events were acquired; non-viable cell populations, determined in control experiments 
by staining with 7-amino-actinomycin D, were excluded from analysis.  For all experiments, the 
net FI of samples was determined by subtracting the mean FI of cells transfected with blank 
pcDNA(3.1+) vector from the mean FI of cells expressing GABAA receptor subunits.  The 
relative fluorescence intensity (“relative FI”) for each condition was calculated by normalizing 
the net FI of each experimental condition to the net FI of cells expressing wildtype β3 subunits.   
Whole cell electrophysiology 
Whole cell voltage-clamp recordings were performed at room temperature on lifted 
HEK293T cells 24-72 hrs after transfection with GABAA receptor subunits as described 
previously367. Briefly, cells were bathed in an external solution containing 142 mM NaCl, 1 mM 
CaCl2, 8 mM KCl, 6 mM MgCl2, 10 mM glucose, and 10 mM HEPES (pH 7.4, ∼325 mOsm), 
and recording electrodes were filled with an internal solution containing 153 mM KCl, 1 mM 
MgCl2, 10 mM HEPES, 5 mM EGTA, 2 mM Mg2+-ATP (pH 7.3, ∼300 mOsm).  All patch 
electrodes had a resistance of 1–2 MΩ.  Cells were voltage-clamped at -20 mV using an 
Axopatch 200B amplifier (Axon Instruments, Union City, CA).  A rapid exchange system (open 
tip exchange times ~ 400 μs), composed of a four-barrel square pipette attached to a Perfusion 
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Fast-Step (Warner Instruments Corporation, Hamden, CT) and controlled by Clampex 9.0 (Axon 
Instruments), was used to apply GABA to lifted whole cells.  All currents were low-pass filtered 
at 2 kHz, digitized at 5-10 kHz, and analyzed using the pCLAMP 9 software suite.   
Single-channel electrophysiology 
Cell-attached single-channel recording was performed as described previously367.  
Briefly, HEK293T cells expressing GABAA receptor subunits were bathed in an external solution 
containing 140 mM NaCl, 2 mM CaCl2, 5 mM KCl, 1 mM MgCl2, 10 mM glucose, and 10 mM 
HEPES (pH 7.4).  Recording electrodes were filled with an internal solution containing 1mM 
GABA, 120 mM NaCl, 0.1 mM CaCl2, 5 mM KCl, 10 mM MgCl2, 10 mM glucose, and 10 mM 
HEPES (pH 7.4), and electrode potential was held at +80 mV.  The electrodes were polished to a 
resistance of 10-20 MΩ.   
Single channel currents were amplified and low-pass filtered at 2 kHz using an Axopatch 
200B amplifier, digitized at 20 kHz using Digidata 1322A, and saved using pCLAMP 9 software 
(Axon Instruments).  Data were analyzed using TAC 4.2 and open time and amplitude histograms 
were generated using TACFit (Bruxton Corporation, Seattle, WA) as described previously (10).  
The number of components required to fit the duration histograms was increased until an 
additional component did not significantly improve the fit377.  Single channel openings occurred 
as bursts of one or more openings or clusters of bursts.  Bursts were defined as one or more 
consecutive openings that were separated by closed times that were shorter than a specified 
critical duration (tcrit) prior to and following the openings378.  A tcrit of 5 ms was used in the 
current study.  Clusters were defined as a series of bursts preceded and followed by closed 
intervals longer than a specific critical duration (tcluster).  A tcluster of 10 ms was used in this study. 
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Homology modeling 
Multiple sequence alignments of human GABAA receptor α1, β3, and γ2L subunits and 
the human nicotinic acetylcholine receptor (nAChR) α1 subunit were performed using ClustalW 
(European Bioinformatics Institute, Hinxton, UK).  Structural models of GABAA receptor N-
terminal domains were generated with SWISS-MODEL379, using the crystal structure of the 
nAChR α1 subunit (PDB ID 2qc1)153 as a template.  Point mutations were introduced into the β3 
subunit sequence using DeepView/Swiss-PdbViewer 4.02 (Swiss Institute of Bioinformatics, 
Lausanne, Switzerland), and SWISS-MODEL project files containing the mutated target 
sequence and the superposed template structure were submitted.  For heteropentamers, subunits 
were threaded in the order γ2L-β3-α1-β3-α1 onto the Lymnaea stagnalis acetylcholine binding 
protein (AChBP) crystal structure (PDB ID 1i9b)98 used as a template.  All models were energy-
optimized using GROMOS96 in default settings within DeepView/Swiss-PdbViewer, and the 
most likely conformations were presented here. 
Statistical analysis 
Statistical analysis was performed using Prism version 5.04 (GraphPad Software, La Jolla, 
CA).  Student’s two-tailed t test or one-way analysis of variance (ANOVA) with Tukey’s and/or 
Bonferroni’s post-tests was used as appropriate to determine statistical significance among 
transfection conditions.  Levels of significance were indicated in figure legends, and all data were 
expressed as mean ± S.E.M. 
 
Results 
Cotransfection of the mutant β3(G32R) subunit with a1 or α3 and γ2LHA subunits was 
associated with increased β3 subunit and decreased γ2LHA subunit surface expression. 
Because the β3(G32R) mutation was reported to reduce the current density of 
heterologously expressed α1β3γ2L receptors310, we sought to determine whether the mutation 
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reduced surface expression of the GABAA receptor subunits under similar conditions.  First, we 
transiently co-expressed α1, γ2LHA, and either wildtype β3 or mutant β3(G32R) subunit cDNAs at 
a 1:1:1 ratio in HEK293T cells and assessed surface expression of all subunits using surface 
biotinylation and Western blotting.   
Immunoblotting revealed two major differences between β3 and β3(G32R) subunit 
proteins (Figure 2A).  First, although both wildtype and mutant subunits migrated as three bands 
with molecular masses of approximately 51, 47, and 43 kDa, the distribution of protein among 
those bands differed considerably (Figure 2A1).  Specifically, a larger fraction of mutant subunits 
migrated at the higher molecular masses.  Second, surprisingly mutant β3(G32R) subunit surface 
levels were increased significantly (154 ± 15 % of wildtype, n = 17, p < 0.01) (Figure 2A2).   
Because it would be highly unusual for a mutation to cause both an increase in surface 
receptor number and a reduction in current density, we first addressed the differences in wildtype 
and mutant subunit expression levels.  Increases in β3 subunit surface expression could reflect 
either a change in receptor subunit composition, including production of α1β3 receptors and/or β3 
subunit homomers, or an overall increase in surface α1β3γ2L receptor number.  To distinguish 
between these two possibilities, we first examined the differences in wildtype and mutant 
partnering subunit expression levels.  Immunoblotting for surface levels of partnering subunits 
suggested that α1 subunit levels did not change but γ2LHA subunit levels decreased when co-
expressed with β3(G32R) rather than β3 subunits (data not shown), indicating a potential change 
in receptor subunit composition.  Because the reduction of γ2LHA surface levels was subtle, we 
employed flow cytometry to confirm and quantify changes in subunit expression levels.  In these 
experiments, we also included a condition modeling heterozygous expression of β3(G32R) 
subunits, in which an equimolar mixture of both β3 and β3(G32R) subunit cDNA was 
cotransfected with α1 and γ2LHA subunit cDNAs (see Methods for exact subunit cDNA ratios and 
concentrations).  Consistent with the prior immunoblotting data, α1 subunit surface levels did not 
differ significantly in the heterozygous or homozygous mutant conditions (Figure 2B), but γ2LHA 
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Figure 2.  Cells expressing α1 or α3, β3(G32R), and γ2LHA subunits had higher surface levels 
of β3 subunits and lower surface levels of γ2LHA subunits compared to cells expressing α1 or 
α3, β3(wt), and γ2LHA subunits.
Α1. Surface protein was isolated from HEK293T cells transfected with equimolar amounts of α
1, γ2LHA, and either wildtype or G32R mutant (hom) β3 GABA
A
 receptor subunit cDNA, 
separated by SDS-PAGE, and evaluated using Western blots.  The upper panel presents staining 
for Na+/K+ ATPase as a loading control (LC), and the lower panel presents staining for β3 
subunits (see Methods for antibody descriptions).  A2. Surface protein levels of β3 subunits 
were quantified in HEK293T cells transfected with equimolar amounts of α1, γ2LHA, and either 
wildtype or G32R mutant (hom) β3 GABA
A
 receptor subunits.  Integrated band intensities of all 
β3 subunits were determined, summed, and normalized to integrated band intensities of Na+/K+ 
ATPase for the same sample.  The normalized intensities of β3 subunits were then expressed as 
proportions of wildtype β3 subunit intensities.  Statistical significance was determined using 
Student’s two-tailed paired t-test.  B-C. Flow cytometry was used to evaluate surface protein 
levels of α1 (B) and γ2LHA (C) subunits in HEK293T cells transfected with α1, γ2LHA, and 
wildtype and/or G32R mutant β3 GABA
A
 receptor subunit cDNA.  Wildtype and homozygous 
mutant (hom) expression were modeled by transfecting 1 μg each of α1, γ2LHA, and either 
wildtype or G32R mutant (hom) β3 subunit cDNA.  Heterozygous mutant expression (het) was 
modeled by transfecting 1 μg each of α1 and γ2LHA cDNA together with 0.5 μg each of β3 and 
β3(G32R) subunit cDNA.   Upper panels present fluorescence intensity histograms; the abscissa 
indicates fluorescence intensity (FI) in arbitrary units plotted on a logarithmic scale, and the 
ordinate indicates percentage of maximum cell count (% of max).  Histograms for cells trans-
fected with blank vector (solid gray line), or wt (solid black line), het (dotted black line), and 
hom (dashed black line) subunit combinations are overlaid.  Lower panels present normalized 
fluorescence intensities for each expression condition.  Mean fluorescence intensities from cells 
transfected with blank vector alone (“mock”) were subtracted from mean fluorescence intensi-
ties of wt, het, and hom expression conditions.  All mock-subtracted fluorescence intensities 
were normalized to the mock-subtracted fluorescence intensity of the wt expression condition.  
D-E. Flow cytometry was used to evaluate surface protein levels of α3 (D) and γ2LHA (E) 
subunits in HEK293T cells transfected with α3, γ2LHA, and wildtype and/or G32R mutant β3 
subunit cDNA.  All panels are presented as described in B-C, but in all cases α3 subunit cDNA 
was substituted for α1 subunit cDNA.  Statistical significance was determined using one-way 
ANOVA with Tukey’s post-test.  *** indicates p < 0.001 compared to wt.
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subunit surface levels were decreased slightly in both heterozygous (84.8 ± 2.2 % of wildtype, n 
= 10, p < 0.001) and homozygous mutant (87.1 ± 2.4 % of wildtype, n = 16, p < 0.001) conditions 
(Figure 2C).   
We chose to co-express α1 and γ2 subunits because they are the most widely expressed 
subunits of their respective families in whole brain; however, subunit expression patterns vary 
widely among brain regions.  Several studies have indicated that absence seizures frequently 
involve dysfunction in the thalamic reticular nucleus (nRT), where the α3 subunit subtype 
predominates and β3 subunit expression is also high 57.  Consequently, we also examined changes 
in partnering subunit expression levels using α3 rather than α1 subunit cDNA.  Results resembled 
those obtained using α1 subunits; that is, α3 subunit surface levels did not differ significantly 
among wildtype, heterozygous, and homozygous mutant receptors (Figure 2D), but γ2LHA subunit 
surface levels decreased in both heterozygous and homozygous mutant conditions, although the 
reduction was significant only in the homozygous mutant condition (Figure 2E). 
Changes in subunit surface expression could reflect alterations in subunit production, 
subunit stability, or receptor trafficking.  Therefore, we also assessed total cellular subunit levels 
(Figure 3) in the same conditions used to study surface expression (Figure 2).  Interestingly, 
coexpressing α1, β3(G32R) and γ2LHA subunits yielded no significant changes in β3 (Figure 3 Α1, 
A2), α1 (Figure 3B), or γ2LHA (Figure 3C) subunit total cellular expression among wildtype and 
heterozygous and homozygous mutant transfections.  Likewise, coexpressing α3, β3(G32R) and 
γ2LHA subunits yielded no significant changes in α3 (Figure 3D) or γ2LHA (Figure 3E) subunit 
total cellular expression. 
The β3 subunit mutation, G32R, affected subunit surface expression independent of 
glycosylation. 
To this point, we observed two principal effects of the β3 subunit mutation, G32R.  First, 
mutant and wildtype receptors had different surface expression patterns (specifically, a small 
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Figure 3.  The β3(G32R) mutation did not significantly affect total cellular levels of GABA
A
 
receptor subunits in cells expressing α1 or α3, β3, and γ2LHA subunits.
Α1. Total cell lysates (40 μg) were obtained from HEK293T cells transfected with equimolar 
amounts of α1, γ2LHA, and either wildtype or G32R mutant (hom) β3 subunit cDNA, separated 
by SDS-PAGE, and evaluated using Western blots.  The upper panel presents staining for 
Na+/K+ ATPase as a loading control (LC), and the lower panel presents staining for β3 subunits 
(see Methods for antibody descriptions).  A2. Total cellular levels of β3 subunits were quantified 
in HEK293T cells transfected with equimolar amounts of α1, γ2LHA, and either wildtype or 
G32R mutant (hom) β3 GABA
A
 receptor subunits.  Integrated band intensities of all β3 subunit 
populations were determined, summed, and normalized to integrated band intensities of 
Na+/K+ ATPase for the same sample.  The normalized intensities of β3 subunits were then 
expressed as proportions of wildtype β3 subunit intensities.  Statistical significance was deter-
mined using Student’s two-tailed paired t-test.  B-C. Flow cytometry was used to evaluate total 
cellular levels of α1 (B) and γ2LHA (C) subunits in HEK293T cells transfected with α1, γ2LHA, 
and wildtype and/or G32R mutant β3 subunit cDNA and permeabilized before staining with 
fluorescently-conjugated antibodies.  Wildtype (wt), heterozygous (het), and homozygous 
(hom) expression patterns were modeled as described for Figure 1.  Upper panels present 
fluorescence intensity histograms; the x axis indicates fluorescence intensity (FI) in arbitrary 
units plotted on a logarithmic scale, and the y axis indicates percentage of maximum cell count 
(% of max).  Histograms for cells transfected with blank vector (solid gray line), or wt (solid 
black line), het (dotted black line), and hom (dashed black line) subunit combinations are 
overlaid.  Lower panels present normalized fluorescence intensities for each expression condi-
tion.  Mean fluorescence intensities from cells transfected with blank vector alone (“mock”) 
were subtracted from mean fluorescence intensities of wt, het, and hom expression conditions.  
All mock-subtracted fluorescence intensities were normalized to the mock-subtracted fluores-
cence intensity of the wt expression condition.  D-E. Flow cytometry was used to evaluate total 
cellular levels of α3 (D) and γ2LHA (E) subunits in HEK293T cells transfected with α1, γ2LHA, 
and wildtype and/or G32R mutant β3 GABA
A
 receptor subunit cDNA and permeabilized before 
staining with fluorescently-conjugated antibodies.  All panels are presented as described in B-C, 
but in all cases α3 subunit cDNA was substituted for α1 subunit cDNA.  Statistical significance 
was determined using one-way ANOVA with Tukey’s post-test.  
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decrease in γ2L subunit levels and a large increase in β3 subunit levels); these changes suggested 
a partial replacement of α1β3γ2L receptors by α1β3 receptors and β3 subunit homopentamers.  
Second, β3(G32R) subunits were more likely than β3 subunits to migrate at the highest of three 
distinct molecular mass populations.  However, it remained unclear if there was a causal 
relationship between these two phenomena. 
Because the mutant subunit had been reported to be hyperglycosylated, we hypothesized 
that the multiple β3 subunit bands represented differently glycosylated protein populations, where 
individual sequons may or may not be occupied by a glycan, occupancy patterns may or may not 
be uniform within a protein population (e.g., among all β3(G32R) subunits), and the glycans 
themselves may contain different combinations of monosaccharides.  To determine if the multiple 
β3 subunit bands represented differently glycosylated protein populations and to characterize β3 
subunit N-glycans, we isolated surface protein from HEK293T cells expressing α1, γ2LHA, and 
either β3 or β3(G32R) subunits and compared the migration patterns of β3 and β3(G32R) 
subunits that were undigested (U); digested with endoglycosidase H (endo H), which cleaves only 
high-mannose, unprocessed glycans; or digested with peptide N-glycosidase F (PNGaseF), which 
removes all N-glycans regardless of modification (Figure 4A).  After digestion with PNGaseF (F), 
both β3 and β3(G32R) subunits migrated as one 43 kDa band, indicating that the G32R mutation 
did indeed increase N-glycosylation of at least one of the three β3 subunit sequons (Figure 4A, 
lanes 3 and 6).  Interestingly, β3 and β3(G32R) subunits also displayed different endo H digestion 
patterns (H); after endo H digestion, a substantial population of β3 subunits migrated at 43 kDa 
and thus were fully endo H sensitive, but virtually none of the β3(G32R) subunits migrated at 43 
kDa and thus were endo H resistant.  Therefore, the G32R mutation increased the efficiency of 
both addition and processing of N-glycans. 
We recently established that partnering subunit incorporation could alter glycosylation 
patterns of β2 subunits335.  Thus, it was possible that the increased endo H resistant population of 
β3(G32R) subunits reflected increased formation of α1β3 and/or β3 receptor isoforms.  To assess 
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Figure 4.  The β3(G32R) mutation increased glycosylation of Asn-33 and reduced γ2LHA 
subunit surface expression independent of glycosylation at Asn-33.  
A. Surface protein was isolated from HEK293T cells expressing equimolar amounts of α1, γ
2LHA, and either β3 or β3(G32R) subunits and left undigested (U) or digested with endoglycosi-
dase H (H) or peptide N-glycosidase F (F).  B. Surface protein was isolated from HEK293T cells 
expressing equimolar amounts of α1 and either β3 or β3(G32R) subunits and left undigested (U) 
or digested with endoglycosidase H (H) or peptide N-glycosidase F (F). C. Surface protein was 
isolated from HEK293T cells expressing equimolar amounts of either β3 or β3(G32R) subunits 
and left undigested (U) or digested with endoglycosidase H (H) or peptide N-glycosidase F (F).  
D-E. Surface (D) or total cellular (E) protein was isolated from HEK293T cells expressing 
equimolar amounts of α1, γ2LHA, and different β3 subunits.  The β3 subunit cDNA constructs 
were modified to inactivate (with an Asn to Gln mutation) or enhance (with a Ser to Thr muta-
tion) the putative N-glycosylation sites of β3 subunits.  In lane 1, the β3 subunit had no muta-
tions (wt), and in lane 2, the β3 subunit had the G32R mutation only (GR).  The three glycosyl-
ation sites (N33, N105, and N174) were inactivated individually in the absence (lane 3, 1Q; lane 
5, 2Q; and lane 7, 3Q) or the presence (lane 4, GR/1Q; lane 6, GR/2Q; lane 8, GR/3Q) of the 
G32R mutation.  The first glycosylation site was also enhanced in either the absence (lane 9, ST) 
or the presence (lane 10, GR/ST) of the G32R point mutation.  The upper panel presents staining 
for Na+/K+ ATPase as a loading control (LC), and the lower panel presents staining for β3 
subunits.  F-G. Surface levels of α1 (F) and γ2LHA (G) subunits in cells expressing α1, γ2LHA, 
and glycosylation sequon mutant β3 subunits were determined using flow cytometry.  The β3 
subunit transfected in each condition is labeled as described in panels D and E.  Upper panels 
present fluorescence intensity histograms in which the abscissa denotes fluorescence intensity 
in arbitrary units graphed on a logarithmic scale (log FI) and the ordinate denotes percentage of 
maximum cell count (% of max).  Fluorescence intensity histograms from mock-transfected 
cells (solid gray line) are overlaid with histograms from cells expressing α1, γ2LHA, and β3 
subunits that either lacked (solid black line) or contained (dashed black line) the G32R point 
mutation.  In the left panels, either β3(wt, solid) or β3(G32R) (GR, dashed) subunit cDNAs were 
transfected; in the middle panels, either β3(N33Q) (1Q, solid) or β3(G32R/N33Q) (GR/1Q, 
dashed) subunit cDNAs were transfected; and in the right panels, either β3(S35T) (ST, solid) or 
β3(G32R/S35T) (GR/ST, dashed) subunit cDNAs were transfected.  The lower panels present 
normalized fluorescence intensities for each expression condition.  Mean fluorescence intensi-
ties from cells transfected with blank vector alone (“mock”) were subtracted from mean fluores-
cence intensities of cells transfected with α1, γ2LHA, and the indicated β3 subunits.  All mock-
subtracted fluorescence intensities were normalized to the mock-subtracted fluorescence inten-
sity of the cells expressing β3 subunits.  One-way ANOVA with Bonferroni’s post-test was used 
to compare normalized fluorescence intensities of each glycosylation sequon pair (i.e., wt v. GR, 
1Q v. GR/1Q, and ST v. GR/ST).  ** p< 0.01; *** p < 0.001.
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this possibility, we studied the digestion pattern of wildtype β3 and mutant β3(G32R) subunits 
after transfecting α1 and β3 (Figure 4B) or only β3 (Figure 4C) subunit cDNA.  We found that 
the increased glycosylation and glycan processing of β3(G32R) mutant subunits compared to β3 
subunits persisted in the absence of α1 and/or γ2L partnering subunits.  Interestingly, the 
proportion of endo H sensitive β3 subunits did decrease with the number of subunits expressed; 
that is, endo H sensitivity was greatest in α1β3γ2LHA receptors, lower in α1β3 receptors, and 
lowest in β3 receptors.  
These results demonstrating altered glycosylation of β3(G32R) subunits contradicted in 
silico analysis.  We used NetNGlyc 1.0 to establish that the G32R mutation did not change the 
occupancy potential of N105 (0.7904) or N174 (0.6229), but it slightly reduced the occupancy 
potential of N33 (β3 0.5947, β3(G32R) 0.5239) (data not shown).  Similarly, meta-analyses have 
concluded that sequons with Arg at the -1 position are considerably less likely to be glycosylated 
than sequons with Gly at the -1 position380.  Finally, although hypoglycosylation disorders 
frequently cause severe pathology376, to our knowledge there are no reports of increased 
glycosylation adversely affecting function or trafficking of other receptors. 
After confirming that β3 and β3(G32R) subunits had different glycosylation patterns, we 
sought to determine if the increased glycosylation and glycan processing of β3(G32R) mutant 
subunits were indeed responsible for changes in subunit surface trafficking.  To identify the 
occupancy of a particular sequon for both wildtype and mutant receptors, we mutated each 
potentially glycosylated asparagine residue (N-glycosylation sites N33, N105, and N174) 
individually to glutamine in wildtype β3 and mutant β3(G32R) subunits, thereby creating 
glycosylation-defective subunits335, 375, 381, 382.  We could not eliminate the possibility that these 
point mutations themselves could alter receptor assembly or function; however, we compared the 
characteristics of glycosylation-defective subunits bearing or lacking the G32R mutation.  
Furthermore, in a previous study we addressed several concerns regarding this method 335. 
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Consistent with previous results, β3 and β3(G32R) subunits displayed clear differences in 
molecular mass distribution when all three glycosylation sites remained intact.  If this difference 
reflected increased glycosylation of β3(G32R) subunits at one specific site (i.e., N33, N105, or 
N174), inactivating that site with an Asn to Gln mutation (“NQ mutation”) should yield proteins 
with identical molecular mass distributions.  Moreover, the 51 kDa band, which presumably 
represented triply-glycosylated proteins, should disappear in any subunit bearing an NQ mutation.  
Therefore, we coexpressed α1 and γ2LHA subunits with each wildtype/glycosylation-deficient β3 
subunit (N33Q, N105Q, and N174Q; labeled as 1Q, 2Q, and 3Q, respectively) and each 
mutant/glycosylation-deficient β3 subunit (G32R/N33Q, G32R/N105Q, and G32R/N174Q; 
labeled as GR/1Q, GR/2Q, and GR/3Q, respectively (Figure 4D and 4E).  Immunoblotting for 
wildtype β3 subunit surface and total protein yielded several interesting results.  Most strikingly, 
inactivating the second or third glycosylation site (2Q or 3Q) drastically reduced expression of 
wildtype β3 subunits; indeed, expression of β3(2Q) subunits was nearly abolished.  While 
intriguing, these deficits in protein expression made it impossible to compare the glycosylation 
patterns of these second- and third- glycosylation site mutants in the presence or absence of the 
G32R mutation and, thus, to determine conclusively if the molecular mass shifts in glycosylation-
competent β3(G32R) subunits were due to increased occupancy of the second or third 
glycosylation sites.  Nonetheless, these data indirectly suggest that glycosylation of N105 or 
N174 was not responsible for the molecular mass shift; given that disruption of these sites so 
drastically reduced protein expression, it seems likely that both sites are usually glycosylated and 
therefore could not have their occupancy increased by the G32R mutation.   
Inactivating the first glycosylation site (1Q) produced remarkably different effects 
(Figure 4D and 4E).  First, β3(N33Q) subunit expression levels were not significantly reduced 
compared to wildtype β3 subunit levels.  Conversely, combining the G32R and N33Q mutations 
(GR/1Q) significantly reduced surface and total β3 subunit levels relative to both β3 and 
β3(N33Q) subunit levels.  Despite the difference in overall β3 subunit levels, β3(N33Q) and 
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β3(G32R/N33Q) subunits had similar molecular mass distributions, suggesting that the G32R 
mutation may indeed have facilitated N33 glycosylation.   
The β3 subunit constructs with NQ mutations allowed us to examine the effects of the 
G32R mutation in the absence of N-glycosylation at specific sequons.  However, when all 
glycosylation sites were intact, the G32R mutation appeared to increase β3 subunit glycosylation; 
therefore, it was valuable to examine the effects of the mutation when both wildtype β3 and 
mutant β3(G32R) subunits had increased glycosylation.  It is not possible to force glycosylation 
of individual sequons, but it is well known that NXT sequons are much more likely than NXS 
sequons to accept N-glycans.  As described above, expression of glycosylation-deficient 
constructs indicated that the N33 site (sequon: NMS) was more likely to be occupied in the 
presence of the G32R mutation.  Therefore, we hypothesized that β3 subunits in which Ser 35 
was mutated to Thr (β3(S35T) subunits; ST) would exhibit a glycosylation pattern similar to that 
of β3(G32R) subunits.  As shown in Figure 4D and 4E, the S35T mutation did increase 
glycosylation of β3 subunits, but the G32R mutation did not increase glycosylation further; that is, 
β3(S35T) and β3(G32R/S35T) subunits exhibited similar molecular mass distributions.  Taken 
together, these results indicated that the G32R mutation increased β3 subunit N-glycosylation at 
N33.   
However, it remained unclear whether glycosylation at N33 was responsible for 
decreased γ2LHA subunit surface incorporation.  We therefore evaluated levels of partnering 
subunits when coexpressed with β3(N33Q), β3(G32R/N33Q), β3(S35T), or β3(G32R/S35T) 
subunits.  Surface levels of α1 subunits remained similar regardless of the coexpressed β3 subunit 
construct (Figure 4F).  Conversely, γ2LHA subunit surface levels decreased whenever the 
coexpressed β3 subunit contained the G32R mutation, but without regard to glycosylation site 
inactivation or strengthening (Figure 4G).  Thus, these data suggested that glycosylation was not 
the mechanism by which the G32R mutation reduced γ2L subunit incorporation and, potentially, 
GABAA receptor function. 
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Presence of a basic residue at position 32 reduced surface expression levels of γ2L subunits 
and increased glycosylation at Asn-33. 
If the change in glycosylation was not responsible for altered subunit expression patterns 
seen with mutant β3(G32R) subunits, some other property of the point mutation itself, such as 
charge, must have been causative.  To investigate the effects of charge at residue 32, we mutated 
the β3 subunit residue G32 to lysine, glutamine, or glutamate (G32K, G32Q, and G32E, 
respectively).  We co-expressed each of these β3 subunits individually with α1 and γ2L subunits 
and evaluated glycosylation patterns of β3 subunits and surface levels of all subunits (Figure 5).  
Interestingly, our results suggested that glycosylation of N33 clearly depended upon the charge of 
residue 32.  Thus, 32.0 ± 3.9% of all wildtype β3 subunit surface protein was fully glycosylated 
(i.e., migrated at 51 kDa), compared to 67.4 ± 5.9 % of β3(G32R) and 56.7 ± 5.4 % of β3(G32K) 
subunit proteins (Figure 5 Α1, A2).  In contrast, 42.0 ± 4.9 % of β3(G32Q) subunit surface 
protein and only 2.8 ± 0.9 % of β3(G32E) subunit surface protein was fully glycosylated.   
As in previous experiments, α1 subunit surface levels changed minimally when 
coexpressed with any β3 subunit (Figure 5B).  Surprisingly, however, α1 subunit surface levels 
did decrease significantly when coexpressed with β3(G32K) subunits (89% of wildtype; p < 0.05).  
Conversely, γ2LHA subunit surface levels were correlated with charge at β3 subunit residue 32.  
Specifically, γ2LHA subunit surface levels decreased significantly when the coexpressed β3 
subunit had a positively-charged residue (arginine or lysine) at position 32 (GK, 79.2 ± 3.3 % of 
wildtype, n = 12, p < 0.001), but γ2LHA subunit surface levels decreased only slightly when the 
coexpressed β3 subunit had an uncharged residue at the same position (GQ, 93.5 ± 3.4 % of 
wildtype, n = 12) and did not change when the coexpressed β3 subunit had a negatively charged 
residue (GE, 1.02 ± 4.0 % of wildtype, n = 11).  Taken together, these data (Figures 4 and 5) 
indicated that the positive charge introduced by the G32R mutation was responsible both for 
increasing N33 glycosylation and for decreasing γ2LHA subunit incorporation; however, these two 
phenomena were not causally related to one another.  
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Figure 5.  Presence of a basic residue at position 32 of β3 subunits increased β3 subunit 
glycosylation at Asn-33 and reduced γ2LHA subunit incorporation into surface a1β3γ2LHA 
GABAA receptors.
A1. Surface proteins were isolated from HEK293T cells expressing equimolar amounts of α1, γ
2LHA, and different β3 subunits. In lane 1, the β3 subunit was not mutated (wt), and in lane 2, 
the β3 subunit contained the G32R mutation (GR).  In lanes 3, 4, and 5, Gly 32 was mutated to 
lysine (GK), glutamine (GQ), or glutamate (GE), respectively.  The upper panel presents stain-
ing for Na+/K+ ATPase as a loading control (LC), and the lower panel presents staining for β3 
subunits.  The β3 subunits migrated as three populations, with bands seen at approximately 51, 
47, and 43 kDa.  A2. Integrated intensity was calculated for all β3 subunit bands and normalized 
to the integrated band intensity of the Na+/K+ ATPase.  The normalized integrated intensities 
for each β3 subunit band were summed, and the proportions of β3 protein migrating at 51 kDa 
(black), 47 kDa (gray), and 43 kDa (white) were calculated.  B-C. Surface levels of α1 (B) and 
γ2LHA(C) subunits in cells expressing α1, γ2LHA, and Gly32 mutant β3 subunits were deter-
mined using flow cytometry.  Upper panels present fluorescence intensity histograms in which 
the abscissa denotes fluorescence intensity in arbitrary units graphed on a logarithmic scale (FI) 
and the ordinate denotes percentage of maximum cell count (% of max).  Fluorescence intensity 
histograms from mock-transfected cells (solid gray line) are overlaid with histograms from cells 
expressing α1, γ2LHA, and either β3(G32K) (dashed black line), β3(G32Q) (dotted black line), 
or β3(G32E) (solid black line) subunits.  Lower panels present normalized fluorescence intensi-
ties for each condition.  Mean fluorescence intensities from cells transfected with blank vector 
alone (“mock”) were subtracted from mean fluorescence intensities of cells transfected with α1, 
γ2LHA, and the indicated β3 subunits.  All mock-subtracted fluorescence intensities were 
normalized to the mock-subtracted fluorescence intensity of the cells expressing β3 subunits.  
Statistical analysis was performed using one-way ANOVA with Tukey’s post-test.  ** p< 0.01, 
*** p < 0.001 compared to wildtype.
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The G32R mutation reduced current density independent of glycosylation. 
Up to now, we observed that the G32R mutation caused glycosylation-independent 
changes in subunit expression patterns that could reduce the function of αβγ GABAA receptors; 
however, those changes were not large enough to account for the reduction in current amplitude 
that was previously reported310.  This discrepancy suggested that expression of β3(G32R) 
subunits might also affect receptor gating.  Furthermore, although subunit expression patterns 
depended upon charge at residue 32 rather than glycosylation at residue 33, any such changes in 
gating might still be glycosylation-dependent. 
To determine how mutant β3(G32R) subunits affected GABAA receptor function, we 
used a rapid exchange system to apply 1 mM GABA for 400 ms to lifted HEK293T cells 
coexpressing α1, γ2L, and β3, β3(G32R), β3(N33Q), or β3(G32R/N33Q) subunits (Figure 6A).  
Wildtype receptors displayed a current density of 845.8 ± 33.93 pA/pF (n = 34), nearly 50% 
higher than current density of receptors containing mutant β3(G32R) subunits (454.3 ± 57.46 
pA/pF, n = 32, p < 0.001 compared to wildtype) (Figure 6A, 6B); this difference was consistent 
with previously reported data310.  When N33 glycosylation was abolished by introducing the 
β3(N33Q) subunit mutation alone, current density also decreased (411.7 ± 19.61 pA/pF, n = 21, p 
< 0.001 compared to wildtype).  However, when the G32R mutation was introduced together with 
the N33Q mutation, current density decreased further (160.4 ± 46.99 pA/pF, n = 13, p < 0.001 
compared to wildtype and p < 0.01 compared to the β3(N33Q) subunit alone).  These results 
suggested that although eliminating N33 glycosylation by introducing the N33Q mutation itself 
reduced current density (due to either the absence of the glycan or the presence of the point 
mutation), the CAE-associated β3(G32R) subunit mutation also impaired receptor function 
independent of N33 glycosylation. 
In summary, both β3(G32R) and β3(N33Q) point mutations significantly reduced current 
densities of α1β3γ2L receptors.  However, the effects of these mutations were additive, indicating 
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Figure 6.  The β3(G32R) mutation reduced current density from α1β3γ2L receptors even if 
the first glycosylation site was inactivated.
Α. Currents were recorded from lifted whole HEK293T cells transfected with equimolar 
amounts of α1, γ2L, and either β3(wt), β3(G32R), β3(N33Q), or β3(G32R/N33Q) subunit 
cDNAs (wt, GR, 1Q, and GR/1Q, respectively).  Cells voltage-clamped at -20 mV and subjected 
to a 400 ms pulse of 1 mM GABA.  Subunit identity and length of GABA application (black 
line) are indicated above the current traces.  Scale bar = 1 nA.  B. Mean current densities 
(pA/pF) from cells expressing α1, γ2L, and either β3(wt), β3(G32R), β3(N33Q), or β
3(G32R/N33Q) subunits were calculated*** indicates p < 0.001 compared to wt, and †† and 
††† indicate p < 0.01 and p < 0.001, respectively, compared to NQ.
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that the G32R point mutation reduced current density even when N33 was not glycosylated.  
Taken together, these data suggest that the G32R mutation reduced current density by a 
mechanism that was independent of increasing N33 glycosylation and furthermore that this region 
of the N-terminal α-helix could play a role in channel gating. 
Presence of a charged residue at position 32 of the β3 subunit reduced current density of 
α1β3γ2L receptors. 
To this point, we demonstrated that the G32R mutation increased glycosylation at β3 
subunit residue N33, altered GABAA receptor assembly, and reduced current density.  Contrary to 
previous hypotheses, the changes in subunit expression and receptor function were not due to 
increased β3 subunit glycosylation; the changes in subunit expression instead could be attributed 
to introduction of positive charge at residue 32.  Therefore, we investigated whether or not the 
charge of residue 32 was also responsible in part for the lower current densities observed in 
α1β3(G32R)γ2L receptors.  We applied 1 mM GABA for 4 s to lifted HEK293T cells 
coexpressing α1, γ2L, and either β3, β3(G32R), β3(G32K), β3(G32E), or β3(G32Q) subunits and 
determined current densities (Figure 7A).  As expected, α1β3(G32R)γ2L receptor current 
densities were lower (p < 0.001) (GR, 409 ± 11 pA/pF, n = 8) than those of α1β3γ2L receptors 
(wt, 903 ± 22 pA/pF, n = 8) (Figure 7B).  When residue 32 was mutated to another basic residue 
(i.e., G32K), α1β3(G32K)γ2L receptor current densities were also significantly reduced (GK, 577 
± 66 pA/pF, n = 13, p < 0.01).  Interestingly, current densities were also reduced in 
α1β3(G32E)γ2L receptors; that is, when residue 32 was mutated to an acidic amino acid (GE, 606 
± 98 pA/pF, n=10, p < 0.05).  However, when residue 32 was mutated to a large but neutral 
amino acid (i.e., G32Q), receptor current density did not differ significantly from that of wildtype 
receptors (GQ, 870 ± 35 pA/pF, n = 10). Thus, receptor function was altered due to introduction 
of a charged residue at this position.  It is possible that the charged residues can form new salt 
bridges that altered channel function (this hypothesis is further addressed below).   
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Figure 7. Introduction of a charged residue at position 32 reduced current amplitudes in          
α1β3γ2L GABA
A
 receptors.
Α. Currents were recorded from lifted whole HEK293T cells transfected with equimolar 
amounts of α1, γ2L, and either β3, β3(G32R), β3(G32K), β3(G32E), or β3(G32Q) subunit 
cDNAs (wt, GR, GK, GE, and GQ, respectively).  Cells were voltage-clamped at -20 mV and 
subjected to a 4 s pulse of 1 mM GABA.  Subunit identity and length of GABA application 
(black line) are indicated above the current traces.  Scale bar = 1 nA.  B. Mean current density 
(pA/pF) from cells expressing α1, γ2L, and either β3, β3(G32R), β3(G32K), β3(G32E), or β
3(G32Q) subunits were calculated.  All data are presented as mean ± S.E.M., and significance 
was determined using one-way ANOVA with Tukey’s post-test.  *, **, and *** indicate p < 0.05, 
0.01, and 0.001, respectively, compared to wildtype.
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a1β3(G32R)γ2L receptors were more likely to enter short open states and had reduced mean 
open times. 
The α1β3(G32R)γ2LHA receptors displayed many macroscopic kinetic changes (slightly 
slower activation, faster desensitization, and faster deactivation) that were consistent with 
reduced charge transfer; however, most of these changes were not significant and could not 
explain the nearly 50% reduction of current density in mutant compared to wildtype receptors.  
Consequently, we employed cell-attached single-channel recording to examine the microscopic 
kinetic properties of α1β3γ2L receptors containing β3 or β3(G32R) subunits (Figure 8A).  
Wildtype and mutant receptors had identical single channel amplitudes (Figure 8B), but mutant 
receptors had significantly reduced mean open times (Figure 8C).  The reduction was not due to 
alterations of open time constants themselves, because the open duration histograms of wildtype 
and mutant receptors (Figure 8D) both were fitted best by three time constants whose mean 
durations did not change (Figure 8E).  However, the relative contributions of the time constants 
did change (Figure 8F); specifically, the relative proportion of the shortest open state was 
significantly increased in mutant receptors (α1β3γ2L receptors τ1% = 23.1 ± 3.3 %; 
α1β3(G32R)γ2L receptors τ1% = 78.4 ± 4.2 %; n = 4, p < 0.001).  Therefore, the G32R mutation 
reduced GABAA receptor-mediated inhibition both by introducing a positive charge that 
discouraged formation of high-functioning α1β3γ2L receptors in favor of low-functioning α1β3 
receptors and β3 homopentameric receptors and by inducing those α1β3γ2L receptors to enter 
shorter open states, thereby reducing mean single channel open time.   
The β3(G32R) mutation was predicted to alter salt bridges and conformation at β3-γ2 and β3-
β3 subunit interfaces 
To gain insight into the mechanism by which the β3(G32R) mutation affected receptor 
assembly and channel gating, we performed homology modeling of wildtype and mutant 
receptors using the nAChR α1 subunit extracellular domain structure (PDB ID 2qc1)153 as a 
template (Figure 10).  In α1β3γ2L receptor isoforms, the major structural changes induced by the 
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Figure 8.  The G32R mutation reduced mean single-channel open time of α1β3γ2L GABAA 
receptors by promoting occupancy of shorter-lived open states.
Α. Single-channel currents were recorded from HEK293T cells expressing α1, γ2L, and either β
3 (upper panel) or β3(G32R) (lower panel) subunits.  Recording was conducted in the 
cell-attached configuration, with cells voltage-clamped at +80 mV and 1 mM GABA present in 
the recording electrode.  B. Single-channel conductance (pA) was calculated for α1β3γ2L and α
1β3(G32R)γ2L GABAA receptors.  C. Mean open time (ms) was calculated for α1β3γ2L and α
1β3(G32R)γ2L GABAA receptors.  D. Frequency histograms of channel open durations were 
best fitted with three exponential functions.  The left panel presents histograms for α1β3γ2L 
receptors and the right panel presents histograms for α1β3(G32R)γ2L receptors.  E. Means of 
the three open durations (ms) were calculated.  F. The relative contribution (%) of each open 
state was calculated.  All data are expressed as mean ± S.E.M., and significance was calculated 
using two-tailed Student’s t-test.  *** indicates p < 0.001 compared to wt.
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β3(G32R) mutation occurred at the interface between the principal (+) side of the γ2L subunit and 
the complementary (-) side of the β3 subunit (γ2-β3 interface).  In both α1β3γ2L (Figure 9A) and 
α1β3(G32R)γ2L (Figure 9B) receptors, all subunits were predicted to begin with a random coil 
leading into an α-helix.  However, the G32R mutation induced a conformational change in the β3 
subunit α-helix, causing the random coil to project in a slightly different direction.  Moreover, the 
side-chain of Arg 32 extended across the γ2-β3 subunit interface, forming a salt bridge with γ2 
subunit residue Asp 123, which lies in a motif previously established to be necessary for γ2-β3 
subunit interaction92.   
Because both α1β3(G32K)γ2L and α1β3(G32E)γ2L receptors also displayed reduced 
current densities, we performed homology modeling of these isoforms as well.  These mutations 
also induced structural changes primarily at the γ2-β3 subunit interface.  Interestingly, the side-
chain of the β3 subunit residue K32 angled toward the cell membrane and formed a salt bridge 
with the γ2 subunit residue E217, which participates in a salt bridge network disrupted by the 
epilepsy-associated γ2(R82Q) mutation316 (Figure 9C).  The side-chain of the β3 subunit residue 
E32, conversely, extended toward the γ2 subunit but did not come within 4 Å of any γ2 subunit 
atoms (Figure 9D).   
We demonstrated that β3(G32R) subunits were expressed on the cell surface at much 
higher levels than β3 subunits, suggesting that mutant subunits might assemble into 
homopentamers.  Consequently, we also created homology models of β3 and β3(G32R) 
homopentameric receptors.  Unsurprisingly, structural changes occurred at subunit interfaces.  
Strong salt bridges existed at the interface of wildtype β3 subunits (Figure 10A), but when R32 
was introduced (Figure 10B), its side chain formed three new salt bridges with D94 of the 
adjacent β3(G32R) subunit.  In summary, homology modeling provided a potential explanation 
for the changes in subunit surface expression associated with the β3 subunit G32R mutation.  All 
structural changes occurred at subunit interfaces, suggesting that the point mutation could perturb 
subunit oligomerization.   
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Figure 9.  β3(G32) mutations changed  conformation and salt bridge formation at the γ2-β3 
interface of heteropentameric α1β3γ2L receptors.
Three-dimensional models of α1, β3, and γ2 subunit extracellular domains were created (see 
Methods) and threaded onto the Lymnaea stagnalis acetylcholine binding protein structure in 
the order γ2-β3-α1-β3-α1 to model ternary heteropentameric α1β3γ2L receptors.  Point muta-
tions were introduced into β3 subunit structures and the resulting energy-minimized models 
were examined for structural changes.  A. A portion of the interface between the γ2 subunit 
(yellow) and the wildtype β3 subunit (blue) is presented.  The perspective is from outside the 
receptor, such that the synaptic cleft would be located at the top of the figure.  Residues 
discussed in the text, including the mutated G32, the first glycosylation sequon residues N33 
and S35, and the second glycosylation site N105, are labeled, and predicted salt bridges are 
indicated by dotted lines.  Adjacent numbers indicate the distance in angstroms between the two 
atoms forming the salt bridge.  Two γ2 subunit residues are also identified: R125, which is 
predicted to form a salt bridge with β3(N33); and R82, which was mutated to Q in a family with 
GEFS+.  Side-chains are colored in the CPK scheme; that is, carbon atoms are grey, oxygen 
atoms are red, and nitrogen atoms are blue.  B-D. Views of the γ2-β3 interface in                               
α1β3(G32R)γ2L (B),  α1β3(G32K)γ2L (C), and α1β3(G32E)γ2L (D) receptors are presented as 
in panel A.  Salt bridges longer than 3.5 Å are indicated by grey dotted lines, while salt bridges 
shorter than 3.5 Å are indicated by black dotted lines.
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Figure 10.  The β3(G32R) mutation changed salt bridge formation at the β3-β3 interface of 
homopentameric receptors.  
Three-dimensional models of β3 homopentamers were constructed as described in Figure 10.  
A. The upper panel illustrates a portion of the interface between two wildtype β3 subunits.  
Although the two subunits are identical, one is presented in red and one in blue for clarity.  The 
lower panel presents a magnification of the area boxed in the upper panel.  B. The upper panel 
illustrates a portion of the interface between two β3(G32R) subunits, and the lower panel 
presents a magnification of the area boxed in the upper panel.
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 Discussion 
The N-terminal α-helix: new roles in receptor assembly and gating?  
A large body of work exists documenting the GABAA receptor subunit domains that are 
responsible for receptor assembly and trafficking, GABA binding, and coupling of agonist 
binding to channel gating167.  However, the distal N-terminal domain, which comprises a random 
coil followed by an α-helix, has not been demonstrated to be important for these processes.  In 
fact, the helix was entirely absent in recently-discovered prokaryotic nAChR homologs156, 383.  
Helical integrity was shown to be necessary for proper biogenesis of nAChR α7 subunits, but 
most residues could be mutated without affecting subunit expression384.  In our experiments, 
multiple point mutations of G32 and N33 residues in the distal α-helix of β3 subunits caused 
changes in assembly as well as gating that were not attributable fully to the glycosylation changes 
induced by the mutations.  Our results suggest that unexpectedly the N-terminal α1-helix may be 
important for assembly and function of GABAA receptors containing β3 subunits. 
The β3 subunit G32R mutation and receptor heterogeneity 
Our data suggested that the G32R mutation promoted formation of binary α1β3 receptors 
and β3 homopentamers and decreased formation of ternary α1β3γ2L receptors.  Wildtype β3 
subunits are known to assemble more promiscuously than most other GABAA receptor subunits 
in heterologous systems; β3 subunits reached the cell surface when expressed alone, and both β3 
and γ2L subunits were detected on the cell surface when coexpressed together without an α 
subunit90.  We obtained similar results when β3 subunits were coexpressed with β, δ, ε, or θ 
subunits (data not shown).  In contrast, β2 subunits are retained intracellularly and degraded in 
the absence of coexpressed α subunits even though β2 and β3 subunits have very similar 
sequences.  In previous studies, four amino acid residues (G171, K173, E179, R180) conferred 
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the ability to form β3 subunit homopentamers90.  According to our model, these residues are also 
predicted to lie on the (-) face of β3 subunits, but are much closer to the cell membrane than the 
G32 residue.  Thus, we may have uncovered a previously unknown role for the N-terminal α-
helix in regulating β3 homopentamer assembly. 
β3 subunit glycosylation: patterns and their dependence on receptor subunit composition 
Although we have shown that hyperglycosylation ultimately was not responsible for the 
effects of the β3(G32R) mutation on receptor assembly and function, our studies elucidate the 
characteristics and importance of β3 subunit N-glycosylation.  We demonstrated that all three N-
glycosylation sites on wildtype β3 subunits could be glycosylated in HEK293T cells, though 
many β3 subunits were not glycosylated at N33.  Importantly, other investigators have observed 
similar β3 subunit glycosylation patterns in mouse cortical neurons (M.J. Gallagher, private 
communication).  Interestingly, we also showed that β3 subunits retain some unprocessed, high-
mannose glycans despite being assembled into receptors and trafficked to the cell surface.  This 
occurred in all tested receptor isoforms (i.e., β3, α1β3, and α1β3γ2L); however, the proportion of 
β3 subunits containing endo H sensitive glycans was correlated with the number of different 
subunits expressed.  We recently observed a similar phenomenon in β2 subunits.  In heterologous 
systems, all β2 subunit bands were endo H resistant when only α1 and β2 subunits were 
coexpressed, but an endo H sensitive population appeared if γ2 subunits were added.  
Furthermore, β2 subunits from heterozygous γ2 subunit knockout mice, which may form α1β2 
receptors due to γ2 subunit deficiency, had a larger endo H resistant population than β2 subunits 
from wildtype mice (W.Y. Lo, A.H. Lagrange, C.C. Hernandez, K.N. Gurba, and R.L. 
Macdonald, in review).  Taken together, these findings suggest that incorporation of non-β 
subunits might alter β subunits such that their glycans become accessible for modification in the 
Golgi apparatus.  It will be interesting to determine if glycan structure contributes to the 
characteristic current properties of binary and ternary receptors.  
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Although the G32R mutation appeared to promote increased assembly of binary α1β3 
and homopentameric β3 receptors, and those isoforms promoted glycan maturation, the G32R 
mutation also affected glycan processing independent of receptor stoichiometry.  All wildtype 
receptors (i.e., β3, α1β3, and α1β3γ2L) contained at least a small population of β3 subunits that 
were fully endo H sensitive.  However, that population virtually disappeared in the corresponding 
mutant receptor isoforms.  It may be worthwhile to investigate whether microheterogeneity (i.e., 
sugar composition) as well as macroheterogeneity (i.e., sequon occupancy) of N-glycans can 
affect receptor function. 
Altered salt bridge formation and receptor conformation may be responsible for changes in 
assembly, glycosylation, and gating, leading to reduced GABAA receptor-mediated inhibition. 
Because GABAA receptors have not been crystallized, homology models are limited to 
nAChR97, 153 and AChBP98, 385 templates, many of which have poor resolution in their N-terminal 
domains.  Therefore, while homology models of GABAA receptors are necessarily speculative, 
they nonetheless provide valuable insight regarding potential interactions.  In our models, 
mutating the G32 residue to R32 induced formation of new salt bridges at the γ2-β3 and β3-β3 
interfaces in ternary and homopentameric receptors, respectively.  The β3-β3 salt bridges were 
particularly strong, and would likely increase the affinity of homodimer formation.  This, in turn, 
could promote formation of isoforms containing a β3-β3 interface.  Such interfaces are not 
predicted to exist in ternary receptors, which are thought to have a γ-β-α-β-α orientation 
(anticlockwise as viewed from the synaptic cleft)328, 340.  However, in binary receptors, the γ2 
subunit presumably is replaced by either an α1 or a β3 subunit; the latter would introduce a β3-β3 
interface.  It is possible that the salt bridges introduced by the G32R mutation promote β3(G32R) 
subunit homodimerization, which in turn could “seed” the formation of (α1)2(β3)3 and β3 receptor 
isoforms, thereby increasing β3 subunit surface expression.  It is somewhat less clear how salt 
bridge formation between R32 and γ2(D123) could discourage incorporation of γ2 subunits; 
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however, it is important to note that salt bridges can be destabilizing386, and that γ2 subunit (122-
129) integrity was essential for γ2-β3 subunit interaction92.  It is also worth mentioning that the 
epilepsy-associated mutation γ2(R82Q), which has been shown to disrupt receptor assembly100, 316 
is located in the γ2 subunit loop nearest to the N-terminal domain of the β3 subunit α-helix.  
Indeed, point mutations throughout this loop impaired γ2 subunit incorporation.  Thus, it is 
possible that any structural changes in this area, whether on γ2 or β3 subunits, could disturb an 
important assembly domain and result in preferential expression of low efficacy binary αβ3 
receptors and homopentameric β3 receptors instead of high efficacy ternary αβ3γ2 receptors, 
thereby causing disinhibition.   
How might the β3(G32R) mutation contribute to epileptogenesis? 
The electroencephalographic signature of an absence seizure involves generalized, 
synchronous spike-wave activity, reflecting oscillations in thalamocortical circuits.  The location 
of the seizure discharge origin within these circuits remains a subject of debate387, making it 
difficult to predict how changes in the function of a particular ion channel could initiate seizures.  
However, it is known that both thalamic reticular nucleus and cortex (particularly somatosensory 
cortex) participate in synchronized activity.  Importantly, the β3 subunit subtype predominates in 
the reticular nucleus throughout life and in cortex during development45, 49, 57. 
It was recently demonstrated that tonic GABAergic current is paradoxically increased in 
thalamocortical neurons from two rat models of absence epilepsy388, whereas we discovered 
many changes wrought by the G32R mutation that decreased mutant receptor function.  This 
could indicate that the G32R mutation might primarily promote hyperexcitability through cortical 
and/or postsynaptic (i.e., phasic current-mediating) GABAA receptors.  If so, this could suggest a 
reason for this mutation being associated with childhood absence epilepsy, because cortical β3 
subunit expression declines throughout childhood.  Thus, it is possible that deficits in GABAA 
receptors containing β3 subunits could affect children more significantly than adults because in 
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children, a substantial proportion of cortical receptors contain β3 subunits. Subsequently, 
associated epilepsy syndromes might remit as β2 subunits displace β3 subunits in adulthood. 
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CHAPTER V 
THE GABRA6 MUTATION, R46W, ASSOCIATED WITH CHILDHOOD ABSENCE 
EPILEPSY, ALTERS α6β2γ2L and α6β2δ GABAA RECEPTOR CHANNEL GATING 
AND EXPRESSION  
 
Abstract 
A GABAA receptor α6 subunit mutation, R46W, was identified as a susceptibility gene 
that may contribute to the pathogenesis of childhood absence epilepsy (CAE), but the molecular 
basis for alteration of GABAA receptor function is unclear.  The R46W mutation is located in a 
region homologous to a GABAA receptor γ2 subunit missense mutation, R82Q, which is 
associated with CAE and febrile seizures in humans.  To determine how this mutation reduces 
GABAergic inhibition, we expressed wild-type (α6β2γ2L and α6β2δ) and mutant 
(α6(R46W)β2γ2L and α6(R46W)β2δ receptors in HEK 293T cells in order to characterize their 
whole-cell and single-channel currents and surface and total expression levels.  Our results 
indicated that the R46W mutation impaired gating and assembly of both α6(R46W)β2γ2L and 
α6(R46W)β2δ receptors by complex mechanisms.  Compared to wild-type currents, 
α6(R46W)β2γ2L and α6(R46W)β2δ receptors had a reduced current density, α6(R46W)β2γ2L 
currents desensitized to a greater extent and deactivated at a slower rate, α6(R46W)β2δ receptors 
did not desensitize but deactivated faster and both α6(R46W)β2γ2L and α6(R46W)β2δ single 
channel current mean open times and burst durations were reduced.  Surface levels of 
coexpressed α6(R46W), β2 and δ, but not γ2L, subunits were decreased.  “Heterozygous” 
coexpression of α6(R46W) and α6 subunits with β2 and γ2L subunits produced intermediate 
macroscopic current amplitudes by increasing incorporation of wild-type and decreasing 
incorporation of mutant subunits into receptors trafficked to the surface.  Taken together, these 
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findings suggest that, similar to the γR82Q mutation, the CAE-associated α6(R46W) mutation 
could cause neuronal disinhibition and thus increase susceptibility to generalized seizures through 
a reduction of αβγ and αβδ receptor function and expression. 
 
Introduction 
GABAA receptors, the major mediators of inhibition in the mammalian central nervous 
system, belong to the Cys-loop ion channel superfamily, which includes glycine, nicotinic 
acetylcholine (nAChR), and serotonin 5-HT3 receptors.  GABAA receptor subunits have a large 
N-terminal extracellular domain and four transmembrane segments (M1, M2, M3, M4) that are 
homologous to the ACh binding protein (AChBP) N-terminal domain98 and the transmembrane 
domain of the Torpedo marmorata ACh receptor (AChR)389.  GABAA receptors are formed by 
pentameric assembly of 19 different subunit subtypes (α1-α6, β1-β3, γ1-γ3, δ, ε, π, θ, and ρ1-ρ3), 
although the majority of receptors are thought to be αβγ and αβδ receptor isoforms that mediate 
both phasic inhibitory synaptic transmission and tonic perisynaptic inhibition390.   
Idiopathic epilepsy syndromes are primarily genetic diseases.  They are characterized by 
typical seizure types and EEG abnormalities that are not associated with structural brain lesions391.  
Mutations or variants associated with idiopathic generalized epilepsies (IGEs) have been 
identified in GABRA1, GABRB3, GABRG2 and GABRD genes392.  A novel GABAA receptor α6 
subunit mutation, R46W, was recently described in an IGE cohort study in a patient with 
childhood absence epilepsy (CAE)393, but no evidence of channel impairment was reported.  The 
mutation is located in a region homologous to that of the GABAA receptor γ2 subunit mutation, 
R82Q (R43Q in the mature peptide), which is associated with CAE and febrile seizures in 
humans314, 394.  Mutant γ2(R82Q) subunits reduced both surface α1β2γ2(R82Q) receptor levels395 
and receptor currents313, suggesting impairment of both assembly and function of GABAA 
receptors. 
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Homology modeling of the N-terminal extracellular domain of human β2-α6-β2-α6-γ2 
and β2-α6-β2-α6-δ GABAA receptors suggested that the R46W mutation (Figure 1A and Figure 
10C) is located within a loop (L1) between the α-helix and the β1-sheet (Figure 1B), where it 
contributes to the α-β, α-γ and α-δ subunit interfaces in assembled receptors.  In contrast, the γ2 
subunit mutation, R82Q, (Figure 1A) only contributes to the γ-α interface.  Sequence alignment of 
the AChBP with the α-helix-L1-β1-sheet region of human α6, γ2L, β2 and δ subunits and the T. 
marmorata AChR α1 subunit showed conserved structural relationships (Figure 1B).   
To gain further insights into the effects of the R46W mutation on GABAA receptor 
function and assembly, we studied the gating properties and surface expression of α6β2γ2, 
α6/α6(R46W)β2γ2, α6(R46W)β2γ2, α6β2δ,  α6/α6(R46W)β2δ and  α6/α6(R46W)β2δ  subunits 
expressed in HEK293T cells.  We found that the R46W mutation impaired gating and assembly 
of both α6(R46W)β2γ2L  and α6(R46W)β2δ receptors and substantially reduced the current 
density of both receptors.  In addition, surface levels of coexpressed α6(R46W), β2 and δ 
subunits, but not γ2L subunits, were decreased.  These findings suggested that the CAE-
associated α6(R46W) mutation could cause neuronal disinhibition and thus increase 
susceptibility to generalized seizures through a reduction of αβγ and αβδ receptor function and 
expression, sharing a mechanism with the γR82Q mutation linked with CAE in humans. 
 
Materials and Methods 
cDNA constructs  
cDNAs encoding human α6, β2, γ2L and delta GABAA receptor subunit subtypes 
(GenBank accessions NM000811, NM000813, NM198904, and NM000815, respectively) were 
subcloned into the plasmid expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA) using 
standard techniques.  The human α6 subunit mutation, R46W, was generated by site-directed 
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Figure 1.  The α6 subunit mutation, R46W, contributes to the α/β and α/γ subunit inter-
faces in assembled GABA
A
 receptors.  
A.  A structural model of the N-terminal extracellular domain of human β2α6β2α6γ2  
receptors viewed from outside the pentamer (left panel) and orthogonal toward the mem-
brane (right panel) was developed.  Mutations at α6R46 (in orange) and γ2R82 (in aqua) on 
the L1-loop at the α/β, α/γ, and γ/β interfaces are shown in a space-fill representation.  Resi-
dues involved in GABA binding at the β/α interface are shown as well (in orange in a stick 
representation).  B.  Sequence alignments of the α-helix, L1-loop and the β1-sheet domain 
of human α6, β2, γ2 and δ subunits from the GABAR family, the nicotinic acetylcholine 
receptor α1 subunit (AChRα1) and the acetylcholine-binding protein (AChBP) are 
presented.  The basic charged residues linked to CAE are shown in red within a pink box 
representing conserved residues into the L1-loop, and the light grey boxes represent 
residues in the α-helix and β1-sheet across the subunits.
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mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and 
verified by sequencing.  FLAG (DYKDDDDK) or HA (YPYDVPDYA) epitopes were inserted 
between amino acids 4 and 5 of the mature α6, γ2L and d subunits, so that subunit total and cell 
surface expression could be determined by flow cytometry.  In this study all mutations were 
specified in the immature peptide, which has been the convention in the literature for α1, β3 and δ 
subunit mutations and variants but not for γ2 subunit mutations, which have generally been 
identified in the mature peptide392.  
Cell culture and transfections 
Human embryonic kidney cells (HEK293T) were grown in 100 mm tissue culture dishes 
(Corning) in DMEM, supplemented with 10% fetal bovine serum at 37C in 5% CO2 / 95% air 
For electrophysiological experiments, cells were plated onto poly-L-lysine–coated (cell-attached 
and excised outside-out patches) or non-coated (lifted whole cells) coverglass chips and 
transfected with 0.3 mg of each subunit plasmid in a ratio of 1α6:1β2:1γ2L/δ (wild-type or 
homozygous mutant α6 subunit expression) or 0.5α6:0.5α6(R46W):1β2:1γ2L/δ (heterozygous wild-type 
and mutant α6 subunit expression) using the FuGENE 5 transfection reagent (Roche Applied 
Science, Indianapolis IN) according to the manufacturer’s instructions.  The terms “heterozygous” 
and “homozygous” are used solely to refer to mixed wild-type and mutant α6 subunit or pure 
mutant α6 subunit transfection, respectively.  Cells were used 24–72 h after transfection.  As a 
marker for successfully transfected cells, cDNA encoding green fluorescent protein was 
cotransfected together with the subunits of interest.  For the surface expression measurement 
using flow cytometry, cells were first passaged onto 60 mm dishes and transfected 24 h later with 
1 µg of each subunit in a ratio of 1:1:1 (homozygous α6 subunit expression) or 0.5:0.5:1:1 
(heterozygous α6 subunit expression) with FuGENE 5 transfection reagent as previously 
described 95.  Experiments were performed over the subsequent 2–3 d. 
180
Whole cell electrophysiology 
Whole cell voltage-clamp recordings were performed on lifted cells or outside-out 
membrane patches excised from transfected HEK293T cells as described previously360.  Cells 
were bathed in an external solution consisting of (mM): NaCl 142, CaCl2 1, KCl 8, MgCl2 6, 
glucose 10, HEPES 10 (pH 7.4, ∼ 325 mOsm).  Glass micropipettes were pulled from thin-walled 
borosilicate glass (World Precision Instruments, Sarasota, FL) using a P2000 laser electrode 
puller (Sutter Instruments, San Rafael, CA) and fire polished with a microforge (Narishige, East 
Meadow, NY).  Patch electrodes had resistances of 1–2 MΩ when filled with an internal solution 
consisting of (mM): KCl 153, MgCl2 1, HEPES 10, EGTA 5, Mg2+-ATP 2 (pH 7.3, ∼300 mOsm).  
This combination of external and internal solutions produced a chloride equilibrium potential of ~ 
0 mV.  Lifted cells were voltage-clamped at –20 mV and outside-out membrane patches at – 50 
mV using an Axopatch 200B amplifier (Axon Instruments, Union City, CA).  No voltage-
dependent changes in kinetics were detected between -20 and -50 mV.  GABA was applied to the 
lifted cells and/or excised macropatches using four-barrel square glass pipettes (Friedrich and 
Dimmock, Millville, NJ) attached to a Warner SF-77B Perfusion Fast-Step (Warner Instrument 
Corporation, Hamden, CT), which was commanded by Clampex 9.0 software (Axon Instruments).  
The solution exchange time across the open electrode tip was ~400 µs.  All experiments were 
performed at room temperature (22-23°C).   
Currents were low-pass filtered at 2 kHz, digitized at 5–10 kHz, and analyzed using the 
pCLAMP 9 software suit.  Current amplitudes and 10–90% rise times were measured using 
Clampfit 9.  Desensitization and deactivation current time courses were fitted using the 
Levenberg-Marquardt least squares method with up to four component exponential functions of 
the form ∑ ane(–t/τn)+C, where n is the number of the exponential components, t is time, a is the 
relative amplitude, τn is the time constant, and C is the residual current at the end of the GABA 
application.  Additional components were accepted only if they significantly improved the fit, as 
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determined by an F-test on the sum of squared residuals.  The time course of deactivation was 
summarized as a weighted time constant, defined by the following expression: ∑ anτn/∑an.  The 
extent of desensitization was measured as (fitted peak-current  fitted steady-state current) / 
(fitted peak current).  Numerical data were expressed as mean ± SEM.  Statistical analysis was 
performed using Prism version 5.04 (GraphPad Software, La Jolla, CA).  Statistical significance 
was taken as p < 0.05, using unpaired two-tailed Student's t test or one-way ANOVA as 
appropriate. 
Single channel electrophysiology 
Single-channel currents were recorded in cell-attached configuration as described 
before396.  Cells were bathed in an external solution consisting of (mM):  140 NaCl, 5 KCl, 1 
MgCl2, 2 CaCl2, 10 glucose, and 10 HEPES (pH 7.4).  During recording, 1 mM GABA was 
present in the electrode solution consisting of (mM): 120 NaCl, 5 KCl, 10 MgCl2, 0.1 CaCl2, 10 
glucose, and 10 HEPES (pH 7.4).  The electrode potential was held at +80 mV.  All experiments 
were conducted at room temperature.   
Single channel currents were amplified and low-pass filtered at 2 kHz using an Axopatch 
200B amplifier, digitized at 20 kHz using Digidata 1322A, and saved using pCLAMP 9.  Data 
were analyzed using TAC 4.2 (Bruxton Corporation, Seattle, WA).  Open and closed events were 
analyzed using the 50% threshold detection method.  All events were carefully checked visually 
before being accepted.  Only patches showing no overlaps of simultaneous openings were 
accepted.  Open and closed time histograms as well as amplitude histograms were generated using 
TACFit 4.2 (Bruxton Corporation, Seattle, WA).  Single-channel amplitudes (i) were calculated 
by fitting all-point histograms with single- or multi-Gaussian curves.  The difference between the 
fitted "closed" and "open" peaks was taken as i.  Duration histograms were fitted with exponential 
components in the form: ∑ ( Ai /τi) ℮^( -t/τi) , where A and τ are the relative area and the time 
constant of the i component, respectively, and t is the time.  The mean open time was then 
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calculated as follows: ∑ Ai τi.  The number of components required to fit the duration histograms 
was increased until an additional component did not significantly improve the fit377.  Single 
channel openings occurred as bursts of one or more openings or clusters of bursts.  Bursts were 
defined as one or more consecutive openings that were separated by closed times that were 
shorter than a specified critical duration (tcrit) prior to and following the openings378.  A tcrit 
duration of 5 ms was used in the current study.  Clusters were defined as a series of bursts 
preceded and followed by closed intervals longer than a specific critical duration (tcluster).  A tcluster 
of 10 ms was used in this study.  Data were expressed as the mean ± SEM.  Statistical analysis 
was performed as described in the previous section.   
Flow cytometry 
Cells were harvested ~48 hours after transfection using 37ºC trypsin-EDTA and placed 
immediately on ice in 4ºC FACS buffer (Ca2+/Mg2+ -free PBS with 2% FBS and 0.05% NaN3).  
Cells were then pelleted by centrifugation, resuspended in 4ºC FACS buffer, and transferred to 
96-well polystyrene V-bottom plates.  For measurements of subunit surface expression, cells were 
stained for 1 h on ice using primary antibodies diluted in 4ºC FACS buffer and then washed 3 
times in 4ºC FACS buffer.  Where necessary, cells were then stained for 1 h on ice using 
fluorophore-conjugated secondary antibodies before fixation in 2% w/v paraformaldehyde diluted 
in PBS.  For measurements of total cellular expression, cells were harvested as described for 
surface staining.  Prior to staining, however, cells were permeabilized for 15 min using 
Cytofix/Cytoperm fixation/permeabilization buffer and washed 2 times using Perm/Wash staining 
buffer (BD Biosciences; San Jose, CA).  Samples were then stained using primary antibodies 
diluted in 4ºC Perm/Wash for 1 h on ice before being washed 4 times in 4ºC Perm/Wash, 2 times 
in 4ºC FACS buffer, and fixed in 2% w/v paraformaldehyde.   
Expression levels were measured using a LSRII 3-laser flow cytometer (BD Biosciences, 
Sparks, MD).  Data were acquired using FACS-DivaTM (BD Biosciences) and analyzed offline 
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using FlowJo 7.5.5 (Tree Star Inc., Ashland, OR).  For each condition, 30,000 cells were 
analyzed.  Non-viable cells were excluded from analysis based on forward- and side-scatter 
properties, as determined in separate experiments by 7-amino-actinomycin-D staining.  For each 
condition, the mean fluorescence obtained from staining cells transfected with empty pcDNA 3.1 
was subtracted and the data were normalized to the wild-type α6β2γ2L/δ condition for 
comparison.  Statistical significance was determined using a Student’s unpaired t-test. 
Homology modeling 
Three-dimensional models of human α6, β2, γ2 and δ subunit N-terminal domains were 
generated using the crystal structure of the N-terminal domain of the nAChR α subunit153 as a 
template (Protein Database accession number 2qc1) using the program SWISS-MODEL379.  The 
initial sequence alignments between GABAA receptor subunits and the nAChR α subunit were 
generated with full-length multiple alignments using ClustalW (European Bioinformatics Institute, 
Hinxton, UK).  Then the alignment of a 212-residue core of N-terminal domains of GABAA 
receptor subunits with residues of the N-terminal domain of nAChR α subunit were submitted for 
automated comparative protein modeling implemented in the program suite incorporated in 
SWISS-MODEL (http://swissmodel.expasy.org/SWISS-MODEL.html) using the GABAA 
receptors sequence as a target protein and the nAChR sequence as a template structure.  The α6 
mutant structural model was individually made by selecting the mutation desired using the 
program DeepView/Swiss-PdbViewer 4.02 (Swiss Institute of Bioinformatics, Lausanne, 
Switzerland).  SWISS-MODEL project files containing the target sequence with a single mutation, 
and the superposed template structure, then were modeled and submitted in the program.  To 
generate pentameric GABAA receptor homology models, α6, β2 and γ2 or d subunit N-terminal 
domain models were assembled in a counter clockwise β2-α6-β2-α6-γ2/δ order by superposition 
onto the acetylcholine binding protein as a template (Protein Database accession number 1i9b)98.  
The resulting models were subsequently energy-optimized using GROMOS96 in default settings 
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within DeepView/Swiss-PdbViewer.  The models with the most likely conformation were 
presented here. 
Reagents 
Reagents used included GABA (Sigma, Aldrich, St. Louis, MO), DMEM (Invitrogen), 
fetal bovine serum (Gibco, Billings, MT), penicillin/streptomycin (Invitrogen), trypsin/EDTA 
(Gibco).  Mouse monoclonal anti-β2/3 antibody (Clone 62-3G1) was obtained from Upstate 
(Lake Placid, NY) and used at a dilution of 1:100 (surface) or 1:200 (total).  Mouse monoclonal 
anti-HA antibody (clone 16B12) and Alexa647 labeling kits were obtained from Invitrogen and 
conjugated per manufacturer instructions; the product was used at a dilution of 1:200 (surface) or 
1:400 (total).  Two different anti-FLAG antibodies (both clone M2) were used to verify results 
and optimize signal; conjugated anti-FLAG-Alexa647 antibody was obtained from Cell Signaling 
Technology (Beverly, MA) and used at a dilution of 1:50 (surface) and 1:100 (total), and 
unconjugated anti-FLAG antibody was obtained from Sigma-Aldrich and used at dilution of 
1:1000 (surface).  Surface staining with unconjugated antibodies was followed by secondary 
antibody staining with Alexa647-conjugated goat anti-mouse IgG1 antibody (Invitrogen) as 
described previously.  Total staining with unconjugated anti-β2/3 was performed using Alexa647-
conjugated Zenon (Invitrogen) per manufacturer instructions. 
 
Results 
The α6 subunit mutation, R46W, decreased current amplitude and altered the time course of 
transient α6β2γ2L receptor currents. 
We initially characterized the effect of the R46W mutation on macroscopic α6β2γ2L 
receptor currents.  Whole-cell currents were elicited from lifted HEK293T cells cotransfected 
with human β2 and γ2L subunits and wild-type α6 or mutant α6(R46W) subunits by applying a 
saturating GABA concentration (1 mM) for 400 ms using a rapid concentration jump technique 
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(Figure 2A).  Peak α6(R46W)β2γ2L receptor current density (89 ± 14 pA/pF, n = 18 p < 0.001) 
was reduced relative to peak α6β2γ2L receptor current density (395 ± 53 pA/pF, n = 21) (Figure 
2A, B).  To characterize the effects of the R46W mutation on macroscopic current kinetic 
properties (rate of activation (10 – 90% rise time), desensitization (current relaxation in the 
present of saturating agonist) and deactivation (current relaxation after removal of agonist)) of 
α6(R46W)β2γ2L currents, we applied a saturating GABA concentration (1 mM) for 400 ms to 
excised outside out patches obtained from cells expressing wild-type and mutant receptors 
(Figure 2C).  Again peak mutant receptor currents were smaller (400 ± 29.6 pA) than wild-type 
receptor currents (1427 ± 298 pA, p < 0.001).  Mutant receptor current activation was slower than 
wild-type receptor current activation (p < 0.01, Table 1), and desensitization of mutant receptor 
currents was slightly more extensive (35 ± 2 %) than that of wild-type receptor currents (29 ± 2 %, 
p < 0.05, Figure 2D, top left panels).  Interestingly the increased extent of desensitization was not 
accompanied by a decrease in the relative contribution of the residual currents (p > 0.05, Figure 
2D, bottom left panel, Table 1).  Both wild-type and mutant receptor currents desensitized with 
fast and slow exponential components (Figure 2D, top central and right panels).  The fast 
component time constant (t1; p < 0.001, Table 1) and relative contribution (a1; p < 0.001, Table 1) 
for mutant receptor currents was much smaller than that for wild-type receptor currents (Figure 
2D, top right panels), but no differences in time constant (t2) or relative contribution (a2) of the 
second exponential component were found (p > 0.05, Figure 2D, bottom right panels, Table 1).   
Deactivation of mutant receptor currents was significantly slower than for wild-type 
receptor currents (Figure 2E, left panel).  The slowing of mutant receptor current deactivation was 
due to larger deactivation time constants t1 and t2 (p < 0.01, p < 0.05, Table 1, Figure 2E, middle 
and right panels) resulting in a larger weighted decay time constant (p < 0.01, Table 1, Figure 2E, 
left panel).  No differences were found in the relative contribution (a1) of the first deactivation 
component for wild-type or mutant receptors (p > 0.05, Table 1).  The longer deactivation time 
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Table 1. Macroscopic kinetics of α6β2γ2L currents after 400ms applications of 1mM GABA 
 Excised outside-out macropatches (n) 
 wt (26) R46W (22) 
Rise time 10-90% (ms) 1.84 ± 0.12 2.56 ± 0.25** 
Desensitization   
     Extent (%) 29 ± 2 35 ± 2* 
     τ1 (ms) 37.9 ± 5.93 2.36 ± 0.46*** 
     τ2 (ms)     460 ± 38.7 488 ± 66.5 
     a1 (%) 15 ± 2 10 ± 1* 
     a2 (%) 34 ± 4 42 ± 4 
     Residual (%) 50 ± 5 49 ± 5 
Deactivation   
     τ1 (ms) 47.3 ± 3.77 93.0 ± 14.3** 
     τ2 (ms)     176 ± 17.4 268 ± 42.2* 
     a1 (%) 60 ± 5 68 ± 5 
     τ-weight (ms) 79.4 ± 3.48 111 ± 9.22** 
Values represent mean ± SEM.  *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 respectively 
(unpaired t-test) compared to wild-type. 
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Figure 2.  The R46W mutation evoked small α6β2γ2L receptor currents with slowed 
activation and deactivation macroscopic kinetics.  
A.  Current responses to 400 ms pulses of 1 mM GABA to lifted cells containing wild-type 
(wt) and mutant R46Wα6β2γ2Lreceptors are shown.  B.  Current densities of wild-type 
(white bars) and mutant R46W(grey bars) α6β2γ2L receptors evoked by 400 ms pulses of 
1 mM GABA to lifted cells are shown.  C.  Current responses to 400 ms pulses of 1 mM 
GABA to excised patches cells containing wild-type and mutant R46W α6β2γ2L receptors.  
D and E.  Summary of macroscopic kinetic parameters obtained from currents evoked by 
400 ms pulses of 1 mM GABA to excised patches for both wild-type (white bars) and 
mutant R46W (grey bars) α6β2γ2L receptors.  Values represent mean ± S.E.M.  Differ-
ences between wild-type and mutant channels are shown as *, ** and ***, which indicate 
p < 0.05, p < 0.01 and p < 0.001 (unpaired t-test).
188
course displayed by mutant receptor currents may have been related to increased time for 
equilibration among desensitized states168.   
The α6 subunit mutation, R46W, decreased mean open time but increased opening frequency 
of single channel α6β2γ2L currents. 
Modifications of macroscopic current kinetic properties can be due to alterations in single 
channel gating properties.  Thus, steady-state on-cell single channel recordings of α6β2γ2L or 
α6(R46W)β2γ2L receptors were obtained in the continuous presence of GABA (1 mM).  Single 
channel openings and complex bursting patterns were recorded from both wild-type (Figure 3A, 
wt) and mutant (Figure 3A, R46W) receptors.  Wild-type receptor channels displayed brief bursts 
of openings and frequent prolonged (1 to 2 s) clusters of bursts; in contrast, mutant receptor 
channel openings occurred as single events and frequent brief bursts of openings.  In addition, 
there was a small but significant difference between wild-type and mutant single channel current 
amplitudes (Figure 3A, B).  Mutant receptor single channel openings were briefer than wild-type 
receptor single channel openings (p < 0.01, Table 2).  This difference might represent a variation 
in the main conductance state of α6β2γ2L receptors, which was 21-27 pS.  Similar results were 
found in our previous reports for αβγ receptors expressed in mouse L929 cells276, 377.  Indeed, to 
rule out the possibility that these conductance levels were due to the presence of αβ receptor 
currents, single channel α6β2 currents were recorded from HEK293T cells in the presence of 
GABA (1 mM).  α6β2 receptors opened to a main current amplitude of 0.86 ± 0.11 pA (n = 5, p < 
0.001 vs. wild-type, p < 0.01 vs. R46W), consistent with an ~ 12 pS channel conductance and in 
agreement with conductance levels for single channel α1β2 currents reported previously276.  The 
twofold difference in current amplitudes between α6β2 and α6β2γ2L single channel excludes the 
presence of a binary receptor population in our recordings.   
To further address how the α6 subunit mutation, R46W, affected channel gating, we 
measured mean open time and opening frequency of both wild-type and mutant receptor single 
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Table 2. Kinetic properties of α6β2γ2L and α6β2δ single-channel currents  
 α6β2γ2L (n) α6β2δ (n) 
 wt (8) R46W (6) wt (7) R46W (6) 
Channel amplitude (pA) 1.76 ± 0.09 1.36 ± 0.05** 1.69 ± 0.02 1.62 ± 0.05 
Mean open time (ms) 1.09 ± 0.08 0.88 ± 0.04* 1.2 ± 0.11 0.89 ± 0.05* 
Opening frequency (s-1) 3.76 ± 0.42 8.42 ± 0.35*** 10.1 ± 1.81 2.77 ± 0.54** 
Open time constants     
     τo1 (ms) 0.62 ± 0.04 0.56 ± 0.05 0.6 ± 0.02 0.44 ± 0.02*** 
     τo2 (ms) 0.75 ± 0.09 0.61 ± 0.06 0.86 ± 0.08 0.58 ± 0.02* 
     τo3 (ms) 2.28 ± 0.31 1.81 ± 0.12 2.18 ± 0.17 2.17 ± 0.12 
     ao1 (%) 25 ± 3 78 ± 6*** 14 ± 1 25 ± 2*** 
     ao2 (%) 71 ± 4 19 ± 5*** 81 ± 2 71 ± 2** 
     ao3 (%) 4 ± 2 3 ± 1 5 ± 1 4 ± 1 
Intraburst closed time constant     
     τc1 (ms) 1.37 ± 0.17 1.21 ± 0.13 0.75 ± 0.05 0.59 ± 0.04 
     τc2 (ms) 5.40 ± 0.72 6.53 ± 1.03 4.79 ± 0.49 2.53 ± 0.50* 
     ac1 (%) 50 ± 4 28 ± 4** 11 ± 1 7 ± 2 
     ac2 (%) 36 ± 4 45 ± 3 22 ± 3 15 ± 3 
Burst kinetics     
     Openings per burst 3.03 ± 0.24 2.27 ± 0.26 1.75 ± 0.21 1.33 ± 0.12 
     Po 0.010 ± 0.003 0.013 ± 0.002 0.018 ± 0.002 0.003 ± 0.001*** 
     Duration (ms) 6.66 ± 0.57 3.8 ± 0.12** 2.90 ± 0.11 1.43 ± 0.12 
     Frequency (s-1) 1.28 ± 0.13 3.93 ± 0.39*** 6.02 ± 1.29 2.18 ± 0.48* 
     τ1 (ms) 0.82 ± 0.03 0.74 ± 0.04 0.61 ± 0.04 0.54 ± 0.04 
     τ2 (ms) 10.1 ± 1.00 6.68 ± 0.43* 5.87 ± 0.76 3.23 ± 0.21* 
     a1 (%) 35 ± 2 50 ± 2*** 64 ± 2 82 ± 2*** 
     a2 (%) 65 ± 2 51 ± 2*** 36 ± 2 18 ± 2*** 
Values represent mean ± SEM.  *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 respectively 
(unpaired t-test) compared to wild-type. 
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Figure 3. The R46W mutation affected gating efficacy by decreasing mean open time of 
single channel α6β2γ2L currents.  
A.  Steady state single channel currents were obtained from cell-attached patches contain-
ing wild-type (wt) and mutant R46W α6β2γ2L receptors.  Patches were voltage clamped at 
+80 mV and continuously exposed to 1 mM GABA.  Note that the upper traces in panel A 
(1 S, black bars) were expanded below them.  B-D.  Single channel kinetics for both wild-
type (white bars) and mutant R46W (grey bars) α6β2γ2Lreceptors are shown.  E.  Repre-
sentative open duration histograms for both wild-type and mutant R46W α6β2γ2L recep-
tors were fitted to three exponential functions.  Values represent mean ± S.E.M.  Differ-
ences between wild-type and mutant channels are shown as *, ** and ***, which indicate 
p < 0.05, p < 0.01 and p < 0.001 (unpaired t-test).
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channel currents.  Overall, mutant receptor channels displayed lower mean open times (Figure 3C) 
and higher opening frequencies (Figure 3D) than wild-type receptor channels (p < 0.05, p < 0.001, 
Table 2).  Open time distributions from wild-type and mutant receptors were fitted best by three 
exponential components (Figure 3E).  While there were no significant differences among the 
three open-time constants (to1, to2 and to3) from wild-type and mutant receptors (p > 0.05, Table 2), 
there was a significant shift in the relative occurrence of the three components (ao1, ao2 and ao3) 
that accounted for the differences in mean open time of wild-type and mutant receptors.  Mutant 
receptor single channel openings were dominated by the shortest open state, accounting for ~ 78 
% of the relative area (ao1) (p < 0.001, Table 2).  In contrast, wild-type receptor single channel 
openings contained a short open state that accounted for only ~ 25 % of the single channel 
openings, and a longer open state that accounted for ~ 71 % of the relative area (ao2) (p < 0.001, 
Table 2).  No differences were found in the relative area of the longest open state (ao3) (p > 0.05, 
Table 2).   
The α6 subunit mutation, R46W, decreased burst duration and increased burst frequency of 
α6β2γ2L single channel currents. 
In response to saturating concentrations of GABA, GABAA receptor channels display 
bursts of fast transitions between open and closed states prior to unbinding of agonist or entering 
into desensitized states.  To determine the effects of the R46W mutation on single channel bursts, 
we analyzed the intraburst kinetics of single channel currents from α6β2γ2L and 
α6(R46W)β2γ2L receptor channels.  First, we focused on the two briefest closed time constants 
that most likely represent closures within bursts of channel activity.  Interestingly, both intraburst 
closed time constants (tc1 and tc2) for mutant receptors were similar to those found for wild-type 
receptors (p > 0.05, Table 2), but the relative contribution of the brief component (ac1) for mutant 
receptors was significantly reduced relative to wild-type receptors (p < 0.01, Table 2).  Thus, 
agonist activation of mutant receptors produced single channel currents with bursts that usually 
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Figure 4.  Mutant α6(R46W)β2γ2L receptor channel bursts occurred as brief single 
openings, which decreased single channel current burst durations.  
A.  Representative steady state single channel current traces from cell-attached patches 
containing wild-type (wt) and mutant R46W (RW) α6β2γ2L receptors.  Patches were 
voltage clamped at +80 mV and continuously exposed to 1 mM GABA.  B-C.  Comparison 
of burst kinetics for both wild-type (white bars) and mutant R46W (grey bars) α6β2γ2L 
receptors are shown.  D.  Representative burst duration histograms for both wild-type and 
mutant R46W receptors were fitted to two exponential functions.  E-F.  Time constants (τ) 
and representative areas (a) of burst duration histograms for both wild-type (white bars) 
and mutant R46W receptors (grey bars) are shown.  Values represent mean ± S.E.M.  
Differences between wild-type and mutant channels are shown as *, ** and ***, which 
indicate p < 0.05, p < 0.01 and p < 0.001 (unpaired t-test).
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occurred as single openings or brief bursts of openings and closings, while wild-type receptors 
produced single-channel openings that contained prolonged bursts of brief openings.  The 
duration of bursts were reduced for mutant receptors relative to wild-type receptors (see 
representative 200 ms traces of bursting wild-type (Figure 4A, wt) and mutant (Figure 4A, R46W) 
receptor currents).  Further analysis showed that burst durations of mutant receptor currents were 
significantly reduced relative to wild-type receptor currents (p < 0.01, Table 2, Figure 4B), and 
this difference was associated with a slight reduction of openings per burst (p > 0.05, Table 2) 
and a substantial increase in burst frequency of mutant receptor currents (p < 0.001, Table 2, 
Figure 4C).   
The burst duration frequency distributions were fitted best by two exponential functions 
for both wild-type and mutant receptors (Figure 4D).  However there were no differences in the 
time constants for the short-duration burst component (t1) for the receptors (p > 0.05, Table 2, 
Figure 4E, left panel), but the time constant for the longer-duration burst component (t2) was 
significant reduced for mutant receptors (p < 0.05, Table 2, Figure 4E, right panel).  In addition, 
with mutant receptors there was a shift in the distribution of the two populations of burst 
durations due to an increase in the relative proportion of bursts with short duration (a1) and a 
reduction in the relative proportion of longer bursts (a2) (p < 0.001, Table 2, Figure 4F).  Taken 
together, mutant receptor burst durations were reduced due to reduction of the time that the 
channel spends in the open state. 
The α6 subunit mutation, R46W, decreased surface expression of α6β2γ2L receptors. 
To gain insight into the effects of the α6 subunit mutation, R46W, on GABAA receptor 
assembly, wild-type α6FLAG and mutant α6(R46W)FLAG subunits were coexpressed in HEK293T 
cells, and surface and total expression levels of each subunit were assessed using flow cytometry 
(Figure 5A, C).  Coexpression of α6(R46W)FLAG with β2 and γ2LHA subunits resulted in a 
significant reduction of both α6(R46W)FLAG and β2, but not γ2LHA, subunits on the cell surface 
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Figure 5.  The R46W mutation 
decreased surface expression of     
α6 and β2, but not γ2L subunits of    
α6β2γ2L receptors.  
A.  GABAA receptor α6F, α
6F(R46W), β2 and γ2LHA subunit 
cell surface levels were measured 
by flow cytometry for cells coex-
pressing wild-type (wt) and mutant 
R46W α6β2γ2L receptors.  Repre-
sentative histograms of positively 
transfected cells (dark grey) were 
superimposed on those from mock 
transfected cells (light grey) and 
shown for surface expression.  Note 
that the abscissa has a log-scale.  B.  
The mean fluorescence intensity 
(FI) of α6, β2, and γ2L subunits 
surface expression was quantified 
for wild-type (white bars) and 
mutant R46W receptors (grey 
bars).  C.  GABAA receptor α6F, α
6F(R46W), β2 and γ2LHA subunit 
total cellular levels were measured 
by flow cytometry for cells coex-
pressing wild-type and mutant 
R46W α6β2γ2L receptors.  Repre-
sentative histograms of positively 
transfected cells (dark grey) were 
superimposed on those from mock 
transfected cells (light grey).  D.  
The mean fluorescence intensity 
(FI) of α6F, β2, and γ2LHA subunit 
total cell expression was quantified 
as well (wild-type as white bars, 
and mutant receptors as grey bars).  
Values represent mean ± S.E.M.  
Differences between wild-type and 
mutant channels are shown as ***, 
which indicate p < 0.001 (unpaired 
t-test).
195
(Figure 5A).  Cell surface levels of mutant α6(R46W)FLAG subunits were reduced compared to 
wild-type α6FLAG subunits (0.69  ±  0.04, n = 10 compared to 1.00 ± 0.002, n = 10, respectively, p 
< 0.001, Figure 5B, left panel), and β2 subunits were also reduced compared to control subunits 
when coexpressed with mutant α6(R46W)FLAG subunits (0.81 ± 0.02, n = 10 compared to 0.995 ± 
0.002, n = 10, respectively, p < 0.001, Figure 5B, middle panel).  No differences were found in 
surface levels of γ2LHA subunits (1.10 ± 0.05, n = 10 compared to 0.998 ± 0.001 n = 10, 
respectively, p > 0.05, Figure 5B, right panel).   
Total cellular levels of coexpressed α6FLAG or α6(R46W)FLAG and β2, and γ2LHA subunits 
were measured by permeabilizing cell membranes prior to staining (Figure 5C).  Comparable to 
surface levels, when coexpressed with β2 and γ2LHA subunits total expression of α6(R46W)FLAG 
subunits was reduced significantly relative to α6FLAG subunits (0.37 ± 0.03, n = 10 compared to 
1.0 ± 0.001, n = 10, respectively, p < 0.001, Figure 5D, left panel).  Interestingly, this reduction 
was associated with a reduction of total levels of γ2LHA subunits (0.67 ± 0.03, n = 10, p < 0.001, 
Figure 5D, right panel), but with no changes in total levels of coexpressed β2 subunits (0.80 ± 
0.10, n = 7, p > 0.05, Figure 5D, middle panel). 
These results suggested that the R46W mutation impaired expression and surface 
trafficking of α6 subunits.  Moreover, α6(R46W) subunits had a dominant negative effect on 
partnering subunits, reducing surface expression of β2 subunits and total cellular expression of 
γ2L subunits.  Importantly, though total α6(R46W) subunit levels were reduced, some α6(R46W) 
subunits could be successfully assembled with β2 and γ2L subunits into α6(R46W)β2γ2L 
receptors that were trafficked to the cell surface.  However, because expression levels of 
α6(R46W), β2 and γ2L subunits were not affected equally, it is likely that the mutation led to 
production of surface receptors with altered stoichiometry.   
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Heterozygous coexpression of mutant α6(R46W) and wild-type α6 subunits with β2 and γ2L 
subunit produced intermediate macroscopic receptor current amplitudes. 
Most epilepsy-associated GABAA receptor subunit mutations were found in heterozygous 
patient.  Therefore, we repeated the preceding experiments in conditions representing 
heterozygous expression of wild-type α6 and mutant α6(R46W) subunits (50/50 mix of wild-type 
and mutant α6 subunits).  First, we compared wild-type α6β2γ2L, heterozygous 
α6/α6(R46W)β2γ2L and homozygous mutant α6(R46W)β2γ2L receptor whole-cell currents 
elicited from lifted HEK293T cells evoked by application of 4 s concentration jumps of saturating 
GABA (1 mM) (Figure 6A).  Heterozygous receptor currents were larger (Figure 6A insert panel, 
p < 0.001, Table 3) and desensitized more extensively (Figure 6B middle panel, p < 0.01, Table 3) 
than homozygous mutant receptor currents.  In addition, the 10-90% activation rise time was 
shorter than for homozygous receptor currents (Figure 6B left panel, p < 0.001, Table 3).  When 
compared with wild-type receptors, heterozygous receptors had decreased maximal peak current 
density with no differences in the extent of desensitization or activation (Figure 6A insert panel 
and B, Table 3).   
The desensitization time courses of wild-type, heterozygous and homozygous mutant 
receptor currents were fitted best by four exponential components (Table 3).  Despite the fact that 
both heterozygous and homozygous mutant receptor currents exhibited a significantly slower 
third component exponential time constant (t3) than wild-type receptor currents (p < 0.05, Table 
3), heterozygous receptors displayed similar desensitization component distribution values (a1, a2, 
a3 and a4) and residuals compared to wild-type receptor currents (p > 0.05, Table 3), but 
significantly different than from homozygous mutant receptor currents (p < 0.01, Table 3, Figure 
6B right panel).  Moreover, heterozygous receptor currents deactivated faster than homozygous 
mutant receptor currents (p < 0.01, Table 3), but with kinetic properties similar to those of wild-
type receptors. 
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Figure 6. Heterozygous coexpression of mutant α6(R46W) and wild-type α6 subunits 
produced intermediate macroscopic receptor current amplitudes by assembling a mixed 
fraction of wild-type/mutant receptors on the surface. 
A.  Current responses to long (4 s) applications of 1 mM GABA to lifted cells containing 
wild-type α6β2γ2L, heterozygous α6/α6(R46W)β2γ2L and α6(R46W)β2γ2L receptors are 
shown.  In the inset, current amplitudes for α6 (white bar), α6/α6(R46W) (black bar) and  
α6(R46W) (grey bar) subunit-containing receptors are shown.  B.  The 10-90% rise time, 
extent of desensitization and residual current for currents evoked by 4 S pulses of 1 mM 
GABA are presented for wild-type, heterozygous and mutant α6β2γ2L receptors.  C.  
Surface levels of heterozygous α6FLAG/α6(R46W) (wtF/RW), α6/α6(R46W)FLAG (wt/RWF), 
and α6FLAG/α6(R46W)FLAG (wtF/RWF) subunits coexpressed with α2 and γ2LHA subunits 
were measured using flow cytometry.  Histograms of positively transfected cells (dark 
grey) were superimposed on those from mock transfected cells (light grey).  D.  The mean 
of fluorescence intensity (FI) of α6F, β2, and γ2LHA subunit surface and total levels were 
quantified for heterozygous α6FLAG/α6(R46W), α6/α6(R46W)FLAG, and α6FLAG/α
6(R46W)FLAG subunit combinations.  Dashed lines represent half-tagged α6F/α6 levels.  
Values represent mean ± S.E.M.. *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001 
(one-way ANOVA) statistically different from wild-type levels (α6 or α6F/α6), respec-
tively.  ## and ### indicate p < 0.01 and p < 0.001 (one-way ANOVA) statistically different 
from α6(R46W) or α6F/α6(R46W). +++ indicate p < 0.001 (one-way ANOVA) statistically 
different from α6/α6(R46W)F.
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With heterozygous coexpression of mutant α6(R46W) and wild-type α6 subunits with β2 and 
γ2L subunits, there was increased incorporation of wild-type subunits over mutant subunits. 
To gain insight into the assembly fate of wild-type α6 and mutant α6(R46W) subunits 
with heterozygous expression, we coexpressed α6, α6(R46W), β2, and γ2LHA subunit cDNA at a 
molar ratio of 0.5 : 0.5 : 1: 1 (see Methods) and evaluated subunit expression levels using flow 
cytometry (Figure 6C). To distinguish wild-type and mutant subunits, we differentially tagged α6 
and α6(R46W) subunits with the FLAG epitope.  Specifically, we determined surface levels of 
wild-type and mutant α6 subunits coexpressed with β2 and γ2L subunits when only the wild-type 
subunit (α6FLAG/α6(R46W), Figure 6D top left panel, white bar), only the mutant subunit 
(α6/α6(R46W)FLAG, Figure 6D top left panel, grey bar) or both subunits (α6FLAG/α6(R46W)FLAG, 
Figure 6D top left panel, black bar) were FLAG-tagged.   
With the “half-tagged” subunits, we compared FLAG-tagged subunit levels obtained with 
heterozygous expression to those obtained with coexpression of “half tagged” wild-type 
α6FLAG/α6 subunits (Figure 6D, dotted line).  Heterozygous expression of half-tagged 
α6FLAG/α6(R46W) subunits (Figure 6D, top panel, white bars) resulted in no significant difference 
in surface levels of α6FLAG (0.76 ± 0.05, n = 7, p > 0.05, Figure 6D, left top panel), β2 (0.91 ± 
0.05, n = 8, p > 0.05, Figure 6D, middle top panel) or γ2LHA (0.96 ± 0.04, n = 8, p > 0.05, Figure 
6D, right top panel) subunits, when compared to coexpression of half-tagged α6FLAG/α6 subunits 
(α6FLAG = 0.83 ± 0.05, n = 7, β2 = 0.92 ± 0.02, n = 7, and γ2LHA = 1.00 ± 0.03, n = 7, respectively, 
Figure 6D, top panels, dotted lines).  These results suggested that incorporation of wild-type 
α6FLAG, β2 and γ2LHA subunits into heterozygous receptors was not affected by the presence of 
the mutant subunit or the FLAG tag.   
Heterozygous expression of half-tagged α6/α6(R46W)FLAG subunits, however, resulted in 
a significant reduction of surface α6(R46W)FLAG subunits (0.50 ± 0.06, n = 7, Figure 6D, left top 
panel grey bar) relative to those obtained with wild-type α6FLAG/α6 subunits (p < 0.001, Figure 
6D, left top panel, black bar) and with heterozygous α6FLAG/α6(R46W) subunits (p < 0.01, Figure 
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6D, left top panel, white bar) levels.  These results suggest that with heterozygous expression, 
both wild-type and mutant α6 subunits could be incorporated into surface-trafficked receptors, but 
that wild-type subunits were preferred over mutant subunits.   
With “full-tagged” heterozygous α6FLAG/α6(R46W)FLAG subunit coexpression, there was a 
small, non-significant increase in α6 subunit levels on the cell surface (0.97 ± 0.03, n = 6, Figure 
6D, left top panel, black bar) relative to those obtained with half-tagged α6FLAG/α6(R46W) 
subunit coexpression (Figure 6D, left top panel, white bar), again suggesting that with 
heterozygous expression, wild-type subunits are incorporated into the receptors much more 
successfully than mutant subunits.   
As would be expected if the FLAG epitope did not disrupt overall assembly of the 
receptors, no significant differences were found in the surface expression levels of β2 (Figure 6D, 
middle panel) (0.84 ± 0.04, n = 8, grey bar, and 0.93 ± 0.04, n = 6, black bar) or γ2L (Figure 6D, 
right panel) (0.99 ± 0.07, n = 8, grey bar, and 0.94 ± 0.06, n = 6, black bar) subunits with 
heterozygous coexpression of either α6/α6(R46W)FLAG or α6FLAG/α6(R46W)FLAG subunits, 
respectively.  Moreover, in all heterozygous conditions, neither β2 nor γ2L subunit surface 
expression was reduced compared to levels obtained with coexpression of “half tagged” wild-type 
α6FLAG/α6 subunits (Figure 6D, upper middle and right panels, all bars compared to dotted line).  
These data indicate that heterozygous expression of α6(R46W) subunits did not reduce surface 
expression levels of β2 or γ2L subunits.   
Using a similar approach, total cellular expression of heterozygous α6FLAG/α6(R46W), 
α6/α6(R46W)FLAG, and α6FLAG/α6(R46W)FLAG subunits coexpressed with β2, and γ2LHA subunits 
was measured (Figure 6D, bottom panels).  Similar to the cell surface results obtained for 
heterozygous coexpression of α6FLAG/α6(R46W) with β2, and γ2LHA subunits, no differences 
were found in total expression of α6FLAG (0.49 ± 0.06, n = 8, p > 0.05, Figure 6D, left bottom 
panel, white bar), β2 (0.87 ± 0.07, n = 5, p > 0.05, Figure 6D, middle bottom panel, white bars) 
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and γ2LHA (0.72 ± 0.05, n = 8, p > 0.05, Figure 6D, right bottom panel, white bar) subunits, when 
compared to those obtained with coexpression of half-tagged α6FLAG/α6 subunits (α6FLAG = 0.56 ± 
0.08, n = 7, β2 = 0.94 ± 0.15, n = 4, and γ2LHA = 0.88 ± 0.08, n = 7, respectively, dotted lines).   
Coexpression of α6/α6(R46W)FLAG subunits, however, resulted in a larger reduction of 
total FLAG expression (0.25 ± 0.03, n = 8, Figure 6D, left bottom panel, grey bar) than with 
either half-tagged wild-type (α6FLAG/α6 = 0.56 ± 0.08, n = 7, p < 0.05, Figure 6D, left bottom 
panel, dotted line) or heterozygous α6FLAG/α6(R46W) (p > 0.05, Figure 6D, left bottom panel, 
white bar) subunits.  Again, when α6FLAG/α6(R46W)FLAG subunits were coexpressed, there was an 
increase in total expression levels of FLAG expression (0.74 ± 0.14, n = 6, Figure 6D, left bottom 
panel, black bar) relative to those obtained with expression of α6(R46W)FLAG subunits (p < 0.001, 
Figure 6D, left bottom panel, grey bar), indicating that both wild-type and mutant subunits were 
expressed.  Similar to expression of α6FLAG/α6(R46W)FLAGβ2γ2LHA receptors on the cell surface, 
there was also more total cell wild-type α6 subunits (~ 66%) than mutant α6(R46W) subunits (~ 
34%).   
As with surface expression, no significant differences were found for total expression 
levels of β2 (Figure 6D, middle bottom panel) (1.00 ± 0.09, n = 5, grey bar, and 0.81 ± 0.08, n = 3, 
black bar ) or γ2L (Figure 6D, right bottom panel) (0.74 ± 0.04, n = 8, grey bar, and 0.75 ± 0.06, 
n = 6, black bar) subunits with heterozygous coexpression of either α6/α6(R46W)FLAG or 
α6FLAG/α6(R46W)FLAG subunits, respectively.  Taken together, these data suggest that when α6 
and α6(R46W) subunits are “heterozygously” coexpressed with β2 and γ2L subunits, all subunits 
are expressed, and the number of GABAA receptors on the cell surface is not affected.  Those 
receptors may contain α6 and/or α6(R46W) subunits, but expression and incorporation of wild-
type α6 subunits is preferred. 
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The α6 subunit mutation, R46W, decreased macroscopic α6β2δ receptor current amplitude by 
reducing single channel mean open time and opening frequency. 
The α6 subunit has been shown to coassemble with both γ2 and δ subunits.  To 
determinate the effect of the α6 subunit mutation, R46W, on the macroscopic kinetic properties 
of α6β2δ currents, we compared wild-type α6β2δ and mutant α6(R46W)β2δ whole-cell currents 
elicited from lifted HEK293T cells by applying 4 s concentration jumps of saturating GABA (1 
mM) (Figure 7A).  Wild-type α6β2δ currents were smaller and desensitized less (Figure 7D, 
Table 3) than α6β2γ2L  receptor currents, consistent with the macroscopic properties of α6β3δ 
and α6β3γ2L receptor currents reported previously397.  Mutant α6(R46W)β2δ receptor currents 
also had much smaller peak currents and less whole-cell current desensitization than mutant 
α6(R46W)β2γ2 receptor currents (Table 3).  Mutant α6(R46W)β2δ receptor currents were 
reduced substantially relative to wild-type α6β2δ receptor currents (p < 0.001, Table 3, Figure 7A, 
B), and their activation was slower than wild-type receptor currents (p < 0.001, Table 3, Figure 
7C).  While wild-type α6β2δ receptor currents exhibited some slow desensitization that was best 
fitted by four exponential functions (Table 3), mutant α6(R46W)β2δ currents displayed negligible 
macroscopic desensitization (p < 0.001, Table 3, Figure 7D).  In addition, mutant α6(R46W)β2δ 
receptor currents had significantly faster current deactivation than wild-type α6β2δ receptor 
currents (p < 0.001, Table 3, Figure 7E).   
The severe alteration of macroscopic properties of α6(R46W)β2δ receptor currents 
should be due to altered single channel currents.  Thus, mutant α6(R46W)β2δ and wild-type 
α6β2δ single channel currents evoked by steady state application of 1 mM GABA were compared.  
Wild-type single channels opened in prolonged bursts (Figure 7F, top panel), while mutant single 
channels opened less frequently in brief bursts (Figure 7F, bottom panel).  The single channel 
open duration histograms for wild-type and mutant receptors were fitted best by the sum of three 
exponential functions (Figure 7G).  For both wild-type and mutant single channel current open 
duration histograms, the time constant (to3) and relative contribution (ao3) of the longest open state 
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Table 3. Macroscopic kinetic properties of α6β2γ2L and α6β2δ currents evoked by 4-second 
applications of 1 mM GABA  
 α6β2γ2L (n) α6β2δ (n) 
 wt (15) R46W (7) wt/R46W (18) wt (11) R46W (6) 
Rise time 10-90% (ms) 1.60 ± 0.07 3.09 ± 0.26*** 1.30 ± 0.07### 2.82 ± 0.28 7.04 ± 1.23*** 
Current density (pA/pF) 4.27 ± 31.6 96.8 ± 14.7*** 289 ± 13***### 130 ± 5.66 2.84 ± 0.29 
Desensitization      
     Extent (%) 56 ± 2 35 ± 10* 57 ± 3## 34 ± 4 2 ± 1*** 
     τ1 (ms) 2.32 ± 0.56 1.89 ± 0.39 1.92 ± 0.61 7.20 ± 2.53 NA 
     τ2 (ms) 190 ± 35.1 171 ± 34.1 278 ± 41 85.2 ± 39.2 NA 
     τ3 (ms) 528 ± 71.5 1312 ± 448* 1138 ± 155* 1606 ± 246 NA 
     τ4 (ms) 2533 ± 386 2322 ± 287 2742 ± 257 2739 ± 378 NA 
     a1 (%) 2 ± 0.3 12 ± 3*** 2 ± 0.4### 6 ± 2 NA 
     a2 (%) 3 ± 0.4 17 ± 6** 9 ± 2# 8 ± 2 NA 
     a3 (%) 31 ± 7 5 ± 3* 33 ± 6# 7 ± 3 NA 
     a4 (%) 45 ± 5 43 ± 11 50 ± 4 33 ± 6 NA 
     Residual (%) 31 ± 1 58 ± 13** 30 ± 3## 52 ± 7 NA 
Deactivation      
     τ1 (ms) 75.1 ± 6.04 120 ± 28.1* 55 ± 3.45### 333 ± 10.6 14.0 ± 3.15***  
     τ2 (ms) 430 ± 38.2 1050 ± 280** 400 ± 55### 1280 ± 153 403 ± 237** 
     a1 (%) 88. ± 3 89 ± 3 90 ± 2 81 ± 3 71 ± 10 
     τweight (ms) 96.2 ± 9.62 184 ± 65* 67 ± 3.14## 425 ± 10.4 25.0 ± 9.97*** 
Values represent mean ± SEM.  *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 respectively 
(unpaired t-test or one-way ANOVA) compared to wild-type.  #, ##, and ### indicate p < 0.05, p < 0.01, 
and p < 0.001 respectively (unpaired t-test or one-way ANOVA) compared to R46W. 
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Figure 7.  The R46W mutation 
had a greater effect on the func-
tion of α6β2δ than on α6β2γ2L 
receptors. 
A.  Current responses to long (4 s) 
applications of 1 mM GABA to 
lifted cells containing wild-type 
(wt) and mutant (R46W) α6β2δ 
receptors are shown.  Note that the 
right trace (1 nA bar scale) of the 
R46W current was expanded to the 
left (50 pA bar scale) to demon-
strate the mutant current amplitude.  
B-E.  Current density, 10-90% rise 
time, desensitization extent and 
deactivation rate were measured 
during 4 S pulses of 1 mM GABA 
for both wild-type (white bars) and 
mutant (grey bars) receptors.  F.  
Steady state single channel currents 
were obtained from cell-attached 
patches containing wild-type (wt) 
and mutant (R46W) α6β2δ recep-
tors.  Patches were voltage clamped 
at +80 mV and continuously 
exposed to 1 mM GABA.  Note that 
the upper traces in panel A (1 s, 
black bars) were expanded below 
them.  G.  Representative open 
duration histograms were plotted 
for both wild-type and mutant 
R46W α6β2δ receptors and were 
fitted to three exponential func-
tions.  H-J.  Current amplitude (H), 
mean open time (I) and opening 
frequency (J) for both wild-type 
(white bars) and mutant R46W 
(grey bars) α6β2δ receptors are 
shown.  Values represent mean ± 
S.E.M.  Differences between wild-
type and mutant channels are 
shown as *, ** and ***, which 
indicate p < 0.05, p < 0.01 and p < 
0.001 (unpaired t-test).
J
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were similar (p > 0.05, Table 2).  The shortest and intermediate open states of mutant single 
channel currents, however, had time constants (to1 and to2) that were briefer than for wild-type 
receptor currents (p < 0.001, p < 0.05, Table 2).  Moreover, there was a shift in the relative 
contributions of both brief open states (ao1 and ao2) for mutant single channel currents that was 
due to increased frequency of occurrence of the fastest component and reduced frequency of 
occurrence of the slowest component (Figure 7G right panel) (p < 0.001, p < 0.01, Table 2).  Thus, 
mutant single channel currents had significantly reduced mean open time relative to that of wild-
type α6β2δ  currents (p < 0.05, Table 2, Figure 7I), and their opening frequency was only about 
one third of wild-type channel opening frequency (p < 0.01, Table 2, Figure 7J).  In contrast, 
there was no alteration of the main conductance state of mutant channels (~ 25 pS) when 
compared to wild-type channels (~ 26 pS) (p > 0.05, Table 2, Figure 7H).   
The α6 subunit mutation, R46W, decreased both burst duration and frequency of α6β2δ 
receptor currents. 
Both α6β2δ and α6(R46W)β2δ receptor channels opened in bursts (Figure 8).  Wild-type 
channels (Figure 8A, top panel) opened with single brief openings and bursts of longer openings, 
while mutant channels opened with very brief openings (Figure 8A, bottom panel).  Since a major 
determinant of burst structure is the time constants of the two shortest closed states that occur 
within bursts (tc1 and tc2), we compared the frequency of occurrence of these intraburst closures 
between wild-type and mutant receptor channels.  Mutant receptors had shorter intraburst 
closures than wild-type receptors (p < 0.05, Table 2), but no differences were found in the relative 
occurrence (ac1 and ac2) of these closures (p > 0.05, Table 2).  Interestingly, the overall relative 
contribution of intraburst closures for both wild-type and mutant d subunit-containing receptors 
were only 1/3 of the wild-type and mutant γ2L subunit-containing receptors (Table 2).  This is 
consistent with the propensity of α6β2δ receptors to open in bursts of brief openings, and for 
α6β2γ2L receptors to open in clusters of bursts 272, 377. 
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Figure 8.  The R46W mutation decreased both burst duration and frequency of α6β2δ recep-
tor currents. 
A.  Representative steady state single channel burst traces from cell-attached patches containing 
wild-type (wt) and mutant R46W α6β2δ receptors are presented.  Patches were voltage clamped 
at +80 mV and continuously exposed to 1 mM GABA.  B-D.  Comparison of burst kinetics for 
both wild-type (white bars) and mutant R46W (grey bars) receptors are shown.  E.  Representa-
tive burst duration histograms for both wild-type and mutant R46W α6β2δ receptors were fitted 
to two exponential functions.  F, G.  Time constants (τ) and representative areas (a) of burst 
duration histograms for both wild-type (white bars) and mutant R46W receptors (grey bars) are 
presented.  Values represent mean ± S.E.M.  Differences between wild-type and mutant chan-
nels are shown as *, ** and ***, which indicate p < 0.05, p < 0.01 and p < 0.001 (unpaired 
t-test). 
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Consistent with the shorter mean open duration, α6(R46W)β2δ channel burst durations 
were reduced when compared to wild-type channels (p < 0.001, Table 2, Figure 8C).  In addition, 
the time that α6(R46W)β2δ channels spent within the burst (Po) was much less than that of 
control channels (p < 0.01, Table 2, Figure 8B), and the burst frequency of mutant channels was 
also less than that of wild-type channels (p < 0.05, Table 2, Figure 8D).  Furthermore, mutant 
channels had a small reduction of the number of openings per burst compared to wild-type 
channels (p > 0.05, Table 2).   
Similar to γ2L subunit-containing GABAA receptors, for both wild-type α6β2δ and 
mutant α6(R46W)β2δ channels, the burst duration frequency distributions were fitted best by two 
exponential functions (Figure 8E).  Again, there were no differences in the time constants (t1 and 
t2) for the short-duration bursts (t1) for wild-type and mutant channels (p > 0.05, Table 2, Figure 
8F, left panel), and the time constant for the longer burst component (t2) was reduced for the 
mutant channel (p < 0.05, Table 2, Figure 8F, right panel).  Again, mutant receptors shifted the 
distribution of the two populations of burst durations by increasing the relative proportion of 
bursts with short duration (a1) and reducing the relative proportion of longer bursts (a2) (p < 0.001, 
Table 2, Figure 8G).  In summary, the α6 subunit mutation, R46W, substantially impaired the 
gating of α6β2δ channels that resulted in reduced macroscopic currents and altered kinetic 
properties. 
The α6 subunit mutation, R46W, decreased surface expression of α6β2δ receptors. 
As described previously, both macroscopic and microscopic kinetic properties of α6β2δ 
receptors were impaired by the α6(R46W) subunit mutation.  Primarily we found a substantial 
reduction in α6(R46W)β2δ current density, which was due in part to the mutation’s effect to 
reduce mean channel open time but could be due also to reduced expression of αβδ receptors on 
the cell surface.  To determine how expression of mutant α6(R46W) subunits affected expression 
of α6β2δ receptors, homozygous wild-type α6FLAG or mutant α6(R46W)FLAG subunits were 
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coexpressed with β2 and δHA subunits in HEK293T cells, and surface and total cell expression 
levels of each subunit (α6FLAG, α6(R46W)FLAG, β2, and γ2LHA) were assessed using flow 
cytometry.   
In contrast to the results obtained for α6β2γ2L receptors, coexpression of α6(R46W)FLAG 
with β2, and δHA subunits resulted in a general reduction of α6, β2 and δ subunits on the cell 
surface (Figure 9A).  Cell surface levels of α6(R46W)FLAG (0.63 ± 0.03, n = 9,), β2 (0.72 ± 0.02, n 
= 10), and δHA (0.59 ± 0.01, n = 10) subunit levels were all lower (p < 0.001) than those 
determined for coexpression of wild-type α6FLAG with β2 and δHA subunits (α6FLAG 0.997 ± 0.001, 
n = 9; β2 0.99 ± 0.001, n = 10; δHA 1.00 ± 0.001, n = 10) (Figure 9B).  Moreover, total expression 
of α6(R46W)FLAG subunits (0.44 ± 0.03, n = 10, p < 0.001, Figure 9C and D, left panels) was half 
that of wild-type α6FLAG subunits (0.999 ± 0.001, n = 10). , This reduction was associated with a 
reduction of δHA subunit total levels (0.81 ± 0.05, n = 10, and 0.99 ± 0.001, n = 10, respectively, p 
< 0.01, Figure 9C and D, right panels) but no changes in coexpressed β2 subunits (0.96 ± 0.09, n 
= 7, and 0.997 ± 0.001, n = 10, respectively, p > 0.05, Figure 9C and D, middle panels).  In 
summary, the R46W mutation caused a major reduction of surface expression of all subunits in 
αβδ receptors.   
Heterozygous coexpression of α6FLAG/α6(R46W) with β2 and dHA subunits resulted in no 
significant difference in α6 subunits (0.64 ± 0.02, n = 7, p > 0.05), and a small reduction of β2 
(0.85 ± 0.03, n = 8, p < 0.05) and δHA (0.78 ± 0.02, n = 8, p < 0.001) subunits (Figure 9E, top 
panels) on the cell surface, when compared to half-tagged α6FLAG/α6 subunits (0.61 ± 0.02, n = 7, 
1.01 ± 0.04, n = 7, and 0.99 ± 0.04, n = 7, respectively, dotted lines).  Coexpression of 
α6/α6(R46W)FLAG subunits, however, resulted in a larger reduction of α6 subunits (0.28 ± 0.03, n 
= 7) relative to both half-tagged (p < 0.001) and heterozygous α6FLAG/α6(R46W) (p < 0.001) 
receptors on the cell surface (Figure 9E, left top panel) and was associated with a reduction of β2 
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Figure 9. The R46W mutation decreased surface expression of all subunits in αβδ-containing 
receptors.
A. GABAA receptor α6F, α6F(R46W), β2 and δHA subunit surface levels were measured by 
ﬂow cytometry for cells coexpressing wild-type (wt) and mutant R46W α6β2δ receptors. Repre-
sentative histograms of positively transfected cells (dark grey) were superimposed on those 
from mock transfected cells (light grey) and are shown for surface expression. Note that the 
abscissa is a log scale. B. mean ﬂuorescence intensity (FI) of α6, β2 and δ subunit surface levels 
was quantiﬁed for both wild-type (white bars) and mutant receptors (grey bars). C. GABAA 
receptor α6F, α6F(R46W), β2 and δHA subunit total cellular expression levels were measured 
by ﬂow cytometry for cells coexpressing wild-type and mutant R46W α6β2δ receptors. Repre-
sentative histograms of positively transfected cells (dark grey) were superimposed on those 
from mock transfected cells (light grey). D. mean ﬂuorescence intensity (FI) of α6F, β2 and δHA 
subunit total levels was quantiﬁed as described above (wild-type as white bars, and mutant 
receptors as grey bars). E. mean ﬂuorescence intensity (FI) of α6F, β2 and δHA subunit surface 
and total expression was quantiﬁed for heterozygous α6F/α6(R46W), α6/α6(R46W)F and α6F/α
6(R46W)F α6β2δ receptor. Dashed lines represent α6F/α6 surface or total levels. 
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(0.83 ± 0.04, n = 8, p < 0.01) and δHA (0.72 ± 0.03, n = 8, p < 0.001) subunit surface levels 
relative to half-tagged wild-type subunits, respectively (Figure 9E, middle and right top panels)   
When full-tagged α6FLAG/α6(R46W)FLAG subunits were coexpressed, α6 subunit levels 
were increased on the cell surface (0.84 ± 0.02, n = 6) when compared to those obtained with 
α6/α6(R46W)FLAG subunit coexpression (p < 0.001), and were slightly increased compared to 
FLAG levels with both half-tagged α6FLAG/α6 (p < 0.001) and heterozygous α6FLAG/α6(R46W) (p 
< 0.001) expression (Figure 9E, left top panel).  No differences were found in surface expression 
levels of β2 subunits (0.93 ± 0.03, n = 6, p > 0.05) coexpressed with α6FLAG/α6(R46W)FLAG 
subunits (Figure 9E, right middle panel), but a reduction in surface levels of δHA subunits (0.79 ± 
0.03, n = 6, p < 0.001) was found when compared to the half-tagged condition (Figure 9E, right 
top panel).  As with αβγ receptors, these results suggested that in heterozygous α6/α6(R46W)β2δ 
receptors, mutant subunits were incorporated into the surface-trafficked receptors less efficiently 
than wild-type subunits.  Specifically, in heterozygous α6/α6(R46W)β2δ receptors, about 2/3 of 
all surface α6 subunits were wild-type and 1/3 were mutant (Figure 9E left top panel).   
We also measured the total cellular expression of heterozygous α6/α6(R46W)β2δHA 
receptors (Figure 9E, bottom panels).  Similar to the results obtained for heterozygous expression 
of α6FLAG/α6(R46W)β2γ2LHA receptors, no differences were found in total expression of α6 (0.53 
± 0.03, n = 7, p > 0.05), β2 (1.00 ± 0.20, n = 5, p > 0.05) or δHA (0.88 ± 0.07, n = 8, p > 0.05) 
subunits when compared to half-tagged α6FLAG/α6 subunit total expression (0.56 ± 0.03, n = 7; 
0.83 ± 0.05, n = 4; and 1.00 ± 0.04, n = 7; respectively, dotted lines), and no significant 
differences were found in total expression levels of β2 (0.87 ± 0.12, n = 5 and 0.96 ± 0.15, n = 3) 
or δHA (0.77 ± 0.06, n = 8, and 0.92 ± 0.06, n = 6) subunits with heterozygous coexpression with 
either α6/α6(R46W)FLAG or α6FLAG/α6(R46W)FLAG subunits, respectively (Figure 9E, middle and 
right bottom panels).  Coexpression of α6/α6(R46W)FLAG subunits, however, resulted in a lower 
levels of total α6 subunits (0.24 ± 0.04, n = 8) than of either half-tagged α6FLAG/α6 (p < 0.001) or 
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heterozygous α6FLAG/α6(R46W) (p < 0.001) subunits (Figure 9E, left bottom panel).  Moreover, 
when full-tagged α6FLAG/α6(R46W)FLAG subunits were coexpressed, there was an increase of total 
FLAG levels (0.68 ± 0.07, n = 6) when compared to FLAG levels with α6/α6(R46W)FLAG 
coexpression (p < 0.001).  Similar results were observed for total expression of α6 subunits (wild-
type α6 subunits ~ 2/3 and mutant α6(R46W) subunits~ 1/3) in α6/α6(R46W)β2γ2L receptors 
(Figures 6D and 9E, left bottom panels).  
 
Discussion 
We determined the functional consequences of the GABAA receptor α6 subunit missense 
mutation, R46W, which was found in a patient with childhood absence epilepsy (CAE) and atonic 
seizures393.  The mutation is located in the N-terminus of the α6 subunit in a region homologous 
to a γ2 missense mutation, R82Q, which was reported in patients affected with both CAE and 
febrile seizures314, 394.  The γ2 subunit mutation, R82Q, reduced current amplitude without 
altering current time course by impairing primarily receptor trafficking, thus reducing receptor 
surface expression313, 395.  In contrast we found that the α6 subunit mutation, R46W, affected both 
gating properties and trafficking of human α6β2γ2 and α6β2δ receptors. 
The α6 subunit mutation, R46W, impaired gating of α6β2γ2 and α6β2δ receptors. 
While the α6(R46W) subunit mutation reduced the current density of γ2 subunit-
containing GABAA receptors by ~25%, the mutation reduced the current density of δ subunit-
containing receptors by 98% when compared with wild-type receptors.  In addition to having 
reduced current amplitude, α6(R46W)β2γ2 currents displayed more macroscopic desensitization 
and slower deactivation kinetics.  In contrast, α6(R46W)β2δ  currents did not desensitize and 
deactivated rapidly.  The mutation slowed activation rates of both α6β2γ2 and α6β2δ currents to a 
similar extent.  The mutation also produced similar changes in the single channel properties of 
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α6β2γ2 and α6β2δ receptors, reducing both mean open time and burst duration.  A reduction in 
current density could be produced by reduction of channel density on the cell surface (an issue 
discussed later) and/or by reduction of the time the channel spends in the open state.  As a result, 
inhibitory postsynaptic current (IPSC) amplitudes would be reduced, potentially causing 
disinhibition and development of epilepsy.  Reduced GABAA receptor function with mutations 
linked to CAE was also described with mutations of γ2(R82Q) and β3(G32R) GABAA receptor 
subunits310, 313, 317.  All of these mutations are located in the N-terminal extracellular subunit 
domain between the α-helix and the first β-sheet.  Within this domain, the γ2(R82Q) mutation is 
predicted to be located at the γ(+)/β(-) subunit interface, and the β3(G32R) subunit mutation is 
predicted to be located at the γ(+)/β(-) and α(+)/β(-) subunit interfaces in assembled receptors.  In 
HEK293 cells, Bianchi et al (2002a) found that α1β3γ2(R82Q) receptors had reduced 
macroscopic peak currents and single channel mean open duration, and Tanaka et al (2008) 
reported that α1β3(G32R)γ2 receptors had reduced current density.  Goldschen-Ohm et al (2010) 
reported that GABAA receptors containing the γ2(R82Q) mutation had slowed deactivation by 
slowing recovery from desensitization and GABA unbinding, but without changes in the 
conductance of the channel.  We conclude that both of these mutations affect channel function 
through structural conformational changes in the extracellular domain that links to channel gating 
and desensitization-deactivation coupling, thus likely altering the amplitude and duration of 
IPSCS.   
Once GABA binds to GABAA receptors, rearrangements at the binding site trigger 
transitions among open, closed, and desensitized states, thereby coupling gating, desensitization 
and deactivation 12, 360, 398, 399.  Our results demonstrate that the R46W mutation affects gating 
efficacy and desensitization-deactivation coupling of both γ and δ subunit-containing GABAA 
receptors.  For γ subunit-containing receptors, gating efficacy was decreased by reducing burst 
duration.  This makes the channel open in brief bursts and can prolong channel deactivation.   
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Desensitization is usually coupled to deactivation in γ2 subunit-containing GABAA 
receptors.  In contrast, with δ subunit-containing GABAA receptors, the smaller opening/burst 
frequencies predict faster deactivation of the channel.  The R46W mutation affected macroscopic 
desensitization and deactivation, but the effects were channel is governed by the subunit that 
completes the pentameric receptor.  This is important since γ (synaptic) and δ (extrasynaptic) 
subunit-containing GABAA receptors confer different properties to the synapse.   
The α6(R46W) subunit mutation impaired assembly and/or trafficking of both α6β2γ2 and 
α6β2δ  receptors.   
Multiple motifs for efficient subunit folding and receptor assembly have been described 
in the N-terminal extracellular domains of GABAA receptor subunits86, 90, 92, 329.  These motifs are 
structurally conserved among GABAA receptor subunits and involve intermolecular binding 
interactions between side chains of residues located on subunit interfaces.  The α6(R46W) 
mutation is located at the α(+) interface of GABAA receptors.  Thus, this mutation could impair 
oligomerization at the α(+)/γ(-),  α(+)/δ(-),  and α1(+)/β(-)  subunit interfaces, potentially 
impairing assembly or altering the stoichiometry of receptors.   
The α6(+) subunit face was reported to interact with a group of residues at the γ(-) 
subunit interface that are homologous to residues at the (-) face of β subunits where the missense 
mutation γ2(R82Q) disrupts a highly conserved inter-subunit contact site92, 100.  Hales and 
colleagues suggested that the mutant γ2(R82Q) subunit has impaired oligomerization at the 
γ2(+)/β2(-) subunit interface during receptor assembly100.  This failure of assembly and folding of 
mutant γ2(R82Q) subunits result in retention of the mutant subunit in the endoplasmic reticulum 
(ER) and reduction of surface expression levels of α1β2γ2 receptors395, 400.  We found that 
coexpression of mutant α6(R46W) subunits decreased surface expression levels of all partnering 
subunits in αβδ receptors, and α and β subunits in αβγ receptors, suggesting misfolding of excess 
subunits and later ER retention and degradation395.  It was proposed that non-degraded or residual 
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mutant GABAA receptor α1(A322D) subunits linked to juvenile myoclonic epilepsy produced a 
dominant negative effect by association and retention of wild-type receptor subunits 308.  
However, heterozygous coexpression of mutant α6(R46W) and wild-type α6 subunits restored ~ 
68% of the macroscopic current amplitude by expressing more wild-type than mutant subunits 
and assembling α6/α6(R46W)β2γ2L receptors on the cell surface.  Thus, mutant α6(R46W) 
subunits can access the cell surface and form GABAA receptors with different subunit 
arrangements.  Although the presumed stoichiometry of ternary GABAA receptors is 2α, 2β and 
1γ/δ subunits329, the assembly and trafficking of other subunits to the cell surface is restricted to a 
limited number of receptor stoichiometries81, 86, 276.  Using concatenated subunits it was suggested 
that the α1(A322D) subunit mutation, which impaired these interactions, produced asymmetrical 
subunit composition of functional heteromeric GABAA receptors on the cell surface401.  It seems 
that the α6(R46W) subunit mutation could also impair intersubunit binding interactions 
differently at the α6β2 and α6γ/δ interfaces, differently affecting the subunit arrangement of 
GABAA receptors expressed on the cell surface.  
Mutation of R46 in the α helix loop 1 zone weakens interactions at the interfaces of γ2, δ and 
β2 subunits and alters channel function through structural conformational changes in the 
extracellular domain that mediate links to channel gating and desensitization. 
Structural studies showed a common mechanism for translating ligand binding to channel 
gating for Cys-loop ligand ion channels97, 402-404.  These included conformational rearrangements 
of the C-loop within the ligand binding pocket followed by movements of loops 2 and 7 (Cys 
loop) where critical residues interact upon agonist binding.  These conformational rearrangements 
in the binding zone are transmitted to the coupling zone through interactions between the β1–β2 
loop and the M2–M3 linker, which propagate structural movements from the binding site to the 
transmembrane domains allowing channel opening.  It is possible that the R46W mutation in the 
α helix-Loop 1 zone of the α6 subunit weakens the interactions at the interfaces of γ2, δ and β2 
subunits, propagating allosteric conformational changes through the rigid β-strands, causing 
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rearrangements within the coupling zone of α6β2γ2/δ receptors.  Thus this mutation could affect 
channel function through structural conformational changes in the extracellular domain that links 
to channel gating and desensitization.  It was proposed that the missense mutation γ2(R82Q) 
eliminates benzodiazepine binding to the putative benzodiazepine-binding site at the α-γ 
interface405, which is on the opposite side of the γ subunit (γ2(-)), through allosteric 
conformational change of a salt-bridge network existing between this arginine and charged 
residues at the γ2(+)/β2(-) interface of α1β2γ2 GABAA receptors.  Charge reversal or 
neutralization of the residues positioned in this salt-bridge network impaired GABAA receptor 
macroscopic kinetics and diazepam sensitivity of α1β2γ2 receptors expressed in HEK293 cells317.  
At the homologous position of α6(R46), a comparative structural model of the extracellular 
domain of α1β2γ2 receptors based on homology with the crystal structure of the nAChR97, 406 
suggested that the arginine (α1R29) shares bonding interactions between the side chains of acidic 
(β2D89, α1D27) and amide (α1N28, γ2N101) residues at the interfaces of β2(-) and γ2(-) subunits 
that stabilizes the tertiary structure of the subunits.  These residues were identified as a part of a 
conserved assembly motif in α1 subunits92.  Homology modeling of the N-terminal extracellular 
domain of α6β2γ2 and α6β2δ receptors shows a lack (α6D44, γN71, β2D41, β2D113 and δD45) 
of interactions between the side chains in the interfaces of α6(+) and β2(-), γ2(-), or δ(-) subunits 
when the α6 subunit R46 is mutated to W46 (Figure 10), which might first change the surface 
accessible area of the residues between the interfaces of the subunits, and second propagate 
intramolecular and/or intermolecular allosteric conformational changes through the rigid β-
strands, causing rearrangements within the coupling zone of GABAA receptors.  Moreover, when 
an agonist binds to these receptors, conformational changes trigger the “capping motion” of the 
C-loop in toward the channel over the agonist, which couples agonist binding to channel gating402, 
404.  A similar mechanism was proposed to occur at the homologous structural region of the C-
loop of α1β2γ2 GABAA receptors407.  Hence electrostatic interactions between charged residues 
of loop-B and loop-C might be involved in the C-loop mobility during activation of GABAA 
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Figure 10.  Mutation of α6R46 in the α-helix-Loop-1 zone weakens interactions at the inter-
faces of γ2, β2 and δ subunits. 
A-C.  Close view of the α-helix-Loop-1 zone of the structural modelling of the GABAA recep-
tor at the interface between α6(+) and γ2(-), β2(-) and δ(-) subunits showing the predicted inter-
actions (< 4.60 Å, black dotted lines; and >4.60 Å, grey dotted lines) between side chains of α
6R46 (wt, left panels) and α6W46 (R46W, right panels).  Note that γ2N71, β2D41 and δD45 are 
conserved residues into the α-helix across the GABAR subunits (see Figure 1B).  The back-
bones of subunits are represented as coloured ribbons as showed in Figure 1A (α6 in green and 
blue, β2 in red, and γ2 and δ in yellow) and labelled residues as CPK representation.  D.  
Sequence alignment of the putative homologous assembly motif at human γ2(-), β2(-) and δ(-) 
subunit interfaces is presented.  Predicted residues at the interfaces are in red.  “*”, “:” and “.” 
means that residues are identical, conserved or semi-conserved in all sequences in the align-
ment.
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receptors and could be affected by structural changes transmitted through the β-strands by either 
modification of glycosylation sites335 or by nearby point mutations located at the top of the N-
terminal extracellular domain of the receptor as suggested for the missense mutation γ2(R82Q)317 
and the α6(R46W) mutation (this study).   
Pathophysiological consequences of GABRA6 mutations in CAE.   
It may be assumed that in pathological conditions, all neural networks are susceptible to 
amplification or intensification of aberrant signals from disinhibited neuronal networks.  However, 
the functional consequences of these networks for epileptogenesis in the cerebellum are unclear.  
Early work408, 409, which failed to demonstrate any behavioral phenotype in mice lacking GABAA 
receptor α6 subunits; however, we cannot necessarily discount the possibility of the presence of 
absence seizures in these models since the detection of such events sometimes requires a 
phenotypic criterion such as abnormal EEG (generalized spike-wave discharges) rather than a 
simple observable behavior.  Nonetheless, the lack of α6 subunits caused a dramatic reduction in 
δ subunit protein levels in the cerebellum of α6 knockout mice408.  We found that the R46W 
mutation caused a similar reduction of surface expression of δ subunits, which unveils a critical 
role of this residue for properly assembling/trafficking of functional GABAA receptors.  Likewise, 
a point mutation in a residue critical for benzodiazepine binding to α6 subunits (R100) conferred 
diazepam-mediated potentiation of α6(Q100)β2γ2 GABA-activated currents and reduced the 
impairment of postural reflexes produced by benzodiazepine agonists such as diazepam in alcohol 
non-tolerant rats410-412.  We suggest that the R46W mutation may increase susceptibility to 
epilepsy syndromes such as CAE through a reduction of α6βγ and α6βδ receptor function and 
expression in the cerebellum.  However, it is unclear whether or not and if so how the mutated α6 
protein contributes to the pathogenesis of the epilepsy syndrome.  Further validation of the 
mutant subunit in vivo will be required to determine whether this mutation contributes to shaping 
the disease phenotype. 
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CHAPTER VI 
GABAA RECEPTOR BIOGENESIS IS IMPAIRED BY THE γ2 SUBUNIT            
FEBRILE SEIZURE-ASSOCIATED MUTATION, GABRG2(R177G)  
 
Abstract 
A missense mutation in the GABAA receptor γ2L subunit, R177G, was reported in a 
family with complex febrile seizures (FS).  To gain insight into the mechanistic basis for these 
genetic seizures, we explored how the R177G mutation altered the properties of recombinant 
α1β2γ2L GABAA receptors expressed in HEK293T cells.  Using a combination of 
electrophysiology, flow cytometry, and immunoblotting, we found that the R177G mutation 
decreased GABA-evoked whole-cell current amplitudes by decreasing cell surface expression of 
α1β2γ2L receptors.  This loss of receptor surface expression resulted from endoplasmic reticulum 
(ER) retention of mutant γ2L(R177G) subunits, which unlike wild-type γ2L subunits, were 
degraded by ER-associated degradation (ERAD).  Interestingly, when compared to the condition 
of homozygous γ2L(R177G) subunit expression, disproportionately low levels of γ2L(R177G) 
subunits reached the cell surface with heterozygous expression, indicating that wild-type γ2L 
subunits possessed a competitive advantage over mutant γ2L(R177G) subunits for receptor 
assembly and/or forward trafficking.  Inhibiting protein synthesis with cycloheximide 
demonstrated that the R177G mutation primarily decreased the stability of an intracellular pool of 
unassembled γ2L subunits, suggesting that the mutant γ2L(R177G) subunits competed poorly 
with wild-type γ2L subunits due to impaired subunit folding and/or oligomerization.  These 
findings support an emerging body of literature implicating defects in GABAA receptor 
biogenesis in the pathogenesis of idiopathic generalized epilepsies (IGEs). 
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Introduction 
Idiopathic generalized epilepsies (IGEs) include a wide variety of epilepsy syndromes, 
ranging from relatively benign forms such as simple febrile seizures (FS) to catastrophic 
syndromes such as Dravet syndrome 310, 413.  The most common childhood seizures are FS414, with 
a prevalence as high as 5% in children under the age of six415.  Although FS typically do not 
occur after six years of age, patients experiencing FS have an increased risk of epilepsy later in 
life416, 417, and many clinically heterogeneous IGEs present in childhood as FS416.  As a result, 
they have been grouped into the generalized epilepsy with FS plus (GEFS+) spectrum of IGEs.  
Many IGEs likely have a genetic component, with monogenic mutations in voltage-gated 
(CACNB4, KCNQ2, KCNQ3, SCN1A and SCN1B) and ligand-gated (CHRNA4, CHRNB2, 
GABRA1, GABRB3, and GABRG2) ion channel subunits having been identified in families with 
various IGE syndromes391, 418-420. 
In the GABAA receptor γ2 subunit, we previously reported the R177G mutation in a 
family with complex FS occurring with an autosomal dominant inheritance pattern421.  
Understanding the effects of this mutation was of particular interest, as introduction of glycine 
residues is known to increase conformational freedom422, and adjacent to this residue there is 
already a conserved glycine at position 176.  The R177G mutation might therefore amplify 
existing conformational freedom in this region of the γ2 subunit.  Since channel gating is 
mediated by subunit conformational changes, which are in turn highly dependent upon the 
integrity of local structural motifs166, 167, 423, this additional flexibility might change the kinetic 
properties of receptors containing mutant γ2(R177G) subunits.  Alternatively, if increased 
conformation freedom were to cause subunit instability and misfolding, the mutation might 
impair assembly and/or trafficking of γ2 subunit-containing receptors, thereby reducing the 
number of functional GABAA receptors on the cell surface. 
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Since GABAA receptors are the primary mediators of fast inhibitory synaptic 
transmission in the mammalian brain, and the γ2 subunit is an important determinant of both 
GABAA receptor current kinetics168 and synaptic targeting136, 137, we hypothesized that the R177G 
mutation promoted neuronal hyperexcitability via loss of GABAergic inhibition due to impaired 
receptor function and/or biogenesis.  To explore these possibilities, we characterized the effects 
of the γ2 subunit R177G mutation on the properties of recombinant α1β2γ2L GABAA receptors 
transiently expressed in HEK293T cells.  Using a combination of patch clamp recording, flow 
cytometry, and immunoblotting, we evaluated the effects of the mutation on GABAA receptor 
current kinetics, surface trafficking, and subunit maturation, respectively.  We identified a novel 
mechanism underlying loss of GABAergic inhibition whereby mutant γ2L(R177G) subunits are 
retained in the ER and degraded by the ubiquitin-proteasome system after failing to “compete” 
with wild-type subunits for incorporation into functional receptors. 
 
Materials and Methods 
Cell culture and expression of recombinant GABAA receptors 
HEK293T cells (a gift from P. Connely, COR Therapeutics, San Francisco, CA) were 
cultured in Dulbecco’s Modified Eagle’s Medium with 10% Fetal Bovine Serum, 100 IU / ml 
penicillin, and 100 μg / ml streptomycin (Invitrogen, Carlsbad, CA) and maintained at 37 °C in 
humidified 5% CO2 / 95% air.   
The cDNAs encoding human GABAA receptor α1, β2S, and γ2L subunits were 
individually subcloned into the pcDNA3.1 expression vector.  The γ2L subunit R177G mutation 
was introduced using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) 
and confirmed by DNA sequencing.  Note that all point mutation residues are numbered 
according to their position in the immature human subunit (i.e., including the signal peptide).  
Due to the lack of a highly specific, commercially available antibody for a native extracellular 
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epitope on the γ2L subunit, FLAG (DYKDDDDK) or HA (YPYDVPDYA) epitopes were 
inserted between amino acids 4 and 5 of the mature γ2L subunit so that subunit surface 
expression could be monitored with flow cytometry or immunoblotting (see Results). 
Using Fugene6 (Roche Diagnostics, Indianapolis, IN) according to the manufacturer’s 
recommended protocol, cells were cotransfected with α1, β2, and either “wild-type” γ2L (α1 : β2 : 
γ2L cDNA ratio of 0.3 µg : 0.3 µg : 0.3 µg), “heterozygous” γ2L/γ2L(R177G) (α1 : β2 : γ2L : 
γ2L(R177G) cDNA ratio of 0.3 µg : 0.3 µg : 0.15 µg : 0.15 µg), or “homozygous” γ2L(R177G) 
(α1 : β2 : γ2L(R177G) cDNA ratio of 0.3 µg : 0.3 µg : 0.3 µg) subunits.  Note that subsequent 
sections use the terms wild-type, heterozygous, and homozygous as shorthand for these 
transfection conditions rather than to imply a specific genotype.  For electrophysiology 
experiments, subunit cDNAs were cotransfected with 1 µg of pHook-1 (Invitrogen, Carlsbad, 
CA), a surface antigen used for immunomagnetic selection 24-30 hours after transfection, as 
previously described 343.  For all transfection conditions, empty pcDNA3.1 vector was added such 
that a total of 0.9 μg of subunit cDNA was used for each experimental condition.  Mock 
transfection conditions included 0.9 µg of empty pcDNA 3.1 expression vector cDNA. 
Electrophysiology 
Cells were plated onto 35-mm culture dishes (Corning Life Sciences, Acton, MA), and 
positively transfected cells were selected with an immunomagnetic selection technique described 
previously343.  For macropatch recordings, the 35-mm dishes were coated with collagen in acetic 
acid (Sigma-Aldrich, St. Louis, MO) and allowed to dry under UV light before plating.  
Recordings were made 18-24 hours after cell selection in an external bath solution consisting of 
(in mM): NaCl 142, KCl 8, MgCl2 6, CaCl2 1, HEPES 10, glucose 10 (pH adjusted to 7.4 using 
NaOH; 318-328 mOsm).  The intrapipette solution consisted of (in mM): KCl 153, MgCl2 1, 
MgATP 2, HEPES 10, EGTA 5 (pH was adjusted to 7.3 using KOH; 305-312 mOsm).  The 
solutions were designed such that the chloride equilibrium potential was approximately 0 mV.  
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Cells were held at a membrane potential of -20 mV for lifted whole cell recordings and -50 mV 
for macropatch recordings.  Recording pipettes were made of thin-walled (whole cell) or thick-
walled (macropatch) borosilicate glass (World Precision Instruments, Pittsburgh, PA) pulled with 
a P-2000 laser puller (Sutter Instruments, San Rafael, CA) and fire polished with a microforge 
(Narishige, East Meadow, NY) to resistances of 0.8-1.5 MΩ (whole cell) or 5-8 MΩ 
(macropatches) when filled with internal solution.  Currents were elicited from lifted whole cells 
or excised outside-out macropatches using the concentration-jump technique424.  The 10-90% 
open tip solution exchange times were consistently < 1 ms for whole cell recordings and < 500 μs 
for macropatch recordings.  Data were acquired at 20 kHz using an Axopatch 200-B (Molecular 
Devices, Sunnyvale, CA), filtered at 2 kHz, and analyzed offline using pClamp 9. For macropatch 
recordings, current desensitization time courses were fitted using the Levenberg-Marquardt least 
squares method to the form ∑ ane
(-t/τn), where n is the number of exponential components, a is 
the relative (fractional) amplitude of the component at time = 0, t is time, and τ is the time 
constant.  The number of components was incremented until additional components did not 
significantly improve the fit as determined by an F-test performed on residuals.  For the time 
course of current deactivation, a weighted sum (af * τf + as * τs) was used.  Data were represented 
as the mean ± SEM, and statistical significance was determined using a Student’s unpaired t-test 
with Welch’s correction for unequal variance. 
Flow cytometry 
Surface and total cellular expression of GABAA receptor subunits was evaluated by flow 
cytometry as previously described335, 367, 425.  Briefly, cells were harvested 48 hours after 
transfection using 37 ºC trypsin/EDTA (Gibco, Carlsbad, CA) and 4ºC FACS buffer composed of 
phosphate-buffered saline (Mediatech, Herndon, FA), 2% fetal bovine serum (Gibco), and 0.05% 
sodium azide (VWR, Weschester, PA).  Cells were then transferred to 96-well plates for antibody 
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staining.  For total protein staining, samples were first fixed and permeabilized using the 
Cytofix/Cytoperm kit from BD Biosciences (San Jose, CA). 
The human α1 antibody (Clone BD24) was obtained from Millipore (Temecula, CA), 
conjugated to the Alexa-647 fluorophore using a kit (Invitrogen, Carlsbad, CA), and used at a 
dilution of 1:200.  The β2/3 antibody (Clone 62-3G1) was obtained from Millipore (Billerica, 
MA), but could not be directly conjugated to fluorophore without substantially reducing its 
affinity.  Thus, after staining at a 1:100 dilution, the samples were stained again for 1 hour using 
rabbit anti-mouse IgG1 Alexa-647-conjugated secondary antibody (Invitrogen) at a 1:500 dilution, 
pelleted and resuspended three times in FACS buffer, and pelleted and resuspended in 2% PFA.  
Since high-affinity antibodies against an extracellular domain of the γ2 subunit were unavailable, 
N-terminal FLAG-tagged γ2L (γ2LFLAG) or HA-tagged subunits were employed.  The FLAG 
antibody (Clone M2) was obtained from Perkin Elmer (Boston, MA) as an allophycocyanin 
conjugate and used at a dilution of 1:200, and the HA antibody was obtained from Covance and 
used at a dilution of 1:5000.  Antibodies were diluted in FACS buffer for surface staining and 
Permwash for total staining. 
Samples were run on a BectonDickson FACS Calibur flow cytometer and data were 
acquired using CellQuest (BD Biosciences, San Jose, CA).  For each staining condition, at least 
50,000 events were recorded, and data were analyzed offline using FlowJo 7.1.  The mean 
fluorescence intensity (FI) of the experimental cells was normalized to the wild-type α1β2γ2L 
condition for comparison (“Relative FI”).  In all experiments, cells were transfected also with an 
equivalent amount of blank pcDNA3.1 vector as a control for the transfection proceedure (mock 
condition).  Statistical significance was determined using a Student’s unpaired t-test or ANOVA 
with Tukey’s post-test, as appropriate. 
For cycloheximide and lactacystin experiments, cells were prepared and transfected as 
described above, except that cells were transfected in 10-cm culture dishes and split 24 hours later 
into separate 6-cm culture dishes for drug application.  Cycloheximide (Supelco, Bellefonte, PA) 
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and lactacystin (Boston Biochem, Cambridge, MA) were dissolved in DMSO (Sigma) and diluted 
1:1000 into the culture dish to final concentrations of 100 μg / mL and 10 μM on the day of the 
experiment.  For control experiments, DMSO was added to the culture dish. 
Protein digestion and immunoblotting 
Transfected cells (as described above) were lysed 48 hours after transfection in RIPA 
buffer composed of: 10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.25% sodium deoxycholate, and 
1% NP-40 (pH adjusted to 7.4).  All reagents were obtained from Sigma.  A Complete Mini™ 
protease inhibitor cocktail tablet (Roche Diagnostics, Mannheim, Germany) was added to the 
RIPA buffer on the day of the experiment.  The protein concentration of each sample was 
determined with a protein assay dye (BioRad, Hercules, CA) on a spectrophotometer measuring 
absorbance at 595 nm against a standard curve generated with BSA.  For each sample, 25 μg of 
protein was included, and sample volumes were adjusted with lysis buffer.  Samples were 
digested with Endo H or PNGase F with 1x dilution of G7 or G5 reaction buffer, respectively 
(New England BioLabs, Beverly, MA).  Undigested samples were incubated with 1x G7 reaction 
buffer and RIPA buffer in place of enzyme.  Digestion proceeded for 3 hours at 37º C and was 
stopped with 5% β-mercaptoethanol (Sigma) in 5x sample buffer (BioRad).  Samples were loaded 
onto a 10% acrylamide gel for SDS-page electrophoresis at 100 V for 4-5 hours and transferred to 
a PVDF membrane (Millipore).  Membranes were blocked in 0.5% non-fat milk in Tris-Buffered 
Saline with 0.2% Tween (TTBS) and incubated in mouse anti-HA antibody (Covance, Berkeley, 
CA) and Na+/K+ ATPase α-chain as a loading control (Abcam, Cambridge, MA).  Membranes 
were secondarily probed with a goat anti-mouse antibody conjugated to HRP (Jackson 
ImmunoResearch, West Grove, PA).  Membranes were washed and incubated with a 
chemiluminescent reagent (GE/Amersham Life Sciences, Piscataway, NJ) before exposure with a 
chemiimager.  Band density was determined using BioRad’s Quantity One software.  Statistical 
significance was determined using a Student’s paired t-test. 
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Sequence alignment and homology modeling 
Multiple sequence alignments of human GABAA receptor subunits and the glutamate-
gated chloride channel were performed using ClustalW (European Bioinformatics Institute, 
Hinxton, UK).  Structural models of GABAA receptor α1, β2, and γ2 subunits were generated 
with SWISS-MODEL379, using the crystal structure of the C. elegans glutamate-gated chloride 
channel (GluCl; PDB ID 3rhw) as a template159.  Point mutations were introduced into the γ2 
subunit sequence using DeepView/Swiss-PdbViewer 4.02 (Swiss Institute of Bioinformatics, 
Lausanne, Switzerland), and project files containing the mutated target sequence and the 
superposed template structure were submitted to SWISS-MODEL.  Completed subunits were 
threaded onto the GluCl crystal structure in the order γ2L-β2-α1-β2-α1.  All models were 
subjected to energy minimization within DeepView/Swiss-Pdb Viewer using GROMOS96 in 
default settings, and the most likely conformations were presented here. 
 
Results 
Whole cell current density was reduced by expression of mutant γ2L(R177G) subunits. 
GABA-evoked currents (1 mM application for 4 s) were obtained from lifted HEK293T 
cells cotransfected with GABAA receptor α1, β2, and either wild-type γ2L, an equimolar mixture 
of wild-type γ2L and mutant γ2L(R177G) (“heterozygous”), or mutant γ2L(R177G) 
(“homozygous”) subunits (Figure 1A; see Methods for subunit cDNA ratios and concentrations 
for each condition).  Peak current densities obtained from cells expressing wild-type γ2L subunits 
(539.6 + 62 pA/pF, n = 10) were greater than those obtained from cells expressing mutant 
γ2L(R177G) subunits in the heterozygous condition (377.4 + 39 pA/pF, n = 13, n.s.) and 
significantly greater than those obtained from cells expressing mutant γ2L(R177G) subunits in 
the homozygous condition (220.6 + 90 pA/pF, n = 9, p < 0.01).  The difference in current density 
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Figure 1.  Cells expressing α1, β2, and mutant γ2L(R177G) subunits had reduced 
current density compared to cells expressing α1, β2, and wild-type γ2L subunits.
A.  GABA-evoked (1 mM; 4 sec) currents were obtained from lifted HEK293T cells 
expressing α1, β2, and either wild-type γ2L (wt), heterozygous γ2L/γ2L(R177G) (het), or 
homozygous γ2L(R177G) (hom) subunits.  B.  Cells expressing either heterozygous or 
homozygous γ2L(R177G) subunits had reduced current density compared to those 
expressing wild-type γ2L subunits.  * p < 0.05, ** p < 0.01 when compared to the wild-type 
condition.
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from cells expressing homozygous as compared to heterozygous mutant γ2L(R177G) subunits 
was not statistically significant (Figure 1B). 
Currents obtained from cells coexpressing α1β2γ2L or α1β2γ2L(R177G) subunits had similar 
kinetic properties. 
To compare the macroscopic kinetic properties of wild-type and mutant GABAA receptor 
currents, GABA-evoked currents (1 mM application for 400 ms) were obtained from outside-out 
macropatches excised from cells coexpressing α1, β2, and either γ2L or γ2L(R177G) subunits.  
Wild-type and homozygous mutant receptors yielded currents with similar rates of activation (10-
90% rise times of <1.5 ms; data not shown), as well as similar time courses of desensitization and 
deactivation (Figure 2A).  Desensitization was consistently biphasic, with time constants of 9.0 + 
1.0 and 141 + 36 ms for wild-type (n = 3) and 7.9 + 2.2 ms and 85 + 5.1 ms for homozygous 
mutant (n = 4) receptors, respectively (Figure 2B).  There was a similar contribution of each 
exponential component (Figure 2C).   
Coexpression of mutant γ2L(R177G) subunits increased α1 and β2 and decreased γ2L subunit 
surface levels. 
The observation that peak current amplitudes were reduced in the context of unchanged 
macroscopic current kinetics suggested that the R177G mutation decreased GABAA receptor 
surface levels without altering subunit composition or stoichiometry.  To test this hypothesis, 
flow cytometry was used to analyze the surface levels of α1, β2, and γ2L subunits when 
cotransfected in either wild-type, heterozygous, or homozygous γ2L subunit combinations.   
Surface α1 subunit levels were increased slightly in the heterozygous condition (117.5 + 
4.0% of wild-type, n = 11-12, p < 0.05), but not in the homozygous condition (Figure 3A).  
Surface β2 levels trended toward an increase in the heterozygous condition (138.3 + 10% of wild-
type, n = 6, and increased significantly in the homozygous condition (146.0 + 16% of wild-type, 
n = 6, p < 0.05) (Figure 3B).  These trends in surface α1 and β2 subunit levels were similar when 
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Figure 2.  The time course of macroscopic desensitization was similar for currents 
recorded from cells expressing α1, β2, and either wild-type γ2L or mutant γ2L(R177G) 
subunits.
A. GABA-evoked (1 mM; 400 ms) currents were recorded from outside-out macropatches 
excised from HEK 293T cells coexpressing α1, β2, and either wild-type γ2L (wt; black) or 
homozygous mutant γ2L(R177G) (hom; grey) subunits.  Each trace represents the average 
of 3-5 currents evoked from the same cell.   B. Currents recorded from cells expressing 
wild-type γ2L and homozygous mutant γ2L(R177G) subunits were analyzed to determine 
time constants of macroscopic desensitization.  C.  Currents recorded from cells expressing 
wild-type γ2L and homozygous mutant γ2L(R177G) subunits were analyzed to determine 
the relative contribution of each desensitization component.
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untagged γ2L or γ2L(R177G) subunits were used (data not shown).  In contrast, γ2LFLAG subunit 
surface levels were decreased in both heterozygous (80.0 + 3.0% of wild-type, n = 7, p < 0.001) 
and homozygous (40.0 + 4.0% of wild-type, n = 7, p < 0.001) conditions (Figure 3C).  The 
γ2LFLAG levels were also significantly different in the heterozygous and homozygous conditions 
(p < 0.001).  Thus, despite the appearance of unaltered macroscopic current kinetics, the 
γ2L(R177G) mutation likely altered the subunit composition and/or stoichiometry of GABAA 
receptors expressed on the cell surface. 
In parallel experiments, HEK293T cells were permeabilized before staining to determine 
the total cellular levels of γ2LFLAG and/or γ2L(R177G)FLAG subunits (Figure 3D).  Total FLAG 
staining was not reduced significantly in the heterozygous condition, but was reduced 
significantly in the homozygous condition (72.5 + 9.0% of wild-type, n = 6, p < 0.05) (Figure 3D).  
However, the R177G mutation decreased surface γ2LFLAG subunit levels to a greater extent than 
total γ2LFLAG subunit levels (compare Figure 3C with Figure 3D), suggesting that mutant 
γ2L(R177G) subunits had either decreased rates of forward trafficking or increased rates of 
surface internalization. 
Receptors containing wild-type γ2L subunits were preferentially trafficked to the cell surface 
with coexpression of mutant γ2L(R177G) and wild-type γ2L subunits. 
To determine the relative contributions of wild-type γ2L and mutant γ2L(R177G) 
subunits in the context of heterozygous expression, the subunits were differentially tagged with 
the FLAG epitope (i.e., γ2LFLAG/γ2L(R177G) or γ2L/γ2L(R177G)FLAG).  Following co-
transfection with α1 and β2 subunits, surface (Figure 4A) and total (Figure 4B) FLAG levels were 
analyzed using flow cytometry.  For comparison, the following conditions were evaluated in each 
experiment: 1) “wt[half-FLAG]”, corresponding to α1β2γ2LFLAG/γ2L subunit coexpression; 2) 
“het[wt-FLAG]”, corresponding to α1β2γ2LFLAG/γ2L(R177G) subunit coexpression; 3) “het[RG-
FLAG]”, corresponding to α1β2γ2L/γ2L(R177G)FLAG subunit coexpression; and 4) “mock”, 
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Figure 3.  The R177G mutation decreased cellular expression levels of the γ2LFLAG, but 
not the α1 or β2, subunits in heterozygous and homozygous transfection conditions.
A-C.  Surface expression levels of the α1 (Panel A), β2 (Panel B), and γ2LFLAG (Panel C) 
subunits were evaluated by flow cytometry for wild-type (“wt”; α1β2γ2LFLAG), heterozy-
gous mutant (“het”; α1β2γ2LFLAG/γ2L(R177G)FLAG), homozygous mutant (“hom”; 
γ2L(R177G)FLAG), and “mock” transfection conditions.  D.  Total cellular expression levels 
of the γ2LFLAG subunit were evaluated by flow cytometry for wild-type, heterozygous, 
homozygous, and mock transfection conditions.  Relative fluorescence intensity (Relative 
FI) was calculated by normalizing the fluorescence intensity obtained for each condition to 
that of wild-type.  * p < 0.05, ** p < 0.01, *** p < 0.001 when compared to the wild-type 
condition; ††† p < 0.001 when compared to the heterozygous condition.
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corresponding to expression of empty pcDNA3.1 vector (see Materials and Methods for cDNA 
concentrations and ratios for each condition). 
In the wt[half-FLAG] condition, surface γ2LFLAG subunit levels were approximately half 
(52.4 + 1.0%, n = 7) of the wt[all-FLAG] condition (Figure 3C), indicating that tagged and 
untagged subunits competed equally for surface expression (Figure 4A).  When wild-type 
γ2LFLAG subunits were coexpressed with untagged mutant γ2L(R177G) subunits (het[wt-FLAG] 
condition), surface FLAG levels were increased slightly compared to the wt[half-FLAG] 
condition (60.0% + 2% of wt[all-FLAG] levels; p < 0.001, n = 7).  In contrast, when mutant 
γ2L(R177G)FLAG subunits were coexpressed with untagged wild-type γ2L subunits (het[RG-
FLAG]), surface FLAG levels were decreased substantially (9.0 + 1% of wt[all-FLAG] levels; p 
< 0.001, n = 7) (Figure 4A).  The combined surface levels of the het[wt-FLAG] and het[RG-
FLAG] conditions were similar to the surface levels observed for the original heterozygous 
condition, where wild-type and mutant subunits were both FLAG-tagged (Figure 3).  Thus, in the 
heterozygous condition, the wild-type γ2L subunit was the predominant γ2L subunit on the cell 
surface.  Of note, while mutant subunit surface levels in the homozygous condition were 
substantially reduced compared to the wild-type condition (Figure 3C), they were much higher 
than mutant subunit levels in the heterozygous condition (het[RG-FLAG], Figure 4A), even when 
corrected for the higher (i.e., double) concentration of mutant cDNA used to transfect for the 
homozygous condition (see Methods).  This suggested that the presence of wild-type subunits 
further compromised the ability of mutant γ2L(R177G) subunits to reach the cell surface. 
To determine if this phenomenon was limited to the surface receptor pool or if the entire 
cellular pool of receptors was similarly affected, the differential epitope tagging approach was 
again employed, but cells were permeabilized prior to staining for the FLAG epitope (Figure 4B).  
The FLAG tag did not affect total cellular expression of γ2L subunits, as the wt[half-FLAG] 
condition yielded total levels that were half (48.3 + 4%, n = 5) of the wt[all-FLAG] condition.  In 
contrast to surface expression patterns (Figure 4A), total cellularexpression levels (Figure 4B) 
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Figure 4.  Differential epitope 
tagging allowed for the relative 
contributions of wild-type γ2L and 
mutant γ2L(R177G) subunits to be 
evaluated in the heterozygous 
transfection condition.
Surface (Panel A) and total (Panel 
B) expression levels of γ2LFLAG 
subunits were evaluated by flow 
cytometry for the heterozygous 
transfection condition (α1β2γ2L/γ
2L(R177G)) when either wild-type 
γ2L subunits (“het[wt-FLAG]’) or 
mutant          γ2L(R177G) subunits 
(“het[RG-FLAG]”) was tagged 
with the FLAG epitope.  For com-
parison, the wild-type transfection 
condition (α1β2γ2L) was also 
evaluated when half of the γ2L sub-
units (“wt[half-FLAG]”) contained 
the FLAG epitope.  “Mock” trans-
fected cells contained empty 
pcDNA3.1 vector.  * p < 0.05, *** 
p < 0.001 when compared to the 
wt[half-FLAG] condition.  ††† p < 
0.001 when compared to the 
het[wt-FLAG] condition.
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were similar in the het[wt-FLAG] condition (41.6 + 4% of wt[all-FLAG] levels, n = 5).  Total 
levels were slightly lower in the het[RG-FLAG] condition (33.5 + 4% of wt[all-FLAG] levels, p 
< 0.05 when compared to wt[half-FLAG] condition and p > 0.05 when compared to the het[wt-
FLAG] condition = 5).  Thus, the R177G mutation primarily compromised surface expression of 
mutant γ2L(R177G) subunits.   
The γ2L subunit R177G mutation reduced protein maturation. 
The results in the previous sections demonstrated that the R177G mutation reduced γ2L 
subunit surface levels to a greater extent than total levels, suggesting that the mutation impaired 
assembly, forward trafficking, or surface stability of receptors containing γ2L(R177G) subunits.  
Since the N-glycosylation pattern of membrane proteins reflects their progression through the 
secretory pathway, these possibilities were explored using enzymes that specifically 
deglycosylate proteins at different stages of processing.  For example, Endoglycosidase H (Endo 
H) removes only high-mannose (core or immature) N-glycans, which are added to proteins in the 
ER before transport to the Golgi apparatus (where further glycan modification, including 
mannose removal, confers Endo H resistance).  Thus, proteins that are Endo H resistant must 
have reached at least the trans-Golgi network426.  In contrast, Peptide N-Glycosidase F (PNGase F) 
cleaves all N-linked carbohydrate modifications427.  By comparing the glycosylation patterns 
following treatment with Endo H and PNGase F, the effect of the R177G mutation on γ2L 
subunit trafficking could be determined.  For example, reduced mature fractions would suggest 
impaired assembly and/or forward trafficking.  In contrast, unchanged mature fractions would 
suggest decreased surface stability. 
Western blots of undigested lysates from wild-type (α1β2γ2LHA), heterozygous 
(α1β2γ2LHA/γ2L(R177G)HA), and homozygous (α1β2γ2L(R177G)HA) subunit combinations 
showed specific bands at 45 and 40 kDa (Figure 5A, lanes U).  In the wild-type condition, both 
bands were similar in density, while in heterozygous and homozygous conditions, the 40 kDa 
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Figure 5.  Mutant γ2L(R177G) subunits matured less efficiently than wild-type γ2L 
subunits.
A.  Western blots were performed on whole cell lysates from HEK293T cells cotransfected 
with α1, β2, and either wild-type γ2LHA (wt), heterozygous mutant γ2LHA/γ2L(R177G)HA 
(het), or homozygous mutant γ2L(R177G)HA (hom) subunits.  Staining of the Na+/K+ 
ATPase α chain was used as a loading control (visible at ~100 kDa).  B.  The integrated 
band density (IBD) of the 45 kDa band in undigested and Endo H digested wt, het, and hom 
samples was calculated and normalized to the IBD of the PNGase F band.  C.  The fraction 
of Endo H insensitive protein was determined for each condition by dividing the IBD of the 
45 kDa band in the Endo H lane by the IBD of the 37 kDa band in the PNGase F lane.  D.  
The PNGase F sensitive band in the heterozygous and homozygous conditions was quanti-
fied using densitometry and normalized to the IBD of the wild-type condition.  * p < 0.05, 
** p < 0.01, *** p < 0.001 compared to the wild-type condition.
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band was denser than the 45 kDa band.  In all conditions, Endo H digestion shifted the 40 kDa 
band to 37 kDa, but did not affect the 45 kDa band, suggesting that the 40 kDa band represented 
“immature” γ2LHA subunits while the 45 kDa band represented “mature” γ2LHA subunits (Figure 
5A, lanes H).  This was confirmed by comparing the integrated band density (IBD) of the 45 kDa 
band before (lanes U) and after (lanes H) Endo H digestion (Figure 5B).  To quantify the fraction 
of mature γ2LHA subunits in each condition, the IBD of the Endo H-resistant band (45 kDa, lanes 
H) was compared to the IBD of the single fully-digested PNGase F band (37 kDa, lanes F) 
(Figure 5C).  While the fraction of mature γ2LHA subunits in the wild-type condition was 58 + 5 
% (n = 5), the fractions of mature γ2LHA subunits in the heterozygous and homozygous conditions 
were only 30 + 6 % (n = 4, p < 0.01) and 16 + 3 % (n = 4, p < 0.001), respectively, supporting the 
hypothesis that mutant γ2L(R177G) subunits had impaired assembly and/or forward trafficking.  
Of note, these experiments also supported the prior observation made with flow cytometry that 
the R177G mutation decreased total γ2L subunit levels (Figure 3D).  Indeed, relative to the IBD 
of the wild-type γ2L subunit PNGase band (Figure 5A; wt lane F), IBDs of γ2L subunit PNGase 
bands (Figure 5A; het and hom lanes F) were decreased in both heterozygous (85.5 + 5% of wild-
type levels, n = 4, p < 0.05) and homozygous (61.0 + 9% of wild-type levels, n = 4, p < 0.05) 
conditions (Figure 5D). 
Maturation of mutant γ2L(R177G) subunits was further compromised in the presence of wild-
type γ2L subunits. 
The flow cytometry results demonstrated that the trafficking deficiency observed for 
mutant γ2L(R177G) subunits was exacerbated in the presence of wild-type γ2L subunits (Figure 
4).  To determine if this phenomenon reflected wild-type γ2L subunits having a competitive 
advantage over mutant γ2L(R177G) subunits at the level of the ER, we combined the specificity 
of the HA immunoblots for mature and immature γ2L subunit proteins with the differential 
epitope tagging paradigm and determined the relative maturity of wild-type γ2L and mutant 
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γ2L(R177G) subunits in the context of heterozygous expression.  This was accomplished by co-
transfecting α1 and β2 subunits with equivalent amounts of either γ2LHA and γ2L(R177G) 
(het[wt-HA] condition) or γ2L and γ2L(R177G)HA (het[RG-HA] condition) subunits.   
As in the previous section, each transfection condition produced two specific bands at 
molecular masses of 40 kDa and 45 kDa, corresponding to immature and mature γ2L subunits, 
respectively (Figure 6A).  To determine the relative contributions of wild-type and mutant 
subunits to total cellular levels in the heterozygous condition, the IBD of mature and immature 
bands were background-subtracted and summed.  The total IBD of HA-tagged wild-type subunits 
(het[wt-HA]; 22.2 + 1.4, n = 3) was greater than that of HA-tagged mutant subunits (het[RG-HA]; 
11.2 + 0.2, n = 3, p < 0.05) (Figure 6B).  Although not statistically significant, this trend was also 
present in the flow cytometry data (Figure 4B).  To determine the mature subunit fraction, the 
IBD of the 45 kDa band was divided by the summed IBD of the 45 and 40 kDa bands (Figure 6C).  
In the het[wt-HA] condition, the fractions of mature (54.1 + 2 %, n = 3) and immature γ2LHA 
subunits (45.6 + 2 %, n = 3) were similar.  However, in the het[RG-HA] condition, the fraction of 
mature γ2L(R177G)HA subunits (11.8 + 1 %, n = 3) was substantially lower than the fraction of 
immature γ2L(R177G)HA subunits (88.2 + 1 %, n = 3) (Figure 6B).  Moreover, the mature mutant 
fraction in the heterozygous condition was less than the mature mutant fraction in the 
homozygous condition (compare Figure 5C and 6C), supporting the conclusion that assembly 
and/or forward trafficking of mutant subunits was further compromised in the presence of wild-
type subunits. 
Mutant γ2L(R177G) subunits were degraded prior to assembly with other GABAA receptor 
subunits by ER associated degradation (ERAD). 
The results in the previous sections demonstrated that the R177G mutation decreased γ2L 
subunit surface levels.  This decrease was associated with retention of mutant γ2L(R177G) 
subunits in the ER.  However, the basis for the ER retention of mutant subunits remained unclear.  
236
0***
***
%
 o
f t
ot
al
 IB
D
45 kDa 40 kDa
het [wt-HA]
45 kDa 40 kDa
het [RG-HA]
60
40
20
80
100
LC
HA
A
C
het
[wt-HA]
het
[RG-HA] mock
50
37
100
B
0
het 
[wt-HA]
het 
[RG-HA]
20
15
10
25
5
To
ta
l I
BD
*
Figure 6.  Differential epitope-tagging was used to independently assess maturation of 
wild-type γ2L and mutant γ2L(R177G) subunits in the heterozygous transfection 
condition. 
A.  Western blots were performed on whole cell lysates from HEK293T cells transfected 
with heterozygous subunit combinations that included wild-type (“het[WT-HA]”; α1β2γ
2LHA/γ2L(R177G)) or mutant (“het[RG-HA]”; α1β2γ2L/γ2L(R177G)HA) γ2L subunits 
tagged with the HA epitope.  Staining of the Na+/K+ ATPase α chain was used as a loading 
control (visible at ~100 kDa).  As shown in Figure 5A, staining for the HA epitope yielded 
specific bands at ~45 kDa and ~40 kDa, and a non-specific band at ~50 kDa (evident by its 
presence in the lane from the “mock” transfection condition).  B.  The total HA-specific 
signal in each of the transfection conditions was determined by adding the IBDs of the 45 
kDa and 40 kDa bands.  C.  The relative contributions of the 45 kDa and 40 kDa bands in 
each transfection condition were determined by dividing the IBD of each band by the total 
IBD shown in Panel B.  * p < 0.05, *** p < 0.001 when compared to the het[WT-HA] 
condition.
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One possibility was that mutant γ2L subunits failed to form ternary receptors with coexpressed 
subunits.  Alternatively, ER retention could have been secondary to failed forward trafficking of 
assembled ternary receptors.  To explore these possibilities, transfected HEK293T cells were 
treated with 100 μg/ml cycloheximide (CHX) to prevent synthesis of GABAA receptor subunits.  
Then, the stability of surface and total cellular pools of wild-type and mutant γ2L subunits was 
compared to stability of partnering α1 subunits using flow cytometry. 
For both wild-type and homozygous mutant conditions, α1 and γ2LFLAG subunit surface 
levels were relatively stable during a four hour incubation in CHX (Figure 7A, B).  Similarly, 
total levels were also stable for α1 subunits in both wild-type and homozygous mutant conditions 
(Figure 7C).  In contrast, total levels of γ2LFLAG subunits declined over the four hour incubation 
period (Figure 7D).  The half-life of γ2L(R177G)FLAG subunits was only ~1 hour (total levels 
were reduced by 45.9 + 8% (n = 6) after 60 minutes), as compared to a half-life of ~3 hours for 
wild-type γ2LFLAG subunits (total levels were reduced by 44.4 + 10% (n = 9) after 180 minutes) 
(Figure 7D).  The observation that total, but not surface, levels of γ2LFLAG subunits declined in 
the presence of CHX indicated that the rapidly degraded fraction was localized intracellularly.  In 
addition, given the absence of associated change in α1 subunit levels, this rapidly degraded 
fraction likely represented an intracellular pool of “unassembled” γ2LFLAG subunits.  Moreover, 
since mutant γ2L subunits were degraded more rapidly than wild-type γ2L subunits, the results 
suggest that the R177G mutation decreased γ2L subunit stability prior to oligomerization with 
other GABAA receptor subunits.  Note that the different stabilities of α1 and γ2LFLAG subunits 
could not be attributed to the presence of the FLAG epitope, as α1FLAG subunit levels were similar 
at each time point to those of untagged α1 subunits when coexpressed with β2 and γ2L subunits 
(not shown). 
Multiple prior studies have demonstrated that GABAA receptor subunits retained in the 
ER, particularly those that are misfolded, are ultimately subjected to ERAD by the ubiquitin-
proteasome system (Gallagher et al., 2007).  To determine if this was also true for γ2L(R177G) 
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Figure 7.  Mutant γ2L(R177G)FLAG subunits were degraded more rapidly than wild-type 
γ2LFLAG subunits.
A, B.  Surface levels of α1 (Panel A) and γ2LFLAG (Panel B) subunits were stable over four 
hours in the presence of cycloheximide (CHX) both for wild-type (α1β2γ2LFLAG; black 
line) and homozygous mutant (α1β2γ2L(R177G)FLAG; grey line) transfection conditions.  
C, D.  Total cellular levels of α1 subunits (Panel C), but not γ2LFLAG subunits (Panel D), 
were stable over four hours in the presence of CHX for both wild-type and homozygous 
mutant transfection conditions.  The degradation rate was higher for mutant γ
2L(R177G)FLAG than for wild-type γ2LFLAG subunits.  *p < 0.05, ** p < 0.01 when com-
pared to Time 0 of same transfection condition.  ++ p < 0.01 when compared to the wild-
type condition at the same time point.
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subunits, cells were incubated with the proteasomal inhibitor, lactacystin, and the CHX assay 
described in the previous section was repeated.  Because lactacystin has previously been shown to 
require 60 minutes to reach maximal levels in cultured cells428, cells were preincubated with 10 
μM lactacystin before treatment with CHX.  In the presence of lactacystin, total wild-type 
γ2LFLAG subunit levels declined in a manner similar to that observed after incubation in CHX 
alone (Figure 8A).  In contrast, total levels of mutant γ2L(R177G)FLAG subunits did not decrease 
significantly after 240 minutes in the presence of lactacystin (Figure 8B).  Thus, while mutant 
γ2LFLAG subunits were subjected to ERAD, degradation of wild-type γ2LFLAG subunits was not 
proteasome-mediated. 
Absence of a basic amino acid at the 177 position of the γ2 subunit caused subunit misfolding. 
The observation that mutant but not wild-type γ2L subunits underwent ERAD suggested 
that the R177G mutation caused subunit misfolding.  To investigate this possibility, we 
performed sequence alignments, mutagenesis studies, and homology modeling of wild-type and 
mutant γ2 subunits.  Sequence analysis revealed that the R177 residue was conserved among γ2 
subunits of multiple species and basic residues also occupied this position in other γ subunits 
(Figure 9A).  In contrast, other GABAA receptor and Cys-loop family member subunits had polar 
and charged amino acid residues at homologous positions.  To determine if a basic residue was 
required at the 177 position in the γ2 subunit, other residues (glutamate (E), valine (V), and lysine 
(K)) were introduced at this position and coexpressed with α1 and β2 subunits.  Subunit subunit 
surface levels were then evaluated using flow cytometry (Figure 9B).  While surface levels of the 
γ2L(R177E)FLAG and γ2L(R177V)FLAG mutants were significantly reduced (41.1 + 2% and 49.2 + 
4% of wild-type levels, respectively; n = 7-10, p < 0.001), the γ2L(R177K) mutation produced no 
change in surface levels.  Thus, it appeared that normal surface trafficking of γ2 subunits required 
the presence of a basic residue at position 177. 
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Figure 8.  Proteasomal inhibition by lactacystin prevented degradation of mutant 
γ2L(R177G)FLAG, but not wild-type γ2LFLAG, subunits.
Total cellular expression of wild-type γ2LFLAG (Panel A) or homozygous mutant γ
2L(R177G)FLAG (Panel B) subunits when coexpressed with α1 and β2 subunits in HEK 
293T cells was evaluated by flow cytometry following treatment with cycloheximide 
either alone (CHX; solid line) or in the presence of lactacystin (L; dashed line).  ** p < 0.01 
when compared to Time 0 of same transfection condition.   + p < 0.05 when compared to 
the CHX-only condition at same time point.
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Interestingly, the R177 residue is located in a highly conserved region at the amino-
terminal end of β-strand 6 (Figure 9A).  Charged residues can contribute to the hydrogen bonding 
that is essential for for beta sheet stability429, 430, suggesting that loss of positive charge at this 
position could adversely affect protein structure.  Indeed, two informatics tools predicted that this 
point mutation would be damaging.  The SIFT (Sorting Intolerant from Tolerant) algorithm 431 
predicted that the R177G mutation would be damaging with a score of 0.03 (zero is most 
damaging), and the PolyPhen 2.0 algorithm432 predicted that the R177G mutation would be 
“possibly damaging” with a score of 0.888 (data not shown). 
To determine if the R177G mutation might alter the tertiary or quaternary structure of 
GABAA receptors, homology modeling of α1β2γ2 and α1β2γ2(R177G) isoforms was performed 
using the C. elegans glutamate-gated chloride channel structure as a template (Figure 9C, D) 159.  
The model predicted that R177 would form hydrogen bonds with T120 in β-strand 2 and W173 in 
β strand 5 (Figure 9C), but neither bond would be formed with G177 (Figure 9D).  Because the 
formation and stability of β-sheets is highly dependent upon hydrogen bonding between residues 
of adjacent β-strands, this loss would be expected to destabilize secondary and tertiary structure 
of γ2(R177G) subunits 433.  
 
Discussion 
The γ2 subunit mutation, R177G, decreased GABA-evoked current amplitudes by decreasing 
GABAA receptor surface levels. 
In this study, we investigated the pathogenesis of FS by determining how the γ2 subunit 
mutation, R177G, altered GABAA receptor biogenesis and physiological properties.  Our results 
demonstrated that α1β2γ2L GABAA receptors containing mutant γ2(R177G) subunits had smaller 
peak current densities, which occurred not because of changes in receptor biophysical properties, 
but rather because of decreases in receptor surface expression.  This, in turn, resulted from ER 
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Figure 9.  R177 was highly conserved among GABAA receptor γ2 subunits and formed 
hydrogen bonds with neighboring β-strands.
A. The sequences of GABAA receptor subunits from various species and families were 
aligned and secondary structure was determined by homology to the glutamate-gated chlo-
ride channel (GluCl).  Residues homologous to human γ2 subunit R177 are bolded and 
highlighted in gray.  Local secondary structure elements are indicated below the alignment.  
B. Surface levels of R177 mutant γ2LFLAG subunits (R177V, R177E, and R177K) were 
evaluated using flow cytometry.  C. Homology modeling of α1β2γ2 receptors was 
performed using the GluCl structure as a template.  The image illustrates a portion of the 
γ2 subunit N-terminal domain including (from left to right) beta strands 5, 6, and 2.  Hydro-
gen bonds among these sheets are indicated by black dashed lines, and the hydrogen bonds 
disrupted by the R177G mutation are indicated by red dashed lines.  The R177 residue is 
colored orange.  D. Homology modeling of α1β2γ2(R177G) receptors was performed and 
presented as in panel C.
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retention of misfolded mutant γ2(R177G) subunits.  The misfolded subunits underwent ERAD, as 
previously demonstrated for other GABAA receptor mutations associated with IGEs100, 307, 395.  
Ultimately, the smaller current density of α1β2γ2L(R177G) receptors is predicted to decrease 
GABAergic phasic inhibition and lower the seizure threshold by promoting neuronal 
hyperexcitability.   
Mutant γ2L(R177G) subunits were trafficked to the cell surface less efficiently in the 
heterozygous than in the homozygous condition. 
Surface expression of α1β2γ2L receptors was significantly reduced by “homozygous” 
expression of γ2L(R177G) subunits.  However, the trafficking deficit caused by the R177G 
mutation was considerably more severe in the presence of wild-type γ2 subunits (i.e., γ2L(R177G) 
expression levels were much lower in heterozygous than homozygous conditions), emphasizing 
the importance of evaluating the heterozygous condition when characterizing the effects of 
disease-causing mutations.  The most likely explanation for this phenomenon was that wild-type 
γ2 subunits possessed a competitive advantage over mutant γ2(R177G) subunits for 
oligomerizing with partnering subunits, forward trafficking once assembled into pentamers, 
and/or remaining on the cell surface.  The increased immature fraction of mutant γ2(R177G) 
subunits in the heterozygous condition suggested that this competitive advantage was present at 
the level of the ER.  Because receptor assembly occurs in the ER membrane, this could have 
reflected either preferential incorporation of wild-type γ2 subunits into ternary receptors or 
preferential recruitment of wild-type α1β2γ2 receptors into the secretory pathway.  However, the 
former seemed more likely since the R177G mutation appeared to destabilize the “unassembled” 
pool of γ2 subunits, consistent with decreased oligomerization efficiency. 
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The γ2L subunit R177G mutation altered the subunit composition and/or stoichiometry of 
GABAA receptors expressed on the cell surface. 
In both heterozygous and homozygous mutant conditions, whole cell currents were 
smaller than those of the wild-type condition.  While this was associated with lower surface levels 
of the γ2 subunit, surface levels of the α1 and β2 subunit surface levels were similar or higher, 
respectively.  Because neither α1 nor β2 subunits can traffic to the cell surface when expressed 
individually81, 276, and the putative stoichiometries of α1β2 and α1β2γ2 receptor isoforms are 
2α:3β and 2α:2β:1γ, respectively340, a likely explanation for these changes in surface expression 
involves the formation of a mixed population of binary α1β2 and ternary α1β2γ2L receptors in 
the presence of the γ2L(R177G) subunit.  In other words, the mutant subunit seemed to 
oligomerize less efficiently with α1 and β2 subunits, allowing a β2 subunit to take the place of the 
mutant γ2 subunit. 
We did not observe changes in the macroscopic current kinetics that would be consistent 
with the presence of α1β2 receptors on the cell surface (e.g., slower rise time, increased fast 
desensitization, or slower deactivation), but it should be noted that αβ receptor whole cell currents 
are between one sixth and one tenth the amplitude of αβγ receptor whole cell currents, depending 
on the subunit subtypes included168, 434.  Consequently, unless α1β2 receptors constituted a 
significant portion of the surface pool, their contribution to the ensemble current would most 
likely be masked by the presence of α1β2γ2 receptors.  The markedly different sensitivities of 
α1β2 and α1β2γ2 receptor peak currents to Zn2+ has been used to determine the contribution of 
α1β2 receptors to the peak current419, but this approach is inherently confounded by the relatively 
slow rise time of α1β2 receptor currents 434. 
Of note, the stoichiometries of α1β2 and α1β2γ2 receptors have been studied primarily 
with concatenated subunits340.  Considering the known limitations of investigating subunit 
stoichiometry with the concatenated-subunit approach435, and the fact that a subset of neuronal 
GABAA receptors has been suggested to contain multiple γ subunits179, 436, 437, it is also possible 
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that the R177G mutation reduced surface levels of the γ2 subunit not by introducing an α1β2 
receptor population, but rather by exchanging receptors containing multiple γ subunits for those 
containing a single γ subunit.  This possibility will need to be addressed in future studies. 
Loss of the required basic residue at the 177 position in the γ2 subunit may impair stability of 
β-sheets 
Mutagenesis studies demonstrated that normal γ2 subunit surface expression required a 
basic residue at position 177.  Although the subunit requirements for beta sheet formation are less 
well defined than those for alpha helix formation, it has been demonstrated that arginine and 
lysine residues are over-represented at the N-terminal cap (beginning) of β-strands, while glycine 
may act as a sheet terminator433.  Although our models did not predict gross structural 
rearrangements, the location and relative sheet-forming propensities of the wild-type and mutant 
amino acids suggest a potential mechanism for misfolding of mutant γ2(R177G) subunits.  
Finally, all three γ2 subunit residues involved in the loss of hydrogen bonding (T120, W173, and 
R177) lie in regions that have been shown to contribute to α1-γ2 subunit interface formation88, 92.  
Structural disruption at these areas might impair subunit oligomerization and thus contribute to 
the apparent changes in stoichiometry. 
What role does the γ2 subunit R177G mutation play in the pathogenesis of FS, and possibly, 
IGEs? 
As has been demonstrated for other epilepsy-associated mutations in GABAA receptor 
subunits, the R177G mutation decreased GABAA receptor current amplitudes, an effect predicted 
to decrease the level of GABAergic inhibition and therefore to promote neuronal 
hyperexcitability.  That being said, it remains unclear why the clinical phenotype of the R177G 
mutation was limited to FS.  Although GABAA receptor surface expression levels have been 
reported to be temperature-sensitive in the context of other mutations in the γ2 subunit395, this 
was not observed for the R177G mutation (data not shown).  Interestingly, precipitation of FS in 
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rats has been linked to respiratory alkalosis438.  Since the sensitivity of α1β2γ2L receptors to 
GABA is inversely related to ambient pH439, one possibility is that the lower level of GABAergic 
inhibition imparted by the R177G mutation coupled with a change in the intracortical pH further 
reduced the seizure threshold.  However, it should be emphasized that the R177G mutation may 
have only appeared to have a relatively homogeneous FS phenotype because of the small 
pedigree in which it was identified421.  While most of the known GEFS+ mutations are associated 
with a heterogeneous group of epilepsies, most were also identified in much larger pedigrees.  As 
such, it is possible that the R177G mutation could further impair neuronal inhibition in a larger 
population.  
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CHAPTER VI 
CONCLUSIONS 
 
Summary of experimental chapters 
This dissertation investigated the assembly, trafficking, heterogeneity, and function of 
GABAA receptor isoforms that contained wild-type subunits and/or subunits bearing epilepsy-
associated point mutations.  Faced with two daunting problems – poor knowledge regarding 
assembly of the myriad potential GABAA receptor isoforms and no way to determine which 
epilepsy-associated mutations might be worth studying in animals – we turned to the high-
throughput approach of heterologous expression combined with flow cytometry.  We created 
cDNA constructs encoding most GABAA receptor subunit subtypes, added epitope tags as 
necessary, transfected various combinations into HEK293T cells (which do not express 
endogenous GABAA receptor subunits), and quantified expression patterns and levels using flow 
cytometry.  To confirm that expressed subunits were incorporated into receptors and to gain 
insight into their arrangement, we employed fluorescence resonance energy transfer (FRET), 
which allowed us to determine subunit adjacency.  After collecting basic information about wild-
type and mutant receptors, we characterized them further using techniques including traditional 
biochemistry, electrophysiology, kinetic analysis, and homology modeling.   
For even the most widely studied isoforms (α1β2, α1β2γ2LHA and α1β2δHA), we found 
remarkable properties that have not been reported previously (Chapter II, Chapter III).  In Chapter 
II, we demonstrated that concatenated subunit constructs are not ideal for determining receptor 
stoichiometry and that differential tagging may constitute a better method.  This approach 
suggested that there was not a homogeneous population of α1β2 receptors; rather, they seemed to 
be a mixture of 2α:3β and 3α:2β isoforms.  This phenomenon also occurs in α4β2 nAChRs, where 
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the 3α:2β isoform preferentially assembles when α4 subunit cDNA is transfected in molar excess 
(and vice versa).  Interestingly, α1β2 GABAA receptors did not behave similarly to α4β2 nAChRs; 
if anything, excess β subunit expression favored formation of 3α:2β isoforms.  The exact ratio of 
α1 to β2 subunits remains unsettled, but it was clear that, whatever that ratio may be, it was 
altered little by subunit cDNA transfection ratios.  However, the α1 subunit was clearly “rate-
limiting” with regard to surface expression levels.  Both α1 and β2 subunit surface expression 
increased proportionally with α1 subunit cDNA levels, but surface expression of both subunits 
declined when β2 subunit cDNA was transfected in molar excess.  Finally, FRET patterns 
supported the conclusions regarding stoichiometry that were drawn from differential tagging.  
FRET occurred between individual α1 subunits, individual β2 subunits, and α1 and β2 subunits.  
It is universally agreed that there are two GABA binding sites per receptor; because these occur at 
β-α subunit interfaces, alternating α1 and β2 subunits must occupy four of the five positions in the 
receptor pentamer.  For both α1-α1 and β2-β2 FRET to occur within a pentamer, the remaining 
position must contain an α1 subunit in some receptors and a β2 subunit in others.  Interestingly, 
β2-β2 FRET was essentially eliminated when a γ2 subunit was coexpressed, but α1-α1 FRET 
persisted (albeit at lower levels).   
The minimal requirement for GABA binding and surface expression is coexpression of 
both α and β subunits, but most GABAA receptor isoforms in vivo are thought to contain a third 
(non-α, non-β) subunit.  Thus in Chapter III, we used similar strategies to address the assembly of 
α1β2γ2L and α1β2δ receptor isoforms and found similarly intriguing results.  For instance, it 
appeared that both γ2LHA and δHA subunits were incorporated at the expense of β2 subunits and 
that δHA subunits were incorporated more efficiently, perhaps due to the fact that they were much 
more stable than γ2LHA subunits.   
In Chapters IV-VI, we used these and other techniques to characterize the effects of three 
epilepsy-associated point mutations on GABAA receptor assembly and function.  The GABRB3 
mutation, G32R (Chapter IV), was associated with childhood absence epilepsy and was formerly 
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proposed to reduce receptor current density by increasing glycosylation of β3 subunits.  However, 
we demonstrated that while the mutation did indeed reduce current density and increase 
occupancy of an adjacent N-glycosylation site, the latter phenomenon did not cause the former.  
Rather, the G32R mutation disfavored incorporation of γ2L subunits, likely by altering 
intersubunit salt bridges, and also made α1β3γ2L receptors more likely to enter short open states.  
The GABRA6 variant, R46W (Chapter V), was also associated with childhood absence epilepsy.  
The mutated arginine is located in a region homologous to the region of the well-studied γ2 
subunit R82Q mutation, which causes ER retention of mutant γ2 subunits and thereby reduces 
αβγ2 receptor currents.  We found that the R46W variant drastically reduced current density and 
changed kinetic properties of both α6β2γ2L and α6β2δ receptor isoforms. This was partially 
attributable to a decrease in surface receptor levels and/or changes in receptor stoichiometry.  
Interestingly, it appeared that the R46W variant altered stoichiometry of α6β2γ2L receptors but 
simply reduced overall surface expression of α6β2δ receptors, indicating that it is unwise to 
assume that a mutant subunit will have identical effects in different receptor isoforms.  Finally, in 
the “heterozygous” condition, wild-type α6 subunits were preferentially incorporated into surface 
receptors, suggesting that the mutation might alter subunit structure such that α6(R46W) subunits 
had lower affinity for partnering β2, γ2L and/or δ subunits.  The GABRG2 mutation, R177G 
(Chapter VI), was associated with a more diverse epilepsy phenotype, generalized epilepsy with 
febrile seizures plus (GEFS+).  Both “heterozygous” α1β2γ2L/γ2L(R177G) receptors and 
“homozygous” α1β2γ2L(R177G) receptors had reduced current density but no apparent changes 
in macroscopic current kinetics.  Similar to α6(R46W) mutant subunits, γ2L(R177G) mutant 
subunits were preferentially excluded from receptors in the “heterozygous” expression condition.  
The majority of γ2L(R177G) subunits were not trafficked beyond the endoplasmic reticulum and 
were then degraded by the proteasome.  We could not conclusively establish cause and effect; 
that is, mutant subunits could have been sent to the proteasome because they were excluded from 
pentamers (an established fate of non-incorporated subunits), or they could have been targeted for 
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degradation (perhaps due to misfolding) and thus have been unavailable for incorporation.  The 
R177 residue is located in a highly conserved region of the N-terminal domain, in a region that is 
likely to contribute to α-γ subunit interfaces.  Mutagenesis indicated that positive charge at this 
position was required for normal subunit surface expression, but homology modeling did not 
identify a particular intersubunit salt bridge formed or broken by the point mutation.  However, 
the R177G mutation did disrupt salt bridges between neighboring β-strands of the γ subunit, 
which could destabilize the mutant protein.   
High-throughput assessment of receptor expression: promises and limitations 
We anticipated that we would be able to characterize systematically and efficiently a 
substantial portion of the possible GABAA receptor isoforms.  Within a single experiment, it is 
quite feasible to test thirty subunit combinations and to stain for all transfected subunits, even in 
ternary combinations.  Prior reports suggest that many subunit combinations would not yield 
surface expression, so these preliminary screenings would reduce substantially the array of 
isoforms to be studied.  The list of combinations yielding surface expression could be narrowed 
further by reviewing subunit coexpression patterns in vivo.  Subsequently, receptor stoichiometry 
and subunit adjacency could be determined using differential tagging and FRET, respectively. 
We remain confident that this approach will eventually succeed in providing copious 
amounts of information regarding receptor assembly.  Unfortunately, the scope of this project was 
reduced somewhat by technical limitations, mostly relating to antibodies.  Obviously, expression 
cannot be assessed without either subunit-specific antibodies or epitope tagging.  The number of 
commercially available GABAA receptor subunit antibodies continues to increase, but we have 
discovered that many do not detect specific bands even on Western blots.  Even fewer are suitable 
for flow cytometry; many antibodies are raised against the poorly-conserved subunit intracellular 
loops and thus cannot be used to assess surface expression, and high nonspecific staining impairs 
quantification.  Consequently, we employed epitope tagging, but we remain concerned about this 
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approach.  It is almost universally claimed that insertion of any epitope tag between the fourth 
and fifth amino acids of mature subunits will not affect trafficking or function of GABAA 
receptors81, 130, 334.  However, in the course of these studies we have found that fluorescent 
proteins can cause abnormal subunit dimerization, that partnering subunit expression levels 
differed between wildtype and FLAG-tagged subunits, and that various tags altered receptor 
kinetics (data not shown).  After careful evaluation, we determined that the HA and myc tags 
were the least disruptive to receptor assembly and function (though the FLAG epitope was 
surprisingly well-tolerated on γ subunits) and thus preferentially used those tags.  Differential 
epitope tagging is a promising approach for determining receptor stoichiometry, but we admit that 
all such results should be thoroughly controlled and interpreted with caution due to the potentially 
disruptive effects of epitope tags.  Another antibody-related technical limitation (albeit one that 
should be tractable) concerns direct conjugation of antibodies and fluorophores.  High-throughput, 
quantitative FRET is invaluable for determining direct subunit adjacency.  However, valid results 
require that antibodies be directly conjugated to fluorophores.  Excellent conjugation kits are 
commercially available, and we used them successfully to conjugate many antibodies.  To our 
dismay, however, several antibodies proved impossible to conjugate efficiently despite meeting 
all technical specifications.  For this reason, the FRET studies presented here are limited to the 
α1β2, α1β2γ2L, and α1β2δ receptor isoforms (Chapters II and III).  
The “alpha” of GABAA receptor assembly 
One of the most intriguing patterns we observed was that α subunits appear to be a 
“constant” in many contexts.  The cDNA levels of α1 subunits determined surface expression 
levels of both α1 and β2 subunits (Chapter II); α1 subunit levels remained stable while β2 
subunits were apparently replaced by γ2L or δ subunits (Chapter III); and α subunit levels were 
not affected by mutations in β3 (Chapter IV) or γ2L (Chapter VI) subunits.  Furthermore, α1-α1 
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subunit FRET was not wholly abolished by γ2L or δ subunit incorporation.   Taken together, 
these paint a fascinating but puzzling picture of α subunit regulation of receptor assembly. 
Although it is evident that α subunits play a critical, central role in pentamer formation 
and trafficking, it has been very difficult to establish a mechanism – or even to enumerate exactly 
what that role might be.  As previously discussed, FRET patterns indicated that α1β2 receptors 
exist as a mixture of 3α:2β and 2α:3β populations, and differential epitope tagging suggested that 
the 3α:2β population would predominate.  Confusingly, despite the α subunit advantage, it was β 
subunit levels that declined when γ2L or δ subunits were introduced.   Finally, at peak γ2L or δ 
expression levels, some α1-α1 (but not β2-β2) subunit adjacency remained.  There are a few 
potential explanations for these phenomena; admittedly, all are somewhat confusing and unlikely.   
First, we need to consider how these “extra” α subunits were arranged.  Our data 
indicated that many α subunits were present on the cell surface but did not establish conclusively 
how those subunits were organized – e.g., as monomers, homomultimers, or components of fully 
assembled pentameric receptors.  Although it is possible that some α subunits were present as 
monomers, the strong α-α FRET patterns demonstrated that the majority of surface α subunits 
must be adjacent to at least one other α subunit.  However, this does not prove that all adjacent α 
subunits were contained within 3α:2β (GABA-responsive) receptor pentamers; they could be 
assembled into homopentamers or lower-order homomultimers (although it is important to note 
that sucrose density centrifugation experiments indicated that nearly all α1 subunits were located 
in pentamers when α1 and β3 subunits were coexpressed)329.  It was clear, however, that very few 
α1 subunits reached the cell surface in any arrangement when α1 subunit cDNA was transfected 
in isolation (Chapter III, Figure 1).  Thus, if α1 subunits existed in homomultimers when α1 
subunit cDNA was co-transfected with β2 (± γ2L or δ) subunit cDNA, β2 subunits would have to 
somehow promote the formation of α1 homomultimers.  Particularly in light of the fact that 
excess β2 subunit expression did not significantly alter the α1/β2 subunit surface level ratio, this 
seems unlikely.   However, we cannot yet exclude the unsettling possibility that a much larger α1 
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homopentamer population existed, but its contribution was underestimated because antibodies 
were sterically hindered from binding to all α1 subunits when they were in their native 
conformation.  This could explain why the α1HA/β2HA subunit level ratio obtained using flow 
cytometry was substantially lower than the ratio obtained using denaturing SDS-PAGE and 
immunoblotting.   
It is also possible that with α1 and β2 subunit co-transfection, all α1 subunits on the cell 
surface were in fact incorporated into 3α:2β or 2α:3β receptor pentamers.  In light of the changes 
in expression, function, and adjacency (Chapter III, Figures 3-5) associated with transfecting 
increasing amounts of γ2L or δ subunit cDNA, this possibility has a few implications.  First, 
because there were ranges of γ2L or δ subunit cDNA that produced decreases in β2 subunit 
expression but no change in α1 subunit expression, γ2L and δ subunits must preferentially replace 
the third β2 subunit of the 2α:3β pentamers.  This theory is problematic for a few reasons.  First, 
the functional signature of the persistent 3α:2β receptor population would have to be completely 
obscured by the αβγ/αβδ receptor population.  This could occur because the αβγ/αβδ receptor 
populations produce far larger currents than the remaining αβ receptors or because the 3α:2β 
receptors are nonfunctional.  The former possibility is somewhat plausible, particularly for αβγ 
receptors, and to our knowledge the second has never been proposed.  That said, one of the 
studies that addressed receptor stoichiometry using functional assessment of the receptors formed 
by concatenated subunits concluded that 3α:2β receptors did not exist because the β2-α1 and α1-
β2 tandems did not produce currents when coexpressed with α1 subunits328.  (Of course, another 
group used the same technique but found precisely the opposite result116, which was one reason 
we began the studies presented here.)  
Finally, it is possible that the “extra” α subunits have a different role entirely.  A recent 
study proposed that the short splice variant of γ2 subunits (γ2S) can act as an “external modulator” 
of receptor function by binding to the outside of a pentameric receptor, essentially serving as an 
accessory protein337.  If α1 subunits could assume a similar role, many of the phenomena that we 
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observed could be explained.  The “accessory” α subunits could promote receptor assembly and 
forward trafficking, which would account for the fact that α1 (but not β2) subunit overexpression 
increases both α1 and β2 subunit surface trafficking (Chapter II, Figure 4).  If the accessory α1 
subunits could not be replaced by β2 subunits, they could essentially “buffer” α1 subunit levels 
such that overall α subunit levels appeared to remain constant while γ2L or δ subunits replaced α1 
subunits in 3α:2β pentamers and β2 subunits in 2α:3β pentamers.  Furthermore, they would 
account for persistent α1-α1 subunit FRET in the presence of an otherwise apparently 
homogeneous α1β2γ2L/α1β2δ receptor population.  As mentioned, sucrose density centrifugation 
indicated that all α subunits were in pentamers, but in principle even that could be reconciled with 
the accessory subunit theory if the interaction between the pentamer and the accessory subunits is 
relatively weak and was disrupted during the process of protein purification.  That said, although 
this is an appealing theory, neither we nor the group reporting accessory γ2S subunits have 
provided any direct evidence that individual GABAA receptor subunits can bind to the outside of 
GABAA receptor pentamers.   Ultimately, atomic force or electron microscopy would be required 
to advance this hypothesis beyond mere speculation. 
The results discussed thus far have made it abundantly clear that α1 subunits guide 
GABAA receptor assembly in some fundamental way.  However, we have not determined if the 
other five α subunits behave in a similar manner.  Although α1 is the most abundant α subunit 
subtype in adult whole brain, each of the other α subunits predominates in particular brain regions 
or at particular times during development (Chapter I).  As such, it will be interesting to repeat 
many of our experiments using other subtypes. 
Finally, we had hoped to gain insight into the first steps of GABAA receptor assembly -- 
the initial oligomerization patterns of newly-synthesized subunits.  When α1, β2, and γ2 subunits 
were coexpressed, assembly intermediates were not successfully detected.  However, if we could 
initiate assembly, harvest cells at several time points shortly thereafter, and stain for intracellular 
FRET, we could determine if, for instance, α1 homomers form before other homomers or 
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heteromers.  Thus, we have conducted pilot studies using inducible expression systems.   The tet-
on system worked poorly; significant subunit expression was detected in the absence of inducer.  
The RheoSwitch system has been more promising, but the inducing ligand is no longer 
commercially produced.  Despite these setbacks, we hope that future optimization of inducible 
expression systems will allow us to determine the order of GABAA receptor subunit assembly and 
potentially determine why α subunits seem to direct receptor assembly. 
Assembly of ternary GABAA receptor isoforms: α1β2γ2, α1β2δ, and beyond 
The levels of both γ2LHA and δHA subunit protein obtained from various amounts of 
subunit cDNA were quite surprising.  Many groups who study GABAA receptors using 
heterologous expression have adamantly maintained that subunits not essential for surface 
trafficking (i.e., non-α, non-β subunits) must be transfected in molar excess in order to eliminate 
the binary (αβ) receptor population and to obtain a homogeneous ternary (e.g., αβγ) receptor 
population.  Intuitively, this approach seems reasonable: we know that αβ receptors assemble 
efficiently in fibroblasts and oocytes, and two separate studies have used different approaches to 
identify αβ receptors in rodent brain.  Sequential co-immunoprecipitation indicated that up to 
50% of all α4 subunit-containing receptors in rat brain membranes did not contain γ1-3 or δ 
subunits281.  Of course, this does not prove that these are binary receptors; they could actually 
contain γ and δ subunits that failed to immunoprecipitate, or they could be ternary receptors 
containing ε/θ/ρ subunits (though the low expression of those subtypes makes the latter 
possibility somewhat unlikely).  Electrophysiology provided more direct evidence for the 
existence in vivo of binary αβ receptors.  While αβγ receptors have primary conductances around 
25-28 pS and are not inhibited by Zn++, αβ receptors have primary conductances of approximately 
11 pS and are inhibited strongly by Zn++.  Somata of cultured hippocampal pyramidal cells 
produced Zn++-sensitive 11 pS single-channel currents282.  Although it was not directly 
demonstrated, it is highly unlikely that these neurons would express no γ or δ subunits.  Thus, it 
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stands to reason that αβ receptors might assemble efficiently enough to exclude subunits of other 
classes unless those subunits are present at levels capable of outcompeting α-β subunit 
association.  Our studies, however, indicated that equivalent amounts of subunit coding sequences 
actually yield excess γ2L and δ subunit protein.  Remarkably low δ subunit cDNA levels were 
required to produce peak δ subunit expression, and even γ2L subunits were not produced at 
strictly linear ratios.  For instance, 0.3 μg of γ2LHA subunit cDNA produced 51.2 ± 11.3 % of the 
protein levels produced by 1 μg of γ2LHA subunit cDNA.  It should be noted that this 
phenomenon does not seem to be restricted to heterologous expression systems; γ2 subunit 
heterozygous knockout mice had only a 20% reduction in γ2 subunit protein compared to 
wildtype mice.  A simple explanation for this, of course, would be that most αβγ pentamers 
contain two α and β subunits but only one γ subunit and thus an equimolar subunit gene dose 
provides excess γ subunit protein.  However, it will be interesting to determine if intersubunit 
affinity and/or receptor-associated proteins might play a role as well. 
As was the case for binary αβ receptors, we have presented ternary receptor assembly 
studies with only a limited number of the available GABAA receptor subunits, and our results 
may not generalize to other subunit subtypes or classes.  For instance, it appeared that the 
difference in γ2LHA and δHA subunit “potency” and degradation rates were intrinsic properties of 
the subunits themselves.  However, it will be interesting to see if γ2L/δ titrations produce similar 
results when α4 subunits (which usually pair with δ subunits in vivo) are expressed in place of α1 
subunits (which usually pair with γ subunits in vivo).  In this case, it is possible that α4 and α1 
subunits have different intersubunit binding affinities and that receptor assembly could affect the 
stability of γ2 and δ subunits differently.   
In addition to demonstrating that very different amounts of γ2L and δ subunit cDNA 
were required to produce similar protein levels, the γ2L/δ  subunit titration experiments clearly 
showed that as γ2L or δ subunit levels increased, β2 subunit levels declined more than α1 subunit 
levels, suggesting that γ2L and δ subunits replaced β2 subunits.  Once again, however, different 
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subunits may produce different results – if β1/β3 subunits replace β2 subunits, or if ε/θ/π subunits 
replace γ2L/δ subunits, expression patterns may be very different.  In fact, considering the 
reported properties of some of these subunits, it might be more surprising if expression patterns 
remained the same.   Unlike β2 subunits, both β1 and β3 subunits can reach the cell surface when 
transfected alone81, 90, 440; ε subunits have been reported to do the same and to substitute for α, β, 
or γ subunits101, 441; and remarkably little is known about θ or π subunit assembly.  We did in fact 
observe diverse assembly patterns when we conducted preliminary studies with some of these 
combinations.  When we substituted β3 subunit cDNA for β2 subunit cDNA in the γ2LHA subunit 
transfection experiments, we found that β3 levels did not drop nearly as dramatically; rather, both 
α1 and β3 subunit surface levels remained stable through equimolar α1:β3:γ2L subunit cDNA 
transfection (Figure 1A).  However, this does not necessarily mean that ternary α1β3γ2L and 
α1β2γ2L receptors have different stoichiometries, because β3 homomers may exist even when 
other subunits are transfected.     
We also expressed ε and π subunits in the presence of α1 and β2 subunits.  Results 
indicated that ε subunits behaved similarly to δ subunits; that is, both α1 and β2 subunit levels 
were much lower with equimolar α1β2ε transfection than with α1β2 transfection, but β2 levels 
decreased more than α1 levels (Figure 1B).  In contrast, both α1 and β2 subunit levels dropped as 
π subunit levels increased (Figure 1C).  The latter was particularly surprising, because π subunit 
surface expression levels were particularly low; in fact, they were nearly undetectable if less than 
0.3 μg of πHA subunit cDNA was transfected.   It should be noted that these results are 
preliminary and that further work will be required to truly determine the assembly patterns of ε, π, 
and θ subunits.  In particular, it will be informative to see if αβε, αβπ, and αβθ receptors have 
FRET patterns similar to those of αβγ and αβδ receptors. 
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Figure 1. Expression patterns of other GABAA receptor isoforms
A. HEK293T cells were transfected with 1 μg each of α1 and β3 subunit cDNA and various 
amounts of γ2L subunit cDNA and subunit surface expression levels were measured using 
flow cytometry.  Surface levels of α1 (black circles) and β3 (grey squares) subunits were 
normalized to levels at 0 μg γ2L subunit cDNA, and γ2L (grey triangles, dotted line) 
subunit levels were normalized to levels at 1 μg γ2L subunit cDNA.  B. HEK293T cells 
were transfected with 1 μg each of α1 and β2 subunit cDNA with or without 1 μg ε subunit 
cDNA.  Surface levels of α1 (black) and β2 (grey) subunits were measured using flow 
cytometry.  C. HEK293T cells were transfected with 1 μg each of α1 and β2 subunit cDNA 
and various amounts of � subunit cDNA and subunit surface expression levels were 
measured using flow cytometry.  Surface levels of α1 (black circles) and β3 (grey squares) 
subunits were normalized to levels at 0 μg � subunit cDNA, and � (grey triangles, dotted 
line) subunit levels were normalized to levels at 1 μg � subunit cDNA.
259
Rules were made to be broken: β3 and ε subunits 
By reaching the cell surface as homomers, β3 and ε subunits already break the 
fundamental rules of assembly established in Chapters II and III.  However, their unusual 
properties extend beyond their ability to forward traffic in the absence of partnering subunits.  As 
shown in Figure 1A, β3 subunit levels did not drop as γ2L subunit levels increased to equimolar 
levels.  Additionally, β3γ2 heteromers were reportedly expressed on the cell surface90.  To 
determine if β3 subunits could form heteromultimers with other subunit subtypes, we measured 
surface levels of HA-tagged subunits when expressed alone or together with β3 subunits.  We 
found that β3 subunit coexpression increased the surface expression of nearly all tested subunits 
(Figure 2A).  Unsurprisingly, α subunit surface levels increased most dramatically, but γ2, δ, ε, 
and π subunit surface expression clearly increased as well.  Thus, it seems probable that β3 
subunits can oligomerize (and likely form pentamers) with most other subunit subtypes, thereby 
permitting forward trafficking in the absence of α subunits.   However, future FRET and sucrose 
density centrifugation studies would be necessary to confirm this hypothesis.    
It might seem that the indiscriminate oligomerization and trafficking induced by β3 
subunits is simply an experimental curiosity because these atypical oligomers would cease to 
exist if α subunits were coexpressed.  Interestingly, when comparing the properties of the three β 
subunits, we discovered indirect evidence that β3 subunits may produce unusual isoforms even 
when canonical αβγ receptors could assemble.  We coexpressed α1 and γ2LHA subunits together 
with β1, β2 or β3 subunits and detected surface α1 and HA levels (Figure 2B).  Because the β 
subunits were not epitope-tagged, their levels could not be compared directly, but we used an 
antibody capable of detecting both β2 and β3 (but not β1) subunits to confirm that they were 
properly expressed.    The antibody did stain cells transfected with either β2 or β3 subunits (grey 
bars); although β3 subunit levels seemed much higher, it should be noted that the antibody 
epitope differs slightly between the two subunits, so relative quantification may be inaccurate.  
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Figure 2. β3 subunits promote GABA
A
 receptor heterogeneity.
A. Flow cytometry was used to measure surface levels of HA-tagged GABAA receptor 
subunits (x-axis) in HEK293T cells transfected with 1 μg of each subunit cDNA with 
(grey) or without (black) 1 μg of β3 subunit cDNA.  B. Flow cytometry was used to 
measure surface levels of α1 (black) β2/3 (dark grey) or γ2LHA (light grey) subunits in 
HEK293T cells transfected with 1 μg each of α1 and γ2LHA  subunit cDNAs together with 
β1 (left), β2 (center), or β3 (right) subunit cDNA.
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Surface α1 subunit levels (black bars) were similar with any of the three β subunits, but 
surprisingly γ2LHA levels (white bars) were significantly higher when coexpressed with β3 
subunits rather than β1 or β2 subunits.  The discrepancy between relative α1 and relative γ2LHA 
levels indicates that β3 subunit expression cannot simply produce more receptors with the same 
stoichiometry as α1β1γ2LHA and α1β2γ2LHA receptors; if so, the α1 and γ2LHA levels should rise 
proportionately.  Considering that γ2LHA subunits could not reach the cell surface alone (Chapter 
III, Figure 1) but could do so in the presence of β3 subunits90, the simplest explanation is that a 
substantial number of β3γ2LHA heteromers persisted even when α1 subunits were available.   
This raises several questions that remain to be answered.  First, would α1 subunit cDNA 
levels be the “rate-limiting” component of α1β3 receptor assembly, or would the β3 subunit’s 
inherent forward trafficking abilities essentially dictate surface expression levels?  Second and 
more importantly, if receptor isoforms such as β3γ2LHA can exist in the presence of α subunits, 
could they also exist in vivo?  The former question should be relatively easy to answer; the α1β2 
subunit titrations (Chapter II, Figure 4) could simply be repeated using β3 rather than β2 subunit 
cDNA.  The second question, though, presents considerably more problems.  Historically, native 
receptor  isoforms have been identified by sequential co-immunoprecipitation57.  To identify 
native β3γ2 receptors with this method, it would be necessary to immunoprecipitate all α subunit 
subtypes expressed in a brain region and then co-immunoprecipitate β3 and γ2 subunits.  Even if 
α subunit immunoprecipitation were perfect, this would prove only that β3γ2 oligomers exist, not 
that they were pentamers expressed on the cell surface.  To establish that native β3 
homopentamers exist, all non-β3 subunits would need to be immunoprecipitated before searching 
for pentamers.  In summary, identifying these isoforms in brain tissue using established 
techniques would require (1) isolation of surface protein, (2) repeated immunoprecipitation, (3) 
sucrose density centrifugation to identify pentamers, and (4) a final 
immunoprecipitation/immunoblot to confirm that the correct subunits were found in the 
pentamers.  Obviously, it would be arduous or even impossible to conduct these studies.  
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However, given the remarkably efficient surface expression of β3 homomers and β3γ2 
heteromers in transfected cells, it would be extremely interesting to search for them in vivo if a 
more efficient method is invented.   
In the absence of a more feasible method for identifying noncanonical GABAA receptor 
isoforms in brain, other heterologous experiments could be used to address how such isoforms 
might assemble – or be prevented from doing so.  If non-α1 subunit-containing/β3 subunit-
containing receptors do not exist in vivo, some neuronal regulatory mechanism must inhibit their 
formation.  Thus, we could coexpress some of the many GABAA receptor-associated proteins 
with β3 subunits (± other non-α subunits) in HEK293T cells and see if any of those binding 
partners could eliminate surface expression of these unconventional isoforms. 
Similar to β3 subunits, ε subunits have been reported to reach the cell surface 
independently101, assemble promiscuously441, and produce spontaneous currents in ternary 
receptors442.  (Interestingly, it has been suggested that ε subunit residues homologous to those 
important for β3 subunit homo-oligomerization are necessary and sufficient for ε subunit self-
exportation101.)  More surprisingly, while we were studying wild-type and mutant ε subunit-
containing isoforms, we noticed that ε subunit-expressing cells displayed striking levels of cell 
death (data not shown).  We assumed that this was due to overexpression (similar to the effects of 
1:1:10 μg γ2L subunit cDNA co-transfection) and/or to the previously-reported spontaneous 
current.  Unexpectedly, cell death persisted when very low levels of ε subunit cDNA were 
transfected, when ε subunits were expressed in the absence of α or β subunits (a condition that did 
not produce spontaneous currents in previous experiments), and when ε subunit-expressing cells 
were cultured in the presence of two different GABAA receptor antagonists.  These results were 
somewhat bewildering, because there is no apparent reason for an ion channel subunit to be pro-
apoptotic.  As with β3 subunit heterogeneity, the ε subunit-induced cell death could be specific to 
transfected fibroblasts or generalizable to neurons – which would be extremely interesting.  To 
begin addressing this question, we will transfect neurons with ε subunit cDNA and examine their 
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viability and morphology.  If there is no effect, we could again co-express ε subunits and GABAA 
receptor-associated proteins in fibroblasts; if there is, this could be highly important in processes 
such as neuronal pruning, and it might be worth using optogenetics or lentivirus vector 
transduction to express ε subunits in regions of mouse brain that do not have endogenous ε 
subunit expression.   
Characterization of epilepsy-associated mutations and variants: common themes? 
Chapters IV-VI present extensive characterizations of three mutations and variants that 
were associated with different idiopathic generalized epilepsies.  Two of these, GABRB3(G32R) 
and GABRG2(R177G), were clearly associated with epilepsy and EEG abnormalities in 
multigenerational families310, 421.  The GABRA6(R46W) variant was identified by screening of 
unrelated epileptic patients; of the variant residues identified in that screen, this was the most 
evolutionarily conserved393.  For these reasons, all seemed worthy of further study. 
We hoped to find a common theme that would help us to predict the effects of other 
epilepsy mutations in the future.  Notably, these mutations include one from each major GABAA 
receptor subunit family, so it would also be interesting if the mutations each had different effects, 
but ones that could theoretically result from the specific roles of each subunit class.  The three 
mutations did in fact have some common elements; homology modeling predicted that each was 
located at or near a subunit interface, and each appeared to affect subunit incorporation or 
stoichiometry.  Presumably, these effects contributed to the functional changes that were also 
seen in each mutant receptor.  Interestingly, however, none of the three mutations was predicted 
to dramatically disrupt tertiary or quaternary structure, suggesting that relatively minor structural 
effects can have relatively major effects on receptor assembly and function. 
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Moving forward with mutations: should we then presume, and how should we begin? 
As the cost of next-generation sequencing has decreased, it has become more feasible 
(and appealing) to perform genetic testing in hopes of delivering individualized treatment for 
various disorders.  Consequently, the number of variants and mutations identified in generalized 
epilepsies is likely to increase rapidly, but it is far from certain that identifying more mutations 
will be useful to clinicians in the near future.  Although it is potentially helpful to study genetic 
epilepsies by comprehensively characterizing mutations as we did in Chapters IV-VI, this method 
is currently too inefficient to provide viable diagnostic or treatment strategies for epileptic 
patients.  It is even more unreasonable to create transgenic or knockin mice for each newly-
discovered mutation, but animal models are the only way to study the complex network effects 
that are central to epileptogenesis.  Finally, only about 2% of genetic epilepsies are monogenic.  
Thus, a means of prioritizing mutations and predicting their effects is greatly needed. 
This problem is not unique to the field of epilepsy.  All complex genetic traits that arise 
from combinations of rare variants will necessarily involve enormous data sets that are nearly 
impossible to interpret.    For instance, autism researchers have struggled to make sense of the 
vast number of mutations, variants, and susceptibility loci that have been identified in various 
cohorts.  As whole-exome sequencing and genome-wide association studies (GWAS) have 
become standard techniques, information has progressively outpaced interpretation.  Aside from 
the fundamental problems of the large sample sizes and statistical tools necessary to detect 
significant associations, GWAS may simply leave the investigator with too many potential 
directions and no idea where to start. 
A recent study highlighted the scope of this problem for idiopathic generalized 
epilepsies327.  The authors sequenced 237 ion channel genes in hundreds of epileptic patients and 
non-epileptic controls.  Surprisingly, cases and controls were mostly indistinguishable; neither the 
overall mutation load, nor the number of mutations predicted to be damaging, nor the number of 
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mutations present in known human epilepsy genes differed significantly between the groups.  
Indeed, the study found individual cases and controls with identical combinations of variants 
(“channotypes”).  Ultimately, they concluded that network modeling would be required to 
understand how rare and common ion channel variants combine to produce hyperexcitability.     
Several approaches have been proposed to address the similar problems that inevitably 
arise in GWAS of complex diseases443.  These include pathway analysis, in which variants are 
sorted into known signaling pathways; meta-analysis, which can be used both to increase 
statistical power and to prioritize SNPs for subsequent studies (cumulative/Bayesian meta-
analysis); and testing for epistasis, which could identify interactions that reduce the seizure 
threshold.  The latter two might be most useful for epilepsy, considering that it is a disorder of 
neuronal hyperexcitability and therefore it may be wiser to focus on ion channels before complex 
signaling pathways.  Undoubtedly, such investigations will yield fascinating results, but they are 
beyond the scope of our work.  As such, we have chosen to address the complexity of epilepsy 
genetics in other ways. 
Appendix 2 presents epilepsy-associated GABAA receptor subunit variants that were 
identified recently by several collaborators.  We have narrowed a wider list to include only point 
mutations in subunit coding sequences, and we are beginning to screen mutant subunits for 
abnormal trafficking and/or function.  The high-throughput technique of flow cytometry is 
particularly suited for this approach, and we hope that screening this wider set of variants will 
help us work toward our goal of predicting the effects of mutations in GABAA receptor subunits. 
A few patterns were apparent when we mapped the variants that appeared only in cases 
(pink highlighting).  First, remarkably few variants were found throughout most of the N-terminal 
domain; indeed, β-strands 1-6 contained no variants whatsoever.  (Interestingly, even among 
previously-reported GABAA receptor epilepsy-associated mutations, only GABRG2(R177G) is 
located within that region, in β-strand 6.)  Two variants were found in the loop connecting the N-
terminal α-helix with the first β-strand (loop 1; L1), one residue with two variants was found in 
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the loop connecting β-strands 8 and 9 (loop 9; L9), and one variant was found in each of β-strands 
7-10 (b7-b10).  In contrast, 11 variants were found in the transmembrane domains (M1-M4).   
The remainder (20 variants) were concentrated in signal peptides (SP; six variants) and the 
cytoplasmic loop (loop; 13 variants) connecting the third and fourth transmembrane domains.  
Notably, two of the cytoplasmic loop variants were located in the predicted “MA” helix that is 
directly N-terminal to the fourth transmembrane domain and has been shown to affect receptor 
function97. 
Seventeen variants were reported to occur in both cases and controls, albeit at varying 
frequencies.  Of these, one variant each was located in β-strands 1 and 8 (b1, b8); one was located 
in the third transmembrane domain (M3); and the remainder were located in the signal peptide 
(four variants), the random coil preceding the N-terminal α-helix (two variants), and the 
cytoplasmic loop (eight variants, two in the MA helix).  In short, only 5 of 17 variants found in 
both cases and controls were located in structured GABAA receptor subunit domains, while 17 of 
36 case-specific variants were located in structured domains or loops known to participate in 
subunit-subunit interactions.   
However, it is by no means certain that mutations located in structured domains will be 
deleterious or that those located in unstructured domains will be benign.  We used the Sorting 
Intolerant From Tolerant (SIFT)431 and Polymorphism Phenotyping (PolyPhen )2.0432 tools to 
predict whether or not a given missense mutation would adversely affect protein function.  
Because these algorithms depend heavily upon sequence conservation, it is perhaps unsurprising 
that the majority of variants predicted to be damaging were located in the transmembrane 
domains.   Interestingly, the GABRE(Y38C) mutation found in both cases and controls was 
predicted to be damaging even though it is located in the random coil that is assumed to form the 
distal N-terminus of all GABAA receptor subunits.  
It was also intriguing that 10 of 53 variants were located in signal peptides.  This might 
simply indicate that there is little selective pressure in this region and that the variants are likely 
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to be benign.  Alternatively, they could alter signal peptide cleavage, thereby changing 
localization or N-terminal structure of mutant subunits, but no change in cleavage site was 
predicted with high confidence by either the SignalP or the Signal CF algorithm444, 445.   However, 
the GABRB3 mutations P11S and S15F also were not predicted to change signal peptide cleavage.  
These mutations were identified in multigenerational families with epilepsy310, 446 and/or autism296 
and clearly reduced current density of α1β2γ2L GABAA receptor isoforms.  However, we found 
no difference in surface expression levels large enough to explain such a current reduction, nor 
did we observe a shift in molecular weight (i.e., lack of signal peptide cleavage) after 
deglycosylation and SDS-PAGE.  (Importantly, most GABAA receptor subunit signal peptides are 
longer than 20 amino acids, and we can detect shifts in molecular mass between β2 subunits 
containing or lacking the 9-aa HA epitope tag.)  Similarly, preliminary studies of signal peptide 
variants listed in Appendix 2 have indicated few significant changes in subunit expression or 
current density, no detectible changes in molecular mass of protein backbones, and some changes 
in receptor kinetic properties.   It is difficult to understand how a signal peptide mutation could 
affect receptor function without changing the sequence or trafficking of the mature protein, but 
the fact that the GABRB3(P11S) mutation has been found in multiple cohorts, in particular, 
suggests that the phenomenon is real and merits further study.  As such, we are planning several 
further experiments.  First, mass spectrometry could be used to determine if signal peptide 
cleavage is altered subtly enough to be undetectable with SDS-PAGE.  Wild-type and mutant 
signal peptides could be coupled with reporter genes to assess any potential differences in rate or 
efficiency of subunit synthesis, and wild-type and mutant subunits could be expressed in cultured 
neurons to evaluate changes in subunit localization.  Finally, a GABRB3(P11S) knockin mouse is 
currently being created.  We eagerly await its arrival and plan to conduct full behavioral, 
histological, and electroencephalographic characterizations at the earliest opportunity.  
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P83S
GABRB2-s ------------------MWRVRKRGYFGIWS-FPLIIAAVCAQ---------------- 25
GABRB3v2 ------------------MCSGLLELLLPIWLSWTLGTRGSEPR---------------- 26
GABRB1 ------------------MWTVQNRESLGLLSFPVMITMVCCAH---------------- 26
GABRQ -----------------MGIRGMLRAAVILLLIRTWLAEGNYPSPIP----KFHFEFSSA 39
GABRD -----------------MDAPARLLAPLLLLCAQQLRGTRAMNDIG-------------- 29
GABRP -----------------MNYSLHLAFVCLSLFTERMCIQGSQFNV--------------- 28
GABRA1 --------MRKS---------PGLSDCLWAWILLLSTLTGR------------------- 24
GABRA2 --------MKTK---------LNIYNMQFLLFVFLVWDPAR------------------- 24
GABRA5 ----MDNGMFSG---------FIMIKNLLLFCISMNLSSHFG------------------ 29
GABRA3 ----MIITQTSH---------CYMTSLGILFLINILPGTTGQGESRRQEPGDFVKQDIGG 47
GABRA4-iso1 --------MVSAKKVPAIALSAGVSFALLRFLCLAVCLNE-------------------- 32
GABRA6 --------MASS----------------LPWLCIILWLEN-------------------- 16
GABRG1 -MGPLKAFLFSPFLLRS---QSRGVRLVFLLLTLHLGNCVD-----------KADDEDDE 45
GABRG2L -MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQ-----------KSDD-DYE 47
GABRG3 -----------------------MAPKLLLLLCLFSGLHARS---------RKVEEDEYE 28
GABRE MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQP---------QPLENQLLS 51
GluCL-3RHW ------------------------------------------------------------
CHRNA1-Tm --------------------MILCSYWHVGLVLLLFSCCG-------------------- 20
CHRNA1-v1 -----------------------MEPWPL-LLLFSLCSAG-------------------- 16
ACHP-L -----------------------MRRNIFCLACLWIVQACLS------------------ 19
ACHBP-A ----------------------MLVSVYLALLVACVGQAHS------------------- 19
GABRB2-s ---------SVNDPSNMSLVKETVDRLLKGYDIRLRPDFGGP-PVAVGMNIDIASIDMVS 75
GABRB3v2 ---------SVNDPGNMSFVKETVDKLLKGYDIRLRPDFGGP-PVCVGMNIDIASIDMVS 76
GABRB1 ---------STNEPSNMSYVKETVDRLLKGYDIRLRPDFGGP-PVDVGMRIDVASIDMVS 76
GABRQ            VPEVVLNLFNCKNCANEAVVQKILDRVLSRYDVRLRPNFGGA-PVPVRISIYVTSIEQIS 98
GABRD ---------DYVGSNLEISWLPNLDGLIAGYARNFRPGIGGP-PVNVALALEVASIDHIS 79
GABRP ----------EVGRSDKLS-LPGFENLTAGYNKFLRPNFGGE-PVQIALTLDIASISSIS 76
GABRA1 --SYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPGLGER-VTEVKTDIFVTSFGPVS 81
GABRA2 --LVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPGLGDS-ITEVFTNIYVTSFGPVS 81
GABRA5 FSQMPTSSVKDETNDNITIFTRILDGLLDGYDNRLRPGLGER-ITQVRTDIYVTSFGPVS 88
GABRA3           LSPKHAPDIPDDSTDNITIFTRILDRLLDGYDNRLRPGLGDA-VTEVKTDIYVTSFGPVS 106
GABRA4-iso1 ----SPGQNQKEEKLCTENFTRILDSLLDGYDNRLRPGFGGP-VTEVKTDIYVTSFGPVS 87
GABRA6 ----ALGKLEVEGNFYSENVSRILDNLLEGYDNRLRPGFGGA-VTEVKTDIYVTSFGPVS 71
GABRG1           DLTVNKTWVLAPKI-HEGDITQILNSLLQGYDNKLRPDIGVR-PTVIETDVYVNSIGPVD 103
GABRG2L          DYASNKTWVLTPKV-PEGDVTVILNNLLEGYDNKLRPDIGVK-PTLIHTDMYVNSIGPVN 105
GABRG3           DSSSNQKWVLAPKS-QDTDVTLILNKLLREYDKKLRPDIGIK-PTVIDVDIYVNSIGPVS 86
GABRE EETKSTETETGSRVGKLPEASRILNTILSNYDHKLRPGIGEK-PTVVTVEISVNSLGPLS 110
GluCL-3RHW -----------------SDSKILAHLFTSGYDFRVRPPTDNGGPVVVSVNMLLRTISKID 43
CHRNA1-Tm ------------LVLGSEHETRLVANLLENYNKVIRPVEHHTHFVDITVGLQLIQLINVD 68
CHRNA1-v1 ------------LVLGSEHETRLVAKLFKDYSSVVRPVEDHRQVVEVTVGLQLIQLINVD 64
ACHP-L -----------------LDRADILYNIRQTSRPDVIPTQRDR-PVAVSVSLKFINILEVN 61
ACHBP-A ----------------QANLMRLKSDLFNRSPMYPGPTKDDP--LTVTLGFTLQDIVKAD 61
.         *         :   . .  :   .
R3S
P11S S15F
A3S
V10M
T20I
A19T
Q40X
G32R
R46W
N79S R82Q
E52K G66S
α1 β1L1
L26M
Y38C
S102A
Appendix 1: Annotated Alignment of GABAA Receptor Subunit Sequences
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3RHW       VVNMEYSAQLTLRESWIDKRLSYGVKGDGQPDFVILTVGHQIWMPDTFFPNEKQAYKHTI 103
GABRB2-s EVNMDYTLTMYFQQAWRDKRLSYNVIPLNLTLDNRVAD--QLWVPDTYFLNDKKSFVHGV 133
GABRB3v2         EVNMDYTLTMYFQQYWRDKRLAYSGIPLNLTLDNRVAD--QLWVPDTYFLNDKKSFVHGV 134
GABRB1           EVNMDYTLTMYFQQSWKDKRLSYSGIPLNLTLDNRVAD--QLWVPDTYFLNDKKSFVHGV 134
GABRQ            EMNMDYTITMFFHQTWKDSRLAYYETTLNLTLDYRMHE--KLWVPDCYFLNSKDAFVHDV 156
GABRD            EANMEYTMTVFLHQSWRDSRLSYNHTNETLGLDSRFVD--KLWLPDTFIVNAKSAWFHDV 137
GABRP            ESNMDYTATIYLRQRWMDQRLVFEG-NKSFTLDARLVE--FLWVPDTYIVESKKSFLHEV 133
GABRA1           DHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMAS--KIWTPDTFFHNGKKSVAHNM 139
GABRA2           DTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMAS--KIWTPDTFFHNGKKSVAHNM 139
GABRA5           DTEMEYTIDVFFRQSWKDERLRFKGPMQRLPLNNLLAS--KIWTPDTFFHNGKKSIAHNM 146
GABRA3           DTDMEYTIDVFFRQTWHDERLKFDGPMKILPLNNLLAS--KIWTPDTFFHNGKKSVAHNM 164
GABRA4-iso1      DVEMEYTMDVFFRQTWIDKRLKYDGPIEILRLNNMMVT--KVWTPDTFFRNGKKSVSHNM 145
GABRA6           DVEMEYTMDVFFRQTWTDERLKFGGPTEILSLNNLMVS--KIWTPDTFFRNGKKSIAHNM 129
GABRG1           PINMEYTIDIIFAQTWFDSRLKFNSTMKVLMLNSNMVG--KIWIPDTFFRNSRKSDAHWI 161
GABRG2L          AINMEYTIDIFFAQTWYDRRLKFNSTIKVLRLNSNMVG--KIWIPDTFFRNSKKADAHWI 163
GABRG3           SINMEYQIDIFFAQTWTDSRLRFNSTMKILTLNSNMVG--LIWIPDTIFRNSKTAEAHWI 144
GABRE            ILDMEYTIDIIFSQTWYDERLCYNDTFESLVLNGNVVS--QLWIPDTFFRNSKRTHEHEI 168
GluCL-
CHRNA1-Tm        EVNQIVETNVRLRQQWIDVRLRWNPADYGGIKKIRLPSD-DVWLPDLVLYNNADGDFAIV 127
CHRNA1-v1        EVNQIVTTNVRLKQQWVDYNLKWNPDDYGGVKKIHIPSE-KIWRPDLVLYNNADGDFAIV 123
ACHP-L           EITNEVDVVFWQQTTWSDRTLAWNSSHSPDQVSVPISS---LWVPDLAAYN---AISKPE 115
ACHBP-A          SSTNEVDLVYYEQQRWKLNSLMWDPNEYGNITDFRTSAA-DIWTPDITAYS---STRPVQ 117
*    * :                  :* **    .
GABRB2-s         TVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWR 193
GABRB3v2         TVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWR 194
GABRB1           TVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWN 194
GABRQ            TVENRVFQLHPDGTVRYGIRLTTTAACSLDLHKFPMDKQACNLVVESYGYTVEDIILFWD 216
GABRD            TVENKLIRLQPDGVILYSIRITSTVACDMDLAKYPMDEQECMLDLESYGYSSEDIVYYWS 197
GABRP            TVGNRLIRLFSNGTVLYALRITTTVACNMDLSKYPMDTQTCKLQLESWGYDGNDVEFTWL 193
GABRA1 TMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHACPLKFGSYAYTRAEVVYEWT 199
GABRA2           TMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSCPLKFGSYAYTTSEVTYIWT 199
GABRA5           TTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDFPMDAHACPLKFGSYAYPNSEVVYVWT 206
GABRA3           TTPNKLLRLVDNGTLLYTMRLTIHAECPMHLEDFPMDVHACPLKFGSYAYTTAEVVYSWT 224
GABRA4-iso1      TAPNKLFRIMRNGTILYTMRLTISAECPMRLVDFPMDGHACPLKFGSYAYPKSEMIYTWT 205
GABRA6           TTPNKLFRIMQNGTILYTMRLTINADCPMRLVNFPMDGHACPLKFGSYAYPKSEIIYTWK 189
GABRG1           TTPNRLLRIWNDGRVLYTLRLTINAECYLQLHNFPMDEHSCPLEFSSYGYPKNEIEYKWK 221
GABRG2L          TTPNRMLRIWNDGRVLYTLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWK 223
GABRG3           TTPNQLLRIWNDGKILYTLRLTINAECQLQLHNFPMDEHSCPLIFSSYGYPKEEMIYRWR 204
GABRE            TMPNQMVRIYKDGKVLYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENEMIYKWE 228
GluCL-3RHW       DKPNVLIRIHNDGTVLYSVRISLVLSCPMYLQYYPMDVQQCSIDLASYAYTTKDIEYLWK 163
CHRNA1-Tm        HMTKLLLDYT--GKIMWTPPAIFKSYCEIIVTHFPFDQQNCTMKLGIWTYDGTKVSISPE 185
CHRNA1-v1        KFTKVLLQYT--GHITWTPPAIFKSYCEIIVTHFPFDEQNCSMKLGTWTYDGSVVAINPE 181
ACHP-L           VLTPQLARVVSDGEVLYMPSIRQRFSCDVSGVDTESG-ATCRIKIGSWTHHSREISVDPT 174
ACHBP-A          VLSPQIAVVTHDGSVMFIPAQRLSFMCDPTGVDSEEG-ATCAVKFGSWVYSGFEIDLKTD 176
:      * : :         *         .   * : . : :    :
β2L2 β3L3 β4L4 L5
L5 β5 L6 β6 L7 β7 L8 β8
E177A
V204I
R177G
loop D loop A
loop E loop B
T187M
270
GABRB2-s         G----DDNAVTGVTKIELPQFSIVDYKLITKKVVFS-TGSYPRLSLSFKLK-RNIGYFIL 247
GABRB3v2         G----GDKAVTGVERIELPQFSIVEHRLVSRNVVFA-TGAYPRLSLSFRLK-RNIGYFIL 248
GABRB1           G----GEGAVTGVNKIELPQFSIVDYKMVSKKVEFT-TGAYPRLSLSFRLK-RNIGYFIL 248
GABRQ            D----NGNAIHMTEELHIPQFTFLGRTITSKEVYFY-TGSYIRLILKFQVQ-REVNSYLV 270
GABRD            E----SQEHIHGLDKLQLAQFTITSYRFTTELMNFKSAGQFPRLSLHFHLR-RNRGVYII 252
GABRP            R----GNDSVRGLEHLRLAQYTIERY-FTLVTRSQQETGNYTRLVLQFELR-RNVLYFIL 247
GABRA1           REPA-RSVVVAE-DGSRLNQYDLLGQTVDSGIVQSS-TGEYVVMTTHFHLK-RKIGYFVI 255
GABRA2           YNAS-DSVQVAP-DGSRLNQYDLLGQSIGKETIKSS-TGEYTVMTAHFHLK-RKIGYFVI 255
GABRA5           NGST-KSVVVAE-DGSRLNQYHLMGQTVGTENISTS-TGEYTIMTAHFHLK-RKIGYFVI 262
GABRA3 LGKN-KSVEVAQ-DGSRLNQYDLLGHVVGTEIIRSS-TGEYVVMTTHFHLK-RKIGYFVI 280
GABRA4-iso1      KGPE-KSVEVPK-ESSSLVQYDLIGQTVSSETIKSI-TGEYIVMTVYFHLR-RKMGYFMI 261
GABRA6           KGPL-YSVEVPE-ESSSLLQYDLIGQTVSSETIKSN-TGEYVIMTVYFHLQ-RKMGYFMI 245
GABRG1           K----PSVEVADPKYWRLYQFAFVGLRNSTEITHTI-SGDYVIMTIFFDLS-RRMGYFTI 275
GABRG2L          R----SSVEVGDTRSWRLYQFSFVGLRNTTEVVKTT-SGDYVVMSVYFDLS-RRMGYFTI 277
GABRG3           K----NSVEAADQKSWRLYQFDFMGLRNTTEIVTTS-AGDYVVMTIYFELS-RRMGYFTI 258
GABRE            N----FKLEINEKNSWKLFQLDFTGVSNKTEIITTP-VGDFMVMTIFFNVS-RRFGYVAF 282
GluCL-3RHW       EHSP-LQLKVGL--SSSLPSFQLTNTSTTYCTSVTN-TGIYSCLRTTIQLK-REFSFYLL 218
CHRNA1-Tm        SDRP-DLSTFMESGEWVMKDYRGWKHWVYYTCCPDT---PYLDITYHFIMQ-RIPLYFVV 240
CHRNA1-v1        SDQP-DLSNFMESGEWVIKESRGWKHSVTYSCCPDT---PYLDITYHFVMQ-RLPLYFIV 236
ACHP-L           TENSDDSEYFSQYSRFEILDVTQKKNSVTYSCCPEA----YEDVEVSLNFR-KKGRSEIL 229
ACHBP-A          TDQV-DLSSYYASSKYEILSATQTRQVQHYSCCPEP----YIDVNLVVKFRERRAGNGFF 231
: . :  :   . .  :      .
GABRB2-s         QTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLP-KIPYVKAID 306
GABRB3v2         QTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLP-KIPYVKAID 307
GABRB1           QTYMPSTLITILSWVSFWINYDASAARVALGITTVLTMTTISTHLRETLP-KIPYVKAID 307
GABRQ            QVYWPTVLTTITSWISFWMNYDSSAARVTIGLTSMLILTTIDSHLRDKLP-NISCIKAID 329
GABRD            QSYMPSVLLVAMSWVSFWISQAAVPARVSLGITTVLTMTTLMVSARSSLP-RASAIKALD 311
GABRP            ETYVPSTFLVVLSWVSFWISLDSVPARTCIGVTTVLSMTTLMIGSRTSLPNTNCFIKAID 307
GABRA1 QTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLP-KVAYATAMD 314
GABRA2           QTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLP-KVAYATAMD 314
GABRA5           QTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLP-KVAYATAMD 321
GABRA3           QTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLP-KVAYATAMD 339
GABRA4-iso1      QTYIPCIMTVILSQVSFWINKESVPARTVFGITTVLTMTTLSISARHSLP-KVSYATAMD 320
GABRA6           QIYTPCIMTVILSQVSFWINKESVPARTVFGITTVLTMTTLSISARHSLP-KVSYATAMD 304
GABRG1           QTYIPCILTVVLSWVSFWINKDAVPARTSLGITTVLTMTTLSTIARKSLP-KVSYVTAMD 334
GABRG2L          QTYIPCTLIVVLSWVSFWINKDAVPARTSLGITTVLTMTTLSTIARKSLP-KVSYVTAMD 336
GABRG3           QTYIPCILTVVLSWVSFWIKKDATPARTALGITTVLTMTTLSTIARKSLP-RVSYVTAMD 317
GABRE QNYVPSSVTTMLSWVSFWIKTESAPARTSLGITSVLTMTTLGTFSRKNFP-RVSYITALD 341
GluCL-3RHW QLYIPSCMLVIVSWVSFWFDRTAIPARVTLGVTTLLTMTAQSAGINSQLP-PVSYIKAID 277
CHRNA1-Tm        NVIIPCLLFSFLTVLVFYLPTD-SGEKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIG 299
CHRNA1-v1        NVIIPCLLFSFLTGLVFYLPTD-SGEKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIG 295
ACHP-L ------------------------------------------------------------
ACHBP-A          RNLFD------------------------------------------------------- 236
β8 β9L9 β9 β10L10 β10 M1
M1 M2 M3
R293W
S292P R293C
W280R
K328M
A303T
loop F loop C
Q237R
271
-------
KRGWA
s         MYLMGCFVFVFMALLEYALVNYIFFGRGPQRQKKAAEKGABRB2- ---------------------- 344
GABRB3v2         MYLMGCFVFVFLALLEYAFVNYIFFGRGPQRQKKLAEK---------------------- 345
GABRB1           IYLMGCFVFVFLALLEYAFVNYIFFGKGPQ--KKGASK---------------------- 343
GABRQ            IYILVCLFFVFLSLLEYVYINYLFYSRGPRRQPRRHRRPRRVIARYRYQQVVVGNVQDGL 389
GABRD            VYFWICYVFVFAALVEYAFAHFNADYRKKQKAKVKVSR---------------------- 349
GABRP            VYLGICFSFVFGALLEYAVAHYSS----LQQMAAKDRG---------------------- 341
GABRA1           WFIAVCYAFVFSALIEFATVNYFT KRGYA------------------------ 343
GABRA2           WFIAVCYAFVFSALIEFATVNYFT-------KRGWA------------------------ 343
GABRA5           WFIAVCYAFVFSALIEFATVNYFT------- ------------------------ 350
GABRA3           WFIAVCYAFVFSALIEFATVNYFT-------KRSWA------------------------ 368
GABRA4-iso1      WFIAVCFAFVFSALIEFAAVNYFTNIQMEKAKRKTSKPPQEVPAAPVQREKHPEAPLQNT 380
GABRA6           WFIAVCFAFVFSALIEFAAVNYFTNLQTQKAKRKAQ------------------------ 340
GABRG1           LFVSVCFIFVFAALMEYGTLHYFT------------------------------------ 358
GABRG2L          LFVSVCFIFVFSALVEYGTLHYFV------------------------------------ 360
GABRG3           LFVTVCFLFVFAALMEYATLNYYS------------------------------------ 341
GABRE FYIAICFVFCFCALLEFAVLNFLI------------------------------------ 365
GluCL-3RHW       VWIGACMTFIFCALLEFALVNHIAN----------------------------------- 302
CHRNA1-Tm        KYMLFTMIFVISSIIVTVVVINTHHRSPSTHTMPQWVR---------------------- 337
CHRNA1-v1 KYMLFTMVFVIASIIITVIVINTHHRSPSTHVMPNWVR---------------------- 333
ACHP-L ------------------------------------------------------------
ACHBP-A ------------------------------------------------------------
GABRB2-s --------------------------AASANNEKMRLDVN-------------------- 358
GABRB3v2 --------------------------TAKAKNDRSKSESN-------------------- 359
GABRB1 --------------------------QDQSANEKNKLEMNK------------------- 358
GABRQ            INVEDGVSSLPITPAQAPLASPESLGSLTSTSEQAQLATSESLSPLTSLSGQAPLATGES 449
GABRD ---------------------------PRAEMDVRNAIV--------------------- 361
GABRP ---------------------------TTKEVEEVSITN--------------------- 353
GABRA1 ------------------------------------------------------------
GABRA2 ------------------------------------------------------------
GABRA5 ------------------------------------------------------------
GABRA3 ------------------------------------------------------------
GABRA4-iso1      NANLNMRKRTNALVHSESDVGNRTEVGNHSSKSSTVVQESS------------------- 421
GABRA6 ------------------------------------------------------------
GABRG1 ------------------------------------------------------------
GABRG2L ------------------------------------------------------------
GABRG3 ------------------------------------------------------------
GABRE ------------------------------------------------------------
GluCL-3RHW ------------------------------------------------------------
CHRNA1-Tm ------------------------------------------------------------
CHRNA1-v1 ------------------------------------------------------------
ACHP-L ------------------------------------------------------------
ACHBP-A ------------------------------------------------------------
M3 M3-M4 loop
M3-M4 loop
A322D
H372P
R354C
I401T
V349A
BIG2 radixinPlic-1
T355A
272
GABRB2-s -----------------------------------KMDPHENILLSTLEIKNEMATSEAV 383
GABRB3v2 -----------------------------------RVDAHGNILLTSLEVHNEMN--EVS 382
GABRB1 ----------------------------------VQVDAHGNILLSTLEIRNETSGSEVL 384
GABRQ            LSDLPSTSEQARHSYGVRFNGFQADDSIFPTEIRNRVEAHGHGVTHDHEDSNESLSSDER 509
GABRD -------------------------------------------LFSLSAAGVTQELAISR 378
GABRP -------------------------------------------IINSSISSFKRKISFAS 370
GABRA1 ------------------------------------------------WDGK-SVVPEKP 354
GABRA2 ------------------------------------------------WDGK-SVVNDK- 353
GABRA5 ------------------------------------------------WDGKKALEAAKI 362
GABRA3 ------------------------------------------------WEGKKVPEALEM 380
GABRA4-iso1 ----------------------------------------KGTPRSYLASSPNPFSRANA 441
GABRA6 ------------------------------------------------FAAPPTVTISKA 352
GABRG1 -------------------------------------------------SNQKGKTATKD 369
GABRG2L -------------------------------------------------SNRK-PSKDKD 370
GABRG3 -------------------------------------------------SCRKPTTTKKT 352
GABRE -------------------------------------------------YNQT--KAHAS 374
GluCL-3RHW ------------------------------------------------------------
CHRNA1-Tm ---------------------------------------------KIFINTIPNVMFFST 352
CHRNA1-v1 ---------------------------------------------KVFIDTIPNIMFFST 348
ACHP-L ------------------------------------------------------------
ACHBP-A ------------------------------------------------------------
GABRB2-s         MGLGDPRSTMLAYDASSIQYR----------------KAGLPRHSFGRNALERHVAQKKS 427
GABRB3v2         GGIGDTRNSAISFDNSGIQYR----------------KQSMPREGHGRFLGDRSLPHKKT 426
GABRB1           TSVSDPKATMYSYDSASIQYR----------------KPLSSREAYGR-ALDRHGVPSKG 427
GABRQ            HGHGPSGKPMLHHGEKGVQEAGWDLDDNNDKSDCLAIKEQFKCDTNSTWGLNDDELMAHG 569
GABRD            RQRRVPGNLMGSYRSVGVETG----------------------------ETKKEGAARSG 410
GABRP            IEISSDN---VDYSDLTMKTS----------------------------DKFK--FVFRE 397
GABRA1           KKVKDPLIKK--NNTYAPTA--------------------TSYTPNLARGDPGLATIAKS 392
GABRA2           KKEKASVMIQ--NNAYAVAV--------------------ANYAPNLSK-DPVLSTISKS 390
GABRA5           KKKREVILNKS-TNAFTTGK--------------------MSHPPNIPK---EQTPAGTS 398
GABRA3 KKKTPAAPAKKTSTTFNIVG--------------------TTYPINLAK-DTEFSTISKG 419
GABRA4-iso1      AETISAARALPSASPTSIRTGYMPR-----------KASVGSASTRHVFGSRLQRIKTTV 490
GABRA6           TEPLEAEIVLHPDSKYHLKK------------------RITSLSLPIVSSSEANKVLTRA 394
GABRG1           RKLKN-------KASMTPGLH----------------PGSTLIPMNNISVPQE--DDYGY 404
GABRG2L          KKKKNPLLRMFSFKAPTIDIR----------------PRSATIQMNNATHLQERDEEYGY 414
GABRG3           TSLLHPDSSRWIPERISLQAPSNYSLL------DMRPPPTAMITLNNSVYWQEFEDTCVY 406
GABRE            PKLRHPRINSRAHARTRARSRACAR--------QHQEAFVCQIVTTEGSDGEERPSCSAQ 426
GluCL-3RHW ------------------------------------------------------------ 309
CHRNA1-Tm        MKRASKEKQENKIFADDIDIS------------------DISGKQVTGEVIFQTPLIKNP 394
CHRNA1-v1        MKRPSREKQDKKIFTEDIDIS------------------DISGKPGPPPMGFHSPLIKHP 390
ACHP-L ------------------------------------------------------------
ACHBP-A ------------------------------------------------------------
M3-M4 loop
M3-M4 loop
H421Q
D389N
A387D
Q390X
M391V
NSF/AP2gephyrin
I394T
F391L
T352A
273
----------------------GABRB2-s         R LRRRASQLKITIP-------------DLTD---VNAI 449
GABRB3v2         H----------------------LRRRSSQLKIKIP-------------DLTD---VNAI 448
GABRB1           R----------------------IRRRASQLKVKIP-------------DLTD---VNSI 449
GABRQ            Q----------------------EKDSSSESEDSCPPSPGCSFTEGFSFDLFNPDYVPKV 607
GABRD            G----------------------QGGIRARLRPIDA---------------------DTI 427
GABRP            K----------------------MGRIVDYFTIQNP---------------------SNV 414
GABRA1           A----------------------TIEPKEVKPETKPPEP-----------KKTFNSVSKI 419
GABRA2           A----------------------TTPEPNKKPENKPAEA-----------KKTFNSVSKI 417
GABRA5           N----------------------TTSVSVKPSEEKTSES-----------KKTYNSISKI 425
GABRA3 A----------------------APSASSTPTIIASPKATY--VQDSPTETKTYNSVSKV 455
GABRA4-iso1      N----------------------TIGATGKLSATPPPSAP----------PPSGSGTSKI 518
GABRA6           P----------------------ILQST---PVTPPPLSP----------AFGG--TSKI 417
GABRG1           Q-------------------CLEGKDCASFFCCFEDCRTG------SWREGRIHIRIAKI 439
GABRG2L          E-------------------CLDGKDCASFFCCFEDCRTG------AWRHGRIHIRIAKM 449
GABRG3           E-------------------CLDGKDCQSFFCCYEECKSG------SWRKGRIHIDILEL 441
GABRE            QPPSPGSPEGPRSLCSKLACCEWCKRFKKYFCMVPDCEGS------TWQQARLCIHVYRL 480
GluCL-3RHW -----------------------------------------------AGTTEWNDISKRV 315
CHRNA1-Tm        D----------------------VKSAIEGVKYIAEHMKS---------DEESSNAAEEW 423
CHRNA1-v1        E----------------------VKSAIEGIKYIAETMKS---------DQESNNAAAEW 419
ACHP-L ------------------------------------------------------------
ACHBP-A ------------------------------------------------------------
GABRB2-s         DRWSRIFFPVVFSFFNIVYWLYYVN------------- 474
GABRB3v2         DRWSRIVFPFTFSLFNLVYWLYYVN------------- 473
GABRB1           DKWSRMFFPITFSLFNVVYWLYYVH------------- 474
GABRQ            DKWSRFLFPLAFGLFNIVYWVYHMY------------- 632
GABRD            DIYARAVFPAAFAAVNVIYWAAYAM------------- 452
GABRP            DHYSKLLFPLIFMLANVFYWAYYMYF------------ 440
GABRA1           DRLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ- 456
GABRA2           DRMSRIVFPVLFGTFNLVYWATYLNREPVLGVSP---- 451
GABRA5           DKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK- 462
GABRA3           DKISRIIFPVLFAIFNLVYWATYVNRESAIKGMIRKQ- 492
GABRA4-iso1      DKYARILFPVTFGAFNMVYWVVYLSKDTMEKSESLM-- 554
GABRA6           DQYSRILFPVAFAGFNLVYWVVYLSKDTMEVSSSVE-- 453
GABRG1           DSYSRIFFPTAFALFNLVYWVGYLYL------------ 465
GABRG2L          DSYARIFFPTAFCLFNLVYWVSYLYL------------ 475
GABRG3           DSYSRVFFPTSFLLFNLVYWVGYLYL------------ 467
GABRE            DNYSRVVFPVTFFFFNVLYWLFCLNL------------ 506
GluCL-3RHW       DLISRALFPVLFFVFNILYWSRFGHHHHHHHH------ 347
CHRNA1-Tm        KYVAMVIDHILLCVFMLICIIGTVSVFAGRLIELSQEG 461
CHRNA1-v1        KYVAMVMDHILLGVFMLVCIIGTLAVFAGRLIELNQQG 457
ACHP-L --------------------------------------
ACHBP-A --------------------------------------
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